


Ph.D. thesis

# Mould growth on building materials

Secondary metabolites, mycotoxins and biomarkers



# Mould growth on building materials

Secondary metabolites, mycotoxins and biomarkers

Ph.D. thesis

Kristian Fog Nielsen

Title Mould growth on building materials  
Subtitle Secondary metabolites, mycotoxins and biomarkers  
Edition 1. edition  
Year 2002  
Author Kristian Fog Nielsen  
Language English  
Pages 120  
References Page 61-80  
Key words Indoor climate, moulds, building materials, spores, mycotoxins

ISBN 87-563-1130-3

Price DKK 250,00 incl. 25 per cent VAT  
Coverphoto Kristian Fog Nielsen  
Printer BookPartner, Nørhaven digital A/S

Publisher By og Byg, Statens Byggeforskningsinstitut  
dbur, Danish Building and Urban Research  
P.O. Box 119, DK-2970 Hørsholm  
E-mail [by-og-byg@by-og-byg.dk](mailto:by-og-byg@by-og-byg.dk)  
[www.by-og-byg.dk](http://www.by-og-byg.dk)

Extracts may be reproduced but only with reference to source: *Mould growth on building materials. Secondary metabolites, mycotoxins and biomarkers. Ph.D. thesis. (2002)*

# Table of Contents

---

<b>Preface</b>	<b>v</b>
<b>Author's preface</b>	<b>vii</b>
<b>Abstract</b>	<b>viii</b>
<b>Resume</b>	<b>ix</b>
<b>Abbreviations and terms</b>	<b>x</b>
<b>Papers prepared in connection with this thesis</b>	<b>xii</b>
<b>1 Introduction</b>	<b>1</b>
<b>2 Moulds in buildings</b>	<b>3</b>
2.1.1 The building associated funga	3
<b>2.2 Growth of moulds on building materials</b>	<b>5</b>
2.2.1 "Water - the key factor" <sup>11</sup>	5
2.2.2 The impact of the material on the mould growth	8
2.2.3 Modelling mould growth on materials	8
<b>2.3 Health problems associated with airborne moulds</b>	<b>9</b>
2.3.1 In vivo and in vitro effect of fungal spores	9
2.3.2 Epidemiologically studies	10
<b>2.4 Biologically active metabolites from moulds</b>	<b>12</b>
2.4.1 <i>Stachybotrys</i>	13
2.4.2 <i>Aspergillus</i>	17
2.4.3 <i>Penicillium</i>	20
2.4.4 <i>Trichoderma</i>	22
2.4.5 <i>Memnoniella</i>	22
2.4.6 <i>Alternaria</i>	22
2.4.7 <i>Chaetomium</i>	23
2.4.8 <i>Cladosporium</i>	23
2.4.9 <i>Ulocladium</i>	23
2.4.10 <i>Paecilomyces</i>	24
<b>2.5 Biomarkers of mould growth</b>	<b>24</b>
2.5.1 Ergosterol	24
<b>2.6 Detection of fungal metabolites</b>	<b>25</b>
2.6.1 Chromatographic methods for detection of mycotoxins	25
2.6.2 Sample preparation	28
2.6.3 Detection of mycotoxins in air and settled dust	28
<b>3 Overview of experimental work</b>	<b>30</b>
<b>4 Results and discussion</b>	<b>31</b>
<b>4.1 The building associated funga</b>	<b>31</b>
4.1.1 <i>Penicillium</i> and <i>Aspergillus</i> cultures received from Finland	31
<b>4.2 Fungal growth on materials</b>	<b>32</b>
4.2.1 Methods for testing the susceptibility of materials	33
4.2.2 Growth assesment	34

<b>4.3 Growth and metabolite production</b>	<b>36</b>
4.3.1 <i>Stachybotrys</i>	36
4.3.2 <i>Aspergillus</i>	44
4.3.3 <i>Penicillium</i>	49
4.3.4 <i>Trichoderma</i>	51
4.3.5 <i>Memnoniella echinata</i>	52
4.3.6 <i>Alternaria</i>	52
4.3.7 <i>Chaetomium globosum</i>	53
4.3.8 <i>Cladosporium</i>	54
4.3.9 <i>Ulocladium</i>	54
4.3.10 <i>Paecilomyces</i>	54
4.3.11 <i>Eurotium</i>	55
<b>4.4 Overall discussion</b>	<b>55</b>
4.4.1 Growth on materials	55
4.4.2 Metabolites	56
<b>5 Conclusion</b>	<b>58</b>
<b>6 Perspectives and future research</b>	<b>60</b>
<b>References</b>	<b>61</b>
<b>Appendix A, list of conference proceedings</b>	<b>81</b>
<b>Appendix B, Review of metabolite data from the examined species</b>	<b>82</b>

# PREFACE

This publication includes the Ph.D. thesis of Kristian Fog Nielsen exclusive the published peer reviewed papers.

The Danish Building Research Institute financed the Ph.D. project. It was agreed upon in 1998 between the Research Academy, Technical University of Denmark (DTU) and the Danish Building Research Institute (SBI) – now Danish Building and Urban Research (By og Byg).

Kristian Fog Nielsen M. Sc. (Chem. & Biotech. Eng) commenced his studies in June 1998 and defended his thesis at a public hearing and evaluation on December 7, 2001.

A major part of the chemical and mycological work was performed in the Mycology Group at BioCentrum – DTU.

Dr. Maija Riitta Hirvonen and dr. Aino Nevalainen, the National Public Health Institute, Kuopio, Finland and dr. Olaf Adan, TNO Bouw, Delft, the Netherlands are gratefully acknowledged for their hospitality to Kristian Fog Nielsen, thereby giving him a broader perspective on his project.

The institute wants to thank the principal supervisor Ulf Thrane, associate professor, Ph.D. for the inspiring, valuable and always positive collaboration during the three years.

DANISH BUILDING AND URBAN RESEARCH

Division of Energy and Indoor Climate

June 2002

*Erik Christophersen*

Head of Division

# Mould growth on building materials

## Secondary metabolites, mycotoxins and biomarkers

The Mycology Group, Biocentrum-DTU  
Technical University of Denmark, Building 221  
Søltofts Plads, Building 221, DK-2800 Kgs. Lyngby, Denmark

Energy and Indoor Climate Division  
Danish Building Research Institute  
Dr. Neergaards Vej 15, DK-2970 Hørsholm, Denmark

### **Supervisors:**

Ulf Thrane, associate professor, Ph.D  
The Mycology Group, Biocentrum-DTU,  
Technical University of Denmark

Suzanne Gravesen, Senior Researcher  
Energy and Indoor Climate Division,  
Danish Building Research Institute

### **Examiners:**

Ib Søndergaard, associate professor, Ph.D  
Biocentrum-DTU, Technical University of Denmark

Brian Flannigan, Professor  
Napier University, Edinburgh, Scotland

Leon Brimer, associate professor, Ph.D  
Royal Veterinary and Agricultural University  
Frederiksberg, Denmark

This thesis was defended at 14 o'clock the 7. December 2001, in auditorium 51, building 208, Technical University of Denmark.

## AUTHOR'S PREFACE

More than seven ago years ago I was introduced to the fascinating world of fungi and mycotoxins by Ole Filtenborg and Thomas O. Larsen. The opportunity to work on my own with an array of sophisticated equipment, made me stay in the Mycology Group, and led to my M.Sc. project where Suzanne Gravesen and Thomas convinced me to work with *satratoxins in buildings*. Successfully ending this work, it resulted in my Ph.D. project financed by the Danish Building Research Institute where Erik Christophersen organised the funds for the project as well as the many travels.

However, it has also been frustrating to work in a field where you are unable to help people, often socially disadvantaged, who are forced to move from their mouldy homes due to massive symptoms, often victims of the ignorance of the authorities.

Working in such a multidisciplinary area requires help from a lot of people, and at the Danish Building Research Institute I would like to thank the librarians, especially Lillian Nielsen who have been a tremendous help in ordering scientific papers. Gunnar Holm has been a great help in constructing experimental set-ups, Lotte P. Uttrup and Per Hansen have prepared material samples, Jan Carl Westphall helped with various photographic problems, Yelva Jensen has been a good secretary, and Solveig Nissen with the language revision of some of the papers as well as this thesis. Peter A. Nielsen is acknowledged for the fruitful discussions on health and building related issues.

Jørgen Ø. Madsen, Department of Organic Chemistry, in preparing the 4-D<sub>2</sub>-ergosterol was a great help in making the ergosterol analytical method work.

The private consultants Mikael Ø. Hansen and Peter Thompson have kindly supplied me with "real" mouldy materials, interesting field observations, and taken their time to show me the real mouldy world outside the laboratories.

I would like to thank Dr. Aino Nevalainen, Dr. Maija-Riitta Hirvonen, and their helpful Ph.D. students for letting me work in their laboratories at the National Public Health Institute, Kuopio, Finland.

Working at TNO Bouw, The Netherlands, with Dr. Olaf Adan and Gerben van der Wel helped me understand the importance of instationary environmental conditions for mould growth.

Having Professor Bruce B. Jarvis in our group for a year raised the level of my work on *Stachybotrys* and natural products significantly and introduced me to a number of other research groups.

The help of colleagues in the Mycology group, in particular Elisabeth Krøger, Kir Lyhne, Flemming Lund, Thomas O. Larsen, Jørn Smedsgaard, Jens C. Frisvad and Birgitte Andersen has been encouraging. Ulf Thrane has been the perfect Ph.D. supervisor who always had time - if needed, and on the other hand never intervened much in my work.

Thanks to Suzanne Gravesen who believed so much in my work and have taught me so much about so many different things and introduced me to so many people as well as helping with the language revision of this report.

The support and understanding of my beloved wife Hanne - especially during my stays in Finland, Holland and various conference as well as the acceptance of the large piles of papers, CD, books etc. during my project cannot be overestimated.

Lyngby, June 2001

*Kristian Fog Nielsen*



## ABSTRACT

The aim of this study was to document if the moulds produce mycotoxins and other biologically active metabolites when growing in buildings, as well as investigate the influence of environmental conditions on the production of these metabolites. The growth of moulds under various humidities should also be investigated along with the use of chemical biomarkers for quantitation of mould growth.

It was shown that *Stachybotrys chartarum* produced a number of mycotoxins when growing in buildings. These components were produced in significantly higher quantities than by other moulds investigated in this study. Only 35% of the isolates from buildings produced the extremely cytotoxic satratoxins. Actually these metabolites are probably not responsible for idiopathic pulmonary hemosiderosis in infants, which is probably caused by other *S. chartarum* metabolites.

For the first time ever *Stachybotrys* metabolites were found in air-samples, where several classes of spiriocyclic drimanes and satratoxins were detected.

*Aspergillus versicolor* produced high quantities of the carcinogenic mycotoxin, sterigmatocystin at water activities ( $a_w$ ) > 0.95. At lower  $a_w$  more than 10 unknown metabolites were produced, including at least 5 metabolites also produced by *A. ochraceus*. *A. versicolor* was often growing in mixed cultures with others moulds where it sporulated poorly, meaning that it may evade detection based on cultivating methods. The *A. ustus* isolates from buildings were macro-morphologically and chemically very different from the cereal isolates, and should be described as a new species.

*Penicillium chrysogenum* produced few detectable metabolites and often none when growing on materials. Combined with the no observed effects on persons experimentally exposed to high quantities of the spores, these observations implies that this species may not be important and is actually obscuring the detection of more toxic genera and species. *P. brevicompactum* produced mycophenolic acid and *P. polonicum* the tremorgenic verrucosidin when they were inoculated on water-damaged materials.

*Chaetomium globosum* produced high quantities of chaetoglobosins whereas *Trichoderma* species did not produce detectable quantities of trichothecenes when growing on materials. Even on laboratory media <1% of the isolates produced trichodermol or esters of it.

Ergosterol content of building materials was quickly and precisely quantified by isotope dilution GC-MS/MS. Determination of ergosterol is only needed as a supplement for assessing mould growth on test materials, as visual assessment, especially supported by dissection microscopy generally was just as sensitive. The minimal RH for growth on wood based materials and material containing starch was just below 80% at room temperature, and increased to about 90% at 5°C. On paper-mineral composites such as gypsumboard the minimal RH was approx. 90% RH from room temperature to 5°C. Pure mineral based materials with few organic additives seem to be able to support growth at  $RH \geq 0.90$ , although  $\geq 95\%$  RH was needed to generate chemical detectable quantities of biomass.

The phylloplane *Cladosporium* was able to outgrow *P. chrysogenum* on materials under transient humidities. This is presumably why phylloplanes like *Cladosporium*, *Ulocladium*, *Phoma* and *Aureobasidium* are very common in bathrooms and other places with instationary humidity conditions.

Mould growth in buildings is causing various health effects among the occupants, however the causal components is still partly unknown making scientifically based guidelines for "how much is too much" and cost efficient remediation of mouldy buildings almost impossible.

## RESUME

Målet med dette studium var at dokumentere om skimmelsvampe producerer mykotoksiner og andre biologisk aktive stoffer, når de vokser på byggematerialer. Anvendelse af kemiske markører til kvantificering af den producerede biomasse skulle også undersøges sammen med svampenes vækst og metabolisme under forskellige temperatur- og fugtforhold.

*Stachybotrys chartarum* producerede en række mykotoksiner, når den voksede på byggematerialer. Mængderne af disse stoffer i svampepartiklerne, der blev frigjort ved en let vakuumpopsamling, var klart større end de mængder, der blev produceret af andre skimmelsvampe. Kun 35% af isolater fra vandskadede bygninger producerede de celledræbende satratoxiner, og inhalationen af netop disse synes næppe at være årsagen til lungeblødninger hos spædbørn; men kunne derimod skyldes andre stoffer fra *Stachybotrys*, eks. de spiriocykliske drimaner. For første gang blev *Stachybotrys* metabolitter fundet i luftprøver. Her blev flere typer af spiriocykliske drimaner samt satratoxiner påvist.

*Aspergillus versicolor* producerede meget store mængder af de kræftfremkaldende sterigmatocystiner når vandaktiviteten ( $a_w$ ) > 0.95, hvorimod den ved lavere  $a_w$  i stedet producerer mindst 10 ukendte metabolitter. Heraf er 5 tidligere set i kulturekstrakter fra *A. ochraceus*.

*A. versicolor* gror oftest i blandede kulturer med mange andre svampe, og da den sporulerer dårligt vil den oftest ikke blive påvist ved dyrkning på vækstmedier. *A. ustus* isolater fra bygninger var både kemisk og makro-morfologisk forskellige fra stammer isoleret fra korn og bør derfor beskrives som en ny art.

*Penicillium chrysogenum* producerer stort set ingen påviselige metabolitter, når den gror på byggematerialer. Sammenholdt med de ikke observerede effekter efter patienters eksponering for meget store mængder luftbårne sporer i et enkelt forsøg indikerer det, at den langtfra har det samme toksiske potentiale som *A. versicolor* og *S. chartarum*. I stedet forhindrer den påvisning af mere vigtige arter. *P. brevicompactum* producerede mycophenolsyre og *P. polonicum* det tremorgene verrucosidin, når de voksede på vandskadede materialer. Under samme forhold producerede *Chaetomium globosum* store mængder af de toksiske chaetoglobosiner, hvorimod *Trichoderma* spp. ikke producerede påviselige mængder trichothecener på materialer, og selv på laboratoriesubstrater producerede <1% af isolaterne trichodermol eller estre af denne.

Ergosterol-indholdet i materialer kunne hurtigt og præcist blive kvantificeret med isotop fortynding GC-MS/MS. Dette er kun nødvendigt som et supplement til bestemmelse af biomasse på testmaterialer, idet visuel bestemmelse kombineret med stereomikroskopi generelt er lige så følsomt. Den minimale relative fugtighed (RH) for at der kan opstå vækst af skimmelsvampe ligger lige under 80% ved stuetemperatur og stiger til ca. 90% RH ved 5°C. På gipsplader kræver skimmelsvampene ca. 90% RH for at kunne vokse. Beton med nogle organiske additiver kan tilsyneladende give anledning til meget minimal vækst ved RH > 90%, og ved RH > 95% kan der blive produceret ikke ubetydelige mængder biomasse på dette materiale. Den phylloplane *Cladosporium* kan udkonkurrere *P. chrysogenum* på materialer under transiente fugtforhold, og det er sandsynligvis årsagen til at phylloplaner som *Cladosporium*, *Ulocladium*, *Phoma* og *Aureobasidium* dominerer i badeværelser og andre steder, hvor der er skiftende fugtforhold.

Skimmelsvampevækst i bygninger er sundhedsskadeligt, med en del af de aktive stoffer og mekanismer en endnu ukendt. Derfor er det ikke muligt at fastsætte hygiejniske grænseværdier for skimmelsvampe i bygninger, ligesom det ikke endnu er muligt at renovere angrebne bygninger økonomisk effektivt, idet man ikke ved hvor langt man skal gå.

## ABBREVIATIONS AND TERMS

AFB <sub>1</sub>	Aflatoxin B <sub>1</sub>
ALK	Alkaloid forming agar
Antibiotic	Activity against microorganisms, usually against bacteria
a <sub>w</sub>	Water activity
CE	Capillary electrophoresis
CFU	Colony forming unit
Conidia	Asexual production structure from fungi /moulds.
CYA	Czapek yeast extract agar
DAD	Diode array detection
DAS	Diacetoxyscirpentriol, a type A trichothecene
DG18	Dichloran 18% glycerol agar
DON	Deoxynivalenol, a type B trichothecene
EI <sup>+</sup>	Positive ion, electron impact ionisation
ESI	Electrospray ionisation, method used extensively in LC-MS
FLD	Fluorescence detection
GC	Gas chromatography
HFB	Heptafluorobuturyl, derivative-group -CO-CF <sub>2</sub> -CF <sub>2</sub> -CF <sub>3</sub> .
HPLC	High performance liquid chromatography, also referred to as LC
IL-1	Interleukin 1, a cytokine
IL-6	Interleukin 6, a cytokine
IPH	Idiopathic pulmonary hemosiderosis
LC	Liquid chromatography
LC <sub>50</sub>	Concentration lethal to 50% of the test organisms
LD <sub>50</sub>	Dose lethal to 50% of the test organisms
MEA	Malt extract agar
MS	Mass spectrometry
MS/MS	Tandem mass spectrometry
MTR	Macrocyclic trichothecene
MVOC	Microbial volatile organic compound
MW	Molecular mass (Da)
NICI	Negative ion chemical ionisation
NIV	Nivalenol, a type B trichothecene
NO	Nitrogen oxide, as inflammatory mediator
OAT	Oatmeal agar
PCR	Polymerase chain reaction
PFP	Pentafluoropropionyl, derivative group, -CO-CF <sub>2</sub> -CF <sub>3</sub> .
PSA	Potato sucrose agar
RE	Roridin E, a macrocyclic trichothecene
RH	Relative humidity (%)
RI	Retention index
RT	Retention time
ROS	Reactive oxygen species
SG	Satratoxin G, a macrocyclic trichothecene
SH	Satratoxin H, a macrocyclic trichothecene
SPE	Solid phase extraction, chemical clean-up method

Spore	Reproductive structure of fungi/moulds and certain bacteria
ST	Sterigmatocystin
5ST	5-methoxysterigmatocystin
T-2	T-2 toxin, a type a trichothecene
TA	Type A trichothecene
TB	Type B trichothecene
TFA	Trifluoroacetic acid
TLC	Thin layer chromatography
TMS	Trimethylsilyl, derivative group, $-\text{Si}(\text{CH}_3)_3$
TNF $\alpha$	Tumor necrosis factor $\alpha$ , a cytokine
TR	Trichothecene
V8	V8 juice agar
VB	Verrucarin B, a macrocyclic trichothecene
VJ	Verrucarin J, a macrocyclic trichothecene
Water-damaged	Floating water present, $a_w \approx 1$
WP	Wallpaper
YES	Yeast extract sucrose agar

# PAPERS PREPARED IN CONNECTION WITH THIS THESIS

1. Nielsen KF, Hansen MØ, Larsen TO, Thrane U. 1998. Production of trichothecene mycotoxins on water damaged gypsum boards in Danish buildings. *International Biodeterioration & Biodegradation* 42:1-7.
2. Nielsen KF, Thrane U, Larsen TO, Nielsen PA, Gravesen S. 1998. Production of mycotoxins on artificially inoculated building materials. *International Biodeterioration & Biodegradation* 42:8-17.
3. Nielsen, KF, Gravesen S, Nielsen PA, Andersen B, Thrane, Frisvad JC. 1999. Production of mycotoxins on artificially and naturally infested building materials. *Mycopathologia* 145:43-56.
4. Gravesen S, Nielsen PA, Iversen R, Nielsen KF. 1999. Microfungal contamination of damp buildings - examples of risk constructions and risk materials. *Environmental Health Perspectives* 107, Supplement 3:505-508.
5. Nielsen, KF, Madsen JØ. 2000. Determination of ergosterol on mouldy building materials using isotope dilution and gas chromatography - tandem mass spectrometry. *Journal of Chromatography A* 898: 227-234.
6. Andersen B, Nielsen, KF, Jarvis BB. Characterization of *Stachybotrys* from water-damaged buildings based on morphology, growth and metabolite production. *Mycologia* (Accepted for publication).
7. Peltola J, Niessen L, Nielsen KF, Jarvis BB, Salkinoja-Salonen M, Möller E. Genetic diversity of *Stachybotrys chartarum* and relatedness to toxicity (submitted).
8. Nielsen KF, Huttunen K, Andersen B, Jarvis BB, Hyvärinen A, Hirvonen M-R. Relationship between metabolite profiles of *Stachybotrys* isolates from water-damaged buildings and their induction of inflammatory mediators and cytotoxicity in macrophages (submitted).
9. Nielsen KF, Huttunen K, Andersen B, Jarvis BB, Hyvärinen A, Hirvonen M-R. 2002. Relationship between metabolite profiles of *Stachybotrys* isolates from water-damaged buildings and their induction of inflammatory mediators and cytotoxicity in macrophages. *Mycopathologia* (in press).
10. Nielsen, KF, Nielsen PA, Holm G, Uttrup LP. Mould growth and metabolism on building materials under different humidities and temperatures (Submitted).
11. Wilkins KC, Nielsen KF, Din SL. 2002. Patterns of volatile metabolites and trichothecenes produced by *Stachybotrys* and other trichothecene producing molds. *Environmental Science & Pollution Research* (in press).
12. Reelsev M, Miller M, Nielsen, KF. Quantifying mold biomass on building materials: A comparison of ergosterol and MycoMeter-test (submitted).
13. van der Wel GK, Nielsen KF, Adan O. Mould growth and metabolism on building materials under constant and transient humidities. (in prep, crude draft)

Appendix A lists the conference proceedings and non peer-reviewed publications prepared during this Ph.D. thesis.



# 1 INTRODUCTION

During the last 10 years several studies have shown that people living and working in damp or mouldy buildings have an increased risk of airways infections, adverse health effects, respiratory problems such as asthma, and CNS symptoms<sup>1-9</sup>. However concern of mould growth in buildings is not a new problem, already in the Bible (Leviticus Chapter 14, 33-48) it is written that contaminated spots on walls should be removed, and if consistently reappearing the house should be torn down.

The estimated proportion of dwellings with microfungus problems in Northern Europe and North America is perhaps as high as 20-40% based on data from the United Kingdom with 30-45%<sup>1,10</sup>, the Netherlands with 20-25%<sup>6,11,12</sup>, Finland with 20-30%<sup>9,13</sup>, USA with up to 40%<sup>2</sup> and Canada with up to 30%<sup>3</sup> buildings affected. No data exist for dwellings in Denmark, but the majority of schools and day-care centres build in the late 1960s and 1970s seem to have problems.

Mould growth only occurs in water-damaged and humid constructions. Consequently the major part of the problems in Scandinavia and North America are due to poorly manufactured constructions and inadequate maintenance<sup>14-16</sup>.

The health problems observed in mouldy or damp buildings can be grouped into three major categories as seen in Table 1.

Table 1 Health problems associated with mouldy and damp buildings		
General symptoms incl. CNS-symptoms	Mucosal symptoms	Lung symptoms
<ul style="list-style-type: none"> <li>• Extreme fatigue<sup>7,8,17-20</sup>.</li> <li>• Lack of concentration and memory<sup>7,8,17-20</sup>, in extreme cases as cognitive impairment<sup>21</sup>.</li> <li>• Nausea<sup>1,7,8,17,18</sup></li> <li>• Lowered immune function due to a misbalance in the lymphocytes sub-populations or chronic stimulation of some of the these<sup>22,23</sup>.</li> </ul>	<ul style="list-style-type: none"> <li>• Blocked nose<sup>1,5,12,19</sup></li> <li>• Itching eyes<sup>19,24,25</sup></li> <li>• Burning sensation of the skin<sup>7,8,17,18,24,25</sup></li> <li>• Hoarseness<sup>1,7,8,17,18</sup></li> <li>• Recurrent airway infections, especially sinusitis<sup>7,8,17,18,24,25</sup>.</li> </ul>	<ul style="list-style-type: none"> <li>• Wheeze<sup>1,2,4</sup></li> <li>• Cough<sup>2,3,5,6,8,12</sup></li> <li>• Bronchitis<sup>2,3</sup></li> <li>• Asthma<sup>2,4,6,8</sup></li> <li>• Pulmonary hemosiderosis in infants<sup>26-28</sup>.</li> </ul>

To cope effectively with the health problems it is essential to identify the causative agents and the cellular mechanisms as it would lead to:

- Clinically valid analyses documenting the patients' complaints.
- Targeted analysis of causative compounds in buildings suspected of having mould problems
- Consent guidelines for "how much is too much".
- Economically sound cleaning procedures.

However, very little knowledge have been established on peoples' specific exposures and the non-immunologic mechanisms, especially toxic reactions, after exposure to moulds<sup>8,29,30</sup>. Non-immune mediated chronic activation of immune competent cells<sup>22,30,31</sup> have been suggested as the major mechanisms.

From the agricultural occupational environment exposure-effect data exist. Here inhalation of fungal spores have been shown to cause cancer<sup>32,33</sup>, premature birth<sup>34</sup> and farmers lung<sup>25</sup>. However the levels of spores and metabolites are magnitudes higher than in indoor air<sup>35</sup>.



A number of potentially causative agents produced by moulds in the water-damaged buildings have been suggested:

- **Proteins** causing the well-known immediate allergic reactions within minutes of exposure (Type I allergy)<sup>24,25,36</sup> and in rare incidences type III allergy<sup>25</sup>.
- **$\beta$ -(1,3)-d-glucans** triggering inflammatory reactions very similar to symptoms observed on exposure to endotoxin<sup>37-39</sup>.
- **Microbial volatile organic compounds (MVOC)** released from the fungi during growth<sup>40-43</sup>.
- **Mycotoxins** released from fungal spores and fragments after inhalation<sup>19,40,44-49</sup>.

Compounds from other organisms associated with moulds such as mites<sup>6</sup> and bacteria<sup>50-53</sup> should also be considered as they may play an important role in the ecosystem of the infested materials. Additional bacteria growing on building materials also produces a number of very potent bacterial toxins<sup>54</sup>.

The work carried out during the study and this report, focused on the secondary metabolites and mycotoxins produced by moulds during growth on building materials, as these metabolites are potential risk factors for the adverse health effects observed in mouldy buildings.

Consequently, a major part of the following literature review will focus on fungal growth on materials and the different metabolites produced by moulds during their growth in buildings.

## 2 MOULDS IN BUILDINGS

Viable mould spores and bacteria are ubiquitous in buildings<sup>10,55</sup> and are well adapted to inhabit this ecological niche if just sufficient water is available<sup>10,55-57</sup>.

The moulds growing on a particular material are referred to as the *associated funga*<sup>58</sup>, and have been divided into three groups by Grand et al<sup>55</sup> following their water requirements on laboratory substrates:

- **Primary colonisers** capable of growth below a water activity ( $a_w$ ) of 0.8 including species of *Wallemia*, *Penicillium*, *Aspergillus* and *Eurotium*<sup>59</sup>.
- **Secondary colonisers**, with a minimal  $a_w$  between 0.8 and 0.9 including species of the phylloplanes: *Cladosporium*, *Phoma*, *Ulocladium* and *Alternaria*.
- **Tertiary colonisers**, demanding  $a_w$  of at least 0.9, including genera such as: *Stachybotrys*, *Chaetomium*, *Trichoderma*, *Aureobasidium*<sup>40,60</sup> as well as actinomycetes and other bacteria<sup>57,61</sup>. These conditions are generally only met by incoming water and not just high humidity or condensation on indoor surfaces<sup>25,55</sup>.

### 2.1.1 The building associated funga

The associated funga reported from different countries varies considerable for a number of reasons, such as different climates, materials, different isolation procedures and difficulties in identifying the isolates to species level especially in *Penicillium*, *Aspergillus* and *Cladosporium*<sup>59,62-64</sup>. In Table 2, the most common fungal species isolated in buildings have been compiled.

In Europe, *P. chrysogenum* is the most abundant<sup>59,63,65</sup>, whereas it seems to be *Penicillium aurantiogriseum* and *P. viridicatum* in North America. However, this is probably due to misidentification with other species from the *P. aurantiogriseum* complex.

For the genus *Aspergillus* consensus seems to exist with *A. versicolor* being the absolutely most frequently isolated species, followed by *A. sydowii* and *A. ustus*<sup>63,64</sup>.

Table 2			
The most common part of the building associated funga*			
Genus	Species	Natural habitat	Common on
<b>Water damage moulds</b>			
<i>Chaetomium</i>	<i>globosum</i>	Soil, straw, wood	Mostly on wood and cellulose containing materials
<i>Stachybotrys</i>	<i>chartarum</i>	Hay and straw <sup>66</sup> , paper, soil	Gypsum boards, pipe insulation
<i>Ulocladium</i>	<i>chartarum</i> and <i>atrum</i>	Soil, dung, grasses	Wood, wallpaper, gypsum boards
<i>Trichoderma</i>	<i>harzianum</i> , <i>citrinoviride</i> , <i>atroviride</i> and <i>longibrachiatum</i>	Wet wood, soil	Mostly on wood
<i>Alternaria</i>	<i>tenuissima</i>	Saprophyte on plants, foods Cereals, leaves	Wallpaper, gypsum
<i>Aureobasidium</i>	<i>pullulans</i>	Soil, leaves, cereals	Paint especially in bathrooms, window frames, paint
<i>Rhodulotorula</i>	<i>rubra</i>		Paints, wood
<i>Phoma</i>	<i>sp.</i>	Plant material, soil,	Paints, wood, wall papers, caulking, especially in bathrooms
<b>High relative humidity moulds</b>			

<b>Table 2</b>			
The most common part of the building associated funga*			
Genus	Species	Natural habitat	Common on
<i>Aspergillus</i>	<i>versicolor</i>	Cheese, cereals, spices, dried meat products	Most materials, primary coloniser, grows in dust
<i>Penicillium</i>	<i>chrysogenum</i>	Various foods, spices, dry cereals	All materials
<i>Penicillium</i>	<i>brevicompactum</i>	Soil, nuts, fruits and juices	Especially wooden materials
<i>Penicillium</i>	<i>corylophilum</i>	Various foods	Most materials, primary coloniser
<i>Aspergillus</i>	<i>Sydowii</i>	Soil, cotton, beans, nuts and straw	Most materials, primary coloniser
<i>Aspergillus</i>	<i>ustus</i>	Soil, cereals, groundnuts	
<i>Cladosporium</i>	<i>sphaerospermum</i>	Dead plants	Paints, wood, wall papers, caulking, especially in bathrooms
<i>Cladosporium</i>	<i>herbarum</i>	Dead plans, stored fruits	Paints, wood, wall papers, caulking, especially in bathrooms
<i>Penicillium</i>	<i>palitans</i>	Cheese, wood	Most materials, but especially wooden
<i>Eurotium</i>	<i>repens</i>	Cakes, dried food, cereals	
<i>Wallemia</i>	<i>sebi</i>	Dried foods, jam, cakes, dates, salted fish, sugar, chocolate	
<i>Paecilomyces</i>	<i>variotii</i>	Compost	
<i>Penicillium</i>	<i>polonicum</i>	Cereals, meat products	
<i>Aspergillus</i>	<i>niger</i>	Dried food, spices	
<i>Penicillium</i>	<i>expansum</i>	Nuts, fruits (apples)	Wood

\*References<sup>14,16,40,49,59,63,65,67,67-72</sup>

When measuring viable fungi, as colony-forming units (CFU), the laboratory media will always favour certain genera and species<sup>65</sup>, thus several media are needed for covering the majority of the building associated funga. Dichloran 18% glycerol agar (DG18) is generally considered the best media for xerophilic fungi (moulds who can grow  $a_w < 0.85$ <sup>73</sup>), and low nutrient high  $a_w$  media as V8 juice agar (V8), malt extract agar (MEA) or rose Bengal agar<sup>74-76</sup> for the secondary and tertiary colonisers<sup>77</sup>. However MEA can be supplemented with cellulose agar to enhance detection of *Stachybotrys* who have difficulties competing with species of *Aspergillus* and *Penicillium* as well as having many sterile spores<sup>49,78</sup>.

### 2.1.1.1 Air measurements

For investigating moulds associated health problems, air measurements would provide the best exposure data. However, as the causal agents have not been identified, it has not been established what should actually be measured. Four main techniques are used for air measurements: i) cultivation of viable spores; ii) collecting spores and counting them microscopically<sup>79</sup>; iii) detecting chemical markers<sup>80,81</sup>; iv) using different molecular-biological (DNA) techniques<sup>82</sup>. In sections 2.5 and 2.6.3 measurements of biomarkers, including mycotoxins, will be dealt with in detail.

A major problem with cultivating techniques is that a major part of the spores may not be viable<sup>83</sup>. In addition, hyphal and spore fragments are also released from the mouldy materials<sup>84</sup>. Aggressive air sampling methods are generally preferred over sedimentation plates which are unreliable<sup>40,59,77</sup>.

Even in rooms with visible mould growth aggressive sampling may give low counts<sup>85-87</sup> although other authors have found clear relationships<sup>10</sup>. Especially if the ratio between outdoors and indoors is used and speciation of the collected moulds is performed, a clear relationship between infested areas and air measurements can be found<sup>14</sup>. Determining the ratio

of *Penicillium* and *Aspergillus* versus outdoors phylloplane moulds as *Cladosporium* and *Alternaria* has been successful for indicating a humid environment<sup>40,87,88</sup>.

A totally different and very elegant approach, is to measure the personal exposure and response by determining inflammatory mediators, such as IL-1, IL-6, TNF $\alpha$ , NO, eosinophil cationic protein and myeloperoxidase in nasal lavage fluid<sup>89-91</sup>.

Nevertheless interpretation and knowledge of the limitations of the different techniques is crucial<sup>78</sup> and generally no single method will provide the full picture of mould exposure and presence in a building<sup>69</sup>.

## 2.2 Growth of moulds on building materials

Moulds can grow on laboratory media at temperatures as low as -7°C<sup>92</sup> and some wood associated cladosporia and penicillia are able to grow at temperatures as low as -5°C on wood, but seem to require at least 0°C to germinate<sup>93</sup>. In comparison *Aspergillus restrictus*<sup>94</sup> requires 9°C, and *A. versicolor* 4°C<sup>25</sup> for growth on a high nutrient substrate such as MEA, indicating that temperature cannot be used to avoid fungal growth in buildings.

The associated fungi is also selected by  $a_w$ , light<sup>92</sup> and especially the composition of the material, including organic carbon, pH, nutrients like trace metals, nitrogen, phosphorus and sulphur<sup>10,56,57,92,95,96</sup>, consequently the most important of these factors will be reviewed in the next subchapters.

### 2.2.1 "Water - the key factor"<sup>11</sup>

This is undoubtedly the most important factor for determining if mould growth will start in a building<sup>11</sup>. Most of the moulds have their optimal  $a_w$  at 0.96-0.98 even though some are able to grow at much lower  $a_w$ <sup>11,95,97</sup>. Some xerophilic fungi like *Eurotium* spp. and *Wallemia* will not grow at such high  $a_w$ <sup>65,73</sup>.

The germination process requires a slightly (approx. 0.02) higher  $a_w$  than the critical  $a_w$  for growth<sup>57,94,98-101</sup>, older spores also require longer time to germinate<sup>99</sup>.

In Table 3, data on the minimal  $a_w$  for growth on food products and agar media have been compiled. On agar media the  $a_w$  was usually regulated by adding glycerol or occasionally sugars to the media.

Medium	<i>Aspergillus versicolor</i>	<i>Eurotium</i> spp.	<i>Penicillium</i> spp.	<i>Cladosporium</i> spp.	<i>Rhodotorula</i> spp.	<i>Alternaria</i> spp.	<i>Stachybotrys chartarum</i>
Food products <sup>73</sup>	0.78	0.70-0.72	0.78-0.84				
MEA <sup>94</sup>		0.71	0.74				
MEA <sup>99</sup>			0.81				
MEA <sup>100</sup>		0.71	0.79-0.82				0.94
MEA <sup>102</sup>				0.81		0.85	
Different agars <sup>56</sup>	0.80	0.70	0.80				
MEA <sup>94</sup>	0.74	0.71					
MEA <sup>103</sup>	0.81	0.76	0.82	0.85	0.92	0.89	0.95
DRBC* <sup>103</sup>	0.81	0.77	0.83	0.86	0.93	0.89	0.95

\* Dichloran Rose Bengal chloramphenicol agar.

Table 4 compiles data on selected mould growth on different building related materials, as the minimal  $a_w$  on these are higher than on the more nutrient rich agar substrates.

Medium	<i>Aspergillus versicolor</i>	<i>Eurotium</i> spp.	<i>Penicillium</i> spp.	<i>Trichoderma</i> spp.	<i>Cladosporium</i> spp.	<i>Rhodotorula</i> spp.	<i>Alternaria</i> spp.	<i>Stachybotrys chartarum</i>
Ceiling tile <sup>104</sup>			0.85-0.90					
Fibre glass <sup>104</sup>			0.85-0.90					
Wood chip paper, 25°C <sup>55</sup>	0.84		0.84-0.89		0.96			no growth
Viscose <sup>105</sup>	0.80	0.80	0.80-0.85	0.85-0.90	0.90			0.90
Woodchip paper, at 12°C <sup>55</sup>	0.91		0.91-0.87		0.97			no growth
Painted woodchip paper, 25°C <sup>55</sup>	0.79		0.84		0.93			0.97
Painted woodchip paper at 12°C <sup>55</sup>	0.87		0.87		0.87-0.91			0.96
Fibre glass earth cont. <sup>106</sup>	0.69-0.72		0.53-0.60		0.85-0.87			
Fibre glass <sup>106</sup>	0.85-0.87				0.96-0.98			
Wallpaper and paper <sup>107</sup>								0.78-0.81
Gypsum <sup>107</sup>								0.84-0.89
Cellulose filter <sup>108</sup>								0.84-0.89
Woodchip wallpaper <sup>103</sup>	0.85	0.77	0.86		0.89	0.93	0.90	0.97

Table 5 shows data on building materials, where the moulds were applied as a mixture, the natural contamination was used or where moulds growing were not identified, often referred to as mildew.

Medium	Mixture
Pinewood, planned <sup>109</sup>	0.80
Painted wood <sup>109</sup>	0.80
Hardened paint <sup>109</sup>	No growth
Distempered wood <sup>109</sup>	0.80
Brick <sup>109</sup>	0.88
Cement rendered brick <sup>109</sup>	0.80 (but almost no growth)
OSB, MDF, Particle board, Fibre board, wood <sup>110</sup>	Growth at 0.70 (after 8 weeks)
Glass wool and cotton <sup>111</sup>	0.92-0.96
Cotton fabrics <sup>112</sup>	0.70
Wood and wool <sup>111</sup>	0.85
Leather <sup>111</sup>	0.76
Different wood <sup>113</sup>	0.80, 0.90 when temp < 5°C
White brick <sup>109,109</sup>	0.80

It is clear from Tables 4 and 5 that no consensus exists on the minimal  $a_w$  for fungal growth on materials. It is however generally known that the humidity calibrations in many studies are not correct<sup>11</sup>. Hence studies are needed with more precisely controlled humidity and other environmental conditions.

### 2.2.1.1 Humidity - some definitions

The water activity is called equilibrated relative humidity in some papers<sup>103</sup> and is the same as the RH/100 (at steady state).  $A_w$  is considered a better descriptor of available water<sup>57,114</sup> than the absolute water contents in the material<sup>56,57,105</sup>. This is perhaps seen more clearly when the  $a_w$  relation to the *osmotic pressure* is shown<sup>56,57,114</sup>, as it is the difference between this pressure and the osmotic pressure in their own cytoplasm the moulds have to maintain:

$$\text{Osmotic pressure} = \frac{-R \times T \times \ln(a_w)}{V}$$

Where  $T$  is the absolute temperature,  $R$  the gas constant, and  $V$  the partial molal volume of water.




Figure 5. Relations between air temperature, relative humidity and absolute humidity.

Large local differences in ventilation and surface temperatures, especially on thermal bridges, can generate *micro climates* with very high  $a_w$ , even in rooms with low RH. This is due to the large temperature dependency of RH and the water contents of air as illustrated in Figure 1. For example, if the indoor air temperature is 22°C and the RH is 50%. The RH at a cold wall of 15°C can be estimated to about 80% RH, which is at the RH point where moulds starts to grow.

Precise measurements of the humidity in materials and the air is difficult especially at RH > 90%. Especially if the measurements are calibrated against sulfuric acid it gives inaccurate determinations<sup>11,57</sup>.

### 2.2.1.2 Transient conditions

Physical parameters including humidity and temperature are not constant in buildings, and greatly influence the mould growth<sup>11,115-117</sup>. A bathroom is one of the extreme examples of this, and in this environment the funga is different than in environments with more constant environmental conditions<sup>65,118</sup> as it is being dominated by phylloplane fungi such as *Phoma*, *Aureobasidium*, and *Cladosporium*. This field observation is explained by data of Park<sup>119</sup> who showed that after drying for one week, phylloplane fungi were able to re-attain growth from the hyphal tip within 60 min, whereas storage moulds (*Penicillium* spp.) and soil fungi (*Fusarium* spp., *Verticillium*, and *Trichoderma*) needed 1-2 days, meaning that the phylloplanes can cope with a few hours of humid environment in the bathroom.

Adan<sup>11</sup>, who worked with mould growth on plaster and painted materials, introduced the term *Time-of-wetness* (TOW) defined as the ratio between the wet period (RH ≥ 80%) and the total period, and the term  $f$ , for the number of cycles per day. It was shown that using air dryer than 65% during the dry period did not affect the growth, and that growth increased slowly with TOW from TOW=0.17 to 0.5, with a dramatic increase of higher TOWs. The parameter  $f$  had only very limited effect on growth, unless very high values were used ( $f > 4$ ). Viitanen<sup>116,120</sup> also showed that when short time fluctuations were applied (0.25 days) the growth occurred more slowly compared with longer periods (1, 2, 7 and 14 days).

## 2.2.2 The impact of the material on the mould growth

Moulds are able to degrade almost all natural and many man made materials<sup>25,65</sup>, especially if they are hygroscopic<sup>11,111</sup>. Even totally inorganic materials will still get mouldy as they over time absorb dust which is a good medium for especially *A. fumigatus*<sup>25</sup> and *A. versicolor*<sup>121,122</sup>.

Wood is still one of the most commonly used materials, and is highly susceptible to mould growth<sup>116,123,124</sup>. It may become infested with *Cladosporium*, *P. brevicompactum* and *P. expansum*, already at the sawmill<sup>93</sup>. Kiln drying makes the surface of the wood more susceptible to mould growth<sup>116,120</sup>, as the surface will get a higher content of nitrogen and low molecular carbohydrates<sup>125</sup>. A number of modified wood materials are commonly used, and materials such as OSB, plywood and MDF are more susceptible to growth of *Aspergillus*, *Trichoderma* and *Penicillium* than solid wood, particleboard<sup>110</sup>, acylated wood<sup>126</sup> and wood-polyethylene composites<sup>127</sup>.

Prefabricated gypsum board is the most commonly used inner-wall material in new Danish buildings. However due to the paper, used to reinforce the material, the boards are highly susceptible to growth of moulds especially the cellulytic *S. chartarum*<sup>14,25,72,107,128</sup>. The gypsum itself (used to plaster walls) can also support fungal growth and the susceptibility is then correlated to the relative nutrient content of gypsum<sup>11</sup> and additives who make it more hygroscopic at lower humidities<sup>129</sup>.

Many indoor surfaces are wallpapered and this increases the susceptibility of the walls, as paper and the glue are very good media for most indoor moulds<sup>55,64,72</sup>.

Plastic materials are being increasingly used, and polyethylene and PVC are vulnerable to mould growth, as the moulds utilise most plasticizers<sup>130</sup>. Already in 1957, Berk, et al<sup>131</sup> showed that 90 of 127 different plasticizers could be degraded by moulds commonly found on indoor surfaces. Even fibre glass insulation<sup>106,132</sup> and fibre glass ceiling tiles (10% urea phenol-formaldehyde resin)<sup>104</sup> support fungal growth of especially *A. versicolor* and *Penicillium* sp. Polyurethanes has been used in many composites as well as insulation materials, and some of them are highly susceptible to mould attack<sup>133</sup> and they should be routinely tested for microbial degradation. Especially *Paecilomyces variotii*, *T. harzianum*, and *Penicillium* spp. are frequently growing on urea-formaldehyde foam insulation materials<sup>72</sup>.

Paints can both increase and decrease the susceptibility of a given base material. Waterborne paints, which are the most commonly used in Europe due to occupational health problems with organic solvents, are highly susceptible to mould growth and should be routinely tested<sup>11,134</sup>. However the base material for paint is also important for the mould growth<sup>11,55</sup>. *Aureobasidium pullulans* is the absolutely most common mould on paints which it deteriorates in contrast to *Penicillium* and *Aspergillus* species which grow superficially on the paints<sup>135</sup>. Actually *A. pullulans* is often succeeding *Aspergillus*, *Alternaria* and *Cladosporium* on acrylic paints<sup>136</sup>.

Mould growth in air filters<sup>137</sup> and in ventilation ducts<sup>138</sup> is of special concern, as the ventilation system will act as an effective carrier of the spores. In the ventilation ducts growth generally occurs on painted surfaces and especially in dust<sup>139</sup>, although certain fibre glass insulation materials may support growth<sup>16,140</sup>.

## 2.2.3 Modelling mould growth on materials

Validated models which can predict fungal growth under different environmental conditions on building materials are extremely important as they can be interfaced with many of the

current PC programs which can model humidity conditions on materials, and simulate real buildings. However only a very few models for growth on materials have been published:

- Rowan<sup>103</sup> predicted RH limit for growth of *S. chartarum*, *A. versicolor* and *Eurotium herbariorum*, as a function of temperature (3rd order polynomial), and interfaced this simple model for transient temperature and humidity conditions in buildings.
- Hukka & Viitanen<sup>141</sup> have an almost identical model, and have improved it<sup>120,141</sup> to include also growth under transient temperature and humidity conditions.

However, none of these models have been validated on a large number of real buildings with and without mould problems, which is the only way to validate these models.

Adan<sup>11</sup> have developed several models for comparing the susceptibility with building materials to both constant and transient humidity conditions. These are however more sophisticated and they are based on a non-linear logistic model, which is able to cope with the non-linear, 6-point scale, used to compare the susceptibility of different materials.

## **2.3 Health problems associated with airborne moulds**

A number of different approaches exist for studying the health effects associated with mouldy buildings. The two major approaches are: i) comparing the toxicity or biological activity, based on in vitro and in vivo data, with the actual exposures in the buildings; ii) epidemiological studies where symptoms in a large population are correlated to exposure in normal and mouldy buildings.

In the first studies of health problems related to mouldy buildings it was believed that people were type I allergic<sup>25,142</sup>, meaning that IgE antibodies are formed against specific proteins, called allergens, from the fungal spores<sup>25</sup>. Type I allergy can be precisely diagnosed by the classic skin prick testing (SPT) or in serum if extracts of the appropriate allergens exist<sup>25</sup>. SPT panels and antibody-allergen-kits for the outdoor air moulds, *Alternaria* and *Cladosporium*, as well as some penicillia and aspergilli have been commercially available for a number of years, but are not available for many of the building associated moulds. Allergic persons are often genetically predisposed<sup>25</sup> and may develop asthma due to inflammation of the lung as a results of large quantities of inflammatory mediators released from the different lung granulocytes. However, as type I allergy is not the main cause of the health problems observed in mouldy buildings<sup>22,30</sup>, the use of SPT or specific IgE in serum has a very limited diagnostic value when working with mouldy buildings.

A number of other types of antibodies, including the IgG antibodies, are naturally produced against most "non-self" proteins and help clearing these from the body. Detection of specific IgG antibodies against these "non-self" proteins can hence be used do determine if a person have actually been exposed to a specific mould. However only positive results can be used, as not all people will develop detectable quantities of IgG antibodies<sup>23</sup>.

High exposures to protein dust may result in such high levels of antigen-antibody complexes, in the blood vessels, that these are deposited in such quantities that they may trigger an immune response (allergic alvolistis / hypersensitivity pneumonitis) seen as malaise, elevated temperature, pains in joints and even asthma<sup>25,143</sup>.

### **2.3.1 In vivo and in vitro effect of fungal spores**

As earlier mentioned, the vehicle for exposure to mycotoxins in the indoor environment seems to be the fungal spores<sup>46</sup> and fragments of these and the mycelia<sup>84</sup>. Hence, studies of



the effects of whole spores are important as they contain the whole "mixture" of metabolites and structural components as well as the particle effect of the spores<sup>144</sup>.

An interesting study showed that rats exposed to naturally released spores of *A. versicolor* (up to  $10 \times 10^6$  CFU/m<sup>3</sup>) originating from growth on the walls, during one month developed severe lung damages including granulomatous lesions, partly due to high production of IL-1 from the macrophages<sup>145</sup>.

Instillation of *P. chrysogenum* spores in mice<sup>146</sup> revealed similar results, and in addition showed that  $10^4$  spores instilled twice a week increased total IgE in serum and IL-4 in the lung bronchoalveolar lavage, interestingly this was not seen when the spores were treated with methanol to kill them or extract metabolites.

Shahan et al<sup>147</sup> showed that spores from different fungal species induced very different responses in rat macrophages, measured as mRNA induction of TNF $\alpha$  and other inflammatory mediators. Spores from *A. terreus* and *P. spinulosum* did not stimulate any inflammatory response, in contrast to *A. fumigatus*, *A. candidus*, *A. niger*, *Eurotium amstelodami*, and *C. cladosporioides* which stimulated production of several inflammatory mediators.

Ruotsalainen<sup>148</sup> showed that *Stachybotrys* isolates (21 different) induced either strong inflammation, by releasing NO, TNF $\alpha$ , IL-6 and reactive oxygen species (ROS), or cytotoxicity (induced by satratoxins producing isolates) in macrophages. *In vitro* studies with instilled *Stachybotrys* spores in mice have showed similar results<sup>45,45</sup> and will be dealt with in details in section 2.4.1.

The cytotoxicity of *Penicillium* and *Aspergillus* isolates from damp buildings in Scotland cultured on MEA was studied at it was found that about 50% of the investigated isolates were cytotoxic to the fibroblasts<sup>149,150</sup>. Such cytotoxicity may cause severe lung damage, especially if the fibroblasts and perhaps also macrophages die by necrosis, as the latter subsequently will liberate high quantities of inflammatory mediators.

However there seems to be many different mechanisms associated with the effects in cell cultures, especially when both cytotoxicity and inflammatory potential are tested simultaneously<sup>151</sup>. Generally many mould spores will kill macrophages before they are able to respond with an inflammatory response.

These studies indicate that the lung damage induced by fungal spores may be partly or fully due to the inflammation induced by the macrophages as it has been shown that excess induction of some cytokines, NO and ROS may play an important role in the pathogenesis of inflammatory diseases such as asthma<sup>152-154</sup>. It is also notable, that isolates/species specific metabolites are involved. However, except for the first, they have all used spores from agar culture, which is seriously biased as moulds usually produces much higher quantities of metabolites on these media<sup>64</sup>.

Literature on *in vitro* and *in vivo* studies of specific metabolites will be found in respective mould species in section 2.4.

## 2.3.2 Epidemiological studies

Epidemiological studies have been widely used to study health effects in mouldy buildings<sup>6,9,155</sup>, especially combined with questionnaires to determine symptoms and/or if the home or workplace has been damp or mouldy. However several studies have concluded that objective measures are needed to obtain statistically significant results<sup>6,30,86,88</sup>.

A large number of studies on general health problems and the association dampness and mould growth have been published (see Table 1, p. 1), however reviewing these is outside

the scope of this work, and only case studies of specific moulds will be further dealt with, as they may be correlated to specific fungal metabolites.

Johanning et al<sup>23,156</sup> studied an office building heavily infested with *S. chartarum*. Only two persons were IgE positive to *S. chartarum*, these persons worked in the same area and some had abnormal complement function and composition of T and B lymphocytes, CD3<sup>+</sup> T cell (CD3 is a protein found on both T<sub>cytotoxic</sub> and T<sub>helper</sub> cells<sup>143</sup>) concentrations were lower among the employees than among controls. IgG measurements showed only small differences between exposed and non-exposed employees and were not significantly correlated with symptoms. In later papers<sup>20,157</sup>, they reported several more cases from the clinic with corresponding surveys of their homes for mould occurrence. Specific IgG antibodies could only be used as exposure markers but was only positive in 25% of the cases of actual exposure.

In a 10 years old building with severe water damages Hodgson et al<sup>19</sup> found that the occupants had significantly more pulmonary problems, as eye irritations, stuffy nose, and especially flue like symptoms, than normal. Air samples in one of the rooms revealed up to 8000 CFU/m<sup>3</sup> of especially *A. versicolor*, and in an other room up to 129 CFU/m<sup>3</sup> but with up to 50% of the colonies being *S. chartarum*.

### 2.3.2.1 Idiopathic pulmonary hemosiderosis cases

A dramatic escalation in the symptoms observed in mouldy buildings has been reported from the Cleveland, Ohio, area<sup>158,159</sup>. Here idiopathic pulmonary hemosiderosis (IPH) in infants (< 6 months old) was associated with growth of *S. chartarum* in the homes. It should be noted that IPH is extremely rare in infants, with a general prevalence of 0.2-1.2 per 10<sup>6</sup> children per year in the Western world<sup>160</sup>. Reports of such life threatening conditions including fatal cases have great legal implications, especially in the USA, as well as economic importance for the rest of the world as it could lead to guidelines not accepting growth of *S. chartarum* in buildings.

The first 10 IPH cases from Cleveland were reported in December 1994 by the US CDC<sup>161</sup> however with no plausible reason. Later CDC reported additional 27 cases from Cleveland<sup>158,159</sup>, and at this time it was concluded that IPH was associated with growth of *S. chartarum*. Additional 7-9 cases were identified in Chicago<sup>162</sup> and 6 from Detroit<sup>163</sup>, however no mould investigation of the houses has been published.

An overview of the IPH cases in USA has been made by Dearborn et al<sup>26</sup>, who found 138 IPH cases in USA the period 1993-1995, and that the IPH incident rate in Cleveland was 1.5 IPH per 10<sup>3</sup> infants per year in the period. The association between IPH and *Stachybotrys* exposure has been questioned by the CDC<sup>164</sup>, after a anonymous review to which the investigators have not been able to respond.

An additional case has been reported from Kansas city<sup>165,166</sup> in a home with a mould infested ventilation system, yielding 420 *Stachybotrys* spores/m<sup>3</sup> (counted by microscopy) from the bedroom of the infant, however also extremely high counts of *Penicillium* and *Aspergillus* (11250 spores/m<sup>3</sup> counted by microscopy) in the air was detected.

From Houston a case has also been described<sup>28</sup>, and here *Stachybotrys* (= Houston strain<sup>167</sup>) was isolated from the lung of a 7 years old white boy with IPH, chronic cough, and chronic fatigue.

From Cleveland an additional case has been reported<sup>168</sup> with no abnormal clinical tests except from the hemosiderin laden macrophages (showing that the bleedings had been occur-

ring over some time) recovered from the lung. The bedroom of the child was heavily infested with *S. chartarum* and air samples revealed  $6 \times 10^4$  CFU/m<sup>3</sup> of the fungus.

From St. Louis there is also a report<sup>27</sup> on a case of IPH in an infant, who was exposed to fungi during a 2 weeks holiday. On the return trip the infant developed the hemorrhage upon exposure to tobacco smoke. Low quantities of hemosiderin in macrophages in the lung indicated no preceding bleedings. During the vacation (14 days) the infant had resided in a room with visible mould growth of *Trichoderma*, *Penicillium*, *Cladosporium* and *Ulocladium*.

Recently a fatal IPH case has been discovered in Belgium (N. Nolard, personal communication), in this case airborne spores were detected, they were released in high numbers due to constructional work in the bathroom.

## 2.4 **Biologically active metabolites from moulds**

Microfungi have the ability to produce a high number of secondary metabolites, which they for various reasons need in their natural habitat<sup>169,170</sup>. Most of these are produced as a response to other organisms especially other fungi<sup>171</sup>. Some of these metabolites can cause a toxic response "when introduced by a natural route in low concentrations to higher vertebrates and animals" and are referred to as mycotoxins<sup>172</sup>.

Sorenson<sup>173</sup> and Miller<sup>69</sup> were some of the first to realise the implications of mycotoxins in the indoor environment. The latter emphasises that moulds generally produce several mycotoxins and synergizers, which are not toxic themselves, but enhance the toxicity of some mycotoxins<sup>174</sup>. It is also stressed that repeated low concentration exposure of airborne mycotoxins would be very difficult to diagnose.

When trying to predict which biologically active compounds of microfungal origin may be present in water-damaged buildings - at least five problems have to be addressed:

- Most secondary metabolites and mycotoxins are species specific making identification of isolates to the species level extremely important. Changes in taxonomy including introduction of new species and synonymisation of others have further complicated this work<sup>62,175</sup>.
- False positive findings of mycotoxins are often common from laboratories which use insufficiently specific methods, or which are not experienced in mycotoxin analysis and the large number of interfering compounds produced by moulds<sup>62</sup>.
- Even in fungal extracts of species, which have been extensively studied for their metabolites as e.g. *Aspergillus flavus*, *A. fumigatus*, and *Fusarium graminearum*, unknown biologically active metabolites are still present<sup>69</sup>.
- A large number of the secondary metabolites described in the literature have been tested in a very few assays, and extremely few compounds have been tested in full animal studies. The latter method is unfortunately often the only way of finding defects in the offspring or reveal metabolites which are activated in special organs such as liver or kidney<sup>144,176</sup>. For exposure assessment even fewer metabolites have been tested in inhalation studies where some metabolites have been magnitudes more potent<sup>177</sup>.
- The produced metabolites vary considerably between media, so the moulds may produce very different metabolites when growing on building materials<sup>63,178</sup>.

It should be considered that on naturally infested materials the moulds do not grow in pure cultures, but in mixed cultures with other moulds and often also bacteria. These conditions may induce production of other metabolites than in pure cultures<sup>50</sup>.

The following review will target the potential fungal metabolites produced in buildings by the building associated fungi, and may have a varying detailing level. This reflects where most of the experimental work has been concentrated and where less known species and genera have been reviewed.

The tables of the metabolites reported from the reviewed species have been moved to Appendix B, as many of them run over several pages, and hence will diminish the readability of this thesis.

## 2.4.1 *Stachybotrys*

*Stachybotrys chartarum* (Ehrenberg ex Link) Hughes (= *S. atra* Corda, and *S. alternans* Bonord.) is the only species from this genus which has been found in buildings.

Jong & Davis<sup>179</sup> made a revision of the genus in 1976 based on available cultures and found that the genus comprised additional ten species: *S. albipes*, *S. bisbyi*, *S. cylindrospora*, *S. dichroa*, *S. kampalensis*, *S. microspora*, *S. nephrospora*, *S. parvispora*, *S. oenanthes* and *S. theobromae*. Later McKenzie<sup>180</sup> described three new species from decaying leaves, and Dorai & Vittal<sup>181</sup> and Hua-zhong<sup>182</sup>, Miyazaki et al<sup>183</sup> additional species.

Most interest of *S. chartarum* has been due to its capacity to deteriorate organic fabric fibres<sup>179</sup> and its ability to produce the highly cytotoxic macrocyclic trichothecenes<sup>184,185</sup> which have given significant problems in mouldy straw in Eastern and Northern Europe<sup>184,186-188</sup>.

Stachybotryotoxicosis was first described in the 1930s by Russian researchers<sup>189</sup>, and later by Forgacs in the English written literature<sup>187,190</sup>. He assisted Russian veterinarians during World War II, where stachybotryotoxicosis in horses was a severe problem for the Russian army<sup>191</sup>. Russian researchers showed that horses were very susceptible to *Stachybotrys* infested straws<sup>192</sup>. Forgacs describes two types of toxicosis: i) A typical form with inflammation of the stomach, and the mouth as well as necrosis of some areas, followed by a decreasing number of thrombocytes and a decrease in the blood clotting, followed by a decreasing number of leukocytes and an almost total absence of blood clotting<sup>192</sup>; ii) An atypical form, characterised by nervous disorders, as loss of reflexes, elevated body temperatures, and altered cardiac action<sup>192</sup>.

The link to indoor air appeared in 1986, when Croft et al<sup>47</sup> described a household in Chicago, where the occupants suffered from symptoms similar to stachybotryotoxicosis. Filters from air sampling in this home was black after sampling due to the many *Stachybotrys* spores (B. B. Jarvis, personal communication).

### 2.4.1.1 Trichothecenes

In 1973, Eppley & Bailey<sup>184</sup> were the first to isolate trichothecenes from *S. chartarum*, they found the known components, trichodermol and roridin E (RE) and three novel components, named satratoxins H, G and F<sup>193</sup>. These three components were first structure elucidated 4-7 years later<sup>185,194</sup>. All trichothecenes produced by *Stachybotrys* species have been compiled in Table 1 in Appendix B.

The trichothecenes (TR) are divided into the following four groups<sup>195</sup>.

- Type A trichothecenes (TA), easily described as the trichothecenes (TR) not included in the following three groups. These trichothecenes have been isolated from species within


the fungal genera *Memnoniella*, *Trichoderma*, *Trichothecium*, *Myrothecium*, *Stachybotrys*, and *Fusarium*, are highly cytotoxic.

- Type B trichothecenes (TB) are characterised by the C<sub>8</sub>-keto group. This group is approximately only 10% as toxic as the TA<sup>176,196</sup> and is only produced by *Fusarium* species.
- Type C trichothecenes are characterised by the ring from R<sup>2</sup> to the R<sup>3</sup> alcohol group and are generally referred to as macrocyclic trichothecenes (MTR). These are at least 10 times more cytotoxic than the type A, and are produced by species of *Stachybotrys* and *Myrothecium*.
- The very rare type D trichothecenes are characterised by a C-7,8 or C-9,10 epoxy group.

The sesquiterpenoid pathway of the trichothecenes produced by *Fusarium* has been examined in detail (see Figure ) due to the economical importance of this genus<sup>197</sup>. An important step in the biosynthesis is the then cyclization to trichodiene by trichodiene synthase, encoded by the *TRI5* gene<sup>197-199</sup>, which has been characterised in *Fusarium*, *Myrothecium* and *Stachybotrys*<sup>197,200,201</sup>.

Trichodiene is volatile and can be used as an indicator for the synthesis of trichothecenes<sup>202,203</sup>. The MTR is the synthesised over trichodermin and the trichoverroids as seen in Figure <sup>197,204</sup>.

Several studies have shown that *S. chartarum* strains isolated from cereals can produce MTR<sup>107,108,205</sup> when grown on building materials and air filters. In naturally infested materials MTR have been detected by Croft et al<sup>47</sup> who found, satratoxin H (SH), verrucarins B (VB), verrucarins J (VJ), and the trichoverrins. Several later studies have verified these findings<sup>50,165,206</sup>. From an exposure point of view, Sorenson<sup>46</sup> has shown that the spores from MTR producing isolates contained approx. 10-40 ppm of the MTR ≈ 40 fg MTR per spore, whereas Nikulin et al<sup>45</sup> found 140 fg/spore. Not all *S. chartarum* strains produces satratoxins, Korpinen & Uoti<sup>188</sup>, showed that 67% of the *S. chartarum* strains isolated from toxic feed in Finland were cytotoxic to fibroblasts (presumably producing satratoxins). Andrienko & Zaichenko<sup>207</sup>, showed that Russian *S. chartarum* isolates grown on seeds, could be grouped in four: i) 19% with highly dermatotoxic properties (presumable being satratoxin produces); ii) 4% with only antifungal activities; iii) 47% strains with antifungal and antibacterial activity also being dermatotoxic; iv) 26% with no biological activity. Jarvis et al<sup>208</sup> found that 80% of the strains isolated from stachybotryotoxicosis cases in farm animals from Eastern



Europe produced MTR. This is significantly different from the strains isolated in water-damaged buildings in the USA where only 30-40%, of the isolates from the IPH case homes produced MTR<sup>44,209</sup> and from Finland<sup>148</sup> where about 50% of the strains were highly cytotoxic to murine macrophages, resembling the biological activity of MTR producing strains.

### **Toxicology of the trichothecenes**

It has long been known that the TR generally inhibited the protein synthesis<sup>196</sup>, where some inhibited the ribosomal termination or the elongation of the translation process. Later both TR and MTR have been shown also to induce apoptosis in cells, by activating SAPK/JNK and p38 MARK kinases by ribosome binding inhibiting the protein synthesis<sup>196,210</sup>. Interestingly trichodermol and trichodermin are the only TR that are non-cytotoxic<sup>196</sup>.

Parent-Massin & Parchment<sup>211</sup> grouped haematotoxicity, abnormal blood cell grouping or malfunction, of mycotoxins in three groups:

- Haematotoxicity not described in literature: patuline, verrucosidin, and fumonisins.
- Compounds able to cause adverse haematotoxic effects, but with the principal mechanism not being haematotoxic: ochratoxin, aflatoxin and zearalenone.
- Compounds giving severe haematotoxic effects, with minor symptoms, like the trichothecenes.

At high concentrations (10-20 mM) T-2 (the most toxic TA) induces haemolysis of red blood cells of rodents, pigs, dogs, horses and humans. Single doses of DAS (a TA) given to humans as anti-cancer drug (Phase I test), resulted in vomiting and central nervous toxification. TR have a significantly lower LD<sub>50</sub> value in new borne animals (mice, lowered by approx. 100 ×) in which the pathologists found severe lesions of bone marrow, thymus and spleen.

As only few MTR are commercially available, only few studies on these components exist. However Hughes et al<sup>212</sup> studied the effect of 11 different MTR on the immune system of mice. They were administered, once, with half the LD<sub>50</sub> dose and sacrificed after 4 days. White blood cell concentration decrease upon exposure to VJ and RE, but some of the others MTR had the opposite effects. This might be due to more circulating white blood cells at the start. ELISA showed a decreased production of antibodies against sheep red blood cells for some components.

Pestka & Bondy<sup>213</sup> who showed that mice exposed to TR had up to a 10 000 lower LD<sub>50</sub> to *Salmonella typhimurium* exposure. This is presumably due to the fact that leukocytes (white blood cells) are affected at far lower concentrations than the acute ones<sup>211</sup>. Especially TA, are cytotoxic to granulocyte, monocyte and erythroblast progenitors<sup>211</sup> at concentrations higher than  $5 \times 10^{-8}$  M. Effects at this level includes inhibition of antibody production, delayed skin graft rejection, and inhibiting phagocytosis of murine macrophages<sup>144</sup>.

These symptoms resemble the ones observed in humans from *Stachybotrys* infested buildings reported by Johanning et al<sup>23,156</sup> (see section 2.3.2), especially when combined with the data of Creasia et al<sup>177,214</sup> who showed that the acute effects of the TR T-2 toxin in rodents was 10-20 time stronger when it was inhaled than when it was administrated through the feed. However Pang et al<sup>215</sup> was not able to verify this effect in pigs.

### **Animal studies on the inhalation of *Stachybotrys* spores**

The association of IPH cases with *S. chartarum*<sup>26</sup> has of course triggered a number of projects on the influence of *S. chartarum* spores on cell cultures and whole animals.

Lung mycotoxicosis in mice was demonstrated by Nikulin et. al.<sup>45</sup> who used two *S. chartarum* strains, isolates #72(=CBS 414.95 = IBT 9460) and #29 (=CBS 413.95 = IBT9472). It was shown that #72 induced much more severe haemorrhage in the mice than #29. The first iso-

late produced satratoxins and high quantities of stachybotrylacetones and the later strain produced only minor quantities of the latter type. The same group<sup>216</sup> also instilled mice with  $10^3$  and  $10^5$  spores of the same two *S. chartarum* isolates 6 times during 3 weeks. In the mice instilled with the highest dose, severe inflammatory changes were observed in the lungs. The mice administered with spores from #72 developed much more severe inflammations than the mice instilled with spores from #29. At the lowest level only the mice instilled with the spores from the satratoxin producing isolate, #72, developed inflammatory changes in the lungs. However due to the few isolates used and the variation in both MTR and stachybotrylacetone production the study remains partly inconclusive on the responsible components.

This is the same for the study of Mason et al<sup>217,218</sup> who instilled *S. chartarum* spores and iso-satratoxin F in the lungs of mice, and observed that both obstructed the lung homeostasis whereas *Cladosporium* spores did not. However the *S. chartarum* spores and the pure toxin induced very different surfactant production (P60 and P100 phosphor lipids), but no chemical analyses were performed on the strain so it is unknown if it produced MTR.

Rao et al<sup>219</sup> instilled spores in rat lungs, and showed that when spores from a highly cytotoxic (presumably a MTR producer) of *S. chartarum* was methanol extracted, the toxicity of the spores almost disappeared compared with unextracted spores. This clearly shows that the pulmonary toxicity is due to extractable metabolites as MTR or most of the metabolites described in the following subchapter.

The conclusion drawn from these studies is that *S. chartarum* spores indeed contains a number of metabolites which can induce severe inflammation, haemorrhage and death in animals. However there is no evidence that these effects are only caused by the MTR.

### 2.4.1.2 Non trichothecene metabolites

Most species in *Stachybotrys* and especially *S. chartarum* produces high quantities of a number of spirocyclic drimanes<sup>183,220</sup> as shown in Figure 3. These components have a number of biological properties, *inter alia* inhibition of TNF $\alpha$  liberation from human macrophages<sup>221</sup>, complement inhibition<sup>183,222</sup> and antiviral activity<sup>223</sup>. When considering that one of the most common symptoms in mouldy buildings is recurrent airway infections,




Figure 3. Left, the spirocyclic drimanes, stachybotrylactone (X=O) and stachybotrylactam (X=NH). Right, SMTP-1, one of their precursors.

metabolites which inhibits the complement system are interesting, as the complement system is an important part of our defence against bacteria<sup>143</sup>. A number of triprenyl phenol metabolites (see Figure 3) have been described from several *Stachybotrys* species. They are precursors of the spirocyclic drimanes, as the triprenyl can be cyclized into the drimane part. These metabolites can activate and enhance the plasminogen-mediated fibrinolysis (at levels down to  $100 \mu\text{M}$ )<sup>224-226</sup> and could in that way be plausible components responsible for IPH, as this could account for the brittle blood vessels in the lungs.

Both the triprenyl phenols and the spirocyclic drimanes are produced by two mixed biosynthetic pathways, partly by the sesquiterpenoid pathway (shown in blue on Figure 3) and partly by the polyketide pathway. Reviewing the literature on these components has been troublesome as Russian groups have published known structures under new names, data on the stereochemistry is often not available, and a significant number of the publications have

been Japanese patents and patent applications. Chemical and biological data on the spirio-cyclic drimanes and other non-trichotehcene metabolites are given in Table 2, Appendix B.

A new type of metabolites has been isolated from non-satratoxin producing isolates of *S. chartarum*, and has been named atranones<sup>209</sup>. They are<sup>227</sup> biosynthetically related to the dolabellanes<sup>228</sup> and altogether 8 atranones and two dolabellanes have been isolated from the *S. chartarum* cultures<sup>209,227</sup>. Three of these metabolites (6 $\beta$ -hydroxydolabella-3E,8E,12-trien-14-one, atranones B and C) have also been detected in material samples from a IPH case home in Cleveland<sup>229</sup>. However the biological activity revealed until now on these components has been rather limited, but with the number of enzymatic steps used to synthesise such complicated components<sup>228</sup> they must have a biological activity.

A component belonging to the immunosuppressing cyclosporin family has also been isolated from a *Stachybotrys* sp.<sup>230</sup>, and is of course interesting due to many infections experienced by people living in mouldy buildings. Also components, shown not to be TR, damaging the cell membrane of boar sperm cells has also been described<sup>231</sup> from *S. chartarum*, however it has not been cleaned up and characterised.

Vesper et al<sup>232</sup> tested the haemolytic activity<sup>229</sup> of *S. chartarum* isolates from the Cleveland IPH cases, grown on gypsum boards. Haemolysis was correlated to growth at 35°C and not at 23°C, and a higher percentage of the spores from IPH case homes were haemolytic. The responsible component has just been partly characterised<sup>233</sup> as a novel haemolytic protein, stachylysin. Additionally the group has showed that the *S. chartarum* strains from the IPH case homes produces higher quantities of siderophores than strains from non-IPH case homes<sup>167</sup>. Iron is a key component for pathogens and iron binding proteins and peptides excreted from pathogenic bacteria<sup>234</sup> and fungi<sup>235</sup> are well known. The authors seem to indicate that a mechanism might be partly due to actual growth of *Stachybotrys* in the lung tissue of the infants.

All these findings clearly show that the biologically active components from *S. chartarum* are far from known, and even when they are all known there will still be much left to do in determining the actual exposure to these in mouldy buildings.

## 2.4.2 *Aspergillus*

As the genus of *Aspergillus* Mich. ex Fr. is one of the anamorph genera placed in the family *Trichocomaceae*, where it is associated with 8 holomorph genera. This is new in comparison with the last monograph by Raper & Fennell<sup>236</sup>, which is still extensively used, although it should only be used in combination with "Integration of modern taxonomic methods from *Penicillium* and *Aspergillus* classification" and "Modern concepts in *Penicillium* and *Aspergillus* classification" from 2000<sup>237</sup> and 1990<sup>238</sup> respectively.

The following sub chapter has been divided into subsections on the most important species.

### 2.4.2.1 *A. versicolor*

*A. versicolor* (Vuillemin) Tiraboschi belong to the subgenus »Nidulantes« section »Versicolores«, with no known teleomorphs. This species is common in many dry environments and is one of the few aspergilli, which are also common in temperate and cold environments<sup>25</sup>. It is the absolutely most common *Aspergillus* in damp and water-damaged buildings.

Together with several streptomycetes<sup>239</sup> and *Chaetomium globosum*<sup>240</sup> it may be one of the major producers of the mouldy smelling component, geosmin, in buildings<sup>241</sup>.



Fragments which are significantly smaller than the spores are liberated from *A. versicolor* infested building materials<sup>84</sup> and may account for the health problems in buildings where it is the predominant species on the materials without being so in cultivation based air-samples. Prolonged exposure may lead to significant lung damage, maybe as a secondary effect of IL-1 liberation<sup>145</sup>, as discussed earlier in the report.

### Sterigmatocystin

Sterigmatocystin (ST) is considered the most important toxic metabolite of *A. versicolor* and as seen in Table 3 in Appendix B, a number of analogues have been isolated including a number of precursors that are also biologically active.

The biosynthesis of ST has been studied in detail, as ST is only two enzymatic steps from aflatoxin B<sub>1</sub> (AFB<sub>1</sub>) which is of great economical importance for the agriculture industry. ST is deca polyketide synthesised over a C<sub>20</sub> precursor, which is then transformed to norsoloric acid, averatin, 1'hydroxyversicolorone, versiconal hemiacetate acetate, versicolorin A and finally ST<sup>242</sup>, meaning that findings of ST would also imply the presence of a significant number biologically active precursors.

ST is cytotoxic by itself, but the major problem is the carcinogenic properties after activation in the liver by the cytochrome P450 mono-oxidase system, to the 8,9-epoxide analogue which then preferable reacts with guanine as seen in Figure 4, just as for AFB<sub>1</sub><sup>176,243</sup>.

ST has been shown to be a very strong inhibitor of the of chicken tracheal cilia<sup>244</sup>, and as this is one of the important ways we clean our upper airways, inhibition of this system may increase the risk of upper airways infections.

No studies of airborne ST have been found. However several exist for AFB<sub>1</sub>, which in rats and mice (one dose 17 mg/kg) suppressed the macrophage phagocytosis for 2 weeks as well as their release of TNF $\alpha$  upon exposure to endotoxin. Airborne dust containing AFB<sub>1</sub> has been shown to increase the risk of liver cancer in workers handling AFB<sub>1</sub> infected animal




Figure 4. Activation of sterigmatocystin and formation of the guanine adduct.

feed by two- to threefold with a 10 years latency<sup>32,33</sup>. Later studies have shown that the AFB<sub>1</sub>-guanine-adduct is an important exposure bio-marker<sup>243</sup>.

ST production is influenced by the humidity on cereals, as

was only detected at RH over 88.5% and the maximum production of the toxin as well as biomass occurred at 93% RH<sup>245</sup>, and hence the same phenomena may be found in buildings.

### Other metabolites

*A. versicolor* produces a number of other metabolites shown in Appendix B, table 4, but their toxicity is generally not very well described. The production of cyclopiazonic acid by *A. versicolor* reported by Ohmomo et al<sup>246</sup> was due to misidentification with *A. oryzae*<sup>62</sup> and isolation of griseofulvin, dechlorogriseofulvin, and 3,8-dihydroxy-6-methoxy-1-methylxanthone from *A. versicolor* reported by Kingston et al<sup>247</sup> must be due to a misidentification or contamination with a griseofulvin producing *Penicillium* (J. C. Frisvad, personal communication).

### 2.4.2.2 *A. ustus*

*Aspergillus ustus* (Bainier) Thom & Church, also belongs to the subgenus »Nidulantes« but is placed in the section »Usti«, and has no known teleomorphs.

The most extensive work on *A. ustus* metabolites have been done in South Africa by the group of Steyn and Vlegaar, due to problems with mycotoxicosis in cattle caused by *A. ustus* infections of grains<sup>248-250</sup>. And as seen in Appendix B, Table 5 the austamides and aust-diols<sup>251,252</sup> are acute toxic and the austocystins both toxic and carcinogenic<sup>253</sup>. The later group is also deca polyketides and closely related to AFB<sub>1</sub> and ST both in structure and biological activity<sup>242</sup> also notable is the production of versicolorin C<sup>254</sup> which is one of the precursors to ST.

*Aspergillus ustus* var. *pseudodeflectus* is very different from *A. ustus* sensu strictu and produces pergillins, the TMC-120's and the ophibolins all showing various biological activities<sup>255</sup> (Appendix 5, Table 5)<sup>254,256,257</sup>.

However no studies of airborne *A. ustus* spores or metabolites have been published, and hence the data on airborne AFB<sub>1</sub> found in the *A. versicolor* section is the best when concerning the austocystins.

### 2.4.2.3 *A. niger* complex

The *Aspergillus* section *Nigri*, found in the subgenus *Circumdati*, is also called the Black *Aspergilli*, and contains 8 species: *A. heteromorphus*, *A. ellipticus*, *A. niger*, *A. bubingensis*, *A. brasiliensis*, *A. japonicus*, *A. carbonarius* and *A. aculeatus*<sup>258</sup>.

The literature review on metabolites deals with the first 6 species, as they are very difficult to differentiate and seem to produce very similar metabolites (J.C. Frisvad, personal communication), and can be seen in Appendix B, Table 6.

When a *Niger* is found in buildings, there are usually significant quantities of biomass but it is not that common that a full overview of its preferred materials has been established.

Extracts of *A. niger* generally contains significant quantities of the low toxic<sup>259</sup> tetra-cyclic compounds and naphtho- $\gamma$ -pyrones<sup>65</sup>, but the distribution of strains producing the highly cytotoxic malformins<sup>260</sup> not known. This together with the low number of isolates which actually produces the highly nephrotoxic component ochratoxin A, makes a this a species which could pose a significant indoor problems if these two latter types of metabolites are produced in buildings.

### 2.4.2.4 Other aspergilli

A number of other aspergilli are also found in buildings especially the teleomorph *Eurotium repens* de Bary (*A. glaucus* group in Raper & Fennell<sup>236</sup>), often isolated from wood containing products and in roof construction which are getting very hot during the day. *Eurotium* is not recognised as a mycotoxin-producing genus<sup>65</sup>, but has however never been tested for their inhalation toxicity. Many of them can grow at 37°C and may cause infections in immunosuppressed persons.

*A. ochraceus* is relatively rare in buildings, but in a household with indoor air problems, growth of *A. ochraceus* was found, and subsequently ochratoxin A was detected in dust using several highly selective analytical methods<sup>261</sup>. This means that growth of this species in a building should be considered a very serious problem.

Two studies<sup>262</sup> have both shown that *A. flavus* does not produce aflatoxins when growing on different building materials. The isolates used with both studies were capable of producing

theses toxins on laboratory media<sup>262,263</sup>. However this species produces a number of other metabolites which many pose a health risk.

*A. fumigatus*, is commonly found in dust and thus isolated frequently on dusty materials, but rarely found growing on materials<sup>25</sup>. When cultivated on wood pieces, it produces tremorgenic components<sup>264</sup>, but the responsible components were not detected. Later, Ren et al<sup>262</sup> showed that two isolates capable of producing verruculogen and helvolic acid, failed to produce these when growing on different materials. This species is the most common infectious mould, growing in the lungs of immunosuppressed persons.

### 2.4.3 *Penicillium*

The genus of *Penicillium* Link ex Fr. is one of the anamorph genera placed in the family *Trichocomaceae*. It is associated to the holomorph genera, *Eupenicillium* and *Talaromyces*<sup>265</sup>. In the last 10-15 years, the use of secondary metabolite profiles, isoenzyme patterns, and genetic approaches has drastically altered the taxonomy of this genus, previously classified on the basis of morphology. At present 225 accepted species exist in *Penicillium*. These include approx. 3 times as many synonymized species<sup>265</sup>, reflecting the difficulties experienced when identifying and classifying *Penicillium* species.

Especially the terverticillate penicillia are difficult to identify to species level as they are very closely related, and secondary metabolite profiling seems to be most the accurate method<sup>266</sup>. Unfortunately misidentification of production cultures has obscured the connection between species and secondary metabolites<sup>62,267,268</sup>.

#### 2.4.3.1 *P. chrysogenum*

*Penicillium chrysogenum* Thom, is placed the series *Chrysogena* Raper & Thom ex Stolk & Samson<sup>269</sup> in the subgenus *Penicillium*.

*P. chrysogenum* has 16 synonymised species<sup>269</sup>:

- *P. griseoroseum* Dierckx
- *P. brunneorubrum* Dierckx
- *P. citreoroseum* Dierckx,
- *P. baculatum* Westling
- *P. notatum* Westling
- *P. meleagrinum* Biourge
- *P. flavidomarginatum* Biourge
- *P. cyaneofulvum* Biourge
- *P. roseocitreum* Biourge
- *P. rubens* Biourge
- *P. camerunense* Heim apud Heim
- *P. chrysogenum* var. *brevisterigma* Romankova
- *P. harmonense* Baghdadi
- *P. verrucosum* var. *cyclopium* strain *ananas-olens* Ramire

*P. chrysogenum* is found in dry habitats and can grow at temperatures as low as 5°C<sup>270</sup>. It is known to produce a large number of metabolites especially antibacterial as shown in Table 7 in Appendix B. However, this also reflects the many screening projects including this species due to its original production of penicillin. The most toxic metabolites isolated have been the neurotoxic roquefortine C but it may also produce secalononic acid D<sup>176,271-273</sup> which is produced by the closely related *P. oxalicum*, (J.C. Frisvad, personal communication).

PR-toxin have been reported from this species by Frisvad & Filtenborg<sup>274</sup> and by Dai et al<sup>275</sup>, but these findings are still discussed (J.C. Frisvad, personal communication).

An inflammatory mediator may be present in the spores, as methanol extracted spores were non active compared with non-extracted spores<sup>146</sup>.

### 2.4.3.2 *P. brevicompactum*

*Penicillium brevicompactum* Dierckx<sup>265</sup> is now placed in the series *Olsonii*<sup>269</sup> in the subgenus *Penicillium*. It is common on wood, some fruits, tropical soil and can grow at a lower  $a_w$  than other penicillia<sup>124,269</sup>.

*P. brevicompactum* has 9 synonymised species<sup>269</sup>:

- *P. griseobrunneum* Dierckx
- *P. stolleniferum* Thom
- *P. tabescens* Westling
- *P. szaferi* K.M. Zalesky
- *P. hagemii* K.M. Zalesky
- *P. biolowiezense* K.M. Zalesky
- *P. patris-meii* K.M. Zalesky
- *P. brunneostoloiferum* Abe
- *P. brunneostoloiferum* Abe ex Ramirez

As seen from Table 8 in Appendix B, this fungus is capable of producing a high number of biologically active metabolites, from which mycophenolic acid is the most well known and most consistently produced<sup>268,276</sup>. This component was the first mould metabolite to be purified and crystallised, as early as in 1893<sup>277</sup>. It is being used as both an antibacterial and immunosuppressant drug. The most toxic component is the mycotoxic botryodiploidin<sup>278-280</sup>, but it has not been proven to be the principle component for a number of mycotoxicosis cases where this species has been the primary contaminant (J.C. Frisvad, personal communication). However most of the biologically active components seem to be able to interact with the growth of plants<sup>281-283</sup>.

### 2.4.3.3 *P. polonicum*

*Penicillium polonicum* K.M. Zalesky also found in the subgenus *Penicillium*, but the series *Viridicata*, some times referred to as the *Penicillium aurantiogriseum* complex. The series are generally found on cereals and produces a high number of secondary metabolites<sup>269</sup>.

*P. polonium* has 2 synonymised species:

- *P. aurantiogriseum* var. *polonicum* (K.M. Zalesky) Frisvad
- *P. carneolutescens* G. Smidth

Some of the most toxic *Penicillium* species are found in the *aurantiogriseum* complex, but it is extremely difficult to distinguish the individual species by other means than metabolite profiling. Consequently literature has been obscured especially in this complex and the literature review will mostly be based on the paper of Frisvad & Lund<sup>284,285</sup>, and can be seen in Table 9, Appendix B.

*P. polonicum* produces at least the groups of highly toxic components, the verrucosidins<sup>286</sup> who are tremorgenic, the cytotoxic penicillic acid, which is extremely active against rodent lung macrophages (*in vitro*)<sup>287</sup>, and nephrotoxic glycopeptides which may be involved in the Balkan nephropathy endemic<sup>288</sup>.

### 2.4.3.4 *P. expansum*

*P. expansum* is occasionally isolated in buildings, where it is often isolated from wood<sup>63</sup>. On this substrate, Land and Hult<sup>289</sup> showed that some *P. expansum* could produce patulin. This mycotoxin is one of the most toxic *Penicillium* metabolites, being very highly cytotoxic and has a high inhibitory effect on the activity of mouse peritoneal macrophages<sup>290</sup>, as well as increases the susceptibility of fungal and bacterial infections<sup>213</sup>.

However on agar substrates this species produces patulin, citrinin, chaetoglobosin C, roquefortine C, and the communisins A and B, one of the most toxic mixtures in this genus<sup>65</sup>.

## 2.4.4 *Trichoderma*

*Trichoderma* Pers. ex Fr. is common on water-damaged wood containing materials, and from Danish buildings six different species have been isolated: *T. longibrachiatum*, *T. harzianum*, *T. citrinoviride*, *T. atroviride*, *T. viride* and *T. harmatum*<sup>71</sup>.

*Trichoderma* was originally known for producing trichodermin and trichodermol which was originally isolated from a *T. viride* strain, and crystallised for the X-ray structure determination as the first TR by Godtfredsen & Vangedal<sup>291,292</sup>. Later another ester, Harzianum A, of trichodermol has been isolated<sup>293</sup>. As trichodermol and esters of it are not commercially available, very few surveys for these metabolites have been performed, probably also due to its very low toxicity.

Cvetnic & Pepelnjak<sup>294</sup> have reported the production of DAS from *T. viride* using TLC, but it has not been possible to obtain any of the strains, for verification of this very unlikely finding.

As seen in Appendix B, Table 10, the majority of the non-peptabols metabolites seems to be antibiotic and especially antifungal, and a large number of these seem to be small pyrones and lactones (<300 g/mol) often being volatile. Production of gliotoxin and viridin have also been reported from several *Trichoderma* species, but these have always been shown to be *T. virens*<sup>295</sup> which has not been found in mouldy buildings<sup>65</sup>.

The major group of biologically active metabolites are the peptabols, and cyclic peptides, Appendix B, Table 11, who often works by making pores in the cell membranes of the target organisms giving free passage of ions over the cell membrane. These metabolites have both antibacterial, and antifungal properties, but few reports exists of their effect on mammalian cells as most of the work on *Trichoderma* has been done to identify new antibacterial, and antifungal components. A number of proteins with severe biological properties ribosome in-activation<sup>296</sup> and high toxicity<sup>297,298</sup> have also been described.

No studies on the inhalation toxicity of these species or their peptabols exist, but they may be significantly more potent when inhaled.

## 2.4.5 *Memnoniella*

Only one species from the genus *Memnoniella* Höhnelt has been identified in buildings and that is *M. echinata* Galloway, which is closely related to *Stachybotrys*<sup>179,299</sup>. As seen in Appendix B, Table 12, a number of biosynthetic groups are produced by this species. The griseofulvins which is a known type of antibiotics<sup>44</sup> and are commercially used as such, can inhibit the polymerisation of turbulin in mammalian cells<sup>176</sup>.

Two mycophenolic acid analogues; memnoconol and memnoconone<sup>300</sup> have also been isolated along with a number of spiriocylic drimanones very similar to the ones produced by *S. chartarum*<sup>223,300-303</sup> also the production of the simple trichothecenes; trichodermol and trichodermin are common with *Stachybotrys*<sup>304</sup>.

## 2.4.6 *Alternaria*

The genus of *Alternaria* Nees ex Fr. comprises more than 40 species<sup>270</sup> and is very common in soil and the phylloplane species *A. alternata* and *A. tenuissima* are found in very high numbers in the outdoors air during the summer<sup>25</sup>. The toxicology of the *Alternaria* toxins have been reviewed thoroughly by Woody & Chu<sup>305</sup>. The acute toxicity (LD<sub>50</sub>) in rodents of alternariols seems to be in the range of 400 mg/kg, which is quite low even though they are reported teratogenic at 10 lower levels. They are mutagenic in the Ames test, but only few data in higher animals exists. Tenuazonic acid (LD<sub>50</sub> 10-200 mg/kg in rodents) is more toxic

and the altertoxins are about 1000 more toxic (LD<sub>50</sub>, 200 µg/kg in rodents). In Appendix B, Table 13 the biologically active metabolites of this groups have been compiled. It should be noted that *A. alternata* in grains may to be associated to esophageal-cancer in China.

The most potent mycotoxins produced by this genus, are the AAL toxins which are related to the fumonisins<sup>306,307</sup> *Alternaria alternata* f.sp. *lycopersici* infecting tomato plants, but these strains have not been linked to buildings.

Ren et al<sup>308</sup> showed that only alternariols were produced on various building materials, whereas the altertoxins were not produced in detectable quantities.

However if species of this genus should be the cause of the health problems observed in mouldy buildings, very different metabolites should be produced selectively in buildings,

### 2.4.7 *Chaetomium*

The teleomorph genus of *Chaetomium* Kunze ex Fr. comprises about 160-180 species<sup>270</sup> and has the genus of *Acremonium* Link ex Fr. as anamorph genus.

The genus one of the most important deteriorators of cotton and cellulose containing materials<sup>270</sup> and in buildings *C. globosum* Kunze ex Steud. is the most common species<sup>16</sup>.

*C. globosum* is known from the cytohalasin mycotoxins, which are also produced by several *Penicillium* species, and who inhibit cytoplasmatic cleavage, and inhibit glucose transport in the tissue<sup>176</sup>. However the knowledge of toxicity of these components during inhalation is not known.

The major work done on the metabolites has been performed in Japan<sup>309</sup>, but as seen in Table 14 from Appendix B, many other metabolites are produced by species of the genus, especially the highly cytotoxic chaetomin which inhibits protein synthesis, the cytotoxic chaetocins, the mutagenic mollicellins and the chaetochromins who are cytotoxic, teratogenic and induces liver injuries<sup>310</sup>.

Interestingly some species also produce sterigmatocystins<sup>311</sup> but these species have not been found in buildings.

### 2.4.8 *Cladosporium*

*Cladosporium* Link ex Fr. is a phylloplane genus and during the summer there can be as many as 10 000 spores per. m<sup>3</sup> air of *C. cladosporioides* and *C. herbarum*<sup>25</sup>, and both contains many of the same allergenic proteins<sup>312</sup>.

On indoor surfaces *C. sphaerospermum* Penz. and some times also *C. herbarum* (Pers.) Link ex Gray is frequently isolated from bathrooms and silicone caulking<sup>11,25</sup>.

As seen in Appendix B, Table 15 no papers on real mycotoxins have been found from this genus, but a number of antifungal metabolites have been isolated along with a few plant growth inhibitors.

### 2.4.9 *Ulocladium*

The genus of *Ulocladium* (Thüm.) Simmons is often isolated from water-damaged materials together with *Stachybotrys*, and generally it is *Ulocladium chartarum* and *U. atrum* which are two commonly species of this genus in buildings<sup>16,63</sup>.

Although this genus is morphologically similar to *Alternaria* and share the same major-allergen, almost no secondary metabolites have been isolated as seen in Table 16 in Appendix B.

## 2.4.10 *Paecilomyces*

From the genus *Paecilomyces* Bain. two species are found in water damaged buildings, *P. variotii* Bain. and *P. lilacinus* (Thom) Samson, with the first being the most abundant.

*P. variotii* is capable of growing on very low nutrient substrates as optical lenses, whereas *P. lilacinus* seems to prefer protein rich media<sup>270</sup>.

*P. variotii* can produce the strongly cytotoxic mycotoxins patulin and viriditoxin<sup>65</sup> as well the metabolites: ferrirubin, variotin, fusigen and indole-3-acetic acid<sup>25</sup>.

## 2.5 Biomarkers of mould growth

As earlier mentioned, not all spores are viable and hence a number of methods for measuring chemical and molecular biological markers are needed. These methods can also provide much faster measurements for mould determination and significantly better quantification. For determination of moulds, four different principles can be used for material samples or air filters:

- **Determination of the activity of fungal enzymes.** Here two methods have been used: i) Fluorescein diacetate hydrolytic activity (by determining fluorescein) will both detect the presence of bacteria and/or moulds in wooden samples<sup>125,313</sup>; ii) Determination of the activity of  $\beta$ -N-acetylglucosaminidase<sup>314</sup> (a enzyme in the chitinase partway) which is now commercially available as the Mycometer Test<sup>TM</sup>. Both methods have the advantage that the samples can be incubated for as long time as wanted, and hence a very high sensitivity can be obtained as many molecules of reactant can be obtained from each enzyme molecule. However these methods only detect functional enzymes.
- **Chemical markers, which can be genus, species, or isolate specific.** These include: i) extracellular polysaccharides from *Penicillium* and *Aspergillus*<sup>30,315</sup>; ii) 18:2 $\omega$ -phospholipid fatty acids<sup>314</sup>; iii)  $\beta$ -glucan from the cell wall, also being an important inflammatory marker<sup>37,39</sup>; iv) mycotoxins or secondary metabolites who are species specific<sup>47</sup>; v) MVOC's in the air<sup>41,316</sup>; vi) chitin from the cell wall<sup>317</sup>; and finally the cell membrane material ergosterol<sup>318,319</sup>. All these metabolites can principally be detected using various analytical methods as described for metabolites in section 2.6.
- **PCR-based methods, detecting specific parts of the fungal DNA,** enabling even isolate recondition if needed, and also recently quantitation<sup>229</sup>. These methods will undoubtedly be very important in the future especially when the DNA-chip technology comes down in price.
- **Bioassay detection,** either by detection cytotoxicity<sup>320,321</sup> or more specific *mode of action*, as the protein translation inhibition which is highly selective against trichothecenes<sup>322</sup>. Such methods give health relevant data but do not give any information on the producing mould.

All these methods are significantly faster than cultivation techniques and can also detect dead spores and mycelia, and will be the predominant methods in the future.

### 2.5.1 Ergosterol

Ergosterol (Erg) is the predominant compound in the fungal cell membrane, making it a suitable indicator for fungal growth, although it should be noted that also some amoebae and green algae are capable of producing Erg<sup>323</sup>.

Erg is partially bound as different esters<sup>324</sup>, and thus three different extractions can be performed: *Free Erg*, extracted without saponification; *Total free Erg* by saponification of the esters after extraction; and *Total Erg* by saponification of the sample during extraction<sup>325-327,327-330</sup>. In plant tissue extraction has shown some matrix dependency due to instability of Erg under various conditions, as exposure to sunlight or low pH<sup>327,328,331</sup>.

Extraction has included reflux in methanol-water with or without NaOH/KOH for 30-90 min, generally being labour intensive compared with the microwave-assisted extraction for total Erg developed by Young<sup>330</sup> and the extraction method of Larsson and co-workers<sup>318,332,333</sup>. These methods have been able to detect quantities down to 500 pg, corresponding to 200 spores<sup>81,88</sup>.

Erg is an excellent marker for quantification of fungal biomass on building materials<sup>318,334</sup> and can also be used as exposure marker in air or dust, where especially Larsson et al<sup>332,335</sup> and Miller et al<sup>22,81,88,336</sup> have used it. However here it was found not to correlate with questionnaire data on mould in the home and not with as self-reported symptoms<sup>81</sup>.

## **2.6 Detection of fungal metabolites**

Although perhaps more than half the time of the present work has been spent on developing analytical methods and trouble shooting on instruments, this subchapter will only give an overview of the analytical methods, as a more detailed literature review can be found in the papers 1-13.

### **2.6.1 Chromatographic methods for detection of mycotoxins**

Fungal metabolites can be detected by various methods, often combined with chromatographic methods<sup>337,338</sup>.

#### **2.6.1.1 Thin layer chromatography**

Thin layer chromatography (TLC) is the oldest of the chromatographic method, and requires less expensive and advanced equipment than the other chromatographic methods<sup>274</sup> and a considerable sample speed can be achieved compared with other methods, unless 2-D TLC is used<sup>337,339</sup>.

Target components can after separation be detected visually or instrumentally under light or under UV-light, the latter being very sensitive to fluorescent components. Usually the target components can be more or less selectively coloured by spraying with various reagents<sup>274,337</sup>. Antimicrobially components can be found by spraying the plate with a suspension of microorganisms in a growth substrate and after incubation for some days spots with no growth can be detected.

Mass spectrometric methods such as MALDI-TOF and FAB-MS can also be used as detection methods of TLC<sup>339</sup> although it seems more troublesome and slower than LC-MS and will probably only be used for very special applications.

TLC is not specific enough for detection of TR<sup>340</sup> although a number of "selective" colouring methods have been published<sup>341,342</sup>.

For sterigmatocystins, spraying with AlCl<sub>3</sub> is considered quite specific when combined with sample preparation methods removing quinones and related components<sup>343</sup>.



## 2.6.1.2 Gas chromatography

As previously mentioned, mycotoxins are generally not volatile and hence gas chromatographic detection of them will always have to face instability problems during injection and chromatography<sup>344</sup>. On the other hand capillary GC gives 10-100 times higher separation power<sup>345</sup> than LC (packed column) and runs very stable with flame ionisation, electron capture detection (ECD), and MS, which are significantly more sensitive than UV and refraction index detectors used in LC.

Almost all GC methods for mycotoxins start with derivatisation of free OH and N-H groups<sup>346</sup> to decrease the thermal lability. Acid groups are usually methylated, and alcohol groups are reacted to their TMS ether or esterified to their acetyl or pentafluoropropionyl esters<sup>340,344</sup>.

GC methods on most mycotoxins have been published, *inter alia* AFB<sub>1</sub> and ST<sup>346</sup>, *Alternaria* mycotoxins<sup>347</sup>, penicillic acid<sup>348</sup>, patulin<sup>349</sup>, the backbone of the AAL toxins and the fumonisins<sup>350</sup>, and especially the TR<sup>340</sup>. The latter, is the only group where GC-MS or GC-ECD has been the primary analytical method.<sup>351-365</sup>

### 2.6.1.2.1 GC-MS for trichothecenes

The use of MS detection of the pentafluoropropionyl- (PFP) or heptafluorobuturyl (HPB) esters will give the highest sensitivity if the MS has a mass range > m/z 800<sup>340</sup>. These derivatives can be formed by the imidazoles PFPI and HFBI respectively or acid anhydrides PFPA and HFBA respectively, although the latter needs a nucleophilic catalyst such as triethylamine, dimethylaminopyridin or imidazole<sup>340</sup>. Unfortunately the TB react slowly with both types of reagents and can undergo isomerisation giving more than one peak<sup>352</sup>. The fluorinated derivatives can be detected selectively to very low levels using negative ion chemical ionisation (NICI)-MS or ECD, but also positive electron impact ionisation (EI<sup>+</sup>)-MS or positive chemical ionisation (PCI)-MS can be used<sup>360,366,367</sup>.

TR lacking free OH groups cannot be detected using NICI and ECD unless they are hydrolysed to their parent alcohols prior to derivatisation<sup>353,360</sup>.

### 2.6.1.2.2 GC-MS for sterols

GC-MS has also been used, usually based on an internal standard, such as cholesterol or dehydrocholesterol<sup>335,368</sup>, as a isotope substituted standard is not commercially available. Erg has usually been derivatised to its tertiary-butyldimethylsilyl or trimethylsilyl (TMS) ether to reduce decomposition during injection and chromatography. On-column injection can also be used to further reduce decomposition<sup>330</sup>, but this method requires cleaner samples and is not as robust as splitless injection<sup>368</sup>.

## 2.6.1.3 High performance liquid chromatography

Since the late 1980s and the start of the 1990s HPLC have been the most important analytical method for mycotoxins<sup>337,369,370</sup>.

The success of HPLC compared with the other methods have several reasons. Firstly the instruments have decreased in price as well as getting easier to maintain. They are easily automated and PCs can sample and do automated detection of target compounds. Many column materials are available from many different manufactures, and significantly larger samples can be injected than in a GC. More over samples do generally not demand derivatisation as GC does.

From the mid 1990s the use of HPLC with MS detection employing atmospheric pressure ionisation techniques (API)<sup>371</sup> such as electrospray<sup>372</sup> and atmospheric pressure chemical

ionisation (APCI) have greatly expanded the use of HPLC for mycotoxins<sup>372,373</sup>. As toxins previously transparent to UV detectors can now be detected, e.g. the fumonisins which previously needed OPA derivatisation<sup>374,375</sup>, small peptides<sup>376,377</sup>, and especially the TR<sup>378</sup>.

#### 2.6.1.4 Capillary electrophoresis

Capillary electrophoresis (CE) has been used for detection of mycotoxins and low molecular-mass compounds since the late 1990s, due to the extreme separation power exceeding capillary GC by several magnitudes, as well as providing very fast separation<sup>379-381</sup>.

The method has, however, a number of limitations as uncharged components cannot be separated unless micellar CE is being used which greatly lowers its separation power<sup>382</sup>. The very small sample volume (<<1 µl) which can be loaded on to the column gives detection-limit problems even though several pre-concentration methods exist<sup>380,383</sup>. This means that CE is still generally used with very sensitive detectors such as Laser-Induced Fluorescence detection<sup>384,385</sup>. CE-MS methods have been used for low molecular-mass compounds but it has not yet been possible to use it in combination with micellar CE<sup>371,371,381</sup>.

#### 2.6.1.5 Immunochemical methods

For routine analysis, enzyme linked immunoassay (ELISA) is used for detection of AFB<sub>1</sub>, the TB DON, ochratoxin A and zearalenone in cereals<sup>386,387</sup>.

An increasingly important and very specific technique is to combine chromatographic detection methods with immunoaffinity clean-up<sup>388</sup>.

Monoclonal antibodies have also been prepared for the TB 3- and 15-acetyl-DON<sup>389,390</sup>, sporidesmin A<sup>391</sup>, the MTR roridin A<sup>392</sup>, the TA DAS<sup>393,394</sup> and presumably a number of other mycotoxins.

A roridin A ELISA has been used to detect SG and SH in building material samples<sup>320</sup>, as the assay cross-reacts with SG (4-7%) and SH (15-19%)<sup>392,394</sup>. Also the MTR hydrolysis product verrucarol, was detected in serum using DAS-ELISA samples after it was derivatised to diacetyl-verrucarol which is structurally similar to DAS.

#### 2.6.1.6 Bioassay for detection of mycotoxins

The first assays for measuring *Stachybotrys* toxins, were rabbit skin test which later have been shown to be highly sensitive for TR<sup>66,188,395</sup>. However due to ethical reasons this method is not used any more, as *in vitro* cultivated cell lines of human or animal origin can provide the same sensitivity and specificity<sup>321</sup>. Cell cultures are the most common assay for cytotoxicity testing, and have been very successful for detection of the cytotoxic trichothecenes<sup>20,321,396</sup> and cytotoxic indoor air organisms<sup>148,149</sup>. It should be noted that great differences in sensitivity and specificity of different cell types exist<sup>321</sup>. Most of the methods are used in combination with the MTT test, which measures if the mitochondria are functioning using a simple colorimetric detection<sup>321,397</sup>. The cell assays can also be used for measuring other reactions than cytotoxicity, e.g. induction of inflammatory mediators such as NO and different interleukins<sup>152,398</sup>.

The major problem with mammalian cell cultures is the need for cultivation in highly sterile environments and frequent sub-cultivation which is very time and material-consuming. Hence a more simple solution can be used, e.g. sperm cells<sup>50,399-401</sup> who are available from local insemination centres, blood cells which can be assayed for haemolysis<sup>229</sup> and/or rings from chicken trachea where the movement of the cilia can be monitored<sup>402</sup>. A very simple assay is the brine shrimp *Artemia salina*<sup>184,403</sup> which has been extensively used for TR and other

mycotoxins as the aflatoxins<sup>403</sup>. Engler et al<sup>404</sup> used the yeast *Kluyveromyces marxianus* grown in microtitre plates for detection of TR by monitoring its expression of  $\beta$ -galactosidase. An assay measuring protein translation inhibition has been reported by Yike et al<sup>322</sup>. This assay has detection limits 20-400 times lower than cell cultures.

## 2.6.2 Sample preparation

The most time-consuming part of analysing for mycotoxins and other fungal metabolites, is extraction and especially the sample clean-up.

### 2.6.2.1 Trichothecenes

TR range from polar compounds like nivalenol (NIV) extracted with methanol-water or acetonitrile-water mixtures to apolar compounds such as diacetoxyscirpentriol (DAS) and T-2 toxin (T-2) extracted with mixtures of chloroform, dichloromethane and ethyl acetate. Thus no method can provide full extraction ( $\approx > 80\%$ ) of all TR unless multiple extractions are performed<sup>340</sup>.

The MTR can be extracted using water-methanol to dichloromethane-methanol mixtures, but the first mixture should extract fewer interfering components<sup>405</sup>.

At least one solid phase extraction (SPE) step has to be included before the TR can be detected. Most successful are normal phases, such as silica gel, florisil, charcoal-alumina or MycoSep columns<sup>340,359</sup>. Reversed phase has also been published<sup>351, 406</sup> but due to the large difference in polarity of the TR and the time-consuming evaporation of water these methods have not been as popular as the normal phase ones. For the MTR the PEI silica has proven to be superior, as it selectively removes the spiriocyclic drimanes, phenolic compounds and the brownish gum always present in extracts from *Stachybotrys*<sup>405,407</sup>.

For the polar TB immunoaffinity clean-up is also widely used, as they are soluble in the water-acetonitrile mixtures used for loading immunoaffinity columns<sup>340,390</sup>, and can be detected using HPLC with UV detection.

## 2.6.3 Detection of mycotoxins in air and settled dust

To estimate the human exposure to mycotoxins, these have to be measured and quantified directly in air samples or in settled dust. But as spores and airborne dust contain interfering components and the spore concentration is very low<sup>408</sup> (usually  $<< 5000 \text{ m}^{-3}$ ), detection of airborne mycotoxins will be very difficult due to the very low quantities. Until now, airborne mycotoxins have only been detected in environments with high concentrations of airborne spores, such as the agricultural industry and the feed-handling industry. Here several studies have demonstrated airborne AFB<sub>1</sub> when handling materials infested with *A. flavus*<sup>32,409</sup>.

Richard et al<sup>261</sup> detected ochratoxin A in dust from a dwelling with growth of *A. ochraceus*, using LC-MS and HPLC-FLD from samples cleaned up using immunoaffinity clean-up.

Sorenson<sup>46</sup> showed that spores released from a *S. chartarum* isolates growing on rice, contained  $\approx 4 \times 10^{-14}$  g MTR per spore, meaning that about 1500 spores (450 spores using the data of Nikulin et al<sup>45</sup>) should be collected, if assuming 80% extraction efficiency and 50 pg detection limit in sample, however as there are different MTR present (unless they are hydrolysed to verrucarol) and rice and MEA are good substrate for MTR production significant more spores may be needed.

Smoragiewicz et al<sup>410</sup> reported that dust from a ventilation system contained the TR roridin A, T-2 tetraol, T-2 toxin, and DAS. They also reported TR from cultures of the non-TR producing

genera *Penicillium*, *Aspergillus*, *Alternaria*, and *Ulocladium*, which demonstrates that all their results must be false positives.

Yike et al<sup>229,322</sup> demonstrated that dust and air samples from houses infested with *S. chartarum* inhibited their protein translation assay, which strongly suggested the presence of trichothecenes in the air.

To conclude it should be possible to detect mycotoxins in air samples, but no validated sampling and clean-up procedures exist, meaning that this major problem has to be addressed first.

### 3 OVERVIEW OF EXPERIMENTAL WORK

The details of the experiments performed during this study can be found in the papers 1-13. However results of a number of small experiments not included in the papers can be found in the discussion part and identification of components initially reported as unknown.




Figure 4. Overview of experimental work.

## 4 RESULTS AND DISCUSSION

The reason for the more detailed comments and results included in the thesis, is that a number of them would not fit into any scientific papers, but that I feel they should be documented somewhere.

### 4.1 The building associated funga

As mentioned in paragraph 2.1.1 the associated funga reported from different countries varies considerably. Unfortunately this study has not analysed field samples enough to make definite conclusions on this issue. However a number of observations are still interesting:

- It was not possible to get any material samples with *Alternaria* infestation, all were instead infested with *Ulocladium*. Although > 15 field samples which should contain *Alternaria* were received).
- Almost all (>50%) of the material samples received were at least partly infested with *P. chrysogenum* and *A. versicolor*, although the presence of the latter could only be revealed by chemical detection of sterigmatocystin (ST), see section 4.3.2.1, page 44.
- When *Trichoderma* spp. or *Chaetomium* spp. were present on a material they grew in almost pure culture and with significant biomass.

#### 4.1.1 *Penicillium* and *Aspergillus* cultures received from Finland

A number of *Aspergillus* and *Penicillium* isolates collected from both material and air samples were received from National Public Health Institute, Kuopio, Finland (KTL). They were cultivated on YES, CYA, CREA and MEA and identified by colony diameter and morphology. Isolates that could not be unquestionably identified were metabolite-profiled by HPLC-DAD (YEA and CYA).

Species	Frequency (%)	Species	Frequency (%)	Species	Frequency (%)
<i>Aspergillus versicolor</i>	23	<i>P. citreonigrum</i>	3	<i>Penicillium charlesii</i>	1
<i>Penicillium brevicompactum</i>	11	<i>Aspergillus ustus</i> <sup>2</sup>	2	<i>Penicillium commune</i>	1
<i>Aspergillus fumigatus</i>	10	<i>Penicillium crustosum</i>	2	<i>Penicillium echnilatium</i>	1
<i>Penicillium corylophilum</i>	5	<i>Penicillium solitum</i>	2	<i>Penicillium janczewskii</i>	1
<i>Aspergillus sydowii</i>	5	<i>Aspergillus niger</i> <sup>3</sup>	2	<i>Penicillium manginii</i>	1
<i>Eurotium repens</i>	5	<i>Penicillium decumbens</i>	2	<i>Penicillium purpogenum</i>	1
<i>Penicillium chrysogenum</i>	5	<i>Penicillium expansum</i>	2	<i>Penicillium roseopurpureum</i>	1
<i>Penicillium palitans</i>	5	<i>Penicillium rugulosum</i>	2	<i>Penicillium variabel</i>	1
<i>Penicillium glabrum</i>	4	<i>Aspergillus flavus</i>	1	<i>Penicillium vinaceum</i>	1
<i>Penicillium italicum</i>	4	<i>Penicillium albocoremium</i>	1		

<sup>1</sup>From Anne Hyvärinen, National Public Health Institute, Kuopio, Finland. <sup>2</sup>Not a classic *A. ustus* but *Aspergillus ustus* var. *pseudodeflectus*. <sup>3</sup>Did not produce detectable quantities (HPLC-FLD) ochratoxin A on CYA or YES agar.

As seen in Table 6, *A. versicolor* was the most predominant mould almost contributing with 25% of the isolates and more than 50% of all aspergilli. Surprisingly *A. fumigatus* was very frequently isolated (10%) which might be due to sampling on dusty surfaces, as *A. fumigatus* is frequently recorded in Danish house dust (S. Gravesen, personal communication).

*P. brevicompactum* was the most frequently isolated *Penicillium*, confirming results from the on-going Danish School study, where *P. brevicompactum*, *P. corylophilum* and *P. chrysogenum* were the most common penicillia.

These results contradict results from North America, reporting *P. aurantiogriseum* and *P. viridicatum* as the most abundant *Penicillium* species. This might be due to misidentification with *P. palitans* and other species from the aurantiogriseum-complex (J.C. Frisvad, personal communication), but unfortunately it has not been possible to obtain any of these *Penicillium* isolates to verify the identification.

## 4.2 Fungal growth on materials

In papers 2 and 3, material samples were water-damaged ( $a_w \approx 1$ ) and significantly higher number of spores were applied to the materials than naturally found in buildings. The moulds were usually able to cover the materials where they occur "naturally" within 4-10 days, clearly demonstrating that when water damages occur, action should be taken the same day if materials should be saved. This also complies with observations by several consultant engineers (M. Ø. Hansen, personal communication), who report complains from the inhabitants within 10-30 days after a single water damage, and complaints within 2-4 days in buildings with a known water damage history.

When using lower  $a_w$  (papers 10 and 13) the growth rate decreased dramatically and with very few exceptions only the primary and secondary colonisers were observed growing on the materials. At stationary conditions (paper 10), only *Penicillium* and *Aspergillus* species grew, with *P. chrysogenum* and *A. versicolor* being the most common species. However on wooden materials *A. flavus* and *Eurotium* spp. were observed quite frequently and always with significant biomass. At 5°C only *P. chrysogenum* and *A. versicolor* grew, with the latter producing conidiophores with very few conidia.

Wooden and wallpapered materials supported growth down to 78% RH (paper 10), which was lower than the other materials. It was seen that the planned pinewood was usually not infested on as much of the surface as the rough materials, but on the areas where growth




Figure 6. Concrete after 4 months at 95% RH and 10°C, at #1 can *A. versicolor* conidiophores be seen and at #2 sterile mycelia.

occurred there was not significant difference in the produced biomass. At 5°C this limit was about 90% RH, whereas the results only indicates a limit between 80 and 90% RH. These results comply perfectly with the results of Hukka & Viitanen<sup>141</sup> and Grant et al<sup>55</sup>, when the uncertainties of the RH measurements of both studies ( $\pm 2\%$ ) are taken into account.

Interestingly, the gypsum boards did not support growth <90% RH, but did support production of significant quantities of biomass at 95% RH, it is also clear that the fibre-gypsum was less susceptible than the cardboard-gypsum, which is the most common type in Denmark. Paper insulation material did not support fungal growth at all due to the high contents of borates, although it should be noted that this material when damaged supports


growth of several moulds including *Stachybotrys* (unpublished results). The almost totally

inorganic concrete materials partly supported germination of especially *A. versicolor* and sterilia mycelia at RH >90% and growth at 95%, as seen in Figure 6. This must be due to trace quantities of organic components in the concrete. As the concrete materials were cleaner than the ones used in buildings concrete based materials will probably support more growth under field conditions (paper 10).

When comparing Tables 2 and 3, it is clear that the temperature drop from 10 to 5°C had a dramatic effect on the fungal growth, showing no growth at 90% RH and 5°C, and that also here was wooden and the wallpapered materials the most susceptible (paper 10).

#### 4.2.1 Methods for testing the susceptibility of materials

As mentioned in the literature part, testing materials for their susceptibility is difficult, even just controlling the humidity is difficult. As this was the first time such a test was performed at



the Danish *Building Research Institute*, it was tried to keep the set-up as simple as possible (paper 10), and regard the study as a pilot project which should explore difficulties such as humidity range, inoculation, and especially assessment of the materials. This set-up is shown in Figure 7, and was primarily built by Gunnar Holm.

Initial conditions may play an important role for the surface  $a_w$  of the materials, and as it was desired to use steel chamber and take the materials out for assesment, it was necessary to use the sample boxes for reasons occupational health.

This meant that the surface  $a_w$  would be controlled by the RH of the incoming air to the sample box and primarily by the absorbance of water by the material until equilibrium, which small experiments had showed would take months. This meant that we had to add the quantity of liquid water to the materials, assuming that it would be equally distributed within a few days. Although this should tested in future experiments.

I paper 13, the set-up at TNO Bouw was used, and the initial humidity was controlled by a high continuous airflow over the materials (see Figure 8). This means that the absorption of water from the airflow was so little that the change in humidity over the 10 materials in each channel could be neglected. However this approach created another problem as the air speed itself can inhibits growth if the speed is too high. This is illustrated in Figure 9, where the air speed was higher in one side of the channel than in the other.

The TNO approach (paper 13) had another advantage, as it is possible to work with transient humidity conditions, and here it




Figure 8. The TNO set-up, 10 material in each row. In this case infested with *P. chrysogenum*.



was seen that the stress of using periods of high and low humidity during a day, trying to mimic a bathroom. This had a strong selectivity stress towards the phylloplane, *Cladosporium*, which under transient conditions was able to outgrow *P. chrysogenum*.

The instationary conditions, with and without surface condensation (paper 13), can cope with conditions which keeps the storage moulds away and still be too dry for the phylloplane. It can also cope with water accumulation in the surface of materials, especially when working with two to three layer systems, like a painted piece of cardboard gypsum (3-layer system)<sup>11</sup>.

Hence, the total growth behaviour of materials is extremely complicated, and to characterise a material well, the performance and associated funga under at least three different environmental conditions is needed:

- The lowest RH which supports growth.
- The performance under transient conditions.
- The performance under water damage.



Figure 9. The influence of too high air velocity on *A. versicolor* growth in one side of the set-up.

## 4.2.2 Growth assessment

In paper 10, the materials had to be taken out of the set-up for assesment. This was very time consuming and obscured the environmental conditions for the samples. Using the approach of Adan<sup>11</sup> as in Paper 13 (see Figure 8), the materials can be assessed several times a day if required. The time resolution of this process describes the susceptibility - as how fast growth started - better than endpoint determinations of biomass. The latter parameter seems to describes how much of the substrate could be utilised (papers 10 and 13).

Visual inspection (paper 13) has a major problem, especially using the 5 point scale described by British Standard<sup>411</sup>, as the assessed coverage area is the output parameter. This does not take the concentration of fungal biomass into account. Thus a material with very light coverage over all of the material will be assessed to have a higher value than a material with heavy growth over only a part of the material.

The use of image analysis was partly explored at the stay at TNO Bouw (unpublished), and this technique will undoubtedly help in future studies, as images for assessing the materials can be taken automatically several times a day. It can also cope with the high growth rate observed on some paints (where the materials had to be assessed 2-3 times per day, paper 13). Also a more standardized assessment including the fungal "concentration" can be made. However this will require that the image-analysis is calibrated carefully against very well-described samples. Here chemical markers could help to compare the appearance of different moulds.

The use of dissection microscopy showed that the moulds often grew in mixtures (see Figure 10). Looking at materials with scarce growth and a fibrous surface was very difficult, and only sporulation could be detected. However it was possible to distin-




Figure 10. Mixture of *A. flavus*, *A. versicolor* and *P. chrysogenum*, growing on pinewood.

guish *A. versicolor*, often seen as white to olive conidiophores with very few spores and *P. chrysogenum*, often as light bluish or white conidiophores with very long chains of spores attached.

When no sporulation occurred on fibrous materials such as the pinewood or gypsum boards it was only the chemical markers which could detect growth, but in no case significant biomass overlooked.

#### 4.2.2.1 Biological markers

One or both the biological markers ergosterol (Erg) and the Mycometer Test™ were used in papers 5, 10, 12 and 13.

Qualitative determination of Erg was easily performed by the standard HPLC and TLC methods already used at the department, but quantitative determination proved to be a painstaking process. External standard quantitation using HPLC or GC-MS proved unreliable, especially using GC-MS where both splitless injection, various ion-trap phenomena, and the breakdown of the GCQ followed by it being rebuilt in USA, complicates things further (paper 5).

All the sterol standards obtained were almost transparent to the HPLC-DAD, leaving GC-MS with internal standard as the only possibility. LC-MS was not available at that time, and will probably not be an alternative, as the low-polar solvents used to elute it will give problems with the ionization process. Several sterols were tried as internal standard for GC-MS, but the high dynamics of the external ionisation ion-trap system did not give better standard deviations (SD) than 25% when working on standards. When using 4-D<sub>2</sub>-ergosterol as internal standard, synthesised by Dr. J.Ø. Madsen, Erg could be determined with a SD of < 5%, as variation in the ionization and the dynamics of the gate lens is no longer interfering with the analysis.

In paper 5 it was shown that no SPE clean-up step was needed when using GC-MS/MS and that the sample did not need to be neutralised after the saponification when splitless injections were used. Microwave assisted extraction was proven to be a very powerful and fast technique but very dangerous, as the vials occasionally exploded and ripped open the microwave oven door.

As many samples could be hydrolysed in standard laboratory vials at the same time - this method was preferred. It was possible to reach 120 samples per day, although the GC-MS/MS can only analyse 60-65 samples per day. The SD ranged from 1-4% in spiked samples and in real samples SD ranged from 4-12%, with detection limits in the sample of 2-10 ng, which is fully sufficient as the variation of fungal growth on surfaces is much higher.

However during analyses of samples described in papers 10 and 13, this detection limit was difficult to reach and the general limit was 10-30 ng, which is significantly higher than reported in paper 5, which was already higher than reported elsewhere<sup>318,330</sup>. One of the major problems was the daughter ion-yield (number of daughter ions / number of the parent ion in the full scan chromatogram), decreased to 4-8% for unknown reasons, compared with a yield of > 50% of the PFP or HFB-trichothecene derivatives. The water and oxygen levels in the system were extremely low, and various q-values, ion-source temperatures and CID voltages were explored as well as alternative tuning of the lenses, but with no increased sensitivity.

Sample decomposition during injection was a particular problem while running the sample described in paper 13, where the painted materials had a dramatic impact on the sensitivity due to deposits in the liner (not visible). In the future such samples should probably, after hydrolysis, be loaded (cold) onto a C<sub>18</sub> cartridge which can be cleaned with water-methanol

mixtures, before the sterols can be eluted with methanol/dichloromethane, but would compromise sample preparation speed.

In paper 12, the  $m/z$  363 and 365 were used as parent ions and  $m/z$  157 and 159 as daughter ions for Erg and 4-D<sub>2</sub>-Erg respectively, this combined with newly cleaned ion source assembly and new liners in the GC every 60 injections lowered the detection limit to 1 ng (20 pg injected).

In paper 10, both Erg and the Mycometer Test™ showed growth or no growth, but the correlation was obscured by the high variability of the fungal growth. This problem was overcome in paper 12, where the same sub-sample of material or agar were analysed for enzyme activity with the Mycometer Test™ and for ergosterol (Erg) using GC-MS/MS. Here it was noticed that the enzyme activity would usually be highest during the initial growth phase and usually decreased to about 50-80% whereas Erg would only decrease to 90-70% of its peak value, as illustrated in Figure 11. When comparing enzyme activity, Erg and dry weight of agar cultures it was noticed that these parameters did not always peak at the same time,




Figure 11. Comparison of Mycometer test and ergosterol determinations on gypsum board inoculated with *Stachybotrys chartarum* (IBT 9694).

probably due to different induction of the enzyme.

Compared with visual inspection, paper 10, the chemical markers generally showed the same, but were a nice alternative on very fibrous surfaces where even the use of a stereomicroscope gave problems with distinguishing fungal growth from fibres. Erg has the advantage of being an absolute method, which can be good for comparing different ratings of mould growth.

The secondary metabolites were very useful species-

specific biomarkers, and in papers 3 and 10, significant growth of *A. versicolor* (see section 4.3.2.1, page 44) was hidden by *P. chrysogenum*.

Metabolites may also indicate how wet the materials have been, e.g. does the presence of the *A. versicolor* metabolites PE1, XO0 and ROQ but not ST, indicates  $0.95 > a_w > 0.90$ , whereas ST indicates  $a_w > 0.95$  (see section 4.3.2.1, page 44).

## 4.3 Growth and metabolite production

In this chapter the most important results of the different moulds and their growth and metabolites production will be discussed.

### 4.3.1 *Stachybotrys*

Experimental growth of *S. chartarum* IBT 7711 could be recognised after 5 days of incubation (paper 2) on new water-damaged ( $a_w \approx 1$ ) gypsum boards, which is partly due to the high dose of spores ( $4 \times 10^3$  spores/cm<sup>2</sup>), but still surprisingly fast. Growth of the other 4 isolates was not as fast, but the gypsum boards were still totally covered with the fungus after 14 days. None of the 5 isolates could grow on chipboard, acoustic ceiling tiles or pinewood pieces.

These findings are in accordance with field observations<sup>14</sup> and paper 4 where consistently wet gypsum boards seem to be the main substrate of *Stachybotrys* in buildings<sup>25</sup>.

In paper 10 where mixtures of common moulds were inoculated under regulated humidities and temperatures (95-70% RH) *Stachybotrys* was only found on the three types of gypsum boards when RH  $\geq$ 95, and here only with very limited production of biomass had occurred, as shown in Figure 12. This demonstrates that this species generally require water-damaged materials to produce significant quantities of biomass and compete with the penicillia and aspergilli. This is in accordance with the literature (see Table , p.5) where *Stachybotrys* is seen to require  $a_w$  0.95 or more for growth, although Pasanen et al<sup>107,108</sup> have reported growth as low as  $a_w$  0.78-0.81




Figure 12. Scarce growth of *S. chartarum* on a gypsum board at 95% RH and 10°C after 4 months.

which is highly unlikely. This is presumable due to the 1 ml spore suspension added to very small samples (down to 0.25 g), meaning that  $a_w$  of the samples would be higher than the RH in the air controlled by the saturated salt solutions for an unknown period.

#### 4.3.1.1 Analysis for trichothecenes


In papers 1 and 2, GC-MS negative ion chemical ionisation (NICI) was used successfully for detection of the trichothecenes (TR) as it gave excellent matrix suppression compared with  $EI^+$  ionization, as illustrated in Figure 2 in paper 2. However, the matrix suppression could also be obtained with more polar extraction mixtures (methanol-water) and more effective removal of acid residues from the derivatised samples. Combined with a number of problems with NICI compared with  $EI^+$  (paper 1, 2 and 8) the latter became the preferred as NICI gave the following problems:

- A decrease in sensitivity after 10-15 samples was observed. This could be avoided by changing the ion volume.
- After changing to the turbo pump, it took 1-2 hr to stabilise the ionisation gas.
- The MS got very dirty much quicker and needed to be cleaned every 2-3 months, which is very time consuming.
- Very short lifetime of the filament (1-2 months)
- The high pressure of methane, which was necessary to obtain a high sensitivity and high  $m/z$  ions, gave a poor mass resolution of approx.  $m/z$  0.5-1 (10% valley), making automatic data processing very difficult.
- If the method should be used on the type A trichothecenes (TA) from *Fusarium*, the ion volume temperature should be raised to 120°C to avoid condensation. However this gave almost no high-mass ions ( $<m/z$  300) especially not for the type B trichothecenes (TB).
- The number of ionised molecules is about 10 times as low in NICI as in  $EI^+$ , meaning than when MS/MS (which loses 10-90% of the ions) was used a significant drop in sensitivity was observed.

In  $EI^+$  the daughter ion spectra were significantly more reproducible than the full scan spectra. Thus  $EI^+$  ionisation combined with MS/MS (paper 8) was used in all other studies except papers 1 and 2.

In the study of TR produced by *Fusarium* (paper 8) it was observed that the methods used in papers 1 and 2, could not fully derivatise the type B trichothecenes (TB) and that a number of artefacts were produced. A number of methods using imidazole or acid anhydride based reagents and mixtures of these were tried but none were successful, until the method of Langseth et al<sup>396</sup> was applied. This method worked both with PFP and HFB esters, but the PFP was chosen as the HFB gives MW exceeding the upper mass range of the GCQ ( $m/z$  1000).

However this derivatisation method did not work for trichodermol and verrucarol as partly facilitated apotrichothecene




rearrangements (ring breakage of the epoxy group)<sup>412</sup>, so the original method (papers 1 and 2) using HFBI was not changed for these trichothecenes (Figure 13).

To speed up the hydrolysis step it was tried to pass the hydrolysed sample through a strong cat-ion exchanger for neutralisation of the NaOH<sup>405</sup>, which worked fine on standards. However with fungal extracts huge quantities of interfering peaks and irreproducible derivatisation were observed, hence the liquid-liquid extraction seems to be a powerful clean-up step.

Parallel to changing the GC-MS method to  $EI^+$ , a clean-up method for HPLC detection was developed to detect the unhydrolysed macrocyclic trichothecenes (MTR). It was clear that reversed phase clean-up was not effective due to the polarity difference between the MTR a problem well known from the simple trichothecenes where normal phase clean-up is the most effective<sup>340</sup>. Silica and PEI silica (provided by B.B. Jarvis<sup>407</sup>) were tested, but it was clear that the latter was significantly better to remove the spiriocylic drimanes. By dry-packing the PEI in syringes between two pieces of filter-support material stamped out by a sharp steel cylinder a SPE-PEI module could be manufactured on less than 30 sec. The dichloromethane sufficient to elute the macrocyclic trichothecenes could then be placed in the RVC (takes 24 vial) and evaporated in 2 hr giving a much higher sample throughput compared with the method of Hinkley & Jarvis<sup>405</sup>. The effect of cleaning up the extract on the PEI columns is illustrated in Figure 14, where the HPLC profiles of crude extract is compared with the cleaned up extracts on a MTR and an non-MTR producing *S. chartarum* on PSA agar.

It was noted that the sample should be totally dry before redissolving it in dichloromethane, as water or methanol traces facilitated the breakthrough of the spiriocylic drimanes in the dichloromethane fraction. When trying to fractionate *Stachybotrys* extracts it was also noted that the dry solvent blanks from the PEI-columns were toxic to the boar sperm used by Pel-tola et al<sup>231</sup> and the human bronchoalveolar cells used by Norn et al<sup>413</sup>.

To study the ratio between trichodermol and trichodermin in the crude extracts, unhydrolysed crude and PEI cleaned extracts were HFB derivatised and analysed using GC-MS/MS. The PEI clean-up step was necessary to avoid huge quantities of interfering peaks and unreproducible derivatisation. It was also shown that the trichodermol TR are predominantly present as trichodermin (paper 6-8).



#### 4.3.1.2 Metabolites produced by *Stachybotrys*

During the first part of study (papers 1 and 2) it was believed that most isolates would produce MTR<sup>208</sup>. This was, however later shown not to be true, papers 6-9 and Jarvis et al<sup>44</sup>, as only 30-40% of the isolates produces MTR.

The samples collected in a school and a dwelling (paper 1) both yielded verrucarol upon hydrolysis (up to 15 ng/cm<sup>2</sup> SH equivalents) as well as trichodermol (not quantified). When incubating different strains on water-damaged new and old gypsum boards (paper 2), only 2 of 5 isolates yielded high quantities of verrucarol upon hydrolysis (up to 120 ng/cm<sup>2</sup> SH equiva-



lents), one isolate produced significantly less MTR. In extracts from the last two isolates verrucarol was perhaps present, but detection could only be performed on the non-specific  $m/z$  213 ion, [HFB-O]<sup>-</sup>, which was observed from many peaks of the chromatogram.

The satratoxin levels detected (15-120 ng/cm<sup>2</sup>) are the same as reported by Johanning et al<sup>23</sup> who found 33 ng cm<sup>-2</sup> satratoxin H in biomass scraped off from a infested building material, but lower than found by Nikulin et al<sup>107</sup> who detected 2-3.5 µg/cm<sup>2</sup> satratoxins from a highly toxic strain of *S. chartarum* (isolate #72 = IBT 9460).

Temperature and humidity did not seem to influence the production of the spiriocyclic drimanes (paper 10) when growing on gypsum boards, as these were detected in substantial quantities at 10°C and 95% RH at gypsum boards.

In papers 6, only *S. chartarum* produced satratoxins G, H and iso-F whereas *S. dichroa* stopped the trichothecene biosynthesis at roridin E (see Figure 2, p. 14). *S. oenantes* produced trichodermol type TR. *S. bisbyi*, *S. albipes*, *S. microspora* *S. nilagrica* *S. parvispora*, *S. theobromae*, and *S. cylindrospora* did not produce any detectable quantities of TR. The latter species has been reported to produce trichodermol and trichodermin<sup>414</sup> and *El-Maghraby et al*<sup>415</sup> have reported that *S. albipes*, *S. kampalensis* and *S. microspora* produced MTR. Unfortunately these strains are not available in any culture collection. However as only 1-3 strains of each species were tested, the study is not big enough for major conclusions on these rare species, as it should also be noted that only ALK and PSA were used for these species.

In papers 6 and 8 it was observed that the strains capable of producing MTR did this on all solid substrates tested (CMA, V8, YES, PSA, OAT, PSA, DRYES, ALK, CYA and rice extracts agar), with PSA and ALK agar yielding the highest quantities. On the latter agar, enhanced production of stachybotrylactones and lactams was observed, often more than 20 different components with the UV spectra illustrated in Figure 14A. As these components are the main interfering components (removed by the PEI silica SPE clean-up), PSA agar was chosen as the standard substrate for chemotaxonomic studies of *S. chartarum*.

The rich substrates CYA and YES, where high quantities of biomass was produced, yielded surprisingly low quantities of MTR together with CMA, V8, OAT and rice extract agar. The low quantities of MTR produced on the latter substrate is surprising since whole rice is a very good substrate used extensively by Jarvis and co-workers<sup>44,204,304</sup>. The construction cardboard used in study 12 gave approx. as much of the MTR per area as PSA agar.

Three taxa was found among the isolates from buildings (paper 6): i) the MTR producing *S. chartarum* isolates; ii) the non MTR producing *S. chartarum* isolates; iii) a new undescribed species, referred to as *Stachybotrys* sp. type A.

The latter taxon did not show PCR amplification of the TR5 gene (paper 7) and did not produce detectable quantities of trichodermol. However this was not the same in paper 6, where 25% of the Type A isolates produced trichodermol or esters of it, which was also confirmed in paper 8, where trichodermol and trichodiene was detected from the type A isolate.

Study paper 6, 7 and 9 showed that and the non-MTR producing *S. chartarum* taxon and the Type A taxon consistently produced 6β-hydroxy-dolabella-3E,8E,12-trien-14-one and often also epoxydolabellane A (see Figure 14C), both precursors to the atranones<sup>227</sup>. Due to the lack of pure reference standards the identity of these had to be confirmed using LC-MS. This was kindly performed by Hanne Jakobsen, on the new Micromass LCT system using electrospray ionization (ESI) with the same or similar eluents as the general LC method<sup>370</sup>. In Figure 15) the ESI spectra of these two dolabellanes can be seen.

When growing on PSA agar, *S. chartarum* rarely produced the atranones themselves, which is different to growth on rice<sup>227</sup>. However, some of the isolates tested in the spring of 2001 also produced the atranones, indicating small changes in the PSA, may induce this.

Two extracts of atranone producing isolates on rice (Jarvis, B.B., Hinkley, S.F., Nielsen, K.F. et al, to be published) contained trace levels of verrucarol upon hydrolysis (GC-MS) and also were significant more toxic than the other atranone producing isolates although still being




Figure 15. Positive ESI spectra of Epoxydolabellane A and 6β-hydroxydolabella-3E,8E,12-trien-14-one.

magnitudes less cytotoxic than the MTR producers. Trace level of verrucarol was also detected in the material sample from the Belgium IPH case home from which none of 6 isolates were MTR producers. When IBT 14915 (an atranone producer) in paper 2 was inoculated on gypsum boards trace level of verrucarol was also detected. Altogether these observations indicate that the atranone producers may be able to synthesise the verrucarol type TR. Hopefully a more sensitive LC-MS method can reveal if MTR are produced by these strains.

The very clear distinction of atranone producers and MTR-producers on agar substrates (papers 6-9) suggests that the genes from the atranone biosynthesis perhaps inserted in,

or near the genes coding for the enzymes used for synthesising trichodermin into verrucarol-type TR or epi-genetic changes (rearrangements in the 3D structure of the genes), so that only of these pathways is expressed.

The isolates studied by Ruotsalainen et al<sup>148</sup> were retrieved from Public Health Institute, Kuopio Finland (KTL). Originally two large groups of isolates were observed, one which was highly cytotoxic and one which induced inflammatory responses in the murine macrophages. When analysing (paper 9) the chemical profiles of the 20 isolates, it was shown that all the 11 isolates being cytotoxic, except one which was probably contaminated or confused by another isolate, belonged to the MTR producing taxon. All the isolates inducing inflammatory responses belonged to the atranone producing *S. chartarum* taxon. In the original study<sup>148</sup> it was also observed that as the only isolate HT16, did not induce the strong inflammatory response as well as not being cytotoxic at 10<sup>5</sup> spores/ml. This isolate was the only *Stachybotrys* sp. type A, suggesting that this taxon is not producing the inflammatory inducing substance(s) and that the effects is not due to the particle effects, as the spores are almost identical in size and shape (paper 6). The pure atranones B and D were did not induce any inflammatory response in the macrophages. Thus, the specific agent triggering the inflammatory response in the macrophages is still unidentified. The inflammatory agent(s) may be present in the MTR-producing isolates, but due to the extremely potent cytotoxins the macrophages are killed before they can respond or that the spores contains components inhibiting the induction of TNFα<sup>221</sup>.

Identification of the component inducing the inflammatory response is of special interest since high induction of TNFα is known to be a significant factor of the induction for lung damage<sup>153</sup>. Nikulin et al<sup>145,216</sup> suggested that the MTR were the main reason of the lung tissue inflammation they observed when installing mice with *S. chartarum* spores from a MTR producer (#72) and a non-MTR producer (#29, later shown to produce atranones, paper 6).



However #29 also produced significantly smaller quantities of the spirocyclic drimanes, making these components an alternative agent.

When looking at the number of papers dealing with possible causative agents to the IPH, it is surprising how little effort has been put into the spirocyclic drimanes, which are produced at considerably higher levels than the atranones and trichothecenes, presumably 10-500 times more, based on their extension coefficient. Especially the spirocyclic drimanes isolated from *S. microspora*<sup>226,416</sup> which enhances the plasminogen-mediated fibrinolysis should be taken into consideration as they might be produced by the *S. chartarum* isolates in buildings. The neurotoxic symptoms reported by Johanning et al<sup>21,23</sup> could be due to the neurotoxic as well as the nerve activator compounds<sup>417,418</sup>.

In the present work attempts were not made to differentiate between the different spirocyclic drimanes as their UV spectra are very similar. Furthermore there was only very limited time to run LC-MS analyses. A single subclass, including 5-7 analogues of the spirocyclic drimanes was, however, tentatively identified (paper





Figure 16. UV and ESI spectra of two MER-NF500 analogues.

6), by their distinct UV-spectra seen in Figure 16, as the Mer-NF5003<sup>221</sup> components. LC-MS analyses pointed at molecular masses (MW) of 470 Da of three analogues, two analogues of 412 Da, one with 368 Da. All with slightly higher MW than the reported B and E analogue<sup>221</sup>, however one minor analogue also fitted MW, 386 Da, with the F analogue<sup>221</sup>. The attention was drawn to these components, as B.B. Jarvis had never seen these in *Stachybotrys* extracts from rice. These components are produced on most agar substrates, especially DRYES and PSA, as well as on hay (unpublished) and in crude extracts from the building materials (paper 1, 2, 10 and 11). In paper 10, it was shown that the spirocyclic drimanes and atranones were produced at 10°C and 95% RH on several types of gypsum boards indicating that these metabolites are produced under most environmental conditions.


### Airborne *Stachybotrys* metabolites

Late in the study a number of air samples (24 hr, 60 m<sup>3</sup>/min) and material samples were received from E. Johanning. The filters and materials had already been shown to be highly cytotoxic in the pig kidney cell line used by Gareis et al<sup>321</sup>, which indicated the presence of MTR. Analysis of these samples revealed that two air samples contained several spirocyclic drimanes including Mer-NF5003 analogues as seen on Figure 17, and probably also satratoxins G and H (the UV spectra were very weak), which were confirmed by the presence of verrucarol in the two hydrolysed samples, detected by GC-MS and GC-MS/MS (Figure 18). Based on HPLC-DAD detection of satratoxins G and H, the total MTR contents were estimated to 75 and 100 ng (± 50%), whereas GC-MS showed 130 and 150 ng (± 50%) respectively.

These quantities correspond to about 100 and 116  $\mu\text{g}/\text{m}^3$ , as about 1.5% of the filter area was extracted, using the MTR contents of Sorenson et al<sup>46</sup> of 40 ppm in the spores from rice cultures which corresponds to about 0.04  $\mu\text{g}/\text{spore}$  (assuming a density of 1  $\text{g}/\text{cm}^3$ , and ellipsoidal shape of 11 x 4  $\mu\text{m}$ ) which correspond to about 2700 spores/ $\text{m}^3$ . Based on data of Nikulin et al<sup>45</sup> who found 0.14  $\mu\text{g}/\text{spore}$  from MEA culture, this corresponds to 770 spores/ $\text{m}^3$ , which are high but realistic concentrations. Several of the material samples (vacuum cleaned onto the ALK filters) from the same building contained significantly higher quantities of the same drimanes as well as satratoxins G and H.



When working with these filters as well as samples from non problem buildings it was clear a significant quantities of black sticky material was also collected on the filters, and more method development is needed to clean-up these samples more efficiently.



When comparing exposure data to animal studies, it seems for the non-toxicologist to be very high quantities that have been instilled in rats and mice. Often  $10^5$  to  $10^6$  spores in single doses<sup>45,217-219,419</sup> and down to  $10^3$  spores in several doses<sup>216</sup>, and with the concentrations of *Stachybotrys* spores even in highly infested buildings generally  $\ll 1000$  spores/m<sup>3</sup>.

As seen in the literature part, many data on the toxicity of trichothecenes exist, however only a few studies take lung toxicity, particle effects, and other metabolites into account.

Using the data of Nikulin et al<sup>45</sup> who used  $10^6$  spores (containing 140 ng MTR) as a single dose, the death of 2 of 4 animals, resembles the LD<sub>50</sub> value (not taking the statistical uncertainty into account). Directly transferred to a human (70 kg) assuming the same susceptibility per weight, corresponds to about 750 µg MTR or  $3 \times 10^9$  spores.

As concentrations of *Stachybotrys* spores even in highly infested buildings, is generally below 1000 per m<sup>3</sup> (Hunter et al<sup>10</sup> have reported 20 times higher values) and with a human respiratory rate of 1.5 m<sup>3</sup>/hr, about 36 000 spores can inhaled per day. This is so much lower than the LD<sub>50</sub> value, that there is no reason to suspect lethal mycotoxicoses even if a 1000x lower LD<sub>50</sub> is used, to cope with individual and species susceptibility as well as more toxic strains into account.

Workers handling infested materials, and not using the prescribed respiratory filters may be exposed to very high levels. Assuming up to 0.1-1 µg/cm<sup>2</sup> MTR and a LD<sub>50</sub> of 750 µg MTR this corresponds to dust from 0.15-1.5 m<sup>2</sup>, and it is not likely that any persons will inhale so much biomass even if working in a small unventilated room. But significant inflammation in the lungs and decrease in platelet concentration, as well as changes in the lymphocyte subpopulations may be possible. Such effects were observed in mice when instilling 6 dose over 3 weeks using  $10^3$  spores each time<sup>216</sup>. This corresponds to the dust from 2-15 cm<sup>2</sup> infested material per day. However these does not take the higher metabolism and shorter life span of the mice into account.

To assess the risk of people living in mouldy homes repetitive exposures of small doses is needed to estimate the *No observed adverse effect level* (NOAEL)<sup>420</sup>. This is especially important for the MTR, as they have immunosuppressing effects at far lower levels than the acute ones and should be combined with the other metabolites.

To conclude on this species, which is the far most investigated indoor contaminants, and still not been established any causal relationship to IPH, although it seems that the MTR are not the principle components. The general immunosuppression of people exposed to *stachybotrys* may also be explained by the spirocyclic drimanes, although exposure to MTR producing strains must be considered to be worse.

Significant is needed to characterise the health effects of spirocyclic drimanes as they are the primary metabolites of *S. chartarum* when growing on building materials. More over they are also produced in its natural habitat, hay, and have been proven pharmacologically active in many assays (Appendix B, Table 2).

## 4.3.2 *Aspergillus*

### 4.3.2.1 *A. versicolor*

In paper 2, it was shown that this species was capable of growing on almost all the water-damaged materials, and that chipboard and wallpaper supported production of the most visible biomass. Furthermore (paper 13), it was observed that *A. versicolor* grew especially fast on paints, and transient humidity conditions greatly slowed its growth.

Two different growth patterns were seen: either low biomass production and heavy sporulation or high biomass production (white-red mycelia) with very low sporulation (papers 2, 3 and 10).

In paper 10, *A. versicolor* was one of the most frequently observed mould growing on the materials, even capable of growing at 5°C. This is contradictory to Smith & Hill<sup>94</sup>, who observed that *A. versicolor* requires 9°C for growth on a high nutrient substrate such as MEA.

It was capable to grow on the three types of concrete at RH > 0.90 (paper 10), although the produced quantities of biomass were very low, except for a few hotspots (illustrated in Figure 19). It was notable, that it always was




Figure 19. A "hotspot" of *A. versicolor* conidiophores on low density concrete (bar is 1 mm).

*A. versicolor* that grew on the concretes and never *P. chrysogenum*, which indicates that *A. versicolor* may require less nutrients or is better grow at high pH. This is confirmed by private consultants who often see *A. versicolor* growing in plaster (M. Ø. Hansen, personal communication).

In paper 2, it was shown that all the 5 isolates of *A. versicolor* from buildings produced, very high quantities of sterigmatocystins (ST) and 5-methoxysterigmatocystin (5ST), up to 30 µg/cm<sup>2</sup> on the material samples. In addition other ST analogues, versicolorins and other components from this biosynthetic pathway were usually also present in lower quantities estimated on the peak areas and the molar absorptivities. The amounts of biomass scraped from the materials were estimated to less than 100 mg, which means that the total contents of sterigmatocystins may have been more than 1% of the biomass. All the materials, especially wall-paper supported production of ST, which was positively correlated to the amount of visible biomass and negative correlated with sporulation. This is quite obvious, as substantial energy is put into sporulation.




Figure 20. UV spectrum and positive ESI spectrum of 5-methoxysterigmatocystin.

In the study on naturally infested materials (paper 3) it was observed that red coloured areas infested with non- or poorly sporulating isolates contained the largest quantities of ST, whereas areas with many conidia contained very small quantities of ST. This is important for exposure assesment, as the spores are considered the source of exposure to ST, although new studies have shown that smaller fragments than the spores are liberated from its mycelium<sup>84</sup>.




Figure 21. UV spectra of two peaks resembling versicolin.

In both paper 2 and 3, the investigated materials were soakingly wet ( $a_w > 0.99$ ) and compared with paper 10 and 13 where different humidities were applied, it was apparent that ST production was correlated with RH, and that ST production was not detectable at  $a_w < 0.90$ . This complies with findings on cereals<sup>245</sup>, where sterigmatocystin production started at  $a_w$  0.89 with a maximum production and biomass at  $a_w$  0.93.

In paper 2 and 3, 5ST was tentative detected based on its UV spectrum, especially the shoulder at 270-280 nm

(Figure 20) not seen in the UV-spectra of other sterigmatocystins. Later it was shown by positive electrospray LC-MS, that the molecular weight was 354 Da. This is seen as the  $[M+H]^+$  ion in Figure 20. The M+64 adduct could not be accounted for but it was also observed for ST.

A number of *A. versicolor* isolates produced one to five components resembling the known component versicolin<sup>421-423</sup> (J.C. Frisvad, personal communication). Two of the UV spectra are shown in Figure 21. At least one of these was produced in substantial quantities on wall-papered gypsum boards (paper 2).

It was tried to clean up 5 of these components by growing a particular good producer on YES agar, where they often are produced in very high quantities. But as the components seem to be unstable when cleaned-up, and as time was short the project (2 weeks) it was abandoned. Later it was tried to tentative identify the analogues by LC-MS as a literature review showed that it might be 2,3,6-trihydroxytoluene<sup>423</sup> and esters hereof. However this analogue was not commercially available, but the two analogues to isomers 3,4,5-trihydroxytoluene, and 2,4,6-trihydroxytoluene were purchased. Especially the 3,5,6 analogue, had a similar UV-spectrum (Figure 22) and a retention time similar to several of the "versicolins".




Figure 22. UV spectra 3,4,5-trihydroxytoluene and 2,4,6-trihydroxytoluene.

LC-MS of extracts containing the "versicolins" indicated MW of 260 and 262 Da, and several with 242 Da. However other, less abundant, unexplained ions were also present, meaning that these MW may not be correct. This was further complicated, as LC-MS of the two commercial analogues indicated the 2,4,6-analogue was not ionised at all, and that the 3,4,5 analogue showed 6 major ions at  $m/z$  253, 294, 311 and 481, with no apparent ionization mechanism. Thus the ionisation conditions, including ion-polarity, have to be optimized for this type of components before any definite MW could be assigned.

In paper 10 and 13, where the sterigmatocystins and their analogues were almost never detected, and number of other metabolites were detected. These have previously been detected in extracts of *A. ochraceus* (J.C. Frisvad, personal communication), and are named ROQ, PE1 and XXO until their structure is known, their UV spectra can be seen in Fig. 11. Especially the latter component was often detected in material extracts. Occasional was the known component penigequinolone detected. Looking at some of the very small peaks in the chromatograms from both agar and material extracts (paper 2 and 3) revealed that these metabolites were present in many *A. versicolor* extracts.




Figure 23. From above, UV spectra of the structurally unknown ROQ, XXO, and PE1.

LC-MS analysis indicated that XXO had a MW of 431 Da, and an analogue eluting at 1-2 min. before a MW of 447 Da. Three analogues of ROQ were detected, however the MW as only determined for one of them as 393 Da. It is interesting that these presumable nitrogen-containing metabolites (nitrogen rule) are still biosynthesised at RH < 90% while the polyketide pathway that produced ST, is shut down. However at 86% RH they were not biosynthesised by the still growing *A. versicolor*.

Four other types of metabolites, eluting between 3 and 10 min, seemed to be strongly associated with growth of this species under low RH, and their UV spectra can be seen in Figure 23, all has several analogues often also seen. A few of the metabolites have been seen in agar culture extracts.

The HPLC-DAD analyses of the samples of paper 10 and 13, also revealed a ERG analogue eluting approx. 2 min after having identical UV spectra, it was only detected in samples infested with *A. versicolor*. Inspection of the full scan segments of the GC-MS analyses indicated no other sterols, which together with the retention time and same UV spectrum strongly indicates that it was an ester of ergosterol.

It is obvious that the metabolism of this species is very diverse, and needs much more attention, as most of the metabolites produced at  $a_w < 0.95$  are unknown. These metabolites may be important for the adverse health effects associated to growth of *A. versicolor*, especially because they were liberated

from the materials by a light vacuum, and hence have the capability of becoming airborne.

Animal tests have also shown that *A. versicolor* induces inflammatory responses in rats and mice<sup>145,151</sup>. These things combined with the small liberated fragments from the spores or hyphae<sup>84</sup>, means that the growth of *A. versicolor* poses a health risk even if air measurements does not show elevated concentrations of spores.




Figure 24. UV spectra of four unknown metabolites presumable produced by *A. versicolor*

### 4.3.2.2 *A. ustus*

In paper 3, *A. ustus* were incubated on a number of materials, they grew very slowly on pure gypsum boards and chipboard whereas growth was much faster on the wallpapered ones, which it covered the surface after 2 weeks. On the gypsum boards solid structures, 1-2 mm in diameter, containing up to 100 Hülle cells were observed. The *A. ustus* isolates studied in paper 3, were all isolated from mouldy buildings, and produced no detectable quantities of any known mycotoxins from this species. The highly toxic austamides, austdiols, and the

austocystins (Appendix B, Table 5) who are consistently found in cereal isolates (J.C. Frisvad, personal communication) were not produced in detectable quantities on the materials or in agar cultures. Instead a number of metabolites with UV spectra resembling the ones seen in Figure 25, with varying UV-max, all eluting between from 14 min to 35 min, were observed. The low toxic kotanines, also seen from isolates of *A. niger* was the only known metabolites produced on the materials.

The indoor isolates appears to be *Aspergillus ustus* var. *pseudodeflectus*, which should be described as a new species, as varieties are not accepted any more<sup>169</sup>.

In agar culture extracts of the indoor air type, components resembling the drimane sesquiterpenes, the TMC's, pergillins and ophibolins seem to be present (Appendix B, Table 5). These metabolites are not described as toxic, and have been isolated from *Aspergillus ustus* var. *pseudodeflectus*, but a definitive identification of these metabolites was not possible due to the lack of reference standards and LC-MS analyses.

The general conclusion on the indoor air *A. ustus* isolates, is that studies on their in vitro and in vitro pulmonary toxicity and inflammatory potential is needed (grown on relevant materials), as well as knowledge on what is actually liberated from materials infested by these isolates.

#### 4.3.2.3 *A. niger* complex

Growth of especially *A. niger* was extremely fast on all artificially infested materials except on gypsum board and the wallpapered gypsum boards where almost no biomass were produced (paper 3). The other materials were covered by black *Aspergillus* heads in one to two weeks, and substantial quantities of biomass could be scraped off the material. This indicates that the gypsum boards contains components inhibiting the growth of this species. All isolates (paper 3) produced high quantities (>20 different) naphtho- $\gamma$ -pyrones and tetracyclic compounds eluting from 6 to 35 min (UV spectra, see Figure 26) and the known compounds orlandin and nigragillin (Appendix B, Table 6). The quantities of these components made detection of the malformins and other end-absorption components impossible, and if the spores are later shown to be highly cytotoxic a more selective method against these small cyclic peptides should be developed. After the study the samples were reanalysed using HPLC-FLD for the presence of ochratoxins, but these analyses were also negative.

When observing the spores on the media it is clear that they contains a high number of other metabolites, but as for *A. ustus*, studies on their in vitro and in vitro pulmonary toxicity and inflammatory potential is needed.




Figure 25. Common UV-spectra from *Aspergillus ustus* var. *pseudodeflectus*.




Figure 26. UV spectra of a tetracyclic compound (left) and naphtho- $\gamma$ -pyrones.



#### 4.3.2.4 *A. flavus*

In paper 10, *A. flavus* contaminated a number of the wooden materials, presumably due to ineffective X-ray sterilisation (25 kGy), as *A. flavus* growth was seen on a piece of pinewood returned from the sterilisation plant. It should be noted that all boxes were marked with small X-ray indicators to assure that they were x-rayed.

However as *A. flavus* usually produces aflatoxins, extracts from materials where it grew were analysed with HPLC-FLD, where the samples had been derivatised using trifluoroacetic acid to produce the stronger fluorescent hemiacetals<sup>424</sup>, which had a 52 times lower detection limit ( $\approx 100$  pg) for the B<sub>1</sub> analogue than the underderivatised. No aflatoxin was detected in any of these samples, which complies with the results of Ren et al<sup>262</sup> and by Rao et al<sup>263</sup>. Surprisingly, the isolate recovered from one of the materials did not produce aflatoxins on CYA or YES agar. However the in vitro and in vivo toxic and inflammatory potential of material cultures should still be investigated as this species produces many other metabolites when growing on materials, and hence may still be a problem.

#### 4.3.3 *Penicillium*

In papers 3 and 10, it was observed that the penicillia produced significantly less biomass than the aspergilli, based on visual observations, what could be scraped off the materials and the size ergosterol peak in the HPLC chromatograms.

It has been a problem to obtain materials with other penicillia than *P. chrysogenum*, as identification to the species level is not done by the consultant engineers we collaborate with, and who have a good source of naturally infested materials.

##### 4.3.3.1 *P. chrysogenum*

In paper 3 it was observed that this species grew very fast on the wallpapered gypsum boards and chipboard, seen as grey to light green discolouring patches. The materials were overgrown in two to three weeks.

On the naturally infested materials investigated it was present in almost all samples, with more substantial amount of biomass than on the artificially infested materials. Isolation often also revealed an additional but limited number of *A. versicolor* colonies, indicating that it often grows in mixed



Figure 27. A MDF plate (20×14 cm) from paper 10, after 4 months at 95%RH and 10°C. # 1 and 2 are *P. chrysogenum* growth (2 mm high) and #3 is a *Eurotium* Sp., #4 is *Ulocladium* sp., and the rest of the material is partly covered with a mixture of *A. versicolor* and *P. chrysogenum*.

cultures, which was also observed in paper 10. The mixed cultures may be due to a lower quantities of antifungal metabolites, or perhaps that the metabolites do not diffuse in these solid materials.



In paper 13, *P. chrysogenum* (CBS 401.92) was surprisingly fast on the painted samples, where it grew faster than *A. versicolor*, and was visible after 2 weeks, here it appeared light blue, but changed colour to grey over time.

*P. chrysogenum* produced (paper 3, 10 and 13) very low quantities of secondary metabolites compared with *Aspergillus* species, e.g. were no *P. chrysogenum* metabolites detected in any of the large areas seen on Figure 27, except for occasional detection of chrysogine, and 2-pyrovoylaminobenzamide no metabolites could be associated to growth of this species under non water damage conditions. A considerable number of the *P. chrysogenum* infested samples in paper 13 were contaminated with an unknown *Aspergillus*, producing totally unknown metabolites perhaps related to *A. ustus* and/or *A. versicolor*.

On water-damaged wallpapered gypsum boards it produced chrysogine (paper 3) whereas this metabolite was not detected on chipboard. The natural samples, meleagrins were detected as the only metabolite, which is interesting as it is a predecessor of the neurotoxic roquefortine C (paper 3). TLC analyses<sup>274</sup> showed that all isolates produced an unknown metabolite appearing as dark blue spots after spraying with anis aldehyde. This metabolite was only detected from *P. chrysogenum* and had approximately 10% higher  $R_f$ -value than griseofulvin. Recently it was shown that double blinded placebo controlled exposure of 8 "sensitive" humans to  $6 \times 10^5$  spores/m<sup>3</sup> for 6 min of *P. chrysogenum*, grown on wallpapered gypsum boards, did not induce any significant changes in self reported symptoms, clinical measurements or blood analyses (Meyer, H.W., Kildesø, J., Nielsen, K.F. et al, to be published). As for most of the other moulds, no data on the long term toxic potential of this species exists, and hence it may produce toxic metabolites, not detectable with HPLC-DAD. However on the other hand, it may be one of the moulds that obscure detection of more toxic species.

#### 4.3.3.2 *P. brevicompactum*

All isolates grew well on water-damaged wallpapered chipboard and chipboard (paper 3) whereas the growth was slower on the wallpapered gypsum-boards, and no growth was observed on gypsumboards. This observation suggest that growth it is stimulated by components present in wood, which corresponds well to field observations where it is frequently isolated from wooden materials<sup>124</sup>.

On chipboard (paper 3), 1/3 of the isolates produced mycophenolic acid, and 1/2 of the stains also produces asperphenamate, a tanzawaid acid analogue<sup>425</sup>(UV in Figure 28), and the structurally unknown metabolite O.

In paper 10, this species was not isolated from any of the materials, indicating that it has difficulties with competing with *P. chrysogenum* and *A. versicolor*. However the dust from one MDF plate (10°C, 95% RH) contained another tanzawaid acid analogue indication the presence of *P. brevicompactum* on the material, and other possible analogue was detected from a beech wood piece (90% RH, 20°C), also indicating the presence of *P. brevicompactum*.

Especially the presence of the immunosuppressing mycophenolic acid, a number of metabolites with unknown biological activities, and the anecdotal mycotoxicoses after ingestion of infected food, suggests that may have strong in vitro and in vivo toxic and inflammatory potential, which of needs further investigation, as it is on of the most common penicillia in mouldy buildings.




Figure 28. UV spectra of unknown tanzawaid acid analogue.

#### 4.3.3.3 *P. polonicum*

Only two indoor strains were available, and they grew on all the materials, although usually with not very much biomass (paper 3). They both produced 3-methoxy-viridicatin, verrucofortine, and the tremorgenic verrucosidin.

However as it is not clear how common this species is in the indoor environment, there are other species which need to have their in vitro and in vivo toxic and inflammatory potential determined before this species.

#### 4.3.3.4 *Penicillium expansum*

Only one isolate of indoor origin was available (paper 3) and it grew very poor on all the four materials, and no metabolites were detected in any of these samples. This is contradictory to Land and Hult<sup>289</sup> who saw production of the patulin, when their strains were inoculated on wood and wood chips.

As this species can produce some of the most toxic components found in this genus, it is necessary to know if its presence in buildings is due to growth on materials or introduced from mouldy fruits.

#### 4.3.4 *Trichoderma*

In paper 2, where the materials were inoculated at  $a_w \approx 1$ , growth of *Trichoderma* could be detected after 3-4 days on wooden materials whereas it was much more slow on other materials and did not occur on the new gypsum boards. These observations are fully in accordance with field observations (paper 4) where *Trichoderma* is generally found on wood products<sup>25,71</sup>.

In paper 10, where the humidity was lower, *Trichoderma* was only growing on a very small fraction at the wooden materials and here not even as the dominating mould. This further demonstrates that this genus requires water-damaged materials to grow.

None of the *T. atroviride*, *T. harzianum*, *T. longibrachiatum* and *T. viride* infested materials from, paper 2, revealed trichodermol upon hydrolysis, which was also the case for the YES extracts from the 36 isolated investigated by Lübeck et al<sup>71</sup>.

In a later paper 8, 150 additional agar extract from U. Thrane's collection were screened for trichodermol, however only one isolate (IBT 9471 = ATCC 90237) was able to produce trichodermol as also found by Corley et al<sup>293</sup>. It was not been possible to obtain other known trichodermol producing isolates, as the isolate used produce the first trichodermin by Godtfredsen & Vangedal<sup>291</sup> at LEO pharmaceuticals, Denmark, is not available.

The literature review on *Trichoderma* showed that the peptides are some of the dominating biologically active metabolites (Appendix B, Table 11), but they were not targeted in this work due to lack of LC-MS facilities.

Recently it was shown that double blinded exposure of 8 "sensitive" humans to  $6 \times 10^5$  spores/m<sup>3</sup> of *T. harzianum*, grown on wallpapered gypsum boards, during 6 min, did not induce any significant changes in self reported symptoms, clinical measurements or blood analyses (Meyer, H.W., Kildesø, J., Nielsen, K.F. et al, to be published). The set-up was (for economic reasons) partly buildt in plastic, and during characterization of the set-up it was shown that particles smaller than the spores were absorbed to the walls of the set-up.

As *T. harzianum* as *A. versicolor*, also produces smaller particles (Kildesø, J.K., Würtz, H., Nielsen, K.F. et al, to be published) than the spores the people were not exposed to these fine particles.

To conclude on this genus, it is important that their *in vitro* and *in vitro* pulmonary toxicity and inflammatory potential is investigated (grown on relevant materials), as well as knowledge on what is actually liberated from materials infested.

#### 4.3.5 *Memnoniella echinata*

No growth tests were performed with this species on materials, but an infested piece of *Memnoniella* infested gypsum board received from Dr. E. Johanning. Dust, sampled by the ALK mouthpiece, from this sample contained griseofulvin and its two dechlorinated derivatives.

Chemical analysis (unpublished) were performed on 11 isolates, grown on ALK, PSA, SYES, CYA and V8 agar: Results showed that the three griseofulvins were consistently produced on all media and in significant quantities compared to other metabolites, and combined with data from rice cultures<sup>44</sup>, it must be concluded that these components seem to be produced on all solid substrates. Spirocyclic drimanes, similar to the ones produced by *S. chartarum*, were also consistently produced, however in significant (ca. 10×) lower quantities than the griseofulvins, based on the UV molecular absorptivities.

The production of trichodermol or esters of it, varied considerably even in the same isolates on the same media (papers 8 and 11).

To conclude on this species, it seems to be isolated in the same places as *S. chartarum* although less frequently, which may be due to difficulties of distinguishing it from *S. chartarum*. However studies on its *in vitro* and *in vitro* pulmonary toxicity and inflammatory potential are needed (grown on relevant materials), as well as knowledge on what is actually liberated from infested materials.

#### 4.3.6 *Alternaria*

All the isolates, except of the *A. infectoria* group isolate, inoculated on different materials (paper 3) grew well and produce alternariol, its mono methyl ether and three to five unknown analogues with identical UV-spectra. However these metabolites are very low toxic and should not be considered mycotoxins (see section 2.4.6, p. 22). No altertoxins, tentoxin or tenuazonic acid was detected in any of the extracts, confirming results of Ren et al<sup>308</sup>.

It was tried to find naturally infested material with growth of *Alternaria*, but all samples (>15) brought to the department were infested with *Ulocladium* sp. and not *Alternaria*. This may indicate that actual *Alternaria* growth on materials may not be that common, and that the many findings of *Alternaria* in the indoor air environment may originate from outdoor sources.

However it has still not been shown if the AAL toxins are produced by *Alternaria* in buildings, although this is very unlikely, as this type of strains are only known as endophytes in plants<sup>350,426</sup>. These metabolites are the only really mycotoxins known from this species, but need LC-MS detection or the unspecific OPA derivatisation also used for fumonisins. Thus, the presence of this fungus in buildings only seems to pose a very limited risk, especially as the main source of exposure comes from outdoors, where the air concentrations are magnitudes higher than indoors.

### 4.3.7 *Chaetomium globosum*

Being an ascomycete this genus has a very characteristic appearance (paper 3) due to its distinct black or dark green, hairy perithecia visible to the naked eye. Field samples were all very wet wallpaper, gypsum board and wood products (paper 3 and 4). On the artificially infested water-damaged material growth was very fast covering the surface with substantial amounts of biomass after two weeks (paper 3).

In paper 10 where mixtures of common moulds were inoculated under controlled humidities *Chaetomium* was only found growing at one material clearly showing that this genus generally requires water-damaged materials to grow.

When growing on building materials (paper 3) *C. globosum* consistently produced high quantities of biomass (up to 10 mg/cm<sup>2</sup>). Very high quantities of secondary metabolites, especially chaetoglobosins A, C and analogues were produced in very similar quantities, 28-50 and 5-7 µg/cm<sup>2</sup> respectively, by six isolates incubated on wallpapered gypsum. An unknown metabolite, was detected in all *Chaetomium* extracts except in IBT 7029, which had visible smaller peritricia than the other isolates. Hence this component may be a species-specific marker. Its UV data (see Figure 29) did not seem to match any of the components found in Table 15 in Appendix B.




Figure 29. Unknown metabolite from *C. globosum*.

The metabolite profile of naturally infested materials were very similar to the artificially infested materials, chaetoglobosin A and C production in quantities up to 3 µg/cm<sup>2</sup>. Besides these, three other chaetoglobosins and approximately 10 unknown metabolites were also detected. Analyses of two old (2-3 years) heavily black-stained materials did not reveal chaetoglobosins A or C, but a number more polar analogues, which are probably hydrolysis or oxidation products of the original metabolites, however these extracts have not yet been subjected to LC-MS analyses.

*C. globosum* grew very well together with gram negative bacteria on various building materials without it was possible to see this in the stereo microscope. However when determining the inflammatory potential of this mixture in mice macrophages huge quantities of TNF $\alpha$  and NO was liberated due to endotoxin from the bacteria. This observation may point against more studies on the interaction between bacteria and moulds as the bacteria may need the moulds powerful enzyme-systems. However spores from the pure cultures did not induce any inflammatory response in macrophages, but was cytotoxic to the cells (unpublished).

When concerning risk assessment of this fungus in buildings, it is clear the cytotoxic and cytoplasmatic cleavage inhibiting chaetoglobosins is the main concern. However as no data on inhalation of the spores have been found in the literature. As the spores of this fungus is packed in the Peritrecia the exposure to airborne spores may be rather limited and smaller particles released from dry mycelia, as it has been shown for *A. versicolor*, must be studied before any attempt on risk assessment is tried.

### 4.3.8 *Cladosporium*

*C. sphaerospermum* seems to be the most predominant species growing in buildings, and was able to out grow *P. chrysogenum* even in a ratio of 1 to 100 (paper 13). This is a result of their ability to re-attain growth from the hyphal tip much faster than penicillia<sup>119</sup>, which is presumably why this and other phylloplanes are so common in bathrooms and on silicon caulking in the window frame, environments which often have very different humidities during the day.

No secondary metabolites were detected in any of the samples in paper 13, and this genus is known for the very few metabolites it produces, and its ability to grow under these special conditions may account for this.

The high number of spores of *C. cladosporioides* (up to 15000m<sup>-3</sup>) found outdoors during the summer and the apparent lack of metabolite production on materials, and no inflammatory response when in instilled mice lungs<sup>217</sup>, suggests that this genus should generally not be considered more than a humidity indicator.

### 4.3.9 *Ulocladium*

All four isolates inoculated on materials (paper 3) grew well, but did not produce any detectable quantities of secondary metabolites, which is in accordance with the literature where extremely few metabolites from this genus have been described. Analyses of natural samples with excessive growth have not either revealed any metabolites in the polarity range we look at using present HPLC-DAD method.

In Study 10, it was only isolates at RH ≈ 0.95, indication that it also requires very high RH, and not metabolite seemed to be associated to it.

To conclude on this genus, it seems to be isolated the same places as *S. chartarum* although more frequently, as it is presumably able to grow under the same humidities as *Alternaria*, but the low production of metabolites and no known knowledge of mycotoxins indicates that it is not a major problem. However this should be confirmed by testing its *in vitro* and *in vitro* pulmonary toxicity and inflammatory potential.

It is a good indicator for wet environments and hence water-damage, but requires significant microscopic training if it should be differentiated from *Alternaria*.

### 4.3.10 *Paecilomyces*

*P. lilacinus* was found to grow poorly on all the artificially infested materials except on gypsum boards, where the characteristic pink cotton-like mycelium was produced, but only in modest amounts, and no metabolites were detected in the extract (paper 3).

*P. variotii* grew well on the artificially infested chipboards and wallpapered chipboard, but the quantities of biomass were very limited, however at the chipboard did support production of seven components with totally unknown UV-spectra.

These two species, both need to have their *in vitro* and *in vitro* pulmonary toxicity and inflammatory potential determined (grown on relevant materials) besides determining the size of particles liberated from materials infested with them.

### 4.3.11 *Eurotium*

In study 10, *Eurotium* sp. was isolated from several of the wooden materials inoculated at 25, 20 and 10°C (materials were not sterilised prior to inoculation at 10°C).

The HPLC analyses revealed the presence of very high quantities of metabolites compared with *A. versicolor* and *P. chrysogenum*. These metabolites were probably present in the ascoma (see Figure 30) as these structures were very predominant. Echinulin and several derivatives were detected along with a high number of anthraquinones, including questin and questinol, several benzoquinones, including flavoglaucin, produced by many *Eurotium* species<sup>427</sup>. Also two isochromane toxin analogues<sup>425,428</sup> were detected.




Figure 30. The ascomata from *Eurotium* sp. on a piece of pinewood after 4 months at 10°C and 95% RH.

The high quantities of metabolites sampled on the filters indicates that this genus may be important, and the in vitro and in vitro pulmonary toxicity and inflammatory potential of dust from infested materials is needed.

## 4.4 Overall discussion

### 4.4.1 Growth on materials

It has been demonstrated that the tertiary colonisers in practise require almost liquid water to grow on the materials. Hence the name water-damage moulds is very appropriate. To avoid growth of these is theoretically very simple, as it just requires dry constructions. However due to insufficient quality assurance in the building industry and partly also insufficient maintenance, these five problems are observed:

- The climate screen, especially the roof, should be watertight, which should not pose any problem. However this is actually a major problem in Denmark, as seen in paper 4, especially due to leaking flat roofs.
- Leaking pipes, especially when they are hidden in the constructions, constitutes a substantial part of the severe water damages (papers 3 and 4).
- Rising damp from the ground, due to lack of drainage or capillary breaking layer.
- Water build into the construction either from hardening concrete, which had not had the time to dry out. Also materials which have been placed on the ground or out in the rain is becoming an increasing problem and a number of these cases have been reported in the press.
- When parts of the building is exposed to rain during the building process, this an engineering or planning problem which demand that the partly finish construction is shielded during the building process.

Solving these problems is not a matter of choosing or developing other materials, as almost all materials were able to support fungal growth (paper 4 and 10). Instead it is a matter of creating new quality assurance systems, which can be practically implemented during the building process.

## 4.4.2 Metabolites

The water-damage moulds produced very high quantities of secondary metabolites, and as secondary metabolites are signal components<sup>169</sup>, these metabolites must be very important for the fungi, as they must use significant energy and internal resources on producing them.

*Trichoderma* spp. produced very low quantities of detected metabolites, which is probably due to the poor extraction and UV-absorption of the metabolites which this genus is so known for.

When comparing the quantities and number of metabolites produced by the aspergilli and penicillia on agar substrates with the metabolites produced on building materials, it was clear that the rich agar substrates *short circuit* the metabolism of these genera. It appeared that the aspergilli produced significant higher quantities on moisture saturated materials, whereas the penicillia seemed to need the many nutrients found in the rich agar media.

When comparing the metabolism of aspergilli and penicillia with *Stachybotrys*, it seems like this *short circuiting* is correlated to the extensively mycelia production, which seemed to be negatively correlated to the sporulation. Thus, when trying to predict the production of metabolites on various matrixes such as building materials, by using agar substrates, media enhancing sporulation and decreasing pure mycelia growth should be used.

Especially when working with *A. versicolor*, it was frustrating to see the numbers of unknown metabolites in the extracts. Hopefully accurate-mass LC-MS, will make identification of some metabolites which is probably known in literature possible.

It is essential to investigate the toxicity and inflammatory responses of all appropriate moulds as function of the humidity, as it may only under certain humidities that they are toxic or inflammagenous. Perhaps it is also isolate dependent or perhaps loses some of the strains the ability of producing important metabolites when held in the lab, as it was observed when working on the membrane-toxin (paper 7).

The total microbial flora still needs to be established, as bacteria presumably means a lot under certain conditions and there may be several types of bacteria present at the materials which have not been determined. The bacteria may need the moulds to degrade the materials, and especially genera as *Stachybotrys*, *Chaetomium* and *Trichoderma* that are very well known producers of cellulases and as they require almost saturated conditions they will have to compete with bacteria which can also grow at these  $a_w$ .

### 4.4.2.1 Analytical methods

Extraction of the metabolites was the most important step, and it was clear that extracting whole materials in organic solvents is not a suitable technique as: i) very huge quantities of interfering material was also extracted from the material (paper 1-3) which may obscure detection or even react with the target components; ii) mycotoxins as ST and TR, could only be extracted from the material-matrix in very limited quantities, <1% of spiked quantities (paper 2); iii) the detected metabolites may not become airborne, especially if they are excreted into the material. It is important to evade interfering components, as it will require a number of different solid phase extracting (SPE) techniques for each or a group of components. This

makes screening impossible, as it perhaps needed to make 2-6 different SPE clean-up steps per analysis, which is very time and resource consuming.

Scraping off the material using a blade worked better (paper 3) but material is easily lost if it is dry and if the material is very wet then significant quantities of interfering material may still be present from the material. Hence the vacuum sampling technique used in paper 10 and 13, is much better as it only samples metabolites that may become airborne and samples a minimum of matrix.

The used detection methods have unfortunately only worked on medium to apolar substances, which could be detected using HPLC-UV, except for the trichothecenes, which were targeted by GC-MS. However important substances as the nephrotoxic glycopeptides, AAL toxins, malformins, cyclosporin analogues, and many peptides would have evaded detection, this also includes unknown toxins and of course metabolites present below the detection limits.

Appropriate bioassays would cope with these problems as these, but it would still need a lot of assays for the different activities, so it would have been perfect to combine this study with a lot of assay tests, unfortunately this was not possible.



## 5 CONCLUSION

Moulds growing on water-damaged materials produce a high number of very toxic metabolites. The production of these metabolites is very dependent on the humidity of and for some moulds also the substrate.

Three taxa of *Stachybotrys* are found in buildings of these only one taxon, approx. 35% of the isolates, actually produced satratoxins whereas most other strains stop the trichothecene biosynthesis at trichodermin. All three taxa produced high quantities of the pharmacologically active spirocyclic drimanes and their precursors. These two groups of metabolites and the atranones, which are produced by the two non-satratoxin producing taxa, are produced on building materials under field conditions. Idiopathic pulmonary hemosiderosis in infants did not seem to be associated with satratoxin production. *Stachybotrys* biomass collected on filters from naturally infested materials samples, contained significant higher quantities of metabolites than any other fungal species investigated during the study.

This study has shown that spirocyclic drimanes and satratoxins were present on filters from air-samplings in a building with severe health problems due to growth of *S. chartarum*.

*Aspergillus versicolor*, which is perhaps the most common species found in mouldy buildings, had a very diverse metabolism, where many of its biosynthetic pathways were only occasionally expressed. When growing on materials under high water activity ( $>0.95$ ) most isolates produced high quantities of the carcinogenic mycotoxin, sterigmatocystin, whereas  $a_w < 0.90$  a number of structurally unknown metabolites, presumably alkaloids, also known from *A. ochraceus* were produced. *A. versicolor* grew often in mixed cultures with other moulds where it sporulated poorly, meaning that it may evade detection by cultivation based methods.

*Penicillium chrysogenum* is the most frequently detected species, but it produces surprisingly few detectable metabolites and often none. Combined with the lack of observed effects in patients experimentally exposed to high quantities of the spores it indicates that it may not be important from a health point of view and is actually obscuring the detection of more toxic genera and species.

On water-damaged materials *Chaetomium globosum* produces high quantities of chaetoglobosins, whereas *P. brevicompactum* produces mycophenolic acid and *P. polonicum* the tremorgenic verrucosidin. The *A. ustus* isolates from buildings are macro-morphologically and chemically very different from cereal isolates, and should be described as a new species.

*Trichoderma longibrachiatum*, *T. harzianum*, *T. citrinoviride*, *T. atroviride* and *T. viride* does not produce detectable quantities of trichothecenes when growing on materials, and even on laboratory media  $<1\%$  of the isolates produce trichodermol or esters of it.

When mouldy material are investigated for mycotoxins they should be vacuum sampled onto filters, as it dramatically decreases the number of interfering substances from the materials and gives a more precise description of peoples exposure.

Except from *Stachybotrys*, almost no data on the pulmonary toxicity and inflammatory potential of the spores and fragments exist from indoor moulds grown on appropriate materials, and not on agar media where the secondary metabolism is often *short circuited*.

The minimal RH for growth on wood-based materials and material containing starch is just below 80% at room temperature, and increases to about 90% at 5°C. On paper-mineral composites such as gypsumboard the min RH is approx. 90% RH from room temperature to

5°C. Pure mineral based materials with few organic additives seems to be able to support growth at  $RH \geq 0.90$ , although 95% RH was needed to generate chemical detectable quantities of biomass. *S. chartarum* requires  $RH \geq 95\%$  to grow on gypsum boards.

When applying transient humidities to material samples during a day, the phylloplane *Cladosporium* was able to outgrow *P. chrysogenum*, even though it can grow under lower RH than *Cladosporium* under constant humidity. This is presumably why phylloplanes like *Cladosporium*, *Ulocladium*, *Phoma* and *Aureobasidium* are very common in bathrooms and other places with instationary humidity conditions.

Ergosterol content of building materials could be very precisely be quantified and quickly analysed (60-100 samples per day) by isotope dilution GC-MS/MS, although not being as sensitive as other GC-MS based methods due to interference from the isotope marked standard and instrumental problems on the ion-trap used. Visual assessment, especially supported by dissection microscopy, was however just a sensitive and is able to cope with the high variation in mould biomass on materials, but should occasionally be supplemented with chemical markers for comparison with other studies.

## 6 PERSPECTIVES AND FUTURE RESEARCH

Although excellent research is being done in this field especially in Scandinavia, The Netherlands and North America, we are far away from a major breakthrough, and hence much more research is needed.

### Smaller projects

Studies on the inhalative toxicity of the spiriocyclic drimanes found in the spores of *Stachybotrys* are needed. This should be followed by development of specialised methods for detecting these metabolites as they are present in substantial quantity and have shown to be good biomarkers in this study.

Studies on the three different *Stachybotrys* taxa are needed, to see if atranone and satratoxin producing isolates coexists, and/or also to see if the atranone producing taxa over long time also can produce low quantities of satratoxins.

An immunochemical assay for detection of sterigmatocystin-guanine and other adducts of this toxin could be used to determine if people are exposed to the toxin through the air or only through the food.

The unknown *A. versicolor* metabolites needs to be structure elucidated and produced in sufficient quantities for a toxicological evaluation.

As exposure to mycotoxins may originate from particles significant smaller than the spores it should be determined if filters or adsorption materials, like activated carbon, should be used for sampling of the mycotoxins. These studies should also face clean-up problems due to interfering substances collected from the air.

### Major projects

General microbiological work is needed so the total indoor funga can be established precisely and to the species level, as a lot of confusion exists, especially in *Penicillium*.

A lot of work is needed on the ecology of the moulds on the materials and the performance of different materials, especially under dynamic conditions. It is also very important to know the response of the moulds to both short and long periods of increased humidity still close to their critical RH.

Co-ordinated and comparable tests of the inflammatory potential and the toxicity of particles released from infested materials, including materials from problem buildings and materials incubated at realistic conditions, should be performed. These tests should be performed from a representative number of isolates from all relevant species. Such results can be used to rate the health impact of the moulds in epidemiological studies and for risk handling in mouldy buildings.

Inhalation experiments where the cognitive performance on mice or rats and their off-spring are measured should also be tried. This was very successful for low concentration exposure to xylene<sup>429</sup>, and if combined with exposures to known areas of naturally infested and artificially infested materials kept under well characterised ventilation conditions, this may be the way to a major breakthrough.

## REFERENCES

1. Platt,SD, Martin,CJ, Hunt,SM, Lewis,CW. 1989. Damp Housing, Mold Growth and Symptomatic Health State. *Brit.Med.J* **298**: 1673-1678.
2. Brunekreef,B, Dockery,DW, Speizer,FE, Ware,JH , Spengler,JD, Ferris,BG. 1989. Home dampness and respiratory morbidity in children. *Am.Rev.Resp.Dis.* **140**: 1363-1367.
3. Dales,RE, Zwanenburg,H, Burnett,R, Franklin,CA. 1991. Respiratory health effects of home dampness and moulds among Canadian children. *Am.J.Epidem.* **134**: 196-203.
4. Dekker,C, Dales,RE, Bartlett,S, Brunekreef,B , Zwanenburg,H. 1991. Childhood asthma and the indoor environment. *Chest* **100**: 922-926.
5. Brunekreef,B. 1992. Association between questionnaire reports of home dampness and childhood respiratory symptoms. *Sci.Tot.Env.* **127**: 79-89.
6. Verhoeff,AP, Strien,RT, Wijnen,JTM, Brunekreef,B. 1995. Damp Housing and Childhood Respiratory Symptoms: The role of sensitization to dust mites and moulds. *Am.J.Epidem.* **141**: 103-110.
7. Koskinen,O, Husman,T, Hyvärinen,A, Reponen,T, Nevalainen,A. 1997. Two Moldy Day-care Centers: a Follow up study of respiratory symptoms and infections. *Indoor Air* **7**: 262-268.
8. Koskinen,O. 1999. Moisture, Mold and Health. Ph.D. dissertation, KTL National Public Health Institute, Kuopio, Finland.
9. Koskinen,O, Husman,T, Meklin,T, Nevalainen,A. 1999. Adverse health effects in children associated with moisture and mold observations in houses. *Int.J.Env.Health Res.* **9**: 143-156.
10. Hunter,CA, Grant,C, Flannigan,B, Bravery,AF. 1988. Moulds in buildings: the air spora of domestic dwellings. *Int.Biodet.* **24**: 81-101.
11. Adan,OCG. 1994. On the fungal defacement of interior finishes. Dr. Dissertation, Eindhoven University, The Netherlands.
12. Brunekreef,B. 1992. Damp housing and adult respiratory symptoms. *Allergy* **47**: 498-502.
13. Nevalainen,A, Partanen,P, Jääskeläinen,E, Hyvärinen,A, Koskinen,O, Meklin,T, Vahteristo,M, Koivisto,J, Husman,T. 1998. Prevalence of moisture problems in Finnish houses. *Indoor Air Suppl.* **4**: 45-49.
14. Miller,JD, Haisley,PD, Reinhardt,JH. 2000. Air sampling result in relation to extend of fungal colonization of building materials in some water-damaged buildings. *Indoor Air* **10**: 146-151.
15. Hilling,R. 1998. 220 Schools. Damage and defects in school buildings. SP Swedish National Testing and Research Institute, Borås [In Swedish].
16. Gravesen,S, Nielsen,PA, Nielsen,KF. 1997. Skimmelsvampe i vandskadede bygninger. SBI rapport 282. Statens Byggeforskningsinstitut, Hørsholm [In Danish].
17. Koskinen,O, Husman T, Hyvärinen A, Reponen T, Ruuskanen J, Nevalainen A. 1994. Respiratory Symptoms and Infections in Mouldy Dwellings and Day-care Centers. In Samson RA, Flannigan B, Flannigan ME, Verhoeff AP, Adan OCG, Hoekstra ES. (eds.), *Health Implications of Fungi in Indoor Environments*. p. 211-214. Elsevier, Amsterdam.
18. Koskinen,O, Husman,T, Hyvärinen,A. 1995. Respiratory symptoms and infections among children in a day-care center with mould problems. *Indoor Air* **5**: 3-9.
19. Hodgson,MJ, Morey,PR, Leung,WY, Morrow,L, Miller,JD, Jarvis,BB, Robbins,H, Halsey,JF, Storey,E. 1998. Building-associated pulmonary disease from exposure to *Stachybotrys chartarum* and *Aspergillus versicolor*. *J.Occup.Env.Med.* **40**: 241-249.
20. Johannung,E, Landsbergis,P, Gareis,M, Yang,CS, Olmsted,E. 1999. Clinical experience and results of a sentinel health investigation related to indoor fungal exposure. *Env.Health Persp.* **107**: 489-494.
21. Gordon,WA, Johannung,E, Haddad,L. 1999. Cognitive impairment associated with exposure to toxigenic fungi. In Johannung E (Ed.), *Bioaerosols, Fungi and Mycotoxins: Health effects, Assessment, Prevention and Control*. Eastern New York Occupational & Environmental Health Center, New York, p. 94-98.

22. Dales,RE, Miller,JD, White,J, Dulberg,C, Lazarovits,AI. 1998. Influence of residential fungal contamination on peripheral blood lymphocyte population in children. *Arch.Env.Health* **53**: 190-195.
23. Johanning,E, Biagini,RE, Hull,D, Morey,PR, Jarvis,BB, Landsbergis,P. 1996. Health and immunology study following exposure to toxigenic fungi (*Stachybotrys chartarum*) in a water-damaged office environment. *Int.Arch.Occup.Health* **68**: 207-218.
24. Gravesen,S. 1994. Allergic and non-allergic manifestations related to indoor fungal exposure - management of cases. In Samson RA, Flannigan B, Flannigan ME, Verhoeff AP. (eds.), *Health implications of fungi in indoor air environment*. p. 241-248. Elsevier, Amsterdam.
25. Gravesen,S, Frisvad,JC, Samson,RA. 1994. *Microfungi*. Munksgaard, Copenhagen.
26. Dearborn,DG, Yike,I, Sorenson,WG, Miller,MJ, Etzel,RA. 1999. Overview of investigations into pulmonary hemorrhage among infants in Cleveland, Ohio. *Env.Health Persp.* **107**: S495-S499
27. Novotny,WE, Dixit,A. 2000. Pulmonary hemorrhage in an infant following 2 weeks exposure of fungal exposure. *Arc.Ped.Adol.Med.* **154**: 271-275.
28. Elidermir,O, Colasurdo,GN, Rossmann,SN, Fan,LL. 1999. Experience and reason - *Stachybotrys* and Pulmonary Hemorrhage. Isolation of *Stachybotrys* from the lung of a child with pulmonary hemosiderosis. *Pediatrics* **104**: 964-966.
29. Gravesen,S. 2000. Microbiology on Indoor Air '99- what is new and interesting? An overview of selected papers presented in Edinburgh August, 1999. *Indoor Air* **10**: 74-80.
30. Douwes,J. 1998. Respiratory health effects of indoor microbial exposure. A contribution to the development of exposure assesment methods. Dr. Dissertation, Landbouwniversiteit Wageningen, Holland.
31. Larsen,FO, Christensen,G, Clementsen,P, Gravesen,S, Skov,P, Norn,S. 1996. Microfungi in indoor air are able to trigger histamine release by non-IgE-mediated mechanisms. *Inflammation Research* **45**: S23-S24
32. Olsen,JH, Dragstead,L, Autrup,H. 1988. Cancer risk and occupational exposure to aflatoxins in Denmark. *Brit.J Cancer* **58**: 392-396.
33. Autrup,JL, Schmidt,J, Seremet,T, Autrup,H. 1991. Determination of exposure to aflatoxins among Danish worker in animal-feed production through the analysis of aflatoxin B<sub>1</sub> adducts to serum albumin. *Scand.J.Work.Env.Health* **17**: 436-440.
34. Kristensen,P, Irgens,LM, Andersen,A, Bye,AS, Sundheim,L. 1997. Gestational age, birth weight and perinatal deaths amongst births to Norwegian farmers 1967-1981. *Am.J.Epidem.* **146**: 329-338.
35. Lappalainen,S, Pasanen,A-L, Pasanen,P, Kalliokoski,P. 1997. Production of fungal volatile compounds in bedding material. *Agric.Food Sci.Finland* **6**: 219-227.
36. Gravesen,S. 1979. Fungi as a cause of allergic disease. *Allergy* **34**: 135-154.
37. Rylander,R, Northall,M, Engdal,U, Tunsäter,A, Holt,PG. 1998. Airways inflammation, atopy, and (1-3)- $\beta$ -D-glucan exposure in two schools. *Am.J.Resp.Crit.Care Med.* **158**: 1685
38. Rylander,R. 1997. Investigation of the relationship between disease and airborne (1-3)- $\beta$ -D-glucan in buildings. *Mediators of Inflammation* **6**: 275-277.
39. Goto,H, Yuasa,K, Rylander,R. 1994. (1-3)- $\beta$ -Glucans in indoor air, Its measurements and *In Vitro* activity. *Am J Ind.Med.* **25**: 81-83.
40. Miller,JD, Laflamme,AM, Sobol,Y, Lafontaine,P, Greenhalgh,R. 1988. Fungi and Fungal products in Canadian houses. *Int.Biodet.* **24**: 103-120.
41. Ström,G, West J, Wessen B, Palmgren U. 1994. Quantitative analysis of microbial Volatiles in damp Swedish houses. In Samson RA, Flannigan B, Flannigan ME, Verhoeff AP. (eds.), *Health implications of fungi in indoor air environment*. p. 291-305. Elsevier, Amsterdam.
42. Wilkins,CK, Nielsen,EM, Wolkoff,P. 1997. Patterns in volatiles organic compounds in dust from mouldy buildings. *Indoor Air* **7**: 128-134.
43. Bock,R, Schleibinger,HW, Ruden,H. 1998. Volatile secondary metabolites as indicators for fungal growth indoors. *Umweltmed.Forsch.Prax* **3**: 359-364.

44. Jarvis,BB, Sorenson,WG, Hintikka,E-L, Nikulin,M, Zhou,Y, Jiang,J, Wang,S, Hinkley,SF, Etzel,RA, Dearborn,DG. 1998. Study of Toxin Production by Isolates of *Stachybotrys chartarum* and *Memnoniella echinata* isolated during a study of pulmonary hemosiderosis in infants. *Appl.Env.Microb.* **64**: 3620-3625.
45. Nikulin,M, Reijula,K, Jarvis,BB, Hintikka,E-L. 1997. Experimental lung mycotoxicosis induced by *Stachybotrys atra*. *Int.J.Experim.Pathol.* **77**: 213-218.
46. Sorenson,WG, Frazer,DG, Jarvis,BB, Simpson,J, Robinson,VA. 1987. Trichothecene Mycotoxins in Aerosolized Conidia of *Stachybotrys atra*. *Appl.Env.Microb.* **53**: 1370-1375.
47. Croft,WA, Jarvis,BB, Yatawara,CS. 1986. Airborne outbreak of Trichothecene Mycotoxicosis. *Atmos.Env.* **20**: 549-552.
48. Flannigan,B, McCabe,EL, McGarry,F. 1991. Allergenic and toxigenic micro-organisms in houses. *J.Appl.Bacter.* **70**: 61-73.
49. Flannigan,B, Miller JD. 1994. Health implications of fungi in indoor environments - An overview. In Samson RA, Flannigan B, Flannigan ME, Verhoeff AP, Adan OCG. (eds.), *Health implications of fungi in indoor air environment*. p. 3-26. Elsevier, Amsterdam.
50. Anderson,MA, Nikulin,M, Kõljalg,U, Anderson,MC, Rainey,F, Reijula,K, Hintikka,E-L, Salkinoja-Salonen,M. 1997. Bacteria, Moulds, and Toxins in Water-Damaged Building Materials. *Appl.Env.Microb.* **63**: 387-393.
51. Hirvonen,M-R, Nevalainen,A, Makkonen,N, Mönkkönen,J, Salvolainen,K. 1997. Streptomyces spores from mouldy houses induce nitric oxide, TNF- $\alpha$  and IL-6 secretion from RAW264.7 macrophage cell line without causing subsequent cell death. *Env.Tox.Pharm.* **3**: 57-63.
52. Rätty,K, Raatikainen,O, Holmalahti,J, Wright,A, Joki,S, Pitkaenen,A, Saano,V, Hyvärinen,A, Nevalainen,A, Buti,I. 1994. Biological activities of actinomycetes and fungi isolated from indoor air of problem houses. *Int.Biodet.Biodegr.* **34**: 143-154.
53. Brunekreef,B, Douwes,J, Doekes,G, van Strien,R. 1999. Health effects of mould and bacterial components in the home environment. *Proceedings of the 8<sup>th</sup> International Conference on Indoor Air Quality and Climate, Indoor Air '99*. p. 897-898.
54. Andersson,M. 1999. Bacterial diversity and toxicity in air, indoor environments and food. Ph.D. Thesis, Department of Applied Chemistry and Microbiology, Division of Microbiology, University of Helsinki.
55. Grant,C, Hunter,CA, Flannigan,B, Bravery,AF. 1989. The Moisture Requirements of Moulds Isolated from Domestic Dwelling. *Int.Biodet.* **25**: 259-284.
56. Ayerst,G. 1966. Influence of physical factors on the deterioration by moulds. *Soc.Chem.Indust.Monograph.* **23**: 14-20.
57. Scott,WJ. 1957. Water relations of food spoilage micro-organisms. *Adv.Food.Res.* **7**: 83-127.
58. Filtenborg,O, Frisvad,JC, Thrane,U. 1996. Moulds in food spoilage. *Int.J Food Microbiol* **33**: 85-102.
59. Samson,RA. 1985. Occurrence of moulds in modern living and working environments. *Eur.J Epidemiol.* **1**: 54-61.
60. Nielsen,KF, Thrane,U, Larsen,TO, Nielsen,PA, Gravesen,S. 1998. Production of mycotoxins on artificially inoculated building materials. *Int.Biodet.Biodegr.* **42**: 8-17.
61. Gaylarde,CC, Morton,LHG. 1999. Deteriogenic biofilms on buildings and their control: a review. *Biofouling* **14**: 59-74.
62. Frisvad,JC. 1989. The connection between the penicillia and aspergilli and mycotoxins with special emphasis on misidentified isolates. *Arch.Env.Contam.Tox.* **18**: 452-467.
63. Frisvad,JC, Gravesen S. 1994. *Penicillium* and *Aspergillus* from Danish homes and working places with indoor air Problems: Identification and mycotoxin determination. In Samson RA, Flannigan B, Flannigan ME, Verhoeff AP. (eds.), *Health implications of fungi in indoor air environment*. p. 281-290. Elsevier, Amsterdam.
64. Larsen,TO, Frisvad JC. 1994. Production of volatiles and presence of mycotoxins in conidia of common indoor *Penicillia* and *Aspergillii*. In Samson RA, Flannigan B, Flannigan ME, Verhoeff

- AP. (eds.), Health implications of fungi in indoor air environment. p. 251-279. Elsevier, Amsterdam.
65. Samson,RA, Hoekstra,ES, Frisvad,JC, Filtenborg,O. 2000. Introduction to Food- and Air Borne Fungi. 6<sup>th</sup> Edition. In Samson RA, Hoekstra ES, Frisvad JC, Filtenborg O(Eds.). Centraalbureau voor Schimmelcultures, Utrecht.
  66. Korpinen,E-L. 1973. Studies on *Stachybotrys alternans*. I. Isolation of toxigenic strains from Finnish grains and feeds. Acta.Pathol.Microbiol.Scand.Sect.B **81**: 191-197.
  67. Hansen,MØ. 2000. Database on moulds and the materials they grow on. Østergaard Miljø, Havdrup [In Danish].
  68. Gravesen,S. 1972. Identification and quantitation of indoor airborne micro-fungi during 12 month from 44 Danish houses. Acta Allergologia **27**: 337-354.
  69. Miller,JD. 1992. Fungi as contaminant of indoor air. Atmos.Env. **26A**: 2163-2172.
  70. Tobin,RS, Baranowski,E, Gilman,AP, Kuiper-Goodman,T, Miller,JD, Giddings,M. 1987. Significance of fungi in indoor air: Report of a working group. Can.J.Public.Health **78**: S1-S32
  71. Lübeck,M, Poulsen,SK, Lübeck,PS, Jensen,DF, Thrane,U. 2000. Identification of *Trichoderma* strains from building materials by ITS1 ribotyping, UP-PCR fingerprinting and UP-PCR cross hybridization. FEMS micro.biol.lett. **185**: 129-134.
  72. Bissett,J. 1987. Fungi associated with urea-formaldehyde foam insulation in Canada. Mycopath. **99**: 47-56.
  73. Pitt,JI. 1975. Xerophilic fungi and the spoilage of foods of plant origin. In Duckworth RB. (ed.), Water relations of foods. Academic press, New York.
  74. Andersen,B, Nissen,A. 2000. Evaluation of media for detection of *Stachybotrys* and *Chaetomium* species associated with water-damaged buildings. Int.Biodet.Biodegr. **46**: 111-116.
  75. *Biological Particles in Indoor Environments*. Report No. 12. European Collaborative Action. Indoor Air Quality & its Impact on Man1993. In. Verhoeff AP(ed.). Commission of the European Communities, Brussels.
  76. Field Guide for the Determination of Biological Contaminants in Environmental Samples1996. In Dillon HK, Heinsohn PA, Miller JD(Eds.). American Industrial Hygiene Association,
  77. Wanner,H, Verhoeff,AP, Colombi,A, Flannigan,B, Gravesen,S, Mouilleseaux,A, Nevalainen,A, Papadakis,J, Seidel,K. 1993. Biological Particles in indoor environments.
  78. Dillon,HK, Miller,JD, Sorenson,WG, Douwes,I, Jacobs R.R. 1999. Review of methods applicable to the assessment of mold exposure to children. Env.Health Persp. **107**: 473-480.
  79. Palmgren,U, Ström,G, Blomquist,G, Malmberg,P. 1986. Collection of airborne micro-organisms on Nucleopore filters and analysis - CAMNEA method. J.Appl.Bacter. **61**: 401-406.
  80. Larsson,L, Saraf,A. 1997. Use of Gas Chromatography-Ion Trap Tandem Mass Spectrometry for the Detection and Characterization of Microorganisms. Molec.Biotech. **7**: 279-287.
  81. Dales,RE, Miller,JD, White,J. 1999. Testing the association between residential fungus and health using ergosterol measures and cough recordings. Mycopath. **147**: 21-27.
  82. Haugland,RA, Vesper,SJ, Wymer,LJ. 1999. Quantitative measurements of *Stachybotrys chartarum* conidia using realtime detection of PCR products with the TaqMan fluorogenic system. Mol.Cell.Prob. **13**: 329-340.
  83. Pasanen,A-L, Kujanpää,L, Pasanen,P, Kalliokoski,P, Blomquist,G. 1997. Culturable and total fungi in dust accumulated in air ducts in single-family houses. Indoor Air **7**: 121-127.
  84. Kildesø,J, Würtz,H, Nielsen,KF, Wilkins,CK, Gravesen,S, Nielsen,PA, Thrane,U, Schneider,T. 2000. The release of fungal spores from water damaged building materials. Proceedings of Healthy Buildings 2000, Espoo. p. 313-318.
  85. Pasanen,A-L, Nhninen,M, Kalliokoski,P, Nevalainen,A, Jantunen,MJ. 1992. Airborne *Cladosporium* and other fungi in damp versus reference residences. Atmos.Env. **26B**: 121-124.
  86. Garrett,MH, Rayment,PR, Hooper,MA, Abramson,MJ, Hooper,BM. 1998. Indoor airborne fungal spores, house dampness and associations with environmental factors and respiratory health in children. Clin.Exp.Allergy **28**: 459-467.

87. Nevalainen,A, Pasanen,A-L, Niinen,M, Reponen,T, Kalliokoski,P, Jantunen,MJ. 1991. The indoor air quality in Finnish homes with mold problems. *Env.Int.* **17**: 299-302.
88. Dales,RE, Miller,JD, McMullen,ED. 1997. Indoor air quality and health: Validity and determination of reported home dampness and mould. *Int.J.Epidemol.* **26**: 120-125.
89. Gosset,P, Malaquin,F, Delneste,Y, Wallaert,B, Capron,BA, Joseph,M , Tonnel,A. 1993. Interleukin-6 and interleukin-1 $\alpha$  production is associated with antigen-induced late nasal response. *J.Allergy Clin.Immunol.* **92**: 878-890.
90. Hirvonen,M-R, Ruotsalainen,M, Roponen,M, Hyvärinen,A, Husman,T, Kosma,V-M, Komulainen,H, Savolainen,K, Nevalainen,A. 1999. Nitric Oxide and proinflammatory cytokines in nasal lavage fluid associated with symptoms and exposure to moldy building microbes. *Am.J.Resp.Crit.Care Med.* **160**: 1943
91. Wålinder,R, Wieslander,G, Norbäck,D, Wessen,B. 2001. Nasal lavage biomarkers: Effects of water damage and microbial growth in an office building. *Arch.Env.Health* **56**: 30-36.
92. Panasenkov,V.T. 1967. Ecology of microfungi. *The Botanical review* **33**: 189-215.
93. Land,CJ, Banhidi,ZG, Albertson,AC. 1985. Surface discoloring and blue stain by cold-tolerant filamentous fungi on outdoor softwood in Sweden. *Mat.Organis.* **20**: 133-156.
94. Smith,SL, Hill,ST. 1982. Influence of temperature and water activity on germination and growth of *Aspergillus restrictus* and *A. versicolor*. *Trans.Brit.Myc.Soc.* **79**: 558-559.
95. Gervais,P, Grajek,W, Bensoussan,M, Molin,P. 1988. Influence of the water activity of a solid substrate on the growth rate and sporogenesis of filamentous fungi. *Biotechnol.Bioeng.* **31**: 457-463.
96. Joffe,AZ. 1962. *Mycopath.Mycl.Appl.* **16**: 201
97. Gervais,P, Berlin,JM, Sarrette,M. 1988. Influence of water activity on aroma production by *Trichoderma viride* growing on solid substrate. *J.Ferment.Tech.* **66**: 403-407.
98. Clayton,CN. 1942. The germination of fungus spores in relation to controlled humidity. *Phytopathology* **32**: 921-943.
99. Groom,P, Panisset,T. 1933. Studies of *Penicillium chrysogenum* Thom in relation to temperature and relative humidity of the air. *Ann.Appl.Biol.* **20**: 633-660.
100. Ayerst,G. 1969. The effect of moisture and temperature on growth and spore germination of some fungi. *J.Stored Prod.Res.* **5**: 127-141.
101. Pitt,JI, Hocking,AD. 1977. Influence of solute and hydrogen ion concentration on the water relations of some xerophilic fungi. *J.General Microb.* **101**: 35-40.
102. Hocking,AD, Miscamble,BF, Pitt,JI. 1994. Water relations of *Alternaria alternata*, *Cladosporium sphaerospermum*, *Curvularia lunata*, and *Curvularia pallescens*. *Mycol.Res.* **98**: 91-94.
103. Rowan,NJ, Johnstone,CM, McLean,RC, Anderson,JG, Clarke,JA. 1999. Prediction of toxigenic fungal growth in buildings by using a novel modelling system. *Appl.Env.Microb.* **65**: 4814-4821.
104. Chang,JCS, Forade,KK, Vanosdell,DW. 1995. Growth evaluation of fungi (*Penicillium* spp. and *Aspergillus* spp.) on ceiling Tiles. *Atmos.Env.* **29**: 2331-2337.
105. Galloway,LD. 1935. The moisture requirements of molds fungi with special reference to mildew in textiles. *J.Textile Inst.* **26**: 123-129.
106. Ezeonu,IM, Noble,JA, Simmons,RB, Prince,DL, Crow,SA, Ahearn,DG. 1994. Effects of Relative Humidity on Fungal Colonization of Fiberglass Insulation. *Appl.Env.Microb.* **60**: 2149-2151.
107. Nikulin,M, Pasanen,A-L, Berg,S, Hintikka,E-L. 1994. *Stachybotrys atra* growth and toxin production in some Building Materials and Fodder under different Relative Humidities. *Appl.Env.Microb.* **60**: 3421-3424.
108. Pasanen,A-L, Nikulin,M, Berg,S, Hintikka,E-L. 1994. *Stachybotrys atra* Corda may produce Mycotoxins in Respiratory Filters in Humid Environments. *Am Ind.Hyg.Assoc.J* **55**: 62-65.
109. Coppock,JBM, Cookson,ED. 1951. The effect of humidity on mould growth on construction materials. *J.Sci.Food Agric.* 534-537.



110. Chung,WY, Wi,SG , Bae,HJ, Park,BD. 1999. Microscopic observation of wood-based composites exposed to fungal deterioration. *J.Wood Sci.* **45**: 64-68.
111. Block,SS. 1953. Humidity requirements for mould growth. *Appl.Env.Microb.* **1**: 287-293.
112. Illman,WI, Weatherburn,MW. 1940. Development of mould on cotton fabrics. *American Dye-stuff Reprtr.* **36**: 343-344.
113. Viitanen,HA. 1994. Factors affecting the development of biodeterioration in wooden constructions. *Mater.Struct.* **27**: 483-493.
114. Atkins,PW. 1990. *Physical Chemistry.* Oxford University Press, Oxford.
115. Becker,R. 1984. Condensation and mould growth in dwellings-parametric and field study. *Build.Env.* **19**: 243-250.
116. Viitanen,HA, Bjrman,J. 1995. Mould growth on wood at fluctuating humidity conditions. *Mat.Organis.* **29**: 27-46.
117. Bjrman,J. 1989. Effect of humidity fluctuation on mould on pine sapwood. *International Research on Wood Preservation,*
118. Moriyama,Y, Nawata,WC, Tsuda,T, Nitta,M. 1992. Occurrence of moulds in Japanese bathrooms. *Int.Biodet.Biodegr.* **30**: 55
119. Park,D. 1982. Phylloplane fungi: tolerance of hyphal tips to drying. *Trans.Brit.Myc.Soc.* **79**: 174-179.
120. Viitanen,HA. 1997. Modelling the time factor in the development of mould fungi - Effects of critical humidity and temperature conditions in pine and spruce sapwood. *Holzforschung* **51**: 6-14.
121. Pasanen,P, Korpi,A, Kalliokoski,P, Pasanen,A-L. 1997. Growth and volatile metabolite production of *Aspergillus versicolor* in house dust. *Env.Int.* **23**: 425-432.
122. Korpi,A, Pasanen,A-L, Pasanen,P, Kalliokoski,P. 1997. Microbial Growth and Metabolism in house dust. *Int.Biodet.Biodegr.* **40**: 19-27.
123. Bjrman,J. 1994. Ergosterol as an Indicator of Mould Growth on Wood in Relation to Culture Age, Humidity Stress and Nutrient Level. *Int.Biodet.Biodegr.* **33**: 355
124. Seifert,KA, Frisvad JC. 2000. *Penicillium* on solid wood products. In Samson RA, Pitt JI. (eds.), *Integration of modern taxonomic methods from Penicillium and Aspergillus classification.* p. 285-298. Harwood academic publishers, Amsterdam.
125. Thelander,O, Bjrman,J, Boutelje,J. 1993. Increase in the content of low molecular carbon hydrates at lumber surfaces during drying and correlation with nitrogen content, yellowing and mould growth. *Wood Sci.Tech.* **27**: 381-389.
126. Suttie,ED, Hill,CAS, Jones,D, Orsler,RJ. 1998. Chemically modified solid wood - I. Resistance to fungal attack. *Mat.Organis.* **32**: 159-182.
127. Mankowski,M, Morrell,JJ. 2000. Patterns of fungal attack in wood-plastic composites following exposure in a soil block test. *Wood.Fibre Sci.* **32**: 340-345.
128. Pasanen,A-L, Juutinen,T, Jantunen,MJ, Kalliokoski,P. 1992. Occurrence and moisture requirements of microbial growth in building materials. *Int.Biodet.Biodegr.* **30**: 273-283.
129. Morgenstern,J. 1982. Einfluss von polyvinylacetat-zusätzen in potzmörtel auf die Schimmelbildung. *Mat.Organis.* **17**: 241-251.
130. Webb,JS, Nixon,M, Eastwood,IM, Greenhalg,M , Robson,GD, Handley,PS. 2000. Fungal colonization and biodeterioration of plasticized polyvinyl chloride. *Appl.Env.Microb.* **66**: 3194-3200.
131. Berk,S, Ebert,H , Teitell,L. 1957. Utilisation of plasticisers and related organic compounds by fungi. *Ind.Eng.Chem.* **49**: 1115-1124.
132. Ezeonu,IM, Prince,DL, Simmons,RB, Crow,SA , Ahearn,DG. 1994. Fungal Production of Volatiles during Growth on Fibreglass. *Appl.Env.Microb.* **60**: 4172-4173.
133. Seal,KJ, Pathirana,RA. 1982. The microbiological susceptibility of polyurethanes: a review. *Int.Biodet.Bull.* **18**: 81-85.
134. Bravery,AF. 1988. Biodeterioration of paints a state of the art review. In Houghton DR, Smith RN, Eggins HOW. (eds.), *Biodeterioration 7.* p. 466-485. Elsevier, London.

135. Jakubowski,J. 1971. The preweather Technique. Paint mildewcide evaluation in the laboratory parallels field performance. Am.Paint J. **56**: 56-76.
136. Winters,H, Isquith,IR, Coll,M. 1975. A study of the ecological succession in Biodegradation of a vinyl acrylic paint film. Dev.Ind.Microbiol. **17**: 167-171.
137. Simmons,RB, Price,DL, Noble,JA, Crow,SA, Ahearn,DG. 1997. Fungal colonization of air filters from hospitals. Am Ind.Hyg.Assoc.J **58**: 900-904.
138. Chang,JCS, Forade,KK, Vanosdell,DW. 1996. Assessment of fungal (*Penicillium chrysogenum*) growth on three HVAC duct materials. Env.Int. **22**: 425-431.
139. Ahearn,DG, Simmons,RB, Switzer,F, Ajello,L , Pierson,DL. 1991. Colonization by *Cladosporium* spp. of painted metal surfaces associated with heating and air conditioning. J.Ind.Microb. **8**: 277-280.
140. Ahearn,DG, Crow,SA, Simmons,RB, Prince,DL, Noble,JA, Mishra,SK, Pierson,DL. 1996. Fungal colonization of fiberglass insulation in the air distribution system of a multi-story office building: VOC production and possible relation to a sick building syndrome. J.Ind.Microb. **16**: 280-285.
141. Hukka,A, Viitanen,HA. 1999. A mathematical model of mould growth on wooden materials. Wood Sci.Tech. **33**: 475-485.
142. Gravesen,S, Larsen,L, Gyntelberg,F, Skov,P. 1986. Demonstration of Microorganisms and Dust in Schools and Offices. Allergy **41**: 520-525.
143. Kuby,J. 1997. Immunology. Freeman, New York.
144. Sorenson,WG. 1997. Aerosolized Mycotoxins: Implications for Occupational settings. In Johanning E, Yang CS (Eds.), Eastern New York Occupational Program, New York, p. 57-67.
145. Sumi,Y, Nagura,H, Takeuchi,M. 1994. Granulomatous lesions in the lung induced by inhalation of mold spores. Virchow Arc. **424**: 661-668.
146. Cooley,JD, Wong,WC, Jumper,CA, Straus,DC. 1999. Cellular and humoral responses in an animal model inhaling *Penicillium chrysogenum* spores. In Johanning E (Ed.), Bioaerosols, Fungi and Mycotoxins: Health effects, Assessment, Prevention and Control. Eastern New York Occupational & Environmental Health Center, New York, p. 304-310.
147. Shahan,TA, Sorenson,WG, Paulauskis,JD, Morey,R, Lewis,DM. 1998. Concentration- and time-dependent upregulation and release of the cytokines MIP-2, KC, TNF, and MIP-1 alpha in rat alveolar macrophages by fungal spores implicated in airway inflammation. Am.J.Resp.Cell Mol.Biol. **18**: 435-440.
148. Ruotsalainen,M, Hirvonen,M-R, Nevalainen,A, Meklin,T, Savolainen,K. 1998. Cytotoxicity, production of reactive oxygen species and cytokines induced by different strains of *Stachybotrys* sp. from mouldy buildings in RAW264.7 macrophages. Env.Tox.Pharm. **6**: 193-199.
149. Smith,JE, Anderson,JG, Lewis,CW, Murad,YM. 1992. Cytotoxic fungal spores in the indoor atmosphere of damp domestic environment. FEMS micro.biol.lett. **200**: 337
150. Smith,JE, Lewis,CW, Murad,YM, Anderson,JG. 1993. A survey of mycotoxin-associated fungal spora with cytotoxic properties collected from the home environment. In Scudamore KA (Ed.), Occurrence and Significance of mycotoxins. Central Science Laboratory, Berks, p. 109-117.
151. Murtoniemi,T, Nevalainen,A, Suutari,M, Toivola,M, Komulainen,H, Hirvonen,M-R. 2001. Induction of cytotoxicity and production of inflammatory mediators in RAW264.7 macrophages by spores grown on six different plasterboards. Inhalation Toxicology **13**: 233-247.
152. Hirvonen,M-R, Nevalainen,A, Makkonen,N, Mönkkönen,J, Salvolainen,K. 1997. Induced production of nitric oxide, tumor necrosis factor, and interleukin-6 in RAW 264.7 macrophages by streptomycetes from indoor air of mouldy houses. Arch.Env.Health **52**: 426-432.
153. Abraham,E, Jesmok,G, Tuder,R, Allbee,J, Chang,Y-H. 1995. Contribution of tumor necrosis factor-alpha to pulmonary cytokine expression and lung injury after hemorrhage and resuscitation. Critical Care Medicine **23**: 1319-1326.
154. Cantry,D, Feldman,M. 1990. The role of cytokines in autoimmunity. Biotech.Ther. **1**: 361-409.

155. Strachan,DP, Sanders,CH. 1989. Damp housing and childhood asthma. Respiratory effects of indoor air temperature and relative humidity. *Journal of Epidemiology and Community Health*, **43**: 7-14.
156. Johanning,E, Morey,PR, Jarvis,BB. 1993. Clinical-epidemiological investigation of health effects caused by *Stachybotrys atra* building contamination. In Jaakkola JJK, Ilmarinen R, Sepänen O (Eds.), *Indoor Air '93*, Helsinki, p. 225-230.
157. Johanning,E. 1995. Health problems related to fungal exposure - the example of toxigenic *Stachybotrys chartarum (atra)*. In Johanning E, Yang CS. (eds.), *Fungi and Bacteria in Indoor Air Environments*. p. 169-182. Eastern New York Occupational Program, New York.
158. Dearborn,DG, Infeld,MD, Smidth,PG. 1997. Update. Pulmonary hemorrhage/hemosiderosis among infants 1993-1996. *MMWR* **46**: 33-35.
159. Montana,E, Etzel,RA, Allan,TM. 1997. Environmental risk factors associated with pediatric idiopathic pulmonary hemosiderosis in a Cleveland community. *Pediatrics* **99**: 117
160. Dearborn,DG. 1997. Pulmonary hemorrhage in infants and children. *Curr.Opin.Pediatr.* **9**: 219-224.
161. CDC. 1994. Acute pulmonary hemorrhage/hemosiderosis among infants - Cleveland, January 1993 - November 1994. *MMWR* **43**: 881-883.
162. Anonymous1995. Acute pulmonary hemorrhage among infants. Chicago, April 1992 to November 1994. *MMWR* **44**: 67-74.
163. Pappas,MD, Sarnaik,AP, Meert,KL, Hasan,RA, Lieh-Lai,MW. 1996. Idiopathic Pulmonary Hemorrhage in Infancy: Clinical Features and Management With High Frequency Ventilation. *Chest* **110**: 553-555.
164. CDC. 2000. Update: Pulmonary hemorrhage/hemosiderosis among infants - Cleveland, Ohio, 1993-1996 (Reprinted from *MMWR*, vol 49, pg 180-184, 2000). *JAMA* **283**: 1951-1953.
165. Flappan,SM, Portnoy,J, Jones,P, Barnes,C. 1999. Infant pulmonary hemorrhage in a suburban home with water damage and mold (*Stachybotrys atra*). *Env.Health Persp.Supp.* **107**: 927-930.
166. Knapp,JF, Michael,JG, Hegenbartk,MA, Jones,PE, Black,PG. 1999. Case records of the Children's Mercy Hospital, case 02-1999: A 1-moth-old infant with respiratory distress and chock. *Ped.Emerg.Care* **15**: 288-293.
167. Vesper,SJ, Dearborn,DG, Elidermir,O, Haugland,RA. 2000. Quantification of siderophore and hemolysin from *Stachybotrys chartarum* strains, including a strain isolated from the lung of a child with pulmonary hemorrhage and hemosiderosis. *Appl.Env.Microb.* **66**: 2678-2681.
168. Tripi,PA, Modlin,S, Sorenson,WG, Dearborn,DG. 2000. Acute pulmonary haemorrhage in an infant during induction of general anaesthesia. *Paed.Anesthes.* **10**: 92-94.
169. Frisvad,JC. 1998. Secondary metabolites and species models in *Penicillium* and *Aspergillus*. Dr. Tech. Dissertation. Department of Biotechnology, Technical University of Denmark, Lyngby.
170. Williams,DH, Stone,MJ, Hauck,PR, Rahman,SK. 1989. Why are secondary metabolites (natural products) biosynthesised? *J.Nat.Prod.* **52**: 1189-1208.
171. Gloer,JB. 1995. The chemistry of fungal antagonism and defense. *Canadian Journal Of Botany-Revue Canadienne De Botanique* **73**: S1265-S1274
172. Smith,JE, Solomons,GL. 1994. Mycotoxins in Human Nutrition and health. European Commission, Directorate-General XII,
173. Sorenson,WG. 1989. Health implications of mycotoxins in the home and workplace: an overview. In O'Rear CE, Llewellyn GC. (eds.), *Biodeterioration Research 2*. p. 201-215. Plenum, New York.
174. Dowd,PF, Miller,JD, Greenhalgh,R. 1989. Toxicity and interactions of some *Fusarium graminearum* metabolites to caterpillars. *Mycologia* **81**: 646-650.
175. Frisvad,JC, Thrane U, Filtenborg O. 1998. Role and use of secondary metabolites in fungal taxonomy. In Frisvad JC, Bridge PD, Arora DK. (eds.), *Chemical fungal taxonomy*. p. 289-319. Marcel Dekker, New York.

176. Ueno,Y. 1985. Toxicology of Mycotoxins. Crit.Rev.Toxicol **14**: 99-132.
177. Creasia,DA, Thurmann,JD, Wannemacher,RWJ. 1990. Acute inhalation toxicity of T-2 toxin in the rat and guinea pig. Fund.Appl.Tox. **14**: 54-59.
178. Smedsgaard,J, Frisvad,JC. 1997. Terverticillate penicillia studied by direct electrospray mass spectrometric profiling of crude extracts. I. Chemosystematics. Biochem.Syst.Ecol. **25**: 51-64.
179. Jong,SC, Davis,EE. 1976. Contribution to the knowledge of *Stachybotrys* and *Memnoniella* in cultures. Mycotaxon **3**: 409-485.
180. McKenzie,EHC. 1991. Dematiaceous hyphomycetes on freycinetia (pandanaceae). 1. *Stachybotrys*. Mycotaxon **41**: 179-188.
181. Dorai,M, Vittal,BPR. 1986. A new *Stachybotrys* from eucalyptus litter. Trans.Brit.Myc.Soc. **87**: 642-644.
182. Hua-zhong,K. 1997. *Stachybotrys yunnanensis* sp. Nov. and *Neosatorya delicata* sp. Nov. isolated from yunna, China. Mycotaxon **62**: 427-433.
183. Miyazaki,W, Tamaoka,H, Shinohara,M, Kaise,H, Izawa,T, Nakano,Y, Kinoshita,T, Inoue,K. 1980. A complement inhibitor produced by *Stachybotrys complementi*, nov. sp. K-76, a new species of fungi imperfecti. Microbiol.Immunol **24**: 1091-1108.
184. Eppley,RM, Bailey,WJ. 1973. 12,13-Epoxy- $\Delta$ 9-Trichothecenes as the Probable Mycotoxins Responsible for Stachybotryotoxicosis. Science. **181**: 758-760.
185. Eppley,RM, Mazzola,EP, Highet,RJ, Bailey,WJ. 1977. Structure of Satratoxin H, a metabolite of *Stachybotrys atra*. Application of Proton and Carbon-13 Nuclear Magnetic Resonance. J.Org.Chem. **42**: 240-243.
186. Bata,A, Harrach,B, Ujszászi,K, Kis-Tamás,A, Laszity,R. 1985. Macrocyclic Trichothecene Toxins Produced by *Stachybotrys atra* Strains Isolated in Middle Europe. Appl.Env.Microb. **49**: 678-681.
187. Forgacs,J, Carl,WT, Herring,AS, Hinshaw,WR. 1958. Toxicity of *Stachybotrys atra* for animals. Trans.New York Acad.Soc. **20**: 787-808.
188. Korpinen,E-L, Uoti,J. 1974. Studies on *Stachybotrys alternans*. II. Occurrence, morphology and toxigenity. Acta Path.Microbiol.Scand.Sec.B. **82**: 1-6.
189. Sarkisov,AK, Orshanskaiya,VN. 1944. Laboratory diagnosis of toxic strains *Stachybotrys alternans*. Veterinariya **21**: 38-40.
190. Forgacs,J. 1972. Stachybotryotoxicosis. In Kadis S, Ciegler A, Ajl SJ. (eds.), Microbial toxins. Vol. VIII. p. 95-128. Academic Press, New York.
191. Khrushchev,N. 1970. Khrushchev Remembers. Little Brown, Boston.
192. Forgacs,J, Carl,WT. 1962. Mycotoxicosis. Adv.Vet.Sci. **7**: 273-293.
193. Gutzwiller,J, Mauili,R, Sigg,HP, Tamm,C. 1964. Die konstitutionen von verrucarol und roridin C. Helv.Chim.Acta **47**: 2234-2262.
194. Eppley,RM, Mazzola,EP, Stack,ME, Dreifuss,PA. 1980. Structure of Satratoxin F and Satratoxin G, a metabolites of *Stachybotrys atra*. Application of Proton and Carbon-13 Nuclear Magnetic Resonance Spectroscopy. J.Org.Chem. **45**: 2522-2523.
195. Ueno,Y. 1983. Trichothecenes - chemical, biological and toxicological aspects. In. Ueno Y(ed.). Elsevier, Amsterdam.
196. Bamberg,JR. 1976. Mycotoxins and Other Fungal Related Food Problems. In Rodricks JV. (ed.), Advances in Chemistry Series 149. p. 144-162. American Chemical Society,
197. Trapp,SC, Hohn,TM, McCormick,S, Jarvis,BB. 1998. Characterization of the gene cluster for biosynthesis of macrocyclic trichothecenes in *Myrothecium roridum*. Mol Gen Genet **257**: 421-432.
198. Rizzo,I, Varavky,E, Haidukowski,M. 1997. Macrocyclic trichothecenes in *Baccharis coridifolia* plants and endophytes and *Baccharis artemissioides* Plants. Toxicon **35**: 753-757.
199. Zamir,LO. 1989. Biosynthesis of 3-acetylnivalenol and sambucinol. Tetrahedron **45**: 2277-2305.
200. Desjardins,AE, Hohn,T, McCormick,SP. 1993. Trichothecene Biosynthesis in *Fusarium* Species: chemistry, genetics, and significance. Microb.Rev. **57**: 595-604.

201. Fekete,C, Logrieco,A, Giczey,G, Hornok,L. 1997. Screening of fungi for the presence of the trichodiene synthase encoding sequence by hybridization to the Tri5 gene from *Fusarium poae*. Mycopath. **138**: 91-97.
202. Wilkins,CK. 2000. Volatile sesquiterpenes from *Stachybotrys chartarum*. Indicators for trichothecene producing mold species? Env.Sci.Pollut.Res. **7**: 77-78.
203. Jelen,HH, Latus-Zietkiewicz,D, Wasowicz,E, Kaminski,E. 1997. Trichodiene as a volatile marker for trichothecenes biosynthesis. J.Microbiol.Meth. **31**: 45-49.
204. Jarvis,BB. 1991. Macrocyclic trichothecenes. In Sharma RP, Salunkhe DK. (eds.), Mycotoxins and Phytoalexins. p. 361-421. CRC Press, Boca Raton.
205. Pasanen,A-L, Nikulin,M, Tuomainen,M, Parikka,P, Hintikka,E-L. 1993. Laboratory Experiments on membrane filter sampling of airborne mycotoxins produced by *Stachybotrys atra* Corda. Atmos.Env. **27A**: 9-13.
206. Tuomi,T, Reijula,K, Johnsson,T, Hemminki,K, Hintikka,E-L, Lindroos,O, Kalso,S, Koukila-Kähköla,P, Mussalo-Rauhamaa,H, Haahtela,T. 2000. Mycotoxins in crude building materials from water-damaged buildings. Appl.Env.Microb. **66**: 1899-1904.
207. Andriienko,OV, Zaichenko,OM. 1997. Certain peculiarities of biological action of the stachybotryotoxin preparations. Mikrobiol.Z. **59**: 41-46.
208. Jarvis,BB, Lee,Y-W, Comezoglu,SN, Yatawara,CS. 1986. Trichothecenes Produced by *Stachybotrys atra* from Eastern Europe. Appl.Env.Microb. **51**: 915-918.
209. Hinkley,SF, Jiang,J, Mazzola,EP, Jarvis,BB. 1999. Atranones: Novel diterpenoids from the toxigenic mold *Stachybotrys atra*. Tetrahedron Lett. **40**: 2725-2728.
210. Yang,GH, Jarvis,BB, Chung,YJ, Pestka,JJ. 2000. Apoptosis induction by the satratoxins and other trichothecene mycotoxins: relationship to ERK, p38 MARK, and SAPK/JNK activation. Toxicol.Appl Pharmacol. **164**: 149-160.
211. Parent-Massin,D, Parchment,RE. 1998. Haematotoxicity of mycotoxins. Rev.Med.Vet. **149**: 591-598.
212. Hughes,BJ, Hsieh,GC, Jarvis,BB. 1989. Effects of macrocyclic Trichothecene Mycotoxins on the Murine immune System. Arch.Env.Contam.Tox. **18**: 388
213. Pestka,JJ, Bondy,GS. 1990. Alternations of immune function following dietary mycotoxin exposure. Can.J.Physiol.Pharmac. **68**: 1009-1016.
214. Creasia,DA, Thurmann,JD, Jones III,LJ, Nealley,ML, York,CG, Wannemacher,RWJ, Bunner,DL. 1987. Acute Inhalation Toxicity of T-2 mycotoxin i Mice. Fund.Appl.Tox. **8**: 230-235.
215. Pang,VF, Lambert,RJ, Felsburg,PJ. 1988. Experimental T-2 toxicosis in swine following inhalation exposure: clinical signs and effect on hematology, serum biochemistry and immune response. Fund.Appl.Tox. **11**: 100-109.
216. Nikulin,M, Reijula,K, Jarvis,BB, Veijalaninen,P, Hintikka,E-L. 1997. Effects of intranasal exposure to spores of *Stachybotrys atra* in mice. Fund.Appl.Tox. **35**: 182-188.
217. Mason,CD, Rand,TG, Oulton,M, MacDonald,JM, Scott,JE. 1998. Effects of *Stachybotrys chartarum* (*atra*) conidia and isolated toxin on lung surfactant production and homeostasis. Natural Toxins **6**: 27-33.
218. Mason,CD, Rand,TG, Oulton,M, MacDonald,J, Anthes,M. 2001. Effects of *Stachybotrys chartarum* on surfactant convertase activity in juvenile mice. Toxicol.Appl Pharmacol. **172**: 21-28.
219. Rao,CY, Brain,JD, Burge,HA. 2000. Reduction of pulmonary toxicity of *Stachybotrys chartarum* spores by methanol extraction of mycotoxins. Appl.Env.Microb. **66**: 2817-2821.
220. Roggo,BE, Hug,P, Moss,S, Stämpfli,A, Kriemler,H-P, Peter,HH. 1996. Novel spirodihydrobenzofuranlactams as antagonists of endothelin and as inhibitors of HIV-1 protease produced by *Stachybotrys* sp. II. Structure determination. J.Antib. **49**: 374-379.
221. Tomishige,T, Miyazaki,K. 1992. Tumor necrosis factor-liberation inhibitors containing sesquiterpene analogs or their salts. Patent
222. Kaise,H, Shinohara,M, Miyazaki,W, Izawa,T, Nakano,Y, Sugawara,M, Sugiura,K, Sasaki,K. 1979. Structure of K-76, a complemet inhibitor. J.Chem.Soc.,Chem.Com. 726-727.

223. Kaneto,R, Dobashi,K, Kojima,I, Sakai,K, Shibamoto,N, Yoshioka,T, Nishid,AH, Okamoto,R, Akagawa,H, Mizuno,S. 1994. Mer-nf5003b, mer-nf5003e and mer-nf5003f, novel sesquiterpenoids as avian-myeloblastosis virus protease inhibitors produced by *Stachybotrys* sp. *J.Antib.* **47**: 727-730.
224. Hasumi,K, Ohyama,S, Kohyama,T, Ohsaki,Y , Takayasu,R, Endo,A. 1998. Isolation of SMTP-3, 4, 5 and -6, novel analogs of staplabin, and their effects on plasminogen activation and fibrinolysis. *J.Antib.* 1059-1068.
225. Hu,W, Ohyama,S, Hasumi,K. 2000. Activation of fibrinolysis by SMTP-7 and -8, novel staplabin analogs with a pseudosymmetric structure. *J.Antib.* **53**: 241-247.
226. Kohyama,T, Hasumi,K, Hamanaka,A, Endo,A. 1997. SMTP-1 and -2, novel analogs of staplabin produced by *Stachybotrys microspora* IFO30018. *J.Antib.* **50**: 172-174.
227. Hinkley,SF, Mazzola,EP, Fettinger,JC, Lam,YKT, Jarvis,BB. 2000. Atranes A-G, from the toxigenic mold *Stachybotrys chartarum*. *Phytochem* **55**: 663-673.
228. Rodriguez,AD, González,E, Ramírez,C. 1998. The structural chemistry, reactivity, and total synthesis of dolabellane diterpenes. *Tetrahedron* **54**: 11683-11729.
229. Vesper,SJ, Dearborn,DG, Yike,I, Allen,T, Sobolewski,J, Hinkley,SF, Jarvis,BB, Haugland,RA. 2000. Evaluation of *Stachybotrys chartarum* in the House of an Infant with Pulmonary Hemorrhage: Quantitative Assessment before, during, and after Remediation. *J.Urb.Health* **77**: 68-85.
230. Sakamoto,K, Tsujii,E, Miyauchi,M. 1993. FR901459, a novel immunosuppressant isolated from *Stachybotrys chartarum* No. 19392. Taxonomy of the producing organism, fermentation, isolation, physicochemical properties and biological activities . *J.Antib.* **46**: 1788-1798.
231. Peltola,J, Anderson,MA, Raimo,M, Mussalo-Rauhamaa,H, Salkinoja-Salonen,M. 1999. Membrane toxic substances in water-damaged construction materials and fungal pure cultures. In Johanning E (Ed.), Eastern New York Occupational & Environmental Health Center, New York, p. 432-443.
232. Vesper,SJ, Dearborn,DG, Yike,I, Sorenson,WG , Haugland,RA. 1999. Hemolysis, toxicity, and randomly amplified polymorphic DNA analysis of *Stachybotrys chartarum* strains. *Appl.Env.Microb.* 3175-3181.
233. Vesper,SJ, Magnuson,ML, Dearborn,DG, Yike,I , Haugland,RA. 2001. Initial Characterization of the Hemolysin Stachylysin from *Stachybotrys chartarum*. *Infect.immun.* **69**: 912-916.
234. Bullen,JJ. 1981. The significance of iron in infections. *Rev.Infect.Dis.* **3**: 1127-1138.
235. Holzberg,M, Artis,WM. 1983. Hydroxamate siderophore production by opportunistic and systemic fungal pathogens. *Infect.immun.* **40**: 1134-1139.
236. Raper,KB, Fennell,DI. 1977. *The Genus Aspergillus*. Robert E. Krieger Publishing Company, New York.
237. Integration of modern taxonomic methods from *Penicillium* and *Aspergillus* classification 2000. In Samson RA, Pitt JI(Eds.). Harwood academic publishers, Amsterdam.
238. Modern concepts in *Penicillium* and *Aspergillus* classification 1990. In Samson RA, Pitt JI(Eds.). Plenum Press, New York.
239. Sunesson,A-L, Nilsson,C-A, Carlson,R, Blomquist,G, Andersson,B. 1997. Production of volatile metabolites from *Streptomyces albidoflavus* cultivated on gypsum board and tryptone glucose extract agar - Influence of temperature, oxygen and carbon dioxide levels. *Ann.Occup.Hyg.* **41**: 393-413.
240. Kikuchi,T, Shigetoshi,K, Suehara,H, Nishi,A, Tsubaki,K. 1981. Odorous metabolite of a fungus, *Chaetomium globosum*, Kinze ex Fr. Identification of geosmin, a musty-smelling compound. *Chem.Pharm.Bull.* **29**: 1782-1784.
241. Bjurman,J, Kristensson,J. 1992. Volatile production by *Aspergillus versicolor* as a possible cause of odor in houses affected by fungi. *Mycopath.* **118**: 173-178.
242. Steyn,PS. 1998. The biosynthesis of mycotoxins. *Rev.Med.Vet.* **149**: 469-478.
243. McConnell,IR, Garner RC. 1994. DNA adducts of aflatoxins, sterigmatocystins and other mycotoxins. In Hemminki K, Dipple A, Shuker DEG, Kadlubar FF, Segerbäck D, Bartsch H.

- (eds.), DNA adducts: Identification and Biological Significance. IARC Scientific publication No. 125. p. 29-55. IARC, Lyon.
244. Piecková,E, Jesenská,Z. 1998. Mold on house walls and the effect of their chloroform-extractable metabolites on the respiratory cilia movement of one-day-old chicks *in vitro*. *Folia Microbiologica* **63**: 672-678.
  245. Bokhari,FM, Flannigan B. 1996. Effect of storage environments on growth of *Aspergillus versicolor* and sterigmatocystin production in cereals. Proceedings of the Tenth International Biodeterioration and Biodegradation Symposium. p. 287-293. DEHEMA, Frankfurt am Main.
  246. Ohmomo,S, Sugita,M, Abe,M. 1973. Isolation of cyclopiazonic acid, cyclopiazonic acid imine and bissecodehydrocycpiazonic acid from cultures of *Aspergillus versicolor* (Vuill.) Tiraboschi. *J.Agric.Chem.Jpn.* **47**: 57-63.
  247. Kingston,GD, Chen,PN, Vercellotti,JR. 1976. Metabolites of *Aspergillus versicolor*: 6,8-dimethylnidurufin, griseofulvin, dechlorogriseofulvin and 3,8-dihydroxy-6-methylxanthone. *Phytochem* 1037-1039.
  248. Jesus,AE, Horak,RM, Steyn,PS, Vleggaar,R. 1987. Metabolites of *Aspergillus ustus*. Part 4. Stable isotope labeling on the biosynthesis of the austalides. *J.Chem.Soc.Perkin I* 2253-2257.
  249. Steyn,PS, Vleggaar,R. 1975. Dihydrofuro[3',s': 4,5]furo,3,2-b-xanthenones: the structures of austocystins G, H and I. *Journal of South Afric.Chem.Inst.* **XXVIII**: 375-377.
  250. Vleggaar,R, Steyn,PS, Nagel,DW. 1974. Constitution and absolute configuration of austdiol, the main toxic metabolite from *Aspergillus ustus*. *J.Chem.Soc.Perkin I* **1**: 45-49.
  251. Steyn,PS. 1973. The structures of five diketopiperazines from *Aspergillus ustus*. *Tetrahedron* **29**: 107-120.
  252. Steyn,PS, Vleggaar,R. 1976. The structure of dihydrodeoxy-8-epi-austdiol and the absolute configuration of the azaphilones. *J.Chem.Soc.Perkin I* 204-206.
  253. Steyn,PS, Vleggaar,R. 1974. Austocystins. Six novel dihydrofuro[3',s': 4,5]furo,3,2-b-xanthenones: from *Aspergillus ustus*. *J.Chem.Soc.Perkin I* **1**: 2250-2256.
  254. Singh,SB, Smith,JL, Sabnis,GS, Dombrowski,AW, Schaeffer,JM, Goetz,MA, Bills,GF. 1991. Structure and conformation of ophiobolin K and 6-epiophiobolin K from *Aspergillus ustus* as a nematocidal agent. *Tetrahedron Lett.* **47**: 6931-6938.
  255. Cutler,HG, Crumley,FG, Cox,RH, Springer,JP, Arrendale,RF, Cole,RJ, Cole,PD. 1984. Ophiobolins G and H: New fungal metabolites from a novel source *Aspergillus ustus*. *J Agr.Food Chem.* **32**: 778-782.
  256. Kohno,J, Sakurai,M, Kameda,N, Shi,N, Matsubara,S. 1999. Production, isolation and biological properties of TMC-120A, B and C, novel inhibitors of eosinophil survival from *Aspergillus ustus*. *J.Antib.* **52**: 913-916.
  257. Kohno,J, Hiramatsu,H, Nishio,M. 1999. Structures of TMC-120A, B and C, Novel Isoquinoline Alkaloids from *Aspergillus ustus* TC 1118. *Tetrahedron* **55**: 11247-11252.
  258. Varga,J, Kevei F, Hamari Z, Toth B, Teren J, Croft JH, Kozakiewicz Z. 2000. Genotypic and phenotypic variability among black *Aspergilli*. In Samson RA, Pitt JI. (eds.), Integration of modern taxonomic methods from *Penicillium* and *Aspergillus* classification. p. 397-411. Harwood academic publishers, Amsterdam.
  259. Kobbe,B, Cushman,M, Wogan,GN, Demain,AL. 1977. Production and antibacterial activity of malfornin C, a toxic metabolite of *Aspergillus niger*. *Appl.Env.Microb.* **33**: 996-997.
  260. Kim,K-W, Sugawara,F, Yoshida,S, Murofushi,N, Takahashi,N, Curtis,RW. 1993. Structure of malfornin B, a phytotoxic metabolite produced by *Aspergillus niger*. *Biosci.Biotech.Biochem.* **57**: 787-791.
  261. Richard,JL, Plattner,RD, Mary,J, Liska,SL. 1999. The occurrence of Ochratoxin A in dust collected from a problem household. *Mycopath.* **146**: 99-103.
  262. Ren,P, Ahearn,DG, Crow,SA. 1999. Comparative study of *Aspergillus* mycotoxin production on enriched media and construction material. *J ind.microbiol.biotechnol.* **23**: 209-213.
  263. Rao,CY, Fink,RC, Wolfe,LB, Liberman,DF, Burge,HA. 1997. A study of aflatoxin production by *Aspergillus flavus* growing on wallboard. *J.Am.Biolog.Safety Assoc.* **2**: 36-42.

264. Land,CJ, Hult,K , Fuchs,R, Hagelberg,S, Lundström,H. 1987. Tremorgenic mycotoxins from *Aspergillus fumigatus* as a possible occupational health problems in sawmills. *Appl.Env.Microb.* **53**: 787-790.
265. Pitt,JI, Samson RA, Frisvad JC. 2000. List of accepted species and their synonyms in the family Trichocomaceae. In Samson RA, Pitt JI. (eds.), *Integration of modern taxonomic methods from Penicillium and Aspergillus classification*. p. 9-49. Harwood academic publishers, Amsterdam.
266. Skouboe,P, Frisvad,JC, Taylor,JW, Lauritsen,D, Boysen,M, Rossen,L. 1999. Phylogenetic analysis of nucleotide sequences from the ITS region of terverticillate *Penicillium* species. *Mycol.Res.* **103**: 873-881.
267. Frisvad,JC, Filtenborg O. 1990. Revision of *Penicillium Furcatum* based on secondary metabolites and conventional characters. In Samson RA, Pitt JI. (eds.), *Modern concepts in Penicillium and Aspergillus classification*. p. 159-172. Plenum Press, New York.
268. Frisvad,JC, Filtenborg O. 1990. Secondary metabolites as consistent criteria in *Penicillium* taxonomy and a synoptic *Penicillium* subgenus *Penicillium*. In Samson RA, Pitt JI. (eds.), *Modern concepts in Penicillium and Aspergillus classification*. p. 373-384. Plenum Press, New York.
269. Frisvad,JC, Filtenborg O, Lund F, Samson RA. 2000. The monogeneous species and series in subgenus *Penicillium* are related to mammal nutrition and excretion. In Samson RA, Pitt JI. (eds.), *Integration of modern taxonomic methods from Penicillium and Aspergillus classification*. p. 265-283. Harwood academic publishers, Amsterdam.
270. Domsch,KH, Gams,W, Anderson,T-H. 1980. *Compendium of soil fungi*. Academic Press, London.
271. Steyn,PS. 1970. The isolation, structure and absolute configuration of secalonic acid D, the toxic metabolite of *Penicillium oxalicum*. *Tetrahedron* **26**: 51-57.
272. Andersen,R, Büchi,G, Kobbe,B, Demain,AL. 1977. Secalonic acids D and F are toxic metabolites of *Aspergillus aculeatus*. *J.Org.Chem.* **42**: 352-353.
273. Kurobane,I, Vining,LC, McInnes,AG. 1979. Biosynthetic relationships among the secalonic acids. Isolation of emodin, endocrin and secalonic acids from *Pyrenochaeta terrestris* and *Aspergillus aculeatus*. *J.Antib.* **31**: 1256-1266.
274. Frisvad,JC, Filtenborg,O. 1983. Classification of Terverticillate *Penicillia* based on profile of Mycotoxins and other Secondary Metabolites. *Appl.Env.Microb.* **46**: 1301-1310.
275. Dai,MC, Tabacchi,R, Saturnin,C. 1993. Nitrogen-containing aromatic compounds from the culture medium of *Penicillium chrysogenum* Thom. *Chimai* **47**: 226-229.
276. Stolk,AC, Samson RA, Frisvad JC, Filtenborg O. 1990. The systematics of the terverticillate *Penicillia*. In Samson RA, Pitt JI. (eds.), *Modern concepts in Penicillium and Aspergillus classification*. p. 121-137. Plenum Press, New York.
277. Bentley,R. 2000. Mycophenolic acid: A one hundred year Odyssey from antibiotic to immunosuppressant. *Chem.Rev.* **100**: 3801-3825.
278. Fujimoto,Y, Kamiya,M, Tsunoda,H, Ohtsubo,K, Tatsuno,T. 1980. Recherche toxicologique des substances metaboliques de *Penicillium carneo-lutescens*. *Chem.Pharm.Bull.* **248**: 1062-1067.
279. Moreau,S, Lablache-Comber,A, Biguet,J, Foulon,C, Delfosse,M. 1982. Botrydiplodin, a mycotoxin synthesised by a strain of *P. roqueforti*. *J.Org.Chem.* **47**: 2358-2359.
280. Moule,Y, Decloitre,F, Hamon,G. 1981. Mutagenicity of the mycotoxin botrydiplodin in the Salmonella typhimurium/Microsomal activation test. *Env.Mutagen.* **3**: 287-291.
281. Castillo,M-A, Moya,P, Couillaud,F, Carcera,MD, Marinez-Pardo,R. 1998. A heterocyclic oxime from a fungus with anti-juvenile hormone activity. *Arch.Insect Biochem.Physiol* **37**: 287-294.
282. Macias,FA, Varela,RM, Simonet,AM, Cutler,HG, Cutler,SJ, Ross,SA, Dunbar,DC, Dugan,FM, Hill,RA. 2000. Allelochemicals from New Zealand fungi. (+)-Brevione A. The first member of a novel family of bioactive spiroditerpenoids isolated from *Penicillium brevicompactum* Dierckx. *Tetrahedron Lett.* **41**: 2683-2686.



283. Moya,P, Primo-Yufero,E. 1997. Brevioxime: A New Juvenile Hormone Biosynthesis Inhibitor Isolated from *Penicillium brevicompactum*. J.Org.Chem. **62**: 8544-8545.
284. Frisvad,JC, Lund F. 1993. Toxic and secondary metabolite production by *Penicillium* species growing in stored cereals. In Scudamore KA. (ed.), p. 146-171. Central Science Laboratory, Berks.
285. Lund,F, Frisvad,JC. 1994. Chemotaxonomy of *Penicillium aurantiogriseum* and related species. Mycol.Res. **98**: 481-492.
286. Steyn,PS, Vleggaar,R. 1985. Tremorgenic mycotoxins. Fortschr.Chem Org.Naturst. **48**: 1-80.
287. Sorenson,WG, Simpson,JP. 1986. Toxicity of penicillic acid for rat alveolar macrophages. Environmental Research **41**: 505-513.
288. Nielsen,KF, Gravesen,S, Nielsen,PA, Andersen,B, Thrane,U, Frisvad,JC. 1999. Production of mycotoxins on artificially and naturally infested building materials. Mycopath. **145**: 43-56.
289. Land,CJ, Hult,K. 1987. Mycotoxin production by some wood-associated *Penicillium* spp. Lett.Appl.Microbiol **4**: 41-44.
290. Bourdiol,D, Escolula,L, Salvayre,R. 1990. Effects on patulin on microbicidal activity of mouse peritoneal macrophages. Food Chemical Toxicology **28**: 29-33.
291. Godtfredsen,WO, Vangedal,S. 1964. Trichodermin, a new Antibiotic, Related to Trichothecin. Proc.Chem.Soc. 188
292. Godtfredsen,WO, Vangedal,S. 1965. Trichodermin, a new Sesquiterpene Antibiotic. Acta Chem.Scand. **19**: 1088-1102.
293. Corley,DG, Miller-Wideman,M, Durley,RC. 1994. Isolation and structure of harzianum A: A new Trichothecene from *Trichoderma harzianum*. J.Nat.Prod. **57**: 442-425.
294. Cvetnic,Z, Pepelnjak,S. 1997. Distribution and Mycotoxin-producing ability of some fungal isolates from the air. Atmos.Env. **31**: 491-495.
295. Dennis,C, Webster,J. 1971. Antagonistic properties of species-groups of *Trichoderma*. I. Production of non-volatile antibiotics. Trans.Brit.Myc.Soc. **57**: 25-39.
296. LIN,A, Chen,CK, Chen,YJ. 1991. Molecular action of tricholin, a ribosome-inactivating protein isolated from *Trichoderma viride*. Mol.Micro. **5**: 3013
297. Hou,CT, Ciegler,A, Hesseltine,CW. 1972. New mycotoxin, trichotoxin A, from *Trichoderma viride* isolated from southern leaf blight-infected corn. App.Microb. **23**: 183-185.
298. Brückner,H, König,WA, Greiner,M, Jung,G. 1979. The sequences of the membrane-modifying peptide antibiotic trichotoxin A-40. Angew.Chem Int Ed.Engl. **18**: 476-477.
299. Haugland,RA, Vesper,SJ, Harmon,SM. 2001. Phylogenetic relationship of *Memnoniella* and *Stachybotrys* species and evaluation of morphological features for *Memnoniella* species identification. Mycologia **93**: 54-65.
300. Hinkley,SF, Fettinger,JC, Dudley,K, Jarvis,BB. 1999. Memnobotriins and Memnoconols: Novel Metabolites from *Memnoniella echinata*. J.Antib. **52**: 988-997.
301. Lam,YKT, Wichman,CF, Huang,L, Burg,RW, Monaghan,RL, Jackson,R, Reid,G, Maguire,JJ, McKnight,AJ, Ragan,CI. 1992. A novel inositol mono-phosphatase inhibitor from *Memnoniella echinata*. J.Antib. **45**: 1397-1403.
302. Giacobbe,RA, Huang,L, Kong,YL, Lam,YT, Del,SM, Wichman,CF. 1991. Drug for treating manic depression. Patent US 4981980.
303. Stefanelli,S, Sponga,F, Ferrari,P, Sottani,C, Corti,E, Brunati,C, Islam,K. 1996. Inhibitors of myo-inositol monophosphatase, ATCC 20928 factors A and C isolation, physicochemical characterization and biological properties. J.Antib. **49**: 611-616.
304. Jarvis,BB, Zhou,Y, Jiang,J, Wang,S, Sorenson,WG, Hintikka,E-L, Nikulin,M, Parikka,P, Etzel,RA, Dearborn,DG. 1996. Toxicogenic Moulds in Water-Damaged Buildings: Dechlorogriseofulvins from *Memnoniella echinata*. J.Nat.Prod. **59**: 553-554.
305. Woody,MA, Chu FS. 1992. Toxicology of *Alternaria* mycotoxins. In Chelkowski J, Visconti A. (eds.), *Alternaria. Biology, plant disease and metabolites*. p. 409-434. Elsevier, Amsterdam.
306. Winter,CK, Gilchrist,DG, Dickman,MB, Jones,C. 1996. Chemistry and biological activity of AAL toxins. Adv.Exp.Med.Biol. **392**: 307-316.

307. Shier,WT, Abbas,H, Mirocha,CJ. 1991. Toxicity of the mycotoxins fumonisins B1 and B2 and *Alternaria alternata* f.sp. *lycopersici* toxin (AAL) in cultured mammalian cells. *Mycopath.* **116**: 97-104.
308. Ren,P, Ahearn,DG, Crow,SA. 1998. Mycotoxins of *Alternaria alternata* produced on ceiling tiles. *J.Ind.Microb.* **20**: 53-54.
309. Udagawa,S. 1984. Taxonomy of mycotoxin-producing *Chaetomium*. In Kurata H, Ueno Y. (eds.), *Toxigenic Fungi - Their toxins and health hazard*. p. 139-147. Elsevier, Amsterdam.
310. Koyama,K, Natori,S. 1987. Chaetochromins B, C and D, bis(naphtho-gamma-pyrone) derivatives from *Chaetomium gracile*. *Chem.Pharm.Bull.* **35**: 578-584.
311. Sekita,S, Yoshihira,K, Natori,S, Udagawa,S , Muroi,T, Sugiyama,Y, Kurata,H, Umeda,M. 1981. Mycotoxin production by *Chaetomium* spp. and related fungi. *Can.J.Microbiol.* **27**: 766-772.
312. Achatz,G, Oberkofler,H, Lechenauer,E. 1995. Molecular cloning of major and minor allergens of *Alternaria alternata* and *Cladosporium herbarum*. *Mol.Immunol.* **32**: 213-227.
313. Bjurman,J. 1993. Determination of microbial activity in moulded wood by the use of fluorescein diacetate. ? 1-16.
314. Miller,M, Palojärvi,A, Rangger,A, Reeslev,M, Kjølner,A. 1998. The use of fluorogenic substrates to measure fungal presence and activity in soil. *Appl.Env.Microb.* **64**: 613-617.
315. Notermans,S. 1988. (1-5)-linked beta-D-galactosidases are immunodominant in extracellular polysaccharides of *Penicillium* and *Aspergillus* species. *Mol.Immunol.* **25**: 975-979.
316. Sunesson,A-L, Nilsson,C-A, Andersson,B, Blomquist,G. 1996. Volatile metabolites produced by two fungal species cultivated on building materials. *Ann.Occup.Hyg.* **40**: 397-410.
317. Swift,MJ. 1973. The estimation of mycelial biomass by determination of hexosamine content of wood tissue decayed by fungi. *Soil Biol Biochem.* **5**: 321-332.
318. Szponar,B, Larsson,L. 2000. Determination of Microbial Colonisation in Water-Damaged buildings using chemical Marker analysis by gas chromatography - mass spectrometry. *Indoor Air* **10**: 13-18.
319. Miller,JD, Young,JC. 1997. The use of ergosterol to measure exposure to fungal propagules in indoor air. *Am Ind.Hyg.Assoc.J* **58**: 39-43.
320. Johanning,E, Gareis,M, Chin,YS, Hintikka,E-L, Jarvis,BB, Dietrich,R. 1998. Toxicity screening of materials from buildings with fungal indoor air quality problems (*Stachybotrys chartarum*). *Mycotoxin Res.* **14**: 60-73.
321. Hanelt,MM, Gareis,M, Kollarczik,B. 1994. Cytotoxicity of mycotoxin evaluated by the MTT cell-culture assay. *Mycopath.* **128**: 167-174.
322. Yike,I, Allan,T , Sorenson,WG, Dearborn,DG. 1999. Highly sensitive protein translation assay for trichothecene toxicity in airborne particulates: Comparison with cytotoxicity assays. *Appl.Env.Microb.* **65**: 88-94.
323. Mercer,EI, Barlett,K. 1974. Sterol esters of *Phycomyces blakesleeanus*. *Phytochem* **14**: 1099-1105.
324. Rezanka,T. 1992. Analysis of sterol esters from alga and yeast by high- performance liquid chromatography and capillary gas chromatography-mass spectrometry with chemical ionization. *J.Chrom.* **598**: 219
325. Bermingham,S, Maltby,L, Cooke,RC. 1995. A critical assessment of the validity of ergosterol as an indicator of fungal biomass. *Mycol.Res.* **99**: 479
326. Gessner,MO, Chauvet,E. 1993. Ergosterol-to-biomass conversion factors for aquatic hyphomycetes. *Appl.Env.Microb.* **59**: 502-507.
327. Newell,SY. 1995. Minimizing Ergosterol Loss during Preanalytical Handling and Shipping of Samples of Plant Lit. *Appl.Env.Microb.* **61**: 2794
328. Suberkopp,K, Gessner,MO, Chauvet,E. 1993. Comparison of ATP and ergosterol as indicators of fungal biomass associated with decomposing leaves in streams. *Appl.Env.Microb.* **59**: 3367-3372.

329. Davis,MW, Lamar,RT. 1992. Evaluation of methods to extract ergosterol for quantification of soil fungal biomass. *Soil Biol Biochem.* **24**: 189
330. Young,JC. 1995. Microwave-assisted extraction of the fungal metabolites ergosterol and total fatty acids. *J Agr.Food Chem.* **43**: 2904-2910.
331. Gessner,MO, Schmitt,AL. 1996. Use of Solid-Phase Extraction To Determine Ergosterol Concentrations in Plant Tissue Colonized by Fungi. *Appl.Env.Microb.* **62**: 415
332. Axelsson,B-O, Saraf,A, Larsson,L. 1995. Determination of ergosterol in organic dust by gas chromatography-mass spectrometry. *J.Chrom.B* **666**: 77-84.
333. Saraf,A. 1999. Microorganisms in the indoor environment. Analysis and structure-bioactivity relationships. Ph.D. Dissertation, Department of infectious diseases and microbiology, University of Lund, Sweden.
334. Pasanen,A-L, Yli-Peitra,K, Pasanen,P, Kalliokoski,P, Tarhanen,J. 1999. Ergosterol content in various fungal species and biocontaminated building materials. *Appl.Env.Microb.* **65**: 138-142.
335. Saraf,A, Larsson,L. 1996. Use of gas chromatography/ion-trap tandem mass spectrometry for the determination of chemical markers of microorganisms in organic dust. *Journal of Mass spectrometry* **31**: 389-396.
336. Dales,RE, Miller,JD. 1999. Residential Fungal Contamination and Health: Microbial Cohabitants as Covariates. *Env.Health Persp.Supp.* **107**: 481-483.
337. Chu,FS. 1992. Recent Progress on analytical techniques for mycotoxins in feedstuffs. *J Anim.Sci* **70**: 3950-3963.
338. Gilbert,J. 1993. Recent advances in analytical methods for mycotoxins. *Food addit.contam.* **10**: 37-48.
339. Lin,L, Zhang,J, Wang,P, Wang,Y, Chen,J. 1998. Thin-layer chromatography of mycotoxins and comparison with other chromatographic methods. *J.Chrom.A* **815**: 3-20.
340. Langseth,W, Rundberget,T. 1998. Instrumental methods for determination of nonmacrocylic trichothecenes in cereals, foodstuffs and cultures. *J.Chrom.A* **815**: 103-121.
341. Novak,TJ, Quinn-Dogget,K. 1991. 2-(Diphenylacetyl)-1,3-indanedione-1-hydrozone (dipain) derivatives for detection of trichothecene mycotoxins. *Analytical Letters* **24**: 913-924.
342. Ramakrishna,Y, Bhat,RV. 1987. Comparison of different spray reagents for the identification of trichothecenes. *Curr Sci* **56**: 524-526.
343. Septien,I, Blanco,JL, Suratz,G, Cutuli,MT. 1994. Solubility and stability of sterigmatocystin in aqueous solutions. *Mycotoxin Res.* **10**: 15-20.
344. Scott,PM. 1993. Gas Chromatography of Mycotoxins. In Betina V. (ed.), *Chromatography of Mycotoxins: Techniques and applications*. Journal of Chromatography Library, Vol **54**. p. 3-11. Elsevier, Amsterdam.
345. Giddings,JC. 1991. *Unified Separation Science*. John Wiley & Sons, Inc, New York.
346. Scott,PM. 1993. Methods for the detection and determination of nitrogen-containing mycotoxins. ? 617-625.
347. Scott,PM, Weber,D, Kanhere,SR. 1997. Gas chromatography-mass spectrometry of some *Alternaria* mycotoxins. *J.Chrom.A* **765**: 255-263.
348. Thorpe,CW, Johnson,RL. 1974. Analysis of penicillic acid by gas-liquid chromatography. *J Assoc.Off.Anal.Chem* **57**: 861-865.
349. Rychlik,M, Schieberle,P. 1999. Quantitation of the mycotoxin patulin by a stable isotope dilution assay. *J Agr.Food Chem.* **47**: 3749-3755.
350. Shepard,GS, Thiel,PG, Marasas,WFO, Sydenham,EW. 1993. Isolation and determination of AAL phytotoxins from corn cultures of the fungus *Alternaria alternata* f. sp. *lycopersici*. *J.Chrom.* **641**: 95-100.
351. Begley,P, Foulger,BE, Jeffery,PD, Black,RM, Read,RW. 1986. Detection of trace levels of trichothecenes in human blood using capillary gas chromatography-electron-capture negative ion chemical ionisation mass spectrometry. *J.Chrom.* **367**: 87-1014.
352. Black,RM, Clarke,RJ, Read,RW. 1986. Detection of trace levels of trichothecene mycotoxins in human urine by gas chromatography-mass spectrometry. *J.Chrom.* **367**: 103-115.

353. D'agostino,PA, Provost,LR, Drover,DR. 1986. Analysis of trichothecene mycotoxins in human blood by capillary column gas chromatography-ammonia chemical ionization mass spectrometry. *J.Chrom.* **367**: 77-86.
354. Mirocha,CJ, Pawliszyn J, Hewetson DW. 1986. Gas chromatography/mass spectral analysis of trichothecenes. In Richard JL, Thurston JR. (eds.), p. 305-322. Kluwer, Dordrecht.
355. Rosen,J, Rosen,RT, Hartman,TG. 1986. Capillary gas chromatography-mass spectrometry of several macrocyclic trichothecenes. *J.Chrom.* **355**: 241-251.
356. Krishnamurthy,T, Sarver,WE, Greene,SL, Jarvis,BB. 1987. Mass Spectral Investigation on Trichothecene Mycotoxins. II. Detection and Quantification of Macrocyclic Trichothecenes by Gas Chromatography/Negative Ion Chemical Ionization Mass Spectrometry. *J.AOAC.* **70**: 132-140.
357. Scott,PM, Lombaert,GA, Pellaers,P, Bacler,S, Kanhere,SR, Sun,WF, Lau,P-Y, Weber,D. 1989. Application of capillary gas chromatography to a survey of wheat for five trichothecenes. *Food addit.contam.* **6**: 489-500.
358. Schwandorf,K, Müller,H-M. 1991. Determination of Trichothecenes in Cereals by Gas Chromatography with Ion Trap Detection. *Chromatographia* **32**: 137-143.
359. Möller,TE, Gustavsson,HF. 1992. Determination of Type A and Type B Trichothecenes in cereal by gas chromatography with electron capture detection. *J AOAC Int.* **75**: 1049-1053.
360. Seidel,V, Fraissler,S, Lang,C, Schiller,K, Lindner,FW. 1993. Analysis of trace levels of trichothecene mycotoxins in Austrian cereals by gas chromatography with electron capture detection. *Chromatographia* **37**: 191-201.
361. Croteau,SM, Prelusky,DB, Trenholm,HL. 1994. Analysis of Trichothecene Mycotoxins by gas chromatography with Electron Capture Detection. *J Agr.Food Chem.* **42**: 926-933.
362. Furlong,EB, Soares,LMV. 1995. Gas Chromatographic method for Quantitation and Confirmation of Trichothecenes in Wheat. *J.AOAC.* **78**: 386-390.
363. Ryu,J-S, Yang,J-S, Song,Y-S, Kwon,O-S, Park,J, Chang,I-M. 1997. Survey of natural occurrence of trichothecene mycotoxins and zearaleone in Korean cereals harvested in 1993 using gas Chromatography/mass spectrometry. *Food addit.contam.* **13**: 333-341.
364. Schollenberger,M, Lauber,U, Jara,HT, Suchy,S, Drocher,W, Müller,H-M. 1998. Determination of eight trichothecenes by gas chromatography-mass spectrometry after sample clean-up by a two stage solid-phase extraction. *J.Chrom.A* **815**: 123-132.
365. Lee,RK, Kee,SYK , Ng,WF, Gopalakrishnakone,R. 1999. Determination of Trichothecene Toxin (T2 Mycotoxin) in Aqueous Sample with Solid Phase Microextraction Technique Followed by Gas Chromatography with Flame Ionization Detection. *J.High Res.Chrom.* **122**: 424-426.
366. Hewetson,DW, Mirocha,CJ. 1987. Development of Mass Spectra Library of Trichothecenes Based on Positive Chemical Ionization Mass Spectra. *J.AOAC.* **70**: 647-653.
367. Krishnamurthy,T, Sarver,WE. 1987. Detection and Quantification of Picogram Amounts of Macrocyclic Trichothecenes in Brazilian *Baccharis* Plants by Direct Chemical Ionization Tandem Mass Spectrometry. *Analytical Chemistry* **59**: 1272-1278.
368. Grob,K. 1993. Split and Splitless Injection in Capillary Gas Chromatography. Hüthig, Heidelberg.
369. Frisvad,JC, Thrane U. 1993. Liquid chromatography of mycotoxins. In Betina V. (ed.), *Chromatography of mycotoxins: Techniques and applications.* Journal of Chromatography Library. p. 253-372. Elsevier, Amsterdam.
370. Smedsgaard,J. 1997. Micro-scale extraction procedure for standardized screening of fungal metabolite production in cultures. *J.Chrom.A* **760**: 264-270.
371. Ashcroft,AE. 1997. Ionization methods in organic mass spectrometry. The Royal Society Chemistry, Cambridge.
372. Jørgensen,K, Vahl,M. 1999. Analysis of ochratoxin A in pig kidney and rye flour using liquid chromatography tandem mass spectrometry (LC/MS/MS). *Food Addit.Contam* **16**: 451-456.

373. Rosenberg,E, Krska,R, Wissiack,R, Kmetov,V, Josephs,R, Razzazi,E, Grasserbauer,M. 1998. High-Performance liquid chromatography-atmospheric-pressure chemical ionization mass spectrometry as a new tool for the determination of the mycotoxin zearalenone in food and feed. *J.Chrom.A* **819**: 277-288.
374. Josephs,J. 1996. Detection and characterization of fumonisin mycotoxins by liquid chromatography electrospray ionization using ion trap and triple quadrupole mass spectrometry. *Rapid communications in mass spectrometry* **10**: 1333-1344.
375. Shepard,GS. 1998. Chromatographic determination of the fumonisin mycotoxins. *J.Chrom.A* **815**: 31-39.
376. Sewram,V, Nieuwoudt,TW, Marasas,WFO, Shephard,CS, Ritieni,A. 1999. Determination of *Fusarium* mycotoxins, fusaproliferin and beauvericin by high-performance liquid chromatography-electrospray ionization mass spectrometry. *J.Chrom.A* **858**: 175-185.
377. Sewram,V, Nieuwoudt,TW, Marasas,WFO, Shephard,CS, Ritieni,A. 1999. Determination of the mycotoxin moniliformin in cultures of *Fusarium subglutinans* and in naturally contaminated maize by high-performance liquid chromatography - atmospheric pressure chemical ionization mass spectrometry. *J.Chrom.A* **848**: 185-191.
378. Berger,U, Oehme,M, Kuhn,F. 1999. Quantitative determination and structure elucidation of type A- and B-trichothecenes by HPLC/ion trap multiple mass spectrometry. *J Agr.Food Chem.* **47**: 4240-4245.
379. McComb,ME, Krutchinsky,AN, Ens,W, Standing,KG, Perreault,H. 1998. Sensitive high-resolution analysis of biological molecules by capillary zone electrophoresis coupled with reflecting time-of-flight mass spectrometry. *J.Chrom.A* **800**: 1-11.
380. Tomlinson,AJ, Benson,LM, Braddock,WD, Oda,RP. 1994. On-line preconcentration-capillary electrophoresis-mass spectrometry (PC-CE-MS). *Journal of High Resolution Chromatography* **17**: 729-731.
381. Wheat,TE, Lilley,KA, Banks,JF. 1997. Capillary electrophoresis with electrospray mass spectrometry detection for low molecular-mass compounds. *J.Chrom.A* **781**: 99-105.
382. Nielsen,MS, Nielsen,PV, Frisvad,JC. 1996. Micellar electrokinetic capillary chromatography of fungal metabolites resolution optimized by experimental design. *J.Chrom.A* **721**: 337-344.
383. Naylor,S, Tomlinson,AJ. 1998. Membrane preconcentration-capillary electrophoresis tandem mass spectrometry (mPC-CE-MS/MS) in the sequence analysis of biologically derived peptides. *Talanta* **45**: 603-612.
384. Corneli,S, Maragos,CM. 1994. Capillary electrophoresis with laser-induced fluorescence: Method for the mycotoxin ochratoxin A. *J Agr.Food Chem.* 3162-3165.
385. Maragos,CM, Greer,JI. 1997. Analysis of Aflatoxin B1 in Corn Using Capillary Electrophoresis with Laser-Induced Fluorescence Detection. *J Agr.Food Chem.* **45**: 4337-4341.
386. Park,JJ, Chu,FS. 1996. Assessment of Immunochemical Methods for the Analysis of Trichothecene Mycotoxins in Naturally Occurring Moldy Corn. *J AOAC Int.* **79**: 465
387. Pestka,JJ, Abouzied,MN, Sutikno. 1995. Immunological assays for mycotoxin detection. *Food Technol.* 120-128.
388. Visconti,A, Pascale,M. 1998. Determination of zearalenone in corn by means of immunoaffinity clean-up and high-performance liquid chromatography with fluorescence detection. *J.Chrom.A* **815**: 133-140.
389. Usleber,E, Märtlbauer,E, Dietrich,R, Terplan,G. 1991. Direct enzyme-linked immunosorbent assay for the detection of the detection of the 8-ketotrichothecene mycotoxins deoxynivalenol, 3-acetyldeoxynivalenol, and 15-acetyldeoxynivalenol in buffer solutions. *J Agr.Food Chem.* **39**: 2091-2095.
390. Usleber,E, Schneider,E, Märtlbauer,E, Terplan,G. 1993. Two formats of enzyme immunoassay for 15-acetyldeoxynivalenol applied to wheat. *J Agr.Food Chem.* **41**: 2019-2023.
391. Collin,R, Schneider,E, Briggs,L, Towers,N. 1998. Development of immunodiagnostic field tests for the detection of the mycotoxin, sporidesmin A. *Food And Agricultural Immunology* **10**: 91-104.

392. Hack,R, Märklbauer,E, Terplan,G. 1988. Production and characterization of monoclonal antibodies to the macrocyclic trichothecene roridin A. *Appl.Env.Microb.* **54**: 2328-2330.
393. Dietrich,R, Johanning,E, Gareis,M, Schneider,E, Usleber,E, Märklbauer,E. 1999. Immunochemical detection of mycotoxins associated with Stachybotryotoxicosis. In Johanning E (Ed.), Eastern New York Occupational & Environmental Health Center, New York, p. 482-491.
394. Märklbauer,E, Gareis,M, Terplan,G. 1988. Enzyme Immunoassay for the Macrocyclic Trichothecene Roridin A: Production, Properties, and Use of Rabbit Antibodies. *Appl.Env.Microb.* **54**: 225-230.
395. Bodon,L, Palyusik,M. 1970. Cytotoxicity of toxic extracts from the fungus *Stachybotrys alternans*. *Acta.Vet.Acad.Sci.Hung.* **20**: 289-294.
396. Langseth,W, Bernhoft,A, Rundberget,T, Kosiak,B, Gareis,M. 1999. Mycotoxin production and cytotoxicity of Fusarium strains isolated from Norwegian cereals. *Mycopath.* **144**: 103-113.
397. Mosmann,T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. *J.Immunol.Methods* **65**: 55
398. Saraf,A, Larsson,L, Larsson,B-M, Larsson,K, Palmberg,L. 1999. House dust induces IL-6 and IL-8 response in A549 epithelial cells. *Indoor Air* **9**: 219-225.
399. Anderson,MA, Mikkola,R, Kroppensted,RM, Rainey,FA, Peltola,J. 1998. The mitochondrial toxin produced by *Streptomyces griseus* strains isolated from an indoor environment is valinomycin. *Appl.Env.Microb.* **64**: 4767-4773.
400. Mikkola,R, Anderson,JM, Peltola,J, Saris,N-E, Grigoriev,P, Salkinoja-Salonen,M. 1999. Purification and properties of toxins isolated from *Streptomyces griseus* and *Bacillus cereus* found in construction materials of buildings. *Proceedings of the 8th International Conference on Indoor Air Quality and Climate, Indoor Air '99*, p. 1110-1111.
401. Peltola,J, Andersson,M, Haatela,T, Mussalo-Rauhamaa,H, Salkinoja-Salonen,M. 1999. Toxicogenic indoor Actinimyceres and fungi case study. *The 8th International Conference on Indoor Air Quality and Climate*, p. 560-561.
402. Piecková,E, Jesenská,Z. 1995. The Effect of Chloroform-Extractable Secondary Metabolites of Filamentous Fungi on the Movement of Respiratory Tract Cilia from One-Day- Old Chicks in vitro. *Folia Microbiologica* **40**: 123-127.
403. Brown,RF, Wildman,JD. 1968. Temperature-Dose Relationship with Aflatoxin on the Brine Shrimp *Artemia salina*. *J.AOAC.* **51**: 905-906.
404. Engler,KH, Coker,R, Evans,IH. 1994. A novel colorimetric yeast bioassay for detecting trichothecene mycotoxins. *J.Microbiol.Meth.* 207-218.
405. Hinkley,SF, Jarvis BB. 2000. Chromatographic method for Stachybotrys toxins. In Pohland A, Trucksess MW. (eds.), *Methods Molecular Biology*. 157. *Mycotoxin Protocols*. p. 173-194. Humana Press, Totowa.
406. Black,RM, Clarke,RJ, Read,RW. 1987. Detection of trace levels of trichothecene mycotoxins in environmental residue and foodstuffs using gas chromatography with mass spectrometric or electron-capture detection. *J.Chrom.* **388**: 365-378.
407. Jarvis,BB. 1992. Macrocyclic trichothecenes from Brazilian *Baccharis* species: from microanalysis to large-scale isolation. *Phytochem.Anal.* **3**: 241-249.
408. Palmgren,U, Ström,G, Malmberg,P, Blomquist,G. 1986. The Nucleopore Method: a technique for enumeration of viable and non viable airborne microorganisms. *Am J Ind.Med.* **10**: 325-327.
409. Sorenson,WG. 1990. Mycotoxins as potential occupational hazards. *Developments Industrial Microbiol.* **31**: 205-211.
410. Smoragiewicz,W, Cossette,B, Boutard,A, Krzystyniak,K. 1993. Trichothecene mycotoxins in the dust ventilation system in office buildings. *Int.Arch.Occup.Health* **65**: 113-117.
411. Anonymous. 1990. Fungal Resistance of panel Products made of or containing materials of organic origin, Part 3. *British Standard* 1982.
412. Grove,JF. 1988. Non-macrocyclic trichothecenes. *Nat.Prod.Rep.* **5**: 187-209.

413. Larsen,FO, Clementsen,P, Hansen,M, Maltbæk,N, Gravesen,S, Skov,P, Norn,S. 1996. The microfungi *Trichoderma viride* potentiates histamine release from human bronchoalveolar cells. *APMIS* **104**: 673-679.
414. Ayer,WA, Miao,S. 1993. Secondary metabolites of the aspen fungus *Stachybotrys cylindrospora*. *Can.J.Chem.* **71**: 487-493.
415. El-Maghraby,OMO, Bean,GA, Jarvis,BB, Aboul-Nasr,MB. 1991. Macrocyclic trichothecenes produced by *Stachybotrys* isolated from Egypt and Eastern Europe. *Mycopath.* **113**: 109-115.
416. Shinohara,C, Hasumi,K, Hatsumi,W, Endo,A. 1996. Staplabin, a novel fungal triprenyl phenol which stimulates the binding of plasminogen to fibrin and U937 cells. *J.Antib.* **49**: 961-966.
417. Orii,Y, Kawamura,Y, Mizobe,F, Sakai,N, Hanada,K. 1994. Extraction of nerve growth factor enhancer from cultured *Stachybotrys parvispora* F-4708. Patent
418. Nozawa,Y, Yamamoto,K, Ito,M, Sakai,N, Mizoue,K, Mizobe,F, Hanada,K. 1997. Stachybotrin C and parvisporin, novel neurotogenic compounds .1. Taxonomy, isolation, physico-chemical and biological properties. *J.Antib.* **50**: 635-640.
419. Rao,CY, Burge,HA, Brain,JD. 2000. The time course of response to intratracheally instilled toxic *Stachybotrys chartarum* spores in rats. *Mycopath.* **149**: 27-34.
420. Caserett and Doull's Toxicology. The basic Science of Poisons1996. In. Klaassen CD(ed.). McGraw-Hill, New York.
421. Dhar,AK, Bose,SK. 1968. Studies on versicolin, a new antifungal antibiotic from *Aspergillus versicolor*. II. Isolation and purification. *Appl.Microbiol* **16**: 749-752.
422. Dhar,AK, Bose,SK. 1969. Studies on versicolin, a new antifungal antibiotic from *Aspergillus versicolor*. *Tetrahedron Lett.* **55**: 4871-4874.
423. Rickards,RW. 1971. Structure of the antifungal antibiotic versicolin. *J.Antib.* **24**: 715-716.
424. Anonymous. 1999. Aflatoxins in corn and peanut butter. AOAC official method 990.33. In Cunniff P. (ed.), Official methods of analysis of AOAC international. AOAC International, Gaithersburg.
425. Malmstrøm,J, Christophersen,C, Frisvad,JC. 2000. Secondary metabolites characteristic of *Penicillium citrinum*, *Penicillium steckii* and related species. *Phytochem* **54**: 301-309.
426. Grogan,RG, Kimble,KA, Misaghi,I. 1975. A stem canker disease of tomato caused by *Alternaria alternata* f. sp. *lycopersici*. *Phytopathology* **65**: 880-886.
427. Enk,M. 1996. Chemotaxonomy of *Eurotium*. M.Sc. Thesis, Department of Biotechnology, Technical University of Denmark.
428. Malmstrøm,J. 2000. Marine fungal chemistry. Ph.D. Thesis. The Marine Chemistry section. University of Copenhagen, Denmark.
429. Hass,U, Lund,SP , Simonsen,L, Fries,AS. 1995. Effects of prenatal exposure to xylene on postnatal development behavior in rats. *Neurotoxicology and Teratology* **17**: 341-349.

## APPENDIX A

Conference proceedings and papers in Danish non peer reviewed journals.

Nielsen, KF. 2001. A review on mycotoxins in the indoor environment. In Juuti S (Ed.), The second Finnish-Danish Workshop on Moulds in buildings. Finnish Research Programme on Environmental health, Kuopio, p. 8-13.

Meyer, HW, Nielsen, KF, Kildesø, J, Jensen, KA, Norn, S, Permin, H, Poulsen, LK, Malling, HJ, Gravesen, S, Gyntelberg, F. 2001. Double blind placebo controlled exposure to moulds. In Juuti S (Ed.), The second Finnish-Danish Workshop on Moulds in buildings. Finnish Research Programme on Environmental health, Kuopio, p. 30-31.

Thrane, U., Andersen, B., and Nielsen, K. F. Skimmelsvampe og indeklimakvallitet. Dansk Kemi 82(2), 33-35. 2001.

Nielsen, KF, Nielsen, PA, Holm, G. 2000. Growth of moulds on building materials under different humidities. Proceedings of Healthy Buildings 2000, Espoo. p. 283-288.

Kildesø, J, Würtz, H, Nielsen, KF, Wilkins, CK, Gravesen, S, Nielsen, PA, Thrane, U, Schneider, T. 2000. The release of fungal spores from water damaged building materials. Proceedings of Healthy Buildings 2000, Espoo. p. 313-318.

Nielsen, KF. 2000. Mycotoxins from Mould infested building materials. Mycotoxin Res. 16A: 113-116.

Nielsen, KF, Thrane, U. 2000. Fast methods for screening of trichothecenes in fungal cultures using GC-MS/MS. Mycotoxin Res. 16A: 252-256.

Jarvis, BB, Hinkley, SF, Nielsen, KF. 2000. Stachybotrys: An unusual mold associated with water-damaged buildings. Mycotoxin Res. 16A: 105-108.

Wilkins, CK, Nielsen, KF, Hoekstra, ES, Larsen, K. 1999. MVOC analysis for detection of microbial growth in buildings I. Variation of Mvoc mycotoxin patterns in *Aspergillus versicolor*. Proceedings of the 8th International Conference on Indoor air quality and Climate, Indoor Air '99, p. 897-901.

Nielsen, KF. 1999. Mycotoxins and other biologically active compounds in water damaged buildings. International Journal of immunopathology and pharmacology p. S20-S21.

Nielsen, KF, Gravesen, S. 1999. Production of mycotoxins on water damaged Building materials. In Johanning E (Ed.), Eastern New York Occupational & Environmental Health Center, New York, p. 423-431.

Nielsen, KF. 1999. Mykotoksiner og biologisk aktive stoffer i vandskadede bygninger. Miljø og Sundhed 10: 4-9.

Nielsen, K. F. Mykotoksinproduktion på vandskadede byggematerialer. Dansk Kemi 79(6/7), 30-34. 1998.

Larsen, FO, Clementsen, P, Hansen, M, Maltbæk, N, Larsen, TO, Nielsen, KF, Gravesen, S, Skov, P, Norn, S. 1998. Volatile organic compounds from the indoor mould *Trichoderma viride* cause histamine release from human bronchoalveolar cells. Inflammation Research 47: S5-S6



## APPENDIX B

Here are listed chemical and biological data from the components the different mould genera and species covered in section 2.4. When the mono isotopic mass was not listed in the paper it was calculated<sup>1</sup>. This appendix has its own reference list.

Component	Producing species	Biologically effect	Elementary composition	$\lambda$ (log $\epsilon$ )	M (Da) <sub>1</sub>
Satratoxin H <sup>2</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>29</sub> H <sub>36</sub> O <sub>9</sub>	225(14700), 255(10400)	528.24
Iso-Satratoxin H <sup>3</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>29</sub> H <sub>36</sub> O <sub>9</sub>		528.24
Satratoxin G <sup>4</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>29</sub> H <sub>36</sub> O <sub>10</sub>	256(6500)	544.23
Iso-satratoxin G <sup>3</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>29</sub> H <sub>36</sub> O <sub>10</sub>	260	544.23
Satratoxin F <sup>4</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>29</sub> H <sub>34</sub> O <sub>10</sub>	250 (5900)	542.33
Iso-satratoxin F <sup>3</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>29</sub> H <sub>34</sub> O <sub>10</sub>	251(17700)	542.33
Roridin E <sup>5</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>29</sub> H <sub>38</sub> O <sub>8</sub>	195(15800), 223(25100), 263(19900)	514.26
Iso-roridin E <sup>6</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>29</sub> H <sub>38</sub> O <sub>8</sub>	223(24000), 262(16000)	514.26
Epi-roridin E <sup>6</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>29</sub> H <sub>38</sub> O <sub>8</sub>	223(24000), 262(16000)	514.26
Verrucarín J <sup>7,8</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>27</sub> H <sub>32</sub> O <sub>8</sub>	196(15500), 219(19900), 262(14500)	484.21
Verrucarín B <sup>7,8</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>27</sub> H <sub>32</sub> O <sub>9</sub>	258.5(23400)	500.20
Roridin L-2 <sup>3,9</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>29</sub> H <sub>38</sub> O <sub>9</sub>	259(24650)	530.25
Trichoverrol A <sup>7,8</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>23</sub> H <sub>32</sub> O <sub>7</sub>	260(36300)	420.21
Trichoverrol B <sup>7,8</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>23</sub> H <sub>32</sub> O <sub>7</sub>	260(33900)	420.21
Trichoverrin A <sup>7,8</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>29</sub> H <sub>40</sub> O <sub>9</sub>	260(39800)	532.27
Trichoverrin B <sup>7,8</sup>	<i>S. chartarum</i>	Highly cytotoxic	C <sub>29</sub> H <sub>40</sub> O <sub>9</sub>	260(33800)	532.27
Trichodermin <sup>10</sup>	<i>S. chartarum</i> , <i>S. cylindrospora</i>		C <sub>17</sub> H <sub>24</sub> O <sub>4</sub>	End abs.	292.38
Trichodermol <sup>10</sup>	<i>S. chartarum</i> , <i>S. cylindrospora</i>		C <sub>15</sub> H <sub>22</sub> O <sub>3</sub>	End abs.	250.34

<sup>1</sup>Molecular ion according to

Component	Producing species	Biologically effect	Elementary composition	$\lambda$ (log $\epsilon$ )	M (Da)
Atranone A <sup>11</sup>	<i>S. chartarum</i>		C <sub>24</sub> H <sub>32</sub> O <sub>6</sub>	224(10500)	416.22
Atranone B <sup>11</sup>	<i>S. chartarum</i>		C <sub>25</sub> H <sub>34</sub> O <sub>7</sub>	231(10800)	446.23
Atranone C <sup>11</sup>	<i>S. chartarum</i>		C <sub>24</sub> H <sub>32</sub> O <sub>6</sub>	End abs	416.22
Atranone D <sup>11</sup>	<i>S. chartarum</i>		C <sub>24</sub> H <sub>34</sub> O <sub>4</sub>	231(14800)	386.25
Atranone E <sup>11</sup>	<i>S. chartarum</i>		C <sub>24</sub> H <sub>34</sub> O <sub>4</sub>	226(12500)	386.2457
Atranone F <sup>12</sup>	<i>S. chartarum</i>		C <sub>24</sub> H <sub>32</sub> O <sub>7</sub>	237(4169)	432.2148
Atranone G <sup>12</sup>	<i>S. chartarum</i>		C <sub>25</sub> H <sub>34</sub> O <sub>8</sub>		462.2254
Epoxydolabellane A <sup>6,12</sup>	<i>S. chartarum</i>		C <sub>20</sub> H <sub>30</sub> O <sub>3</sub>	235(8870)	318.2206
6 $\beta$ -hydroxydolabella-3E,8E,12-trien-14-one <sup>13</sup>	<i>S. chartarum</i>		C <sub>20</sub> H <sub>30</sub> O <sub>2</sub>	236(8710)	302.2246
Mellin <sup>5</sup>	<i>S. chartarum</i>		C <sub>10</sub> H <sub>10</sub> O <sub>3</sub>	246, 314	178.063
K-76 COOH <sup>14-16</sup>		Anti diabetics, necrosis factor-liberation inhibitors	C <sub>23</sub> H <sub>30</sub> O <sub>7</sub>		418.1992
6,8-dihydroxy-3,5,7-trimethylisochroman <sup>10</sup>	<i>S. cylindrospora</i>		C <sub>11</sub> H <sub>13</sub> O <sub>3</sub>	202(38000), 25(8000), 275(41007), 281(1400)	208.1091
Bisbynin <sup>17</sup>	<i>S. bisbyi</i>	Enhances fibrinolytical activity	C <sub>15</sub> H <sub>22</sub> O <sub>5</sub>	End abs.	282.1467
Epi-cochliquinone <sup>18,19</sup>	<i>S. bisbyi</i>	Inhibitor of cholesterol acetyltransferase	C <sub>30</sub> H <sub>44</sub> O <sub>8</sub>	270(10200), 386(1100)	523.3004
F1839-A <sup>20,21</sup>		Inhibitor of Pancreatic cholesterol esterase	C <sub>23</sub> H <sub>31</sub> NO <sub>5</sub>	218(37424), 301(3182), 262(6553)	401.2202
F1839-B <sup>20,21</sup>		Inhibitor of Pancreatic cholesterol esterase	C <sub>24</sub> H <sub>33</sub> NO <sub>6</sub>	218(41271), 308(2910), 271(6230)	431.2308
F1839-C <sup>20,21</sup>		Inhibitor of Pancreatic cholesterol esterase	C <sub>24</sub> H <sub>33</sub> NO <sub>6</sub>	217(33069), 302(2525), 267(5293)	431.2308
F1839-D <sup>20,21</sup>		Inhibitor of Pancreatic cholesterol esterase	C <sub>23</sub> H <sub>31</sub> NO <sub>5</sub>	225(31615), 298(4924), 255(10385)	401.2202
F1839-E <sup>20,21</sup>		Inhibitor of Pancreatic cholesterol esterase	C <sub>25</sub> H <sub>35</sub> NO <sub>6</sub>	217(31462), 302(2314), 262(6408)	445.2464
F1839-F <sup>20,21</sup>		Inhibitor of Pancreatic cholesterol	C <sub>28</sub> H <sub>39</sub> NO <sub>7</sub>	217(33069), 267(5293)	501.2727

Table 2 Non-trichothecene secondary metabolites and mycotoxins from <i>Stachybotrys</i> species					
Component	Producing species	Biologically effect	Elementary composition	$\lambda$ (log $\epsilon$ )	M (Da)
		esterase		300(2525)	
F1839-I <sup>20,21</sup>		Inhibitor of Pancreatic cholesterol esterase	C <sub>23</sub> H <sub>32</sub> NO <sub>4</sub>	229(11384), 282(9412), 325(3683)	386.2331
F1839-J <sup>20,21</sup>		Inhibitor of Pancreatic cholesterol esterase	C <sub>29</sub> H <sub>41</sub> NO <sub>6</sub>	218(32041), 301(2323)	499.2934
FR901459 <sup>22, 23</sup>	<i>S. chartarum</i>	Immunosuppressant, cyclosporin analogue	C <sub>62</sub> H <sub>111</sub> N <sub>11</sub> O <sub>13</sub>	End abs	1217.8363
K-76 <sup>24,25</sup>	<i>S. complementi</i>	Complement inhibitor Inhibitor of Pancreatic cholesterol esterase	C <sub>23</sub> H <sub>30</sub> O <sub>6</sub>	246(16500), 359(5400)	402.2043
Kampanol A <sup>26</sup>	<i>S. kampalensis</i>	RAS farnasyl-potein transferase inhibitor	C <sub>25</sub> H <sub>32</sub> O <sub>6</sub>	223(13330), 308(2408)	428.2199
Kampanol B <sup>26</sup>	<i>S. kampalensis</i>	RAS farnasyl-potein transferase inhibitor	C <sub>27</sub> H <sub>38</sub> O <sub>7</sub>		474.2617
Kampanol C <sup>26</sup>	<i>S. kampalensis</i>		C <sub>25</sub> H <sub>25</sub> O <sub>6</sub>	208(23369), 230(sh), 282(7480), 314(3360)	428.2199
L-671 776 <sup>27-29</sup>	<i>S. chartarum</i> , <i>S. cylindrospora</i>	Complement inhibitor, antimanic depressive drug	C <sub>23</sub> H <sub>32</sub> O <sub>5</sub>	230 (230%), 330(118%)	388.2250
Mer-NF5003 B <sup>28,30</sup>		Cytotoxic, antiviral	C <sub>23</sub> H <sub>32</sub> O <sub>6</sub>	229(12200), 328(4700), PP*	404.2199
Mer-NF5003 E <sup>28,30</sup>		Cytotoxic, antiviral	C <sub>23</sub> H <sub>32</sub> O <sub>5</sub>	225(15100), 328(5430), PP	388.2250
Mer-NF5003 F, <sup>28,30,31</sup>		Cytotoxic, antiviral, cholesterol lowering	C <sub>23</sub> H <sub>30</sub> O <sub>5</sub>	245(14900), 352(4090), PP	386.2093
NG-242 <sup>32,33</sup>	<i>S. parvispora</i>	Activator of nerve growth	C <sub>27</sub> H <sub>37</sub> NO <sub>6</sub>	214(41800), 306(3300)	471.2622
NG-243 <sup>32,33</sup>	<i>S. parvispora</i>	Activator of nerve growth	C <sub>25</sub> H <sub>35</sub> NO <sub>5</sub>	214(40800), 302(3300)	429.2515
NG-245 <sup>34</sup>	<i>S. parvispora</i>	Activator of nerve growth	C <sub>31</sub> H <sub>39</sub> NO <sub>5</sub>	222(27800), 285(4900), 296(4700)	505.2828
Parvisporin <sup>35</sup>	<i>S. parvispora</i>	Neurotoxic	C <sub>23</sub> H <sub>34</sub> O <sub>5</sub>	206(16700), 295(5800)	390.2406
SMTP-1 <sup>36</sup>	<i>S. microspora</i>	Enhances plasminogen activity	C <sub>25</sub> H <sub>35</sub> NO <sub>5</sub>	214(39700), 299(2800)	429.2515
SMTP-2 <sup>36</sup>	<i>S. microspora</i>	Enhances plasminogen activity	C <sub>25</sub> H <sub>37</sub> NO <sub>7</sub>	212(34000), 294(3000)	463.2570
SMTP-3 <sup>37</sup>	<i>S. microspora</i>	Enhances plasminogen activity	C <sub>26</sub> H <sub>35</sub> NO <sub>7</sub>	214(43000), 298(3400)	473.2414
SMTP-4 <sup>37</sup>	<i>S. microspora</i>	Enhances plasminogen activity	C <sub>32</sub> H <sub>39</sub> NO <sub>6</sub>	214(40700), 302(2500)	533.2777
SMTP-5 <sup>37</sup>	<i>S. microspora</i>	Enhances plasminogen activity	C <sub>29</sub> H <sub>41</sub> NO <sub>6</sub>	215(36700), 300(2300)	499.2934
SMTP-6 <sup>37</sup>	<i>S. microspora</i>	Enhances plasminogen activity	C <sub>34</sub> H <sub>40</sub> N <sub>2</sub> O <sub>6</sub>	216(50300), 282(6200), 308(2500)	572.2886
SMTP-7 <sup>38</sup>	<i>S. microspora</i>	Enhances plasminogen activity	C <sub>51</sub> H <sub>68</sub> N <sub>2</sub> O <sub>10</sub>	213(82500), 302(5820)	868.4876
SMTP-8 <sup>38</sup>	<i>S. microspora</i>	Enhances plasminogen activity	C <sub>52</sub> H <sub>70</sub> N <sub>2</sub> O <sub>10</sub>	213(79500), 302(5600)	882.5033
Spirodihydrobenzofuran-lactam 1 <sup>39,40</sup>	<i>S. chartarum</i>	HIV protease inhibitor Anti-manic depression drug	C <sub>23</sub> H <sub>31</sub> NO <sub>4</sub>		385.2253
Spirodihydrobenzofuran-lactam 2 <sup>39,40</sup>	<i>S. chartarum</i>	HIV protease inhibitor	C <sub>25</sub> H <sub>35</sub> NO <sub>5</sub>		429.2515
Spirodihydrobenzofuran-lactam 3 <sup>39,40</sup>	<i>S. chartarum</i>	HIV protease inhibitor	C <sub>28</sub> H <sub>39</sub> NO <sub>6</sub>		485.2777
Spirodihydrobenzofuran-lactam 4 <sup>39,40</sup>	<i>S. chartarum</i>	HIV protease inhibitor	C <sub>28</sub> H <sub>37</sub> NO <sub>8</sub>		515.2519
Spirodihydrobenzofuran-lactam 5 <sup>39</sup>	<i>S. chartarum</i>	HIV protease inhibitor	C <sub>23</sub> H <sub>29</sub> NO <sub>5</sub>		399.2046
Spirodihydrobenzofuran-lactam 6 <sup>39,40</sup>	<i>S. chartarum</i>	HIV protease inhibitor	C <sub>52</sub> H <sub>70</sub> N <sub>2</sub> O <sub>10</sub>		882.5030
Stachybotcin A <sup>41-43</sup>	<i>S. chartarum</i>	Endothelium receptor antagonist	C <sub>52</sub> H <sub>70</sub> N <sub>2</sub> O <sub>10</sub>	218(70500), 266(15400), 300-310(5300) PP	882.5030
Stachybotcin B <sup>41-43</sup>	<i>S. chartarum</i>	Endothelium receptor antagonist	C <sub>52</sub> H <sub>70</sub> N <sub>2</sub> O <sub>11</sub>	218(70500), 265(15700), 300-310(5400) PP	898.4980
Stachybotcin C <sup>41-43</sup>	<i>S. chartarum</i>	Endothelium receptor antagonist	C <sub>52</sub> H <sub>70</sub> N <sub>2</sub> O <sub>11</sub>	218(69100), 265(15300), 300-310(5400) PP	898.4980
Stachybotcin D <sup>44</sup>	<i>S. chartarum</i>		C <sub>52</sub> H <sub>70</sub> O <sub>12</sub> N <sub>2</sub>	218(77100), 265(17100), 295-315(5800)	914.4929

Component	Producing species	Biologically effect	Elementary composition	$\lambda$ (log $\epsilon$ )	M (Da)
Stachybotramide <sup>6,10</sup>	<i>S. chartarum</i> , <i>S. cylindrospora</i>		C <sub>25</sub> H <sub>37</sub> O <sub>5</sub> N		431.2672
Stachybotrin <sup>45</sup>	<i>S. alternans</i>		C <sub>25</sub> H <sub>35</sub> NO <sub>5</sub>		429.2383
Stachybotrin A <sup>46</sup>	<i>S. alternans</i>		C <sub>26</sub> H <sub>37</sub> NO <sub>5</sub>		443.2673
Stachybotral <sup>46</sup>	<i>S. alternans</i>		C <sub>23</sub> H <sub>32</sub> O <sub>4</sub>		372.2302
RF-4667A <sup>47</sup>	<i>S. elegans</i>	ACAT inhibitor	C <sub>29</sub> H <sub>44</sub> O <sub>10</sub>	End abs.	552.66
RF-4667D <sup>47</sup>	<i>S. elegans</i>	ACAT inhibitor	C <sub>25</sub> H <sub>40</sub> O <sub>8</sub>		468.2723
RF-4667F <sup>47</sup>	<i>S. elegans</i>	ACAT inhibitor	C <sub>25</sub> H <sub>40</sub> O <sub>8</sub>		468.2723
RF-4667G <sup>47</sup>	<i>S. elegans</i>	ACAT inhibitor	C <sub>23</sub> H <sub>38</sub> O <sub>7</sub>		426.2618
RF-4667H <sup>47</sup>	<i>S. elegans</i>	ACAT inhibitor	C <sub>23</sub> H <sub>38</sub> O <sub>7</sub>		426.2618
RF-4667I <sup>47</sup>	<i>S. elegans</i>	ACAT inhibitor	C <sub>23</sub> H <sub>38</sub> O <sub>7</sub>		426.2618
RF-4667J <sup>47</sup>	<i>S. elegans</i>	ACAT inhibitor	C <sub>21</sub> H <sub>36</sub> O <sub>6</sub>		384.2512
Q-11270 A <sup>48</sup>	<i>S. chartarum</i>		C <sub>28</sub> H <sub>39</sub> NO <sub>6</sub>	PP	485.2777
Q-11270 B <sup>48</sup>	<i>S. chartarum</i>		C <sub>28</sub> H <sub>39</sub> NO <sub>7</sub>	PP	501.2726
BR-011 <sup>49</sup>		Bone resorption suppressant	C <sub>23</sub> H <sub>32</sub> O <sub>4</sub>	230(120000), 240(73000), 300(84000), 340(3000)	372.2302
Stachybotrin A <sup>50</sup>		Antibacterial, antifungal	C <sub>23</sub> H <sub>31</sub> NO <sub>5</sub>	220(17000), 254(6400), 302(2900)	401.2202
Stachybotrin B <sup>50</sup>		Antibacterial, antifungal	C <sub>23</sub> H <sub>31</sub> NO <sub>4</sub>		385.2254
Stachybotrin C <sup>35</sup>	<i>S. parvispora</i>		C <sub>31</sub> H <sub>39</sub> NO <sub>5</sub>	216(52800), 258(12600), 301(4000)	505.2828
Stachybotrydial <sup>6,10</sup>	<i>S. chartarum</i>	Complement inhibitor, Inhibitor of Pancreatic cholesterol esterase	C <sub>23</sub> H <sub>30</sub> O <sub>5</sub>	248, 307, 359,PP	386.21
Stachybotrylactone <sup>6,10</sup> (Stachybotrolide <sup>46</sup> )	<i>S. chartarum</i>	Complement inhibitor	C <sub>23</sub> H <sub>30</sub> O <sub>5</sub>	218(28000), 268(5300), 309(2600)	386.21
Stachyflin <sup>51</sup>		Antiviral	C <sub>23</sub> H <sub>31</sub> NO <sub>4</sub>		385.229
1 <sup>52</sup>	<i>S. cylindrospora</i>		C <sub>25</sub> H <sub>26</sub> O <sub>5</sub>	260(10600), 320(3700)	406.1780
2 <sup>52</sup>	<i>S. cylindrospora</i>		C <sub>25</sub> H <sub>26</sub> O <sub>5</sub>	265(8500), 278(6900)	406.1780
3 <sup>52</sup>	<i>S. cylindrospora</i>		C <sub>25</sub> H <sub>26</sub> O <sub>5</sub>	330(7700)	406.1780
1 <sup>53</sup>		HIV protease inhibitor	C <sub>28</sub> H <sub>37</sub> NO <sub>9</sub>	218, 265, 300	531.2468
1 <sup>54</sup> , several tautomer	<i>S. parvispora</i>	Chymase inhibitor, antifungal	C <sub>26</sub> H <sub>30</sub> O <sub>5</sub>	222(31700), 255(13400), 315(5100)	422.2093
Stachylisin <sup>55</sup>	<i>S. chartarum</i>	Haemolytic	Pentamer		11920, monomer
Staplabin <sup>36,56,57</sup>	<i>S. microspora</i>	Enhances plasminogen activity	C <sub>28</sub> H <sub>39</sub> NO <sub>6</sub>	216(33500), 258(7300), 300(500)	485.2777

\* Printed in paper

Component	Biologically effect	Elementary composition	$\lambda$ (log $\epsilon$ )	M (Da)
5-Methoxysterigmatocystin <sup>58,59</sup>	Cytotoxic	C <sub>19</sub> H <sub>14</sub> O <sub>7</sub>	232(24100), 248(26800), 279(11200), 331(12100)	354.0739
Aversin <sup>59</sup>		C <sub>20</sub> H <sub>16</sub> O <sub>7</sub>	224(36700), 251(13400), 285(33600), 313(8900), 363(4960), 440(7830)	368.0896
Averufin <sup>59,61</sup>		C <sub>20</sub> H <sub>16</sub> O <sub>7</sub>	223(33000), 256(16500), 265(18500), 286(24800), 294(30800), 319(12500), 454(10500)	368.0895
Deoxyaverufinon <sup>62</sup>		C <sub>20</sub> H <sub>16</sub> O <sub>7</sub>	210(21900), 222.7(30150), 254.5(13400), 266(14500), 292.4(23900), 320.5(7050), 454.5(6900)	368.0895
Deoxyaverufin <sup>62</sup>		C <sub>20</sub> H <sub>14</sub> O <sub>7</sub>		366.0739
Demethylsterigmatocystin <sup>63</sup>		C <sub>17</sub> H <sub>10</sub> O <sub>6</sub>		310.0477
Dihydrodemethylsterigmatocystin <sup>59,64</sup>		C <sub>17</sub> H <sub>12</sub> O <sub>6</sub>	233(26800), 250(33100), 259(30300), 335(19400)	312.0633
Dihydrosterigmatocystin <sup>59,64</sup>	Cytotoxic	C <sub>18</sub> H <sub>14</sub> O <sub>6</sub>	208(20400), 232(26300), 247(30900), 325(16300)	326.0790
Norsolorinic acid <sup>59</sup>		C <sub>20</sub> H <sub>18</sub> O <sub>7</sub>	234(23667), 265(16650), 283(17352), 297(19872), 313(23763), 465(7336)	370.1052
Demethyl solorinic acid <sup>65</sup>		C <sub>20</sub> H <sub>18</sub> O <sub>7</sub>	223(30903), 280(33884), 335(4786), 400(4571)	370.1052
O-methylaversin		C <sub>21</sub> H <sub>18</sub> O <sub>7</sub>	222(33800), 285(39200), 348(4700), 407(4200)	382.1052
O-Methylsterigmatocystin <sup>59</sup>		C <sub>19</sub> H <sub>14</sub> O <sub>6</sub>	236(40700), 310(16500)	338.0790
Sterigmatin <sup>66</sup>		C <sub>17</sub> H <sub>10</sub> O <sub>6</sub>		310.0477
Sterigmatocystin <sup>59</sup>	LD <sub>50</sub> 30-120 mg/kg in animals, carcinogenic	C <sub>18</sub> H <sub>12</sub> O <sub>6</sub>	208(19000), 235(24500), 249(27500), 329(13100)	324.0633
Averufanin <sup>63,67</sup>		C <sub>20</sub> H <sub>18</sub> O <sub>7</sub>		370.1952
Averufin <sup>67,68</sup>		C <sub>20</sub> H <sub>16</sub> O <sub>7</sub>	223(33000), 256(16500), 265(18500), 286(24800)	368.0896

Component	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
			294(30800), 319(12500), 454(10500)	
Versiconol <sup>59,63</sup>		C <sub>18</sub> H <sub>16</sub> O <sub>8</sub>	224(30100), 266(14100), 294(23900), 315(12300), 455(7499)	360.0845
Versicolorin A <sup>59,69</sup>		C <sub>18</sub> H <sub>10</sub> O <sub>7</sub>	222(28100), 255(13500), 267(18200), 290(25100), 326(6700), 450(7000)	338.0426
Versicolorin B <sup>59,69</sup>		C <sub>18</sub> H <sub>12</sub> O <sub>7</sub>	223(23900), 255(13500), 266(19500), 291(24000), 324(12800), 450(8700)	340.0582
Versicolorin C <sup>59,69-71</sup>	Toxic to ducklings	C <sub>18</sub> H <sub>12</sub> O <sub>7</sub>	223(23800), 255(15800), 267(20400), 292(28800), 326(10000), 450(10700)	340.0582
6-Deoxyversicolorin A <sup>72</sup>		C <sub>18</sub> H <sub>10</sub> O <sub>6</sub>		322.0477
5,6-Dimethoxydihydrosterigmatocystin <sup>73</sup>		C <sub>20</sub> H <sub>18</sub> O <sub>8</sub>	233(25100), 248(33500), 276(7600), 330(18000)	386.1001
5,6-Dimethoxysterigmatocystin <sup>73</sup>	Cytotoxic	C <sub>20</sub> H <sub>16</sub> O <sub>8</sub>	233(27200), 248(34000), 275(7700), 330(19200)	384.0845
6,8-dimethylnidurufin <sup>59,74</sup>		C <sub>22</sub> H <sub>20</sub> O <sub>8</sub>	224(48200), 251(19000), 288(30900), 314(8540), 444(8790)	412.1157
6,8-O-Dimethylversicolorin A <sup>75</sup>		C <sub>20</sub> H <sub>14</sub> O <sub>7</sub>	223(47900), 250(18200), 282(46800), 312(10700), 435(11200)	366.0739
Versicolone <sup>76</sup>		C <sub>20</sub> H <sub>16</sub> O <sub>7</sub>	224(23988), 254(11749), 263(13800), 291(25500), 320(8320), 454(10715)	368.0896

Component	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
A <sup>77</sup>	Cholesterol lowering	C <sub>31</sub> H <sub>40</sub> O <sub>8</sub>	240, 340	540.2724
B <sup>77</sup>	Cholesterol lowering	C <sub>31</sub> H <sub>40</sub> O <sub>8</sub>		554.2881
SIPI-1-2 <sup>78</sup>	Cholesterol lowering	C <sub>21</sub> H <sub>22</sub> O <sub>7</sub>	223, 263, 292, 451	386.1366
SIPI-1-3 <sup>78</sup>	Cholesterol lowering	C <sub>22</sub> H <sub>24</sub> O <sub>7</sub>	223, 263, 292, 449	400.1522
SIPI-1-4 <sup>78</sup>	Cholesterol lowering	C <sub>24</sub> H <sub>28</sub> O <sub>7</sub>	223, 263, 293	428.1835
Aspercolorin <sup>71</sup>	Toxic to ducklings	C <sub>25</sub> H <sub>28</sub> N <sub>4</sub> O <sub>5</sub>	210(28080), 226(18920), 260(13620), 315(4170)	464.206
Versiol <sup>79</sup>		C <sub>16</sub> H <sub>22</sub> O <sub>3</sub>		262.157
Ferricrocin <sup>80</sup>	Iron III binding peptide	C <sub>29</sub> H <sub>44</sub> FeN <sub>9</sub> O <sub>13</sub>		782.2408
Ferrirhodin <sup>81</sup>	Iron III binding peptide	C <sub>41</sub> H <sub>64</sub> FeN <sub>9</sub> O <sub>17</sub>		1010.377
MM 4084 <sup>82</sup>				
Versimide (MM4086) <sup>83-85</sup>	Insecticide	C <sub>9</sub> H <sub>11</sub> NO <sub>4</sub>	204.5(10260)	197.0688
Nidulotoxin <sup>86,87</sup>				
Nitrobenzoyl ester 2 <sup>88</sup>		C <sub>22</sub> H <sub>25</sub> NO <sub>8</sub>	257(21100)	431.1581
Nitrobenzoyl ester 3 <sup>88</sup>		C <sub>22</sub> H <sub>25</sub> NO <sub>7</sub>	256(8200)	415.1631
Nitrobenzoyl ester 4 <sup>88</sup>		C <sub>22</sub> H <sub>25</sub> NO <sub>8</sub>	258(7600)	431.1581
FK17-P2a <sup>89</sup>		C <sub>13</sub> H <sub>16</sub> O <sub>5</sub>		252.0998
FK17-P2b1 <sup>89</sup>		C <sub>13</sub> H <sub>16</sub> O <sub>4</sub>		236.1049
FK17-P2b2 <sup>89</sup>		C <sub>13</sub> H <sub>16</sub> O <sub>4</sub>		236.1049
FK17-P3 <sup>89</sup>		C <sub>13</sub> H <sub>15</sub> ClO <sub>4</sub>		270.066
Insulicoline A <sup>88,90</sup>	Cytotoxic to cancer cells in NCI assay (0.3-1µg/ml)	C <sub>22</sub> H <sub>25</sub> NO <sub>8</sub>	255(16900)	431.1581
Lactone 1 <sup>91</sup>		C <sub>16</sub> H <sub>12</sub> O <sub>6</sub>		300.0643
Lactone 2 <sup>91</sup>		C <sub>16</sub> H <sub>12</sub> O <sub>7</sub>		316.0583
Versicolin = 2,3,6-trihydroxy toluene <sup>92-95</sup>	Antifungal	C <sub>7</sub> H <sub>8</sub> O <sub>3</sub>	222(25120), 256(7943), 390(400), 520(150)	140.0473
Versilin <sup>96</sup>	Antifungal	C <sub>7</sub> H <sub>6</sub> O <sub>4</sub>	212, 257, 387	154.0266
Mycoversilin <sup>97-99</sup>	Antifungal	C <sub>18</sub> H <sub>16</sub> O <sub>8</sub>	End, 269(1290), PP	360.0845

Component	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
10,20-dehydro[12,13-dehydropropyl]-2-(1',1'-dimethylallyltryptophyl) diketopiperazine <sup>100</sup>		C <sub>21</sub> H <sub>21</sub> O <sub>2</sub> N <sub>3</sub>	224(27540), 272(8510), 284(6920), 292(5130)	347.1635
12,13-dehydropropyl-2-(1',1'-dimethylallyltryptophyl) diketopiperazine <sup>100</sup>		C <sub>21</sub> H <sub>23</sub> N <sub>3</sub> O <sub>2</sub>	223(34674), 268(10715), 283(10000), 292(7760)	349.1792
12,13-dihydro-12-		C <sub>21</sub> H <sub>23</sub> N <sub>3</sub> O <sub>4</sub>	231(30200), 255(10965), 390(2950)	381.169

Table 5 Secondary metabolites and mycotoxins from <i>Aspergillus ustus</i>				
Component	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
hydroxaustamide <sup>101</sup>				
12,13-dihydro-austamide <sup>100</sup>		C <sub>21</sub> H <sub>23</sub> O <sub>3</sub> N <sub>3</sub>	238(30900), 256(13490), 390(3310)	365.1741
4,6-bisdemethylautocystin A <sup>67</sup>		C <sub>17</sub> H <sub>9</sub> ClO <sub>6</sub>	231(31623), 241(32359), 254(37154), 261(35481), 270(32359), 325(25119), 360(12300)	224.0088
4-O-demethylautocystin A <sup>67</sup>		C <sub>18</sub> H <sub>11</sub> ClO <sub>6</sub>	225(26300), 249(26915), 257(25120), 269(15488), 314(12023), 361(4075)	344.0088
6-demethylautocystin A <sup>67</sup>		C <sub>18</sub> H <sub>11</sub> ClO <sub>6</sub>	239(35480), 254(32359), 261(31625), 270(24547), 312(16980), 362(5888)	358.0244
6-epi-Ophiobolin K <sup>102</sup>	Antibiotic	C <sub>25</sub> H <sub>36</sub> O <sub>3</sub>	239(21395)	384.2631
7-chloro-2-(3-furyl)-1,3,8-trimethoxyxanhone <sup>67</sup>		C <sub>20</sub> H <sub>15</sub> ClO <sub>6</sub>		386.0558
8-deoxy-6-O-methylversicolorin A <sup>67</sup>		C <sub>19</sub> H <sub>12</sub> O <sub>6</sub>	221(22387), 240(14125), 274(20893), 412(7080), 436(2344)	336.0634
Austalide A <sup>102,103</sup>		C <sub>28</sub> H <sub>36</sub> O <sub>9</sub>	222(35400), 267(17140)	516.236
Austalide B <sup>102,103</sup>		C <sub>26</sub> H <sub>34</sub> O <sub>9</sub>	223(28700), 269(16800)	490.2203
Austalide C <sup>102,103</sup>		C <sub>30</sub> H <sub>38</sub> O <sub>11</sub>	221(26900), 265(13800)	574.242
Austalide D <sup>102,103</sup>		C <sub>28</sub> H <sub>36</sub> O <sub>10</sub>	222(32700), 268(17700)	532.2308
Austalide E <sup>102,103</sup>		C <sub>28</sub> H <sub>36</sub> O <sub>10</sub>	222(34600), 266(19600)	532.2308
Austalide F <sup>102</sup>		C <sub>26</sub> H <sub>34</sub> O <sub>9</sub>	220(30900), 264(16800)	490.2203
Austalide G <sup>104</sup>		C <sub>28</sub> H <sub>38</sub> O <sub>9</sub>	221(26500), 267(14100)	518.251
Austalide H <sup>104</sup>		C <sub>26</sub> H <sub>36</sub> O <sub>8</sub>	221, 267	476.240
Austalide I <sup>104,105</sup>		C <sub>27</sub> H <sub>34</sub> O <sub>8</sub>	221(35600), 266(17000)	486.225
Austalide J <sup>105</sup>		C <sub>25</sub> H <sub>32</sub> O <sub>7</sub>	221(31900), 267(16200)	444.214
Austalide K <sup>104,105</sup>		C <sub>25</sub> H <sub>32</sub> O <sub>5</sub>	222(18900), 267(11000)	412.224
Austalide L <sup>104,105</sup>		C <sub>25</sub> H <sub>32</sub> O <sub>6</sub>	223(31200), 269(16600)	428.219
Austamide <sup>100</sup>	Acute toxic to ducklings	C <sub>21</sub> H <sub>21</sub> O <sub>3</sub> N <sub>3</sub>	234(26300), 256(117), 256(1100), 282(8709), 392(2691)	363.1584
Austdiol <sup>106,107</sup>	Acute toxic to ducklings	C <sub>12</sub> H <sub>12</sub> O <sub>5</sub>	256(15100), 376(24000)	236.0685
Austin <sup>108</sup>		C <sub>27</sub> H <sub>32</sub> O <sub>9</sub>	243(11900)	500.2047
Austinol <sup>107</sup>		C <sub>25</sub> H <sub>30</sub> O <sub>8</sub>	246(8080)	458.1941
Austocystin A <sup>88</sup>	Mutagenic, cytotoxic	C <sub>19</sub> H <sub>13</sub> ClO <sub>6</sub>	229( 25120), 239(33110), 247(34675), 258(10715), 303(12300), 335(5623)	372.0401
Austocystin B <sup>88</sup>	Mutagenic, cytotoxic	C <sub>22</sub> H <sub>20</sub> O <sub>7</sub>	227(24550), 240(25120), 254(33113), 263(21878), 274(23442), 328(16218), 372(7244)	396.1209
Austocystin C <sup>88</sup>	Mutagenic, cytotoxic	C <sub>23</sub> H <sub>22</sub> O <sub>7</sub>	229(20417), 238(24000), 255(20895), 277(18200), 304(12590), 368(4570)	398.1366
Austocystin D <sup>88</sup>	Mutagenic, cytotoxic	C <sub>22</sub> H <sub>20</sub> O <sub>8</sub>	227(19500), 254(31625), 263(22910), 273(23440), 329(12883), 370(4365)	412.1158
Austocystin E <sup>88</sup>	Mutagenic, cytotoxic	C <sub>22</sub> H <sub>22</sub> O <sub>8</sub>	228(19500), 236(23442), 257(22910), 262(22390), 273(21380), 304(10233), 368(4365)	414.1315
Austocystin F <sup>88</sup>	Mutagenic, cytotoxic	C <sub>17</sub> H <sub>10</sub> O <sub>7</sub>	224(27542), 252(34675), 259(30200), 268(25120), 325(14791), 368(4266)	326.0426
Austocystin G <sup>109</sup>	Mutagenic, cytotoxic	C <sub>18</sub> H <sub>11</sub> ClO <sub>7</sub>	225(18620), 249(23442), 309(9772), 340(3236)	374.0193
Austocystin H <sup>109</sup>	Mutagenic, cytotoxic	C <sub>22</sub> H <sub>18</sub> O <sub>7</sub>	226(11482), 253(14791), 272(10233), 328(6166), 360(2455)	394.1053
Austocystin I <sup>109</sup>	Mutagenic, cytotoxic	C <sub>18</sub> H <sub>12</sub> O <sub>7</sub>	229(21878), 238(27542), 252(29302), 264(19953), 300(13800), 355(5129)	340.0583
Aversin <sup>59</sup>		C <sub>20</sub> H <sub>16</sub> O <sub>7</sub>	224(36700), 251(13400), 285(33600), 313(8900), 363(4960), 440(7830)	368.0896
Averufanin <sup>63,67</sup>		C <sub>20</sub> H <sub>18</sub> O <sub>7</sub>		370.1952
Averufin <sup>67,88</sup>		C <sub>20</sub> H <sub>16</sub> O <sub>7</sub>	223(33000), 256(16500), 265(18500), 286(24800), 294(30800), 319(12500), 454(10500)	368.0896
Dehydroaustin <sup>107</sup>		C <sub>27</sub> H <sub>30</sub> O <sub>9</sub>	End, 239(3800)	498.189
Deoxybrevianamide E				
Dihydropergilin <sup>110</sup>		C <sub>15</sub> H <sub>18</sub> O <sub>4</sub>	218(21400), 260(12000)	262.1204
Dihydroxy-8-epi-austdiol <sup>106</sup>		C <sub>12</sub> H <sub>14</sub> O <sub>4</sub>	231(6920), 352(20000)	222.0892
Drimane sesquiterpene 1 <sup>111</sup>	Binds to endo-thelium receptor	C <sub>23</sub> H <sub>30</sub> O <sub>5</sub>	304(36600)	386.2094
Drimane sesquiterpene 2 <sup>111</sup>	Binds to endo-thelium receptor	C <sub>23</sub> H <sub>32</sub> O <sub>4</sub>	303(37000)	372.2302
Drimane sesquiterpene 3 <sup>111</sup>	Binds to endo-thelium receptor	C <sub>23</sub> H <sub>32</sub> O <sub>5</sub>	205(6000), 303(32000)	388.2251
Drimane sesquiterpene 4 <sup>111</sup>	Binds to endo-thelium receptor	C <sub>23</sub> H <sub>32</sub> O <sub>4</sub>	202(8400), 294(34500)	372.2302
Drimane sesquiterpene 5 <sup>111</sup>	Binds to endo-	C <sub>21</sub> H <sub>28</sub> O <sub>5</sub>	255(24100)	360.1937

Component	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
	thelium receptor			
Drimane sesquiterpene 6 <sup>111</sup>	Binds to endo-thelium receptor	C <sub>23</sub> H <sub>30</sub> O <sub>5</sub>	300(36200)	386.2094
Drimane sesquiterpene 7 <sup>111</sup>	Binds to endo-thelium receptor	C <sub>15</sub> H <sub>24</sub> O <sub>3</sub>	232(1800)	252.1726
Iso-austin <sup>107</sup>		C <sub>27</sub> H <sub>32</sub> O <sub>9</sub>	240(7300)	500.2047
Mer-NF8054X <sup>112</sup>		C <sub>38</sub> H <sub>42</sub> O <sub>5</sub>	242(20400)	458.3032
Ophibolin G <sup>113</sup>	Inhibiting wheat and bacteria	C <sub>25</sub> H <sub>34</sub> O <sub>2</sub>	235(36300)	366.2559
Ophibolin H <sup>113</sup>	Antibiotic	C <sub>25</sub> H <sub>38</sub> O <sub>3</sub>	243(19500)	386.2821
Ophibolin K <sup>102</sup>	Antibiotic	C <sub>25</sub> H <sub>36</sub> O <sub>3</sub>	240(23470)	384.2631
Pergillin <sup>114</sup>	Plant growth inhibitor	C <sub>15</sub> H <sub>16</sub> O <sub>4</sub>	225(9550), 287(10700)	260.105
Phenylahistin <sup>115,116</sup>	Mammalian cell cycle inhibitor, anti-tumor activity	C <sub>20</sub> H <sub>22</sub> N <sub>4</sub> O <sub>2</sub>	202(24000), 233(11220), 320(26900)	350.1743
Prolyl-2-(1',1'-dimethylallyl) tryptophyldiketopiperazine <sup>100</sup>		C <sub>21</sub> H <sub>25</sub> N <sub>3</sub> O <sub>2</sub>	225(32359), 275(7079), 283(8128), 291(7079)	351.1949
TMC-120A <sup>117,118</sup>	Inhibitor of IL-5 mediated prolonged eosinophil survival	C <sub>15</sub> H <sub>14</sub> NO <sub>2</sub>	210(31520), 250(33880), 323(7080), 340(11220), 354(12880)	241.1103
TMC-120B <sup>117,118</sup>	Inhibitor of IL-5 mediated prolonged eosinophil survival	C <sub>15</sub> H <sub>12</sub> NO <sub>2</sub>	212(34670), 233(12880), 239(12880), 271(23440), 295(21380), 302(21380), 365(7760)	239.0946
TMC-120C <sup>117,118</sup>	Inhibitor of IL-5 mediated prolonged eosinophil survival	C <sub>15</sub> H <sub>14</sub> NO <sub>3</sub>	211(32360), 253(31620), 354(10230), 413(1120)	257.1052
Ustic acid <sup>119,120</sup>		C <sub>21</sub> H <sub>18</sub> O <sub>6</sub> Cl <sub>2</sub>		436.0481
Normidulin (Ustin) <sup>119</sup>		C <sub>19</sub> H <sub>15</sub> O <sub>5</sub> Cl <sub>3</sub>		427.9987
Versicolorin C <sup>59,102</sup>		C <sub>18</sub> H <sub>12</sub> O <sub>7</sub>	223(23800), 255(15800), 267(20400), 292(28800), 326(10000), 450(10700)	340.0582
PR-1636 <sup>88</sup>				

Component	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
10, 23-Dihydro-24,25,dehydro-21-oxo-aflavinine <sup>121</sup>	Antiinsectan	C <sub>28</sub> H <sub>37</sub> NO <sub>2</sub>	224(18200), 267(4200), 273(1400), 283(2100), 291(1750)	419.2824
10, 23-Dihydro-24,25,dehydro-aflavinine <sup>121</sup>		C <sub>28</sub> H <sub>39</sub> NO	226(31600), 284(4400), 291(4100)	405.3032
14-Epi-14-hydroxy-10, 23,dihydro-24,25,dehydro-aflavinine <sup>121</sup>		C <sub>28</sub> H <sub>39</sub> NO <sub>2</sub>	226(16400), 284(2290), 292(2100)	421.2980
16-Keto-aspergillimide <sup>122</sup>	Anthelmintic	C <sub>20</sub> H <sub>27</sub> N <sub>3</sub> O <sub>4</sub>		373.2003
1-Hydroxyyanuthone A <sup>123</sup>	Antifungal, antibacterial	C <sub>24</sub> H <sub>32</sub> O <sub>5</sub>	234(8510), 290(220)	400.2251
1-Hydroxyyanuthone C <sup>123</sup>	Antibacterial	C <sub>24</sub> H <sub>32</sub> O <sub>5</sub>	232(4680), 282(468)	400.2251
22-Deacetylyanuthone A <sup>123</sup>	Antibacterial	C <sub>22</sub> H <sub>32</sub> O <sub>4</sub>	238(16220), 302(480)	360.2302
2-Methylene-3-(6-hydroxyhexyl)-butanedioic acid <sup>124,125</sup>	Plant growth regulator	C <sub>11</sub> H <sub>18</sub> O <sub>4</sub>		214.1225
2-Methylene-3-hexyl-butanedioic acid <sup>124</sup>		C <sub>11</sub> H <sub>18</sub> O <sub>5</sub>		230.1154
2-Methylene-3-hexyl-maleic acid anhydride <sup>124,126</sup>	Plant growth regulator	C <sub>12</sub> H <sub>16</sub> O <sub>5</sub>	253	240.0998
4-hydroxymandelic acid*		C <sub>8</sub> H <sub>8</sub> O <sub>4</sub>		168.0423
Orbole*				
Antifumicin A*				
Antifumicin B*				
Aspergillone*				
6'-O-demethylnigerone <sup>127</sup>		C <sub>31</sub> H <sub>24</sub> O <sub>10</sub>	226(39810), 278(63095), 408(10000)	556.139
Aflavinine <sup>121</sup>		C <sub>28</sub> H <sub>39</sub> NO	225(18700), 283(3010), 291(2710)	405.3032
Antafumicin A <sup>128</sup>	Antifungal	C <sub>13</sub> H <sub>14</sub> O <sub>6</sub>	217(21000), 279(15500), 317(8720)	266.0786

Table 6				
Secondary metabolites and mycotoxins from <i>Aspergillus niger</i>				
Component	Biologically effect	Elementary composition	$\lambda$ (log $\epsilon$ )	M (Da)
Antafumicin B <sup>128</sup>	Antifungal	C <sub>13</sub> H <sub>14</sub> O <sub>6</sub>	217(21000), 279(15500), 317(8720)	266.0786
Asniapyrone A <sup>129</sup>		C <sub>21</sub> H <sub>22</sub> O <sub>3</sub>	240(18600), 290(19055), 378(31625)	322.1570
Asniapyrone B <sup>129</sup>		C <sub>20</sub> H <sub>20</sub> O <sub>3</sub>	235(16600), 265(15490), 376(33885)	308.1413
Asperazine <sup>130,131</sup>	Cytotoxic, anti leukemic	C <sub>40</sub> H <sub>36</sub> N <sub>6</sub> O <sub>4</sub>	225, 275, 300	
Asperenone <sup>132</sup>		C <sub>22</sub> H <sub>24</sub> O <sub>3</sub>	242(13800), 300(9200), 414-416(94200)	312.1726
Asperic acid <sup>130</sup>		C <sub>16</sub> H <sub>28</sub> O <sub>4</sub>	225, 280	
Asperparaline A (Aspergillimide) <sup>122,133,134</sup>	Paralyses silkworms, Anthelmintic	C <sub>20</sub> H <sub>29</sub> N <sub>3</sub> O <sub>3</sub>	206	359.2209
Asperparaline B <sup>133</sup>	Paralyses silkworms	C <sub>19</sub> H <sub>27</sub> N <sub>3</sub> O <sub>3</sub>		345.2053
Asperparaline C <sup>133</sup>	Antiins Paralyses silkworms ectan	C <sub>19</sub> H <sub>27</sub> N <sub>3</sub> O <sub>3</sub>		345.2053
Asperubrol <sup>132,135</sup>		C <sub>20</sub> H <sub>22</sub> O	242(9800), 293(11200), 400(63200)	278.1672
Aurasperone A <sup>136-138</sup>	Acute toxic	C <sub>32</sub> H <sub>26</sub> O <sub>10</sub>	225(51300), 258(53700), 280(100000), 325(8710), 406(12880), PP	570.1526
Aurasperone B <sup>136,138</sup>	Acute toxic	C <sub>32</sub> H <sub>30</sub> O <sub>12</sub>	235(51000), 282(87700), 321(20100), 334(20000), 410(13600), PP	606.1737
Aurasperone C <sup>136,138</sup>	Acute toxic	C <sub>31</sub> H <sub>28</sub> O <sub>12</sub>	236, 283.5, 323, 336, 412, PP	592.1581
Aurasperone D <sup>137,138</sup>	Depress central nervous system	C <sub>31</sub> H <sub>24</sub> O <sub>10</sub>	235-240(50119), 280(51286), 320-325(15136), 380(7080)	556.139
Aurasperone E <sup>137</sup>	Depress central nervous system	C <sub>32</sub> H <sub>28</sub> O <sub>11</sub>	230(72444), 282(147910), 322(22387), 330(20418), 400(19500)	588.1631
BMS-192548 <sup>139</sup>				
BMS-192548 <sup>140</sup>	Neuropeptide Y receptor inhibitor	C <sub>21</sub> H <sub>18</sub> O <sub>9</sub>	280(4440), 320(35548), 414(38822), PP	414.0950
Dianhydro-aurasperone C <sup>141</sup>	Acute toxic, <i>Anti-cancer cell drug</i>	C <sub>31</sub> H <sub>24</sub> O <sub>10</sub>	225(22908), 255(26915), 280(85113), 325(3715), 405(5754)	556.1369
Flavasperone <sup>136-138</sup>		C <sub>16</sub> H <sub>14</sub> O <sub>5</sub>	225(28184), 254(47863), 406(5495), PP	286.0841
Fonsecin monomethylether <sup>138,142</sup>		C <sub>16</sub> H <sub>16</sub> O <sub>6</sub>	232(28500), 277(40500), 317(9100), 330(10000), 395(8400)	304.0947
Fonsecinone A <sup>143</sup>		C <sub>32</sub> H <sub>26</sub> O <sub>10</sub>	228(45700), 256(44670), 278(67600), 325(11480), 398(7080)	570.1526
Fonsecinone B <sup>143</sup>		C <sub>32</sub> H <sub>28</sub> O <sub>11</sub>	229(38900), 255(41700), 280(70800), 320(14125), 328(14125), 403(9120)	588.1631
Fonsecinone C <sup>143</sup>		C <sub>32</sub> H <sub>28</sub> O <sub>11</sub>	234(51285), 254(38000), 279(60255), 315(19500), 327(14800), 398(7080)	588.1631
Fonsecinone D <sup>143</sup>		C <sub>32</sub> H <sub>26</sub> O <sub>10</sub>	227(26900), 279(48975), 316(8128), 328(6920), 403(6310)	570.1526
Heminigerone <sup>127</sup>		C <sub>16</sub> H <sub>14</sub> O <sub>5</sub>	225(25119), 242(32360), 247(31623), 277(33884), 378(4467)	286.0841
Hexylitaconic acid <sup>125,130</sup>	Plant growth inhibitor			
Hydroxyhexyl-butanedioic acid <sup>125</sup>				
Iso-aurasperone A <sup>137,138</sup>	Depress central nervous system	C <sub>32</sub> H <sub>26</sub> O <sub>10</sub>	255(33884), 275(38905), 385-390(3467)	570.1626
Iso-nigerone <sup>127</sup>		C <sub>32</sub> H <sub>26</sub> O <sub>10</sub>	228(50119), 248(56234), 279(66069), 390(9550)	570.1626
Kotanin <sup>136,144</sup>		C <sub>23</sub> H <sub>20</sub> O <sub>8</sub>	203(92%), 208(100), 237(35), 259(15%), 296(36%), 306(41%), 317(35%)	424.1158
Malformin A <sup>59,145</sup>	Cytotoxic	C <sub>23</sub> H <sub>39</sub> O <sub>5</sub> N <sub>5</sub> S <sub>2</sub>	End abs.	529.2396
Malformin A <sub>2</sub> <sup>59,145</sup>	Cytotoxic	C <sub>22</sub> H <sub>37</sub> O <sub>5</sub> N <sub>5</sub> S <sub>2</sub>	End abs.	515.2239
Malformin B <sub>1a</sub> , B <sub>1b</sub> , B <sub>3</sub> , B <sub>5</sub> <sup>59,145,146</sup>	Cytotoxic	C <sub>23</sub> H <sub>39</sub> O <sub>5</sub> N <sub>5</sub> S <sub>2</sub>	End abs.	529.2396
Malformin B <sub>2</sub> , B <sub>5</sub> <sup>59,145,146</sup>	Cytotoxic	C <sub>22</sub> H <sub>37</sub> O <sub>5</sub> N <sub>5</sub> S <sub>2</sub>	End abs.	515.2239
Malformin C <sup>59,147</sup>	Cytotoxic	C <sub>23</sub> H <sub>39</sub> O <sub>5</sub> N <sub>5</sub> S <sub>2</sub>	End abs.	529.2396
Nigerazine A <sup>148</sup>	Plant growth inhibitor			
Nigerazine B <sup>148</sup>	Plant growth inhibitor	C <sub>16</sub> H <sub>22</sub> N <sub>2</sub> O	280(22400)	258.1732
Nigerone <sup>127</sup>		C <sub>32</sub> H <sub>26</sub> O <sub>10</sub>	226(51286), 278(83186), 407(14125)	570.1626
Nigragillin <sup>59</sup>	Toxic to silkworms	C <sub>13</sub> H <sub>22</sub> ON <sub>2</sub>	262(26200)	222.1739
Ochratoxin A <sup>86,149</sup>	Cytotoxic, nephrotoxic	C <sub>20</sub> H <sub>18</sub> ClNO <sub>6</sub>	205(94%), 215(98%), 218(21%), 283(2%), 332(17%)	403.0823
Orlandin <sup>144</sup>	Plant growth inhibitor	C <sub>22</sub> H <sub>18</sub> O <sub>8</sub>	311(29500), 321(25120)	410.1002
Oxalic acid <sup>86,150</sup>	Toxic			
Pyrophen <sup>130,151</sup>		C <sub>16</sub> H <sub>17</sub> NO <sub>4</sub>		287.1158
Rubrofusarin B <sup>137,141</sup>	Anti-cancer cell drug	C <sub>16</sub> H <sub>14</sub> O <sub>5</sub>	225(39810), 250(37153), 375(79433), 320(5248), 395(9120)	286.0841
Rubrofusarin <sup>127</sup>				
SB200437 <sup>122,122,152</sup>	Anthelmintic			
SB203105 <sup>122,122,152</sup>	Anthelmintic			
Tubingensin A <sup>153</sup>	Antiviral			
Tubingensin B <sup>153</sup>	Cytotoxic	C <sub>28</sub> H <sub>35</sub> NO	218(17200), 237(25500), 260(10100)	401.2720

Component	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
			299(10100), 325(2200), 338(6700)	
VM54159 <sup>122, 122, 152</sup>	Anthelmintic			
Yanuthone A <sup>123</sup>	Antibacterial	C <sub>24</sub> H <sub>34</sub> O <sub>5</sub>	232(7950), 310(500)	402.2407
Yanuthone B <sup>123</sup>	Antifungal, antibacterial	C <sub>24</sub> H <sub>32</sub> O <sub>5</sub>	244(4470), 290(1950), 338(830)	400.2251
Yanuthone C <sup>123</sup>	Antibacterial	C <sub>24</sub> H <sub>34</sub> O <sub>5</sub>	232(13180), 280(2040), 322(1070)	402.2407
Yanuthone D <sup>123</sup>	Antifungal, antibacterial	C <sub>28</sub> H <sub>38</sub> O <sub>8</sub>	226(7940), 254(3715), 298(1150)	502.2567
Yanuthone E <sup>123</sup>	Antibacterial	C <sub>28</sub> H <sub>42</sub> O <sub>8</sub>	234(9120), 280(1000), 340(450)	518.2881

\* J.C. Frisvad, personal communication.

Component	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
$\omega$ -hydroxyemodin <sup>154</sup>		C <sub>15</sub> H <sub>10</sub> O <sub>6</sub>		286.0477
2-Acetyl-4(3H)-quinazolinone <sup>155, 156</sup>		C <sub>10</sub> H <sub>8</sub> N <sub>2</sub> O <sub>2</sub>		188.0586
2-pyrovoylaminobenzamide <sup>154, 157, 158</sup>		C <sub>10</sub> H <sub>10</sub> N <sub>2</sub> O <sub>3</sub>	211(16500), 242(9700), 305(6930)	206.0690
2-[(2-hydroxypropionyl)amino] benzamide <sup>159, 160</sup>		C <sub>10</sub> H <sub>12</sub> O <sub>3</sub> N <sub>2</sub>	249(23440), 293(5838)	208.0849
Chrysogine <sup>154, 155, 161</sup>		C <sub>10</sub> H <sub>10</sub> N <sub>2</sub> O <sub>2</sub>	226(21877), 230(20892), 238(12882), 265(7244), 273(6606), 292(2884), 305(3890), 316(3235)	190.0743
Emodic acid <sup>154</sup>		C <sub>15</sub> H <sub>8</sub> O <sub>6</sub>		284.032
Meleagrins <sup>154</sup>			218(60%), 229(67%), 259(20%), 283(25%), 329(66%)	
N-acetyl-amino-3H-phenoxazine-3-one <sup>154</sup>				
N-formyl-O-aminophenol <sup>154</sup>				
Questionmycin A <sup>154, 162, 163</sup>		C <sub>12</sub> H <sub>8</sub> N <sub>2</sub> O <sub>2</sub>	425(23200)	212.0586
Questionmycin B <sup>154</sup>				
Roquefortine C <sup>59, 154</sup>		C <sub>22</sub> H <sub>23</sub> O <sub>2</sub> N <sub>5</sub>	209(29500), 240(16200), 328(27000)	389.1854
Roquefortine D <sup>59, 154</sup>			203(67%), 218(100%), 283(43%), 288(45%), 294(44%), 302(45%)	
Sorbicillin <sup>164-167</sup>	Antioxidant	C <sub>14</sub> H <sub>16</sub> O <sub>3</sub>	320(22900), 380(8000)	232.1100
Xanthocillin X (Brevicid <sup>®</sup> ) <sup>154, 168, 169</sup>	Antibiotic	C <sub>18</sub> H <sub>12</sub> O <sub>2</sub> N <sub>2</sub>	221(18%), 239(21%), 265(5%), 294(12%), 362(100%)	288.0900
Xanthocillin X monomethylether <sup>170</sup>	Antibiotic	C <sub>19</sub> H <sub>14</sub> O <sub>2</sub> N <sub>2</sub>	243, 303, 368, 385 <sup>170</sup> 236(14200), 295(17200), 360(30000) <sup>171</sup>	302.1056
Xanthocillin X dimethylether <sup>170</sup>	Antibiotic	C <sub>20</sub> H <sub>16</sub> O <sub>2</sub> N <sub>2</sub>	230, 296, 363, 380	316.1212
Methoxy xanthocillin X dimethylether <sup>170</sup>	Antibiotic		243, 303, 368, 385	346
$\alpha$ -Penitricin <sup>172</sup>		C <sub>14</sub> H <sub>17</sub> NO <sub>3</sub>	PP	247.1208
$\beta$ -Penitricin <sup>164, 172</sup>		C <sub>14</sub> H <sub>17</sub> NO <sub>3</sub>	PP	247.1208
Penitricinic acid <sup>164, 172</sup>		C <sub>15</sub> H <sub>17</sub> NO <sub>5</sub>	PP	291.1107
Tiglic acid <sup>164</sup>		C <sub>8</sub> H <sub>8</sub> O <sub>2</sub>		100.0524
d- $\alpha$ -methylbutyric acid <sup>164</sup>				
Furoic acid <sup>164</sup>				
$\beta$ -Indoleacetic acid <sup>164</sup>				
Phenylacetic acid <sup>164</sup>				
2-Decenedioic acid <sup>164</sup>		C <sub>10</sub> H <sub>10</sub> O <sub>4</sub>		194.0579
Xanthocillin Y <sub>1</sub> (Brevicid <sup>®</sup> ) <sup>168, 173</sup>		C <sub>18</sub> H <sub>12</sub> N <sub>2</sub> O <sub>3</sub>		304.0849
Xanthocillin Y <sub>2</sub> (Brevicid <sup>®</sup> ) <sup>168, 173</sup>		C <sub>18</sub> H <sub>12</sub> N <sub>2</sub> O <sub>4</sub>		320.0798
1,4-Di-4-hydroxyphenyl-2,3-diformamid-(1,3)-butandien <sup>168</sup>				
2-Aminophenol <sup>163, 168</sup>		C <sub>6</sub> H <sub>7</sub> NO		109.0528
N-formyl-2-amino-phenol <sup>168</sup>		C <sub>12</sub> H <sub>8</sub> N <sub>2</sub> O <sub>2</sub>	237(27990), 422(21827)	212.0586
2-Amino-3H-phemoxazon-(3) <sup>168</sup>				
N-Acetyl-2-amino-3H-phemoxazon-(3) <sup>168</sup>				
A <sup>168</sup>		C <sub>12</sub> H <sub>18</sub> N <sub>2</sub> O <sub>2</sub>	237(28184), 422(21827), 434(22029)	222.1368
e <sup>168</sup>		C <sub>14</sub> H <sub>10</sub> N <sub>2</sub> O <sub>3</sub>	243(20417), 406(15136)	254.0691
B <sup>168</sup>			218(10233), 245(12023), 286(6310)	
d <sup>168</sup>		C <sub>18</sub> H <sub>16</sub> N <sub>2</sub> O <sub>4</sub>		324.1111
C <sup>168</sup>				
Penicillin G <sup>174, 154</sup>			208(100%), 244(4%), 259(4%)	
Penicillin F <sup>154</sup>		C <sub>14</sub> H <sub>20</sub> N <sub>2</sub> O <sub>4</sub> S		312.1145
Chrysogenin <sup>175</sup>		C <sub>18</sub> H <sub>22</sub> O <sub>6</sub>		334.1417
Sorrentanone <sup>167</sup>		C <sub>14</sub> H <sub>14</sub> O <sub>4</sub>	194(5300), 272(8700)	246.0892
Secalonic acid D <sup>176-179**</sup>	Toxic, teratogenic, toxic to mitochondria	C <sub>32</sub> H <sub>30</sub> O <sub>14</sub>	239(18200), 267(16200), 338(33885)	638.1635



Component	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
	dria			
Bisvertinolone <sup>167,180</sup>	Antibacterial			512
Lumdidin = met Ø				

Produced by the closely related *P. oxalicum*, making it very likely that it is also produced by *P. chrysogenum* (J. C. Frisvad, personal communication).

Component	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
1,4-Dimethyl-hydroxy-3-[4'-methoxyphenylmethyl]-2-5-piperazinedione 5 <sup>181</sup>		C <sub>14</sub> H <sub>18</sub> N <sub>2</sub> O <sub>4</sub>	213(6600), 228(8700), 276(1200)	278.1267
11-(5'-epoxy-4'-hydroxy-3'-hydroxymethylcyclo-2'-hexenone)- $\Delta$ -drimene <sup>181</sup>	Antifungal	C <sub>22</sub> H <sub>32</sub> O <sub>4</sub>	221(4650), 239(8250)	360.2301
1-Deoxypebrolide <sup>182</sup>		C <sub>24</sub> H <sub>30</sub> O <sub>6</sub>		414.2042
2,4-Dihydroxy-6-(1,2-dioxopropyl)benzoic acid <sup>120,183-187**</sup>	acid	C <sub>10</sub> H <sub>8</sub> O <sub>6</sub>	214(100%), 239(18%), 261(46%), 279(15%), 296 (23%)	224.0320
2,4-Dihydroxy-6-(1-hydroxy-oxopropyl)benzoic acid <sup>120,183-186**187</sup>	acid	C <sub>10</sub> H <sub>10</sub> O <sub>6</sub>	212(100%), 240(22%), 261(33%), 287(18%), 3098(20%)	226.0477
2,4-Dihydroxy-6-(2-oxopropyl)benzoic acid <sup>183,184,188**</sup>	acid	C <sub>10</sub> H <sub>10</sub> O <sub>5</sub>	214(100%), 239(18%), 263(37%), 287(18%), 298(21%)	210.0528
2,4-Dihydroxy-6-propylbenzoic acid <sup>154</sup>				
2-Carboxy-3,5-dihydroxybenzylmethylketone <sup>154</sup>				
2-Carboxy-3,5-dihydroxyphenylethyl carbinol <sup>154</sup>				
3,5-Dihydroxyphthalic acid <sup>154,184,188</sup>		C <sub>8</sub> H <sub>6</sub> O <sub>6</sub>		198.0164
3-Thiomethyl-3-[4'-(3"-methyl-2"-butenyl)phenylmethyl]-2-5-piperazinedione <sup>181</sup>		C <sub>17</sub> H <sub>22</sub> O <sub>3</sub> S	207(14125), 229(15136), 277(4000)	334.1352
6-Hydroxy-3-methylthio-3-[4'-(3"-methyl-2"-butenyl)phenylmethyl]-2-5-piperazinedione 4 <sup>181</sup>		C <sub>17</sub> H <sub>22</sub> N <sub>2</sub> O <sub>4</sub> S		350.1301
Adenophostin A <sup>189-191</sup>	Ca <sup>2+</sup> release in muscle <sup>189</sup>	C <sub>14</sub> H <sub>26</sub> N <sub>5</sub> O <sub>18</sub> P <sub>3</sub>	256	645.0486
Adenophostin B <sup>189-191</sup>	Ca <sup>2+</sup> release in muscle <sup>189</sup>	C <sub>18</sub> H <sub>28</sub> N <sub>5</sub> O <sub>19</sub> P <sub>3</sub>	256	711.0591
Asperphenamate <sup>192,193</sup>		C <sub>30</sub> H <sub>26</sub> N <sub>2</sub> O <sub>4</sub>		478.1894
Botryodiploidin <sup>154,194-196</sup>	Genotoxic	C <sub>7</sub> H <sub>12</sub> O <sub>3</sub>	278	144.0787
Brevianamide A <sup>154,197-199</sup>		C <sub>21</sub> H <sub>23</sub> N <sub>3</sub> O <sub>3</sub>	235(28600), 256(7100), 404(3260)	365.1739
Brevianamide B <sup>154,197,200</sup>		C <sub>21</sub> H <sub>23</sub> N <sub>3</sub> O <sub>3</sub>	As Brevianamide A	365.1745
Brevianamide C <sup>*197,200</sup>		C <sub>21</sub> H <sub>23</sub> N <sub>3</sub> O <sub>3</sub>	234, 259, 450	365.1741
Brevianamide D <sup>*197,200</sup>		C <sub>21</sub> H <sub>23</sub> N <sub>3</sub> O <sub>3</sub>	235, 264, 306, 479	365.1741
Brevianamide E <sup>198,199</sup>		C <sub>21</sub> H <sub>15</sub> N <sub>3</sub> O <sub>3</sub>	239(7500), 296(2050)	357.1113
Brevianamide F <sup>197,200</sup>		C <sub>16</sub> H <sub>17</sub> N <sub>3</sub> O <sub>2</sub>	223, 275, 280, 288	283.1321
Brevicompanine A <sup>201</sup>	Inhibit plant growth	C <sub>22</sub> H <sub>29</sub> N <sub>3</sub> O <sub>2</sub>	210, 245, 303	367.2236
Brevicompanine B <sup>201</sup>	Inhibit plant growth	C <sub>22</sub> H <sub>29</sub> N <sub>3</sub> O <sub>2</sub>	208, 245, 300	367.2246
Brevigellide <sup>154</sup>				
Brevigellin A <sup>202</sup>		C <sub>31</sub> H <sub>41</sub> N <sub>5</sub> O <sub>7</sub>	230(10000)	595.3019
Brevione A <sup>203</sup>	Inhibit plant growth	C <sub>27</sub> H <sub>34</sub> O <sub>4</sub>		422.2457
Brevioxime <sup>204,205</sup>	Plant hormone activity	C <sub>15</sub> H <sub>22</sub> N <sub>2</sub> O <sub>3</sub>		278.1630
Cis-bis(methylthio)silvatins <sup>181,206</sup>				
Cis-bis(methylthio)silvatins <sup>181,206</sup> parent alcohol				
Compactin <sup>208</sup>		C <sub>23</sub> H <sub>34</sub> O <sub>5</sub>	230(19050), 237(19950), 246(12882)	390.2403
Deoxybrevianamide E <sup>197</sup>		C <sub>21</sub> H <sub>25</sub> N <sub>3</sub> O <sub>2</sub>	227, 279, 291.5	351.1947
Desacetylpebrolide <sup>182</sup>		C <sub>22</sub> H <sub>28</sub> O <sub>6</sub>	230(11900)	388.1886
Erthryo mycophenolic acid <sup>209</sup>		C <sub>17</sub> H <sub>20</sub> O <sub>7</sub>		336.1209
Ethyl mycophenolat <sup>209</sup>		C <sub>19</sub> H <sub>24</sub> O <sub>6</sub>	303(4700)	348.1573
Iso Brevianamide A <sup>154</sup>				
Metabolites O				
Mycochromenic acid <sup>154,209</sup>		C <sub>17</sub> H <sub>18</sub> O <sub>6</sub>	246(20500), 280(3200), 321.5(3500), 332.5(300)	318.1103
Mycophenolic acid <sup>154,184,210</sup>	Anti-cancer <sup>211</sup>	C <sub>17</sub> H <sub>20</sub> O <sub>6</sub>	214(100%), 235(14%), 249(22%), 273(2%), 303(11%)	320.1260
Mycophenolic acid diol lactone <sup>154,209</sup>				
N-(2-methyl-3-oxodec-8-enoyl)-pyrrole <sup>212</sup>	Plant hormone activity	C <sub>15</sub> H <sub>21</sub> NO <sub>2</sub>		247.1572
N-(2-methyl-3-oxodecanoyl)-2-pyrroline <sup>213</sup>	Plant hormone activity	C <sub>15</sub> H <sub>25</sub> NO <sub>2</sub>		251.1885
N-(2-methyl-3-oxodecanoyl)-pyrrole <sup>212</sup>	Plant hormone activity	C <sub>15</sub> H <sub>23</sub> NO <sub>2</sub>		249.1729
N-Benzoylphenylalanine <sup>193,214,215</sup>		C <sub>17</sub> H <sub>17</sub> NO <sub>3</sub>		283.1209

Table 8 Secondary metabolites and mycotoxins from <i>Penicillium brevicompactum</i>				
Component	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
N-benzoylphenylalaninol <sup>193,214,215</sup>		C <sub>16</sub> H <sub>17</sub> NO <sub>2</sub>		255.126
Pebrolide <sup>182,216</sup>		C <sub>24</sub> H <sub>30</sub> O <sub>7</sub>	230(9700)	430.1992

\* Only produced when extract of culture are irradiated with light. \*\*Has a tautomer.

Table 9 Secondary metabolites and mycotoxins from <i>Penicillium polonicum</i>				
Component	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
3-methoxyviridicatin <sup>217</sup>			203(100%), 212(88%), 221(98%), 263(16%), 281(21%), 300(14%), 315(19%), 323(23%), 335(17%)	
Anacine <sup>217</sup>				
Cyclophenin <sup>154</sup>			203(93%), 210(100%), 231(59%), 251(25), 275(5), 288(7%)	
Cyclophenol <sup>154</sup>			201(100%), 214(67%), 233(35%), 269(5%), 285(7%)	
Cyclopetin <sup>217</sup>				
Dehydrocyclopetin <sup>217</sup>				
Leucyltryptophanyldiketopiperazine <sup>217</sup>				
Met AA4				
Met B <sup>217</sup>				
Met C <sup>217</sup>				
Met DO <sup>217</sup>				
met FO <sup>217</sup>				
Nephrotoxic glycopeptides, Normeyhylverrucosidin <sup>154</sup>	Nephrotoxic			
Orsellinic acid <sup>154</sup>				
Aspterric acid				
Anasine				
Pseurotins				
4-methyl-4-[2-(2R)-hydroxyl-3-butynyloxy]				
Ruglosuvine				
Penicillic acid <sup>154</sup>	Cytotoxic			
Met POLX <sup>217</sup>				
Puberuline <sup>217</sup>				
Verrucofortine <sup>154</sup>				
Verrucosidin <sup>154,218</sup>	Tremorgenic	C <sub>24</sub> H <sub>32</sub> O <sub>6</sub>	241(21000), 294(13000)	416.22
Viridicatin <sup>154</sup>			205(83%), 219(81%), 223(100%), 239(55%), 265(14%), 288(21%), 297(20%), 308(24%), 318(29%), 329(22%)	
Viridicatol <sup>154</sup>				

Table 10 Secondary metabolites and mycotoxins from <i>Trichoderma</i> species					
Component	Producing species	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
(2S,3S,4R)-2-[(2R)-2-hydroxytetracosanoylamino]-1,3,4-octadecatriol <sup>219</sup>	<i>T. koningii</i>		C <sub>42</sub> H <sub>85</sub> O <sub>5</sub> N		683.6428
24,25-Dihydro trichotetronine <sup>220</sup>			C <sub>28</sub> H <sub>34</sub> O <sub>8</sub>	257(35500), 368(39800)	498.2254
3-(2-hydroxypropenyl)-4-(hexa-2E,4E-dien-6-yl)furan-2(5H)-one <sup>221</sup>	<i>T. harzianum</i>		C <sub>13</sub> H <sub>18</sub> O <sub>3</sub>		222.1256
3-(propenyl)-4-(hexa-2E,4E-dien-6-yl)furan-2(5H)-one <sup>221</sup>	<i>T. harzianum</i>		C <sub>13</sub> H <sub>20</sub> O <sub>4</sub>		240.1362
3-3'-isocyanocyclopent-2-enylidene)propionic acid <sup>222</sup>					
3-Dimethylamino-5-hydroxy-5-vinyl-2-cyclopenten-1-one <sup>223</sup>	<i>T. koningii</i>	Antifungal	C <sub>9</sub> H <sub>13</sub> NO <sub>2</sub>	Unstable	167.0952
4-Hydroxyphenetyl alcohol <sup>219</sup>	<i>T. koningii</i>		C <sub>8</sub> H <sub>10</sub> O <sub>2</sub>		138.0681
4 $\beta$ -Epi- exahydrobenzopyran-5-one <sup>221,224</sup>	<i>T. harzianum</i>	Antifungal	C <sub>16</sub> H <sub>26</sub> O <sub>5</sub>		298.1780
4 $\beta$ -Epi-dihydropyran <sup>221,224</sup>	<i>T. harzianum</i>		C <sub>16</sub> H <sub>26</sub> O <sub>4</sub>		282.1831
6-n-pentenyl-2H-pyran-2-one <sup>225,226</sup>		Antifungal	C <sub>10</sub> H <sub>12</sub> O <sub>2</sub>	302	166.0994
6-n-pentyl-2H-pyran-2-one <sup>225,226</sup>		Antifungal	C <sub>10</sub> H <sub>14</sub> O <sub>2</sub>	302	164.0845
Bisorbibutenolide <sup>227</sup>		Antioxidant	C <sub>28</sub> H <sub>32</sub> O <sub>8</sub>	263(14700), 293(16300), 369(14500)	496.2097
Bisorbicillinolide <sup>227</sup>		Antioxidant	C <sub>28</sub> H <sub>32</sub> O <sub>8</sub>	293(20900), 374(17900),	496.2097

Table 10					
Secondary metabolites and mycotoxins from <i>Trichoderma</i> species					
Component	Producing species	Biologically effect	Elementary composition	$\lambda$ (log $\epsilon$ )	M (Da)
Bisvertinol <sup>180,228</sup>	<i>T. longibrachiatum</i>			227(9900), 274(15400), 300(15000), 313sh, 400(24000)	
Bisvertinolone <sup>180,228</sup>	<i>T. longibrachiatum</i>			272(23000), 294(23000), 366(24000)	
Chrysophanol <sup>86,229</sup>	<i>T. viride</i>		C <sub>15</sub> H <sub>10</sub> O <sub>4</sub>	208(51%), 225(100%), 237(33%), 259(65%), 275(30%), 279(31%), 283(30), 287(31%), 308(30%), 428(30%)	254.0579
Cyclo-(L-Pro-L-Leu) <sup>219,230,231</sup>	<i>T. koningii</i>		C <sub>11</sub> H <sub>18</sub> O <sub>2</sub> N <sub>2</sub>		210.1368
Cyclonerodiol <sup>219,230,231</sup>	<i>T. harzianum</i> , <i>T. koningii</i>	Plant growth regulator	C <sub>18</sub> H <sub>28</sub> O <sub>2</sub>		276.2089
Cyclonerodiol-keto-diol <sup>224</sup>	<i>T. harzianum</i> , <i>T. koningii</i>		C <sub>16</sub> H <sub>26</sub> O <sub>4</sub>		282.1831
Demethylsorbicillin <sup>232</sup>		Antioxidant	C <sub>13</sub> H <sub>14</sub> O <sub>3</sub>	206(16300), 325(13800)	218.0946
Diene isocyanide <sup>222,233</sup>	<i>T. harmatum</i>				
Dihydropyran <sup>221,224</sup>	<i>T. harzianum</i>		C <sub>16</sub> H <sub>26</sub> O <sub>4</sub>	260(79400)	282.1831
Diterpenoid diketone 4 <sup>234</sup>	<i>T. harzianum</i>				
Emodin <sup>86,229</sup>	<i>T. viride</i>		C <sub>15</sub> H <sub>10</sub> O <sub>5</sub>	207(58%), 223(100%), 237(37%), 255(51%), 267(56%), 275(52%), 288(60%), 331(6%), 441(33%)	270.0528
Ergokonin A <sup>235</sup>	<i>T. koningii</i>	Antifungal	C <sub>34</sub> H <sub>53</sub> NO <sub>10</sub> S		667.3390
Ergokonin B <sup>235</sup>	<i>T. koningii</i>	Antifungal	C <sub>28</sub> H <sub>42</sub> O <sub>5</sub>		458.3032
Harzandione <sup>224,231</sup>	<i>T. harzianum</i>				
Harzianolide <sup>236</sup>	<i>T. harzianum</i>		C <sub>13</sub> H <sub>16</sub> O <sub>3</sub>		222.125
Harzianum A <sup>237</sup>	<i>T. harzianum</i>	Antifungal	C <sub>23</sub> H <sub>28</sub> O <sub>6</sub>	204(9200), 303(21600)	400.1886
Hexahydrobenzopyran-5-one <sup>221</sup>	<i>T. harzianum</i>	Antifungal	C <sub>16</sub> H <sub>26</sub> O <sub>5</sub>		298.1780
Homothallin II <sup>233</sup>	<i>T. koningii</i>	Antibacterial, antifungal	C <sub>8</sub> H <sub>7</sub> NO <sub>2</sub>	257	149.0527
Iso nitril acid 1 <sup>238</sup>	<i>T. harmatum</i>		C <sub>9</sub> H <sub>7</sub> NO <sub>3</sub>		177.0426
Iso nitril acid 2 <sup>238</sup>	<i>T. harmatum</i>		C <sub>9</sub> H <sub>9</sub> NO <sub>2</sub>		163.0634
4,4-Dihydroxy-2-(1-hydroxyheptyl)-3,4,5,6,7,8-hexahydro-2H-1-benzopyran-5-one <sup>239</sup>	<i>T. koningii</i>	Antifungal	C <sub>16</sub> H <sub>26</sub> O <sub>5</sub>	260(7943)	298.1780
Isoharzandione <sup>240</sup>	<i>T. viride</i>	Antifungal	C <sub>20</sub> H <sub>28</sub> O <sub>2</sub>	255.5(1760)	300.2089
Isonitrin D <sup>233</sup>	<i>T. koningii</i>		C <sub>8</sub> H <sub>7</sub> NO <sub>2</sub>	236	149.0527
Koninginin A <sup>241,242</sup>	<i>T. koningii</i>	Inhibiting wheat growth	C <sub>16</sub> H <sub>26</sub> O <sub>4</sub>	End abs.	284.1988
Koninginin B <sup>243,244</sup>	<i>T. koningii</i>	Inhibiting wheat growth	C <sub>16</sub> H <sub>26</sub> O <sub>4</sub>	262(17400)	282.1831
Koninginin D <sup>243</sup>	<i>T. koningii</i>		C <sub>16</sub> H <sub>26</sub> O <sub>5</sub>		298.1780
Koninginin E <sup>243</sup>	<i>T. koningii</i>	Inhibiting wheat growth	C <sub>16</sub> H <sub>26</sub> O <sub>4</sub>	262	282.1831
Koninginin G <sup>245</sup>	<i>T. aureoviride</i>	Inhibiting wheat growth	C <sub>16</sub> H <sub>30</sub> O <sub>5</sub>	212(8510), 260(7590)	302.2069
Methyl Benzoate <sup>219</sup>	<i>T. koningii</i>		C <sub>8</sub> H <sub>8</sub> O <sub>2</sub>		136.25
MR-304A <sup>246</sup>	<i>T. harzianum</i>	Melanin synthesis inhibitor	C <sub>8</sub> H <sub>11</sub> NO <sub>4</sub>	209(4204), 268(726)	174.9906
MR-93A <sup>247</sup>	<i>T. harzianum</i>		C <sub>8</sub> H <sub>11</sub> NO <sub>3</sub>	226(8991)	169.0751
Octaketide-acetat diol 3 <sup>221</sup>	<i>T. harzianum</i>	Antifungal	C <sub>16</sub> H <sub>28</sub> O <sub>4</sub>		284.1988
Octaketide-triol 10 <sup>224</sup>	<i>T. harzianum</i>	Antifungal	C <sub>16</sub> H <sub>26</sub> O <sub>5</sub>		298.1780
Oxosorbicillinol <sup>232</sup>		Antioxidant	C <sub>14</sub> H <sub>16</sub> O <sub>5</sub>	231(11000), 301(9000), 377.5(17600)	264.0996
Pachybasin <sup>229</sup>	<i>T. viride</i>		C <sub>15</sub> H <sub>10</sub> O <sub>3</sub>	327(3.47), 403(3.78)	238.0630
Sorbicillin <sup>165,227,228</sup>	<i>T. longibrachiatum</i>	Antioxidant	C <sub>14</sub> H <sub>16</sub> O <sub>3</sub>	318(27000)	232.1099
Sorbiquinol <sup>248</sup>	<i>T. longibrachiatum</i>			292(23000), 359(22500), 374(19500)	480.2132
Tricho-acorenol <sup>219</sup>	<i>T. koningii</i>		C <sub>15</sub> H <sub>26</sub> O		222.1984
Trichodermin <sup>249</sup>	<i>T. longibrachiatum</i> , <i>T. harzianum</i> , <i>T. viride</i>	Cytotoxic	C <sub>17</sub> H <sub>24</sub> O <sub>4</sub>	End abs.	292.1675
Trichodermol <sup>249</sup>	<i>T. longibrachiatum</i> , <i>T. harzianum</i> , <i>T. viride</i>	Cytotoxic	C <sub>15</sub> H <sub>22</sub> O <sub>3</sub>	End abs.	250.1569
Trichodermolide <sup>248</sup>	<i>T. longibrachiatum</i>		C <sub>24</sub> H <sub>28</sub> O <sub>5</sub>	280(52480), 217(14125)	396.1937
Trichodimerol <sup>220,228</sup>	<i>T. longibrachiatum</i>		C <sub>28</sub> H <sub>32</sub> O <sub>8</sub>	362(4.48), 307(4.20), 295(4.17), 240(4.0)	496.2090
Trichotetronine <sup>220</sup>			C <sub>28</sub> H <sub>32</sub> O <sub>8</sub>	271(38000), 291(42660), 384(19500)	496.2098
Trichoviridin <sup>233,250</sup>			C <sub>8</sub> H <sub>9</sub> NO <sub>4</sub>	220(2500)	183.0532
U-21963 <sup>251</sup>	<i>T. viride</i>	Antibiotic	C <sub>9</sub> H <sub>7</sub> NO <sub>3</sub>	223(15115)	177.0426

Component	Producing species	Biologically effect	Elementary composition	$\lambda$ (log $\epsilon$ )	M (Da)
Harzianic acid <sup>252</sup>	<i>T. harzianum</i>	Antibiotic	C <sub>19</sub> H <sub>27</sub> NO <sub>6</sub>	244(10964), 299(10471), 343(23422), 359(25120), 376(23422), 398(10471)	365.1838

Component	Producing species	Biologically effect	Amino acids	M (Da)
Atroviridin A, B, C <sup>253</sup>	<i>T. atroviride</i>		20 aa	1863
Harzianin HB I <sup>254</sup>	<i>T. harzianum</i>	Antibacterial, membrane modifying	11aa	1160
Harzianin HC: I, III, IX, VI, VIII, X, XI, XII, XIII, XIV, XV <sup>255</sup>	<i>T. harzianum</i>	Antibacterial, membrane modifying	14aa	1401, 1415, 1413, 1385, 1399, 1413, 1415, 1429, 1443, 1399, 1427
Harzianin HK VI <sup>256</sup>	<i>T. psedokoningii</i>	Membrane modifying	11aa	1174
Hypomurocin A-1, A-2, A-3, A-4, A-5 <sup>257</sup>	<i>Hypocrea muroiana</i>	Antibacterial	11aa	1160, 1174, 1174, 1174, 1188
Hypomurocin B-1, B-2, B-3a, B-3b, B-5, B-5 <sup>257</sup>	<i>Hypocrea muroiana</i>	Antibacterial	18 aa	1718, 1722, 1702, 1732, 1732, 1746
Trichocellin A, A-I, A-II, A-III, A-IV, A-V, A-VI, A-VII, A-VIII <sup>258</sup>	<i>T. viride</i>	Membrane modifying	20aa	1921, 1935, 1921, 1935, 1949, 1963, 1949, 1963
Trichocellin B-I, B-II <sup>258</sup>	<i>T. viride</i>	Membrane modifying	20aa	1922, 1936
Trichokindin TK-Ia, Ib, IIa, IIb, IIIa, IIIb, IV, Va, Vb, VI, VII <sup>259</sup>	<i>T. harzianum</i>	Membrane modifying	18aa	1748, 1748, 1762, , 1762, 1762, 1762, 1776, 1776
Tricholin <sup>260,261</sup>	<i>T. viride</i>	Fungicide	Protein (14200 Da)	
Trichorozin I, II, III, IV <sup>262</sup>	<i>T. harzianum</i>	Membrane modifyng	11aa	1161, 1175, 1175, 1189
Trichorzianin B, IIa, IIc, IVb, Vb, VIa, Vb, VII <sup>263</sup>	<i>T. harzianum</i>	Antifungal	19aa (UV data <sup>86</sup> )	
Trichorzianin A IIA, IIIA, IIIB, IIIC, IVB, VB, VIA, VIB VII <sup>263</sup>	<i>T. harzianum</i>	Antifungal	19aa (UV data <sup>86</sup> )	
Trichorzin HA I, II, III, V, VII <sup>264,265</sup>	<i>T. harzianum</i>	Antibacterial, membrane modifying	18aa	
Trichorzin HC VIII, XV <sup>264</sup>	<i>T. harzianum</i>	Antibacterial, membrane modifying	14aa	
Trichorzin KA V <sup>264</sup>	<i>T. harzianum</i>	Antibacterial, membrane modifying	19aa	
Trichorzin MA I, II, III <sup>264,265</sup>	<i>T. harzianum</i>	Antibacterial, membrane modifying	18aa	
Trichorzin PA VI, II, IV, V, VII, VIII, IX <sup>266,267</sup>	<i>T. harzianum</i>	Membrane modifying	18aa	
Trichorzin SA II <sup>264</sup>	<i>T. harzianum</i>	Antibacterial, membrane modifying	20aa	
Trichorzin TA IIc <sup>264</sup>	<i>T. harzianum</i>	Antibacterial, membrane modifying	19aa	
Trichotoxin A <sup>268</sup>	<i>T. viride</i>		191 aa	
Trichotoxin A-40 <sup>269</sup>	<i>T. viride</i>	Membrane modifyng	18 aa	
Trichotoxin A-50 <sup>269</sup>	<i>T. viride</i>	Membrane modifyng		
Trikoningin KA V <sup>270</sup>	<i>T. koningii</i>	Antibacterial, membrane modifying	19aa	1889
Trikoningin KB I, II <sup>270</sup>	<i>T. koningii</i>	Antibacterial, membrane modifying	11aa	1037, 1051
Trichokonin TK-IIa, IIb, IIc, V, VI, VII, VIII <sup>271,272</sup>	<i>T. koningii</i>		20 aa	1907, 1923, 1921, 1865, 1936, 1950, 1950

Component	Biologically effect	Elementary composition	$\lambda$ (log $\epsilon$ )	M (Da)
Dechlorgriseofulvin <sup>3</sup>		C <sub>17</sub> H <sub>18</sub> O <sub>6</sub>	235(21400), 253(15100), 290(24500), 322(4100)	318.1104
Epidechlorgriseofulvin <sup>3</sup>		C <sub>17</sub> H <sub>18</sub> O <sub>6</sub>	248(21880), 288(28840), 320(7244)	318.1104
Griseofulvin <sup>3</sup>		C <sub>17</sub> H <sub>17</sub> O <sub>6</sub> Cl	236(21300), 252(12500), 291(21800), 324(5200)	352.0714
Memnobotrin A <sup>273</sup>	Cytotoxic to breast cells in NCI assays	C <sub>25</sub> H <sub>33</sub> NO <sub>5</sub>	217(26200), 257.5(5600), 300(2300)	427.2359

Component	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
Memnobotrin B <sup>273</sup>	Cytotoxic to cells in NCI assays	C <sub>27</sub> H <sub>37</sub> NO <sub>6</sub>	218.5(37200), 259(10600), 302(3300)	471.2621
Memnoconol <sup>273</sup>	Cytotoxic to cells in NCI assays. Related to mycophenolic acid	C <sub>23</sub> H <sub>32</sub> O <sub>6</sub>	219(28700), 261.5(11100), 290(3000)	404.2199
Memnoconone <sup>273</sup>	Cytotoxic to cells in NCI assays Related to mycophenolic acid	C <sub>23</sub> H <sub>30</sub> O <sub>5</sub>	219(38000), 261(14600), 289(2900)	386.2093
Norlicxanthone <sup>86,274-276</sup>		C <sub>14</sub> H <sub>12</sub> O <sub>5</sub>	205(68%), 218(84%), 241(100%), 267(26%), 281(19%), 313(60%), 346(29%)	260.0685
L-671 776 <sup>27-29,277</sup>	Complement inhibitor, antimanic depressive drug, inhibitor of myo-inositol monophosphatase	C <sub>23</sub> H <sub>32</sub> O <sub>5</sub>	230 (230%), 286(187%), 330(118%)	388.2250
Trichodermin <sup>274</sup>	Cytotoxic	C <sub>17</sub> H <sub>24</sub> O <sub>4</sub>	End abs	292.1675
Trichodermol <sup>274</sup>	Cytotoxic	C <sub>15</sub> H <sub>22</sub> O <sub>3</sub>	End abs	250.1569
Factor A <sup>277</sup>	Inhibitor of myo-inositol monophosphatase	C <sub>23</sub> H <sub>30</sub> O <sub>5</sub>	247, 308, 356	386.2093
Factor C <sup>277</sup>	Inhibitor of myo-inositol monophosphatase	C <sub>23</sub> H <sub>30</sub> O <sub>6</sub>	247, 308, 356	402.2042

Component	Producing species	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
Altenuene <sup>278</sup>	<i>A. alternata</i> , sp.(= <i>A. tenuis</i> )	Cytotoxic	C <sub>15</sub> H <sub>16</sub> O <sub>6</sub>	319(6600), 278(10000), 240(30000)	292.0946
Altenusin <sup>278</sup>	<i>A. alternata</i> , sp.(= <i>A. tenuis</i> )		C <sub>15</sub> H <sub>14</sub> O <sub>6</sub>	217, 247, 290	290.0790
Alterosin I <sup>278</sup>	<i>A. alternata</i>		C <sub>20</sub> H <sub>14</sub> O <sub>7</sub>	256(31500), 285(15700), 366(5100)	366.0752
Alterosin II <sup>278</sup>	<i>A. alternata</i> ,		C <sub>20</sub> H <sub>16</sub> O <sub>7</sub>	225(30400), 348(5000)	368.0669
Alternariol <sup>278-280</sup>	<i>A. alternata</i> , <i>A. tenuissima</i>	Teratogenic, 100 mg/kg in mice	C <sub>14</sub> H <sub>10</sub> O <sub>5</sub>	218, 258(38000), 302, 330	258.0528
Alternariol mono methyl ether <sup>278,279</sup>	<i>A. alternata</i> , <i>A. tenuissima</i>	Cytotoxic	C <sub>15</sub> H <sub>12</sub> O <sub>5</sub>	335-342, 301, 290, 257, 230	272.0684
Altenuisol <sup>278</sup>	<i>A. alternata</i> , sp.(= <i>A. tenuis</i> )		C <sub>14</sub> H <sub>19</sub> O <sub>6</sub>	216(9000), 256(11000), 278(3500)	274.0476
Altertoxin I <sup>280,281</sup>	<i>A. alternata</i> , <i>A. tenuissima</i>	Mutagenic, LC <sub>50</sub> 200µg/ml to brine shrimp, toxic to fibroblast >5µg/ml	C <sub>20</sub> H <sub>16</sub> O <sub>6</sub>	215(25500), 256(34600), 285(16300), 296(13300), 356(6000)	352.0946
Altertoxin II <sup>281</sup>	<i>A. alternata</i>	Mutagenic, LC <sub>50</sub> 200µg/ml brine shrimp, toxic to fibroblast >0.02 µg/ml	C <sub>20</sub> H <sub>14</sub> O <sub>6</sub>	215(27000), 258(31700), 286(17000), 297(13500), 358(5300)	350.0790
Altertoxin III <sup>281</sup>	<i>A. alternata</i>	Mutagenic, , toxic to fibroblast >0.2 µg/ml	C <sub>20</sub> H <sub>12</sub> O <sub>6</sub>	210(19500), 265(14500), 352(5200)	348.0636
Dehydroaltenusin <sup>278</sup>	<i>A. alternata</i> , sp.(= <i>A. tenuis</i> )		C <sub>15</sub> H <sub>12</sub> O <sub>6</sub>	217(33800), 249(12600), 300(7500)	288.0633
Dihydroalternosin <sup>278</sup>	<i>A. alternata</i>	Interferes with chlorophyll formation	C <sub>22</sub> H <sub>32</sub> N <sub>4</sub> O <sub>4</sub>	258	416.2392
Helmidiol <sup>282</sup>	<i>A. alternata</i>		C <sub>16</sub> H <sub>24</sub> O <sub>6</sub>	207(17850)	312.1573
Iso-altenuene <sup>278</sup>	<i>A. alternata</i> , sp.	Phytotoxic.	C <sub>15</sub> H <sub>16</sub> O <sub>6</sub>	243(25800), 281.4(8490), 325.7(4863)	292.0946
Muculosin <sup>283</sup>	<i>A. alternata</i>		C <sub>14</sub> H <sub>16</sub> N <sub>2</sub> O <sub>3</sub>		260.1161
Stemphytoxin <sup>278</sup>	<i>A. alternata</i>	Mutagenic	C <sub>20</sub> H <sub>12</sub> O <sub>6</sub>	215(29000), 269(24600), 287(20000), 300(16500), 374(4700)	348.0636
Tentoxin <sup>278</sup>	<i>A. alternata</i>	Interferes with chlorophyll formation	C <sub>22</sub> H <sub>30</sub> N <sub>4</sub> O <sub>4</sub>	285(17500)	414.2270
Tenuazonic acid	<i>A. alternata</i> , <i>A. tenuissima</i>	Monkey LD <sub>50</sub> 50mg/kg	C <sub>10</sub> H <sub>15</sub> NO <sub>3</sub>	218(5000), 277.5(12500)	197.1051

Component	Producing species	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
Aureonitol <sup>284</sup>	<i>C. cochlioides</i>		C <sub>13</sub> H <sub>18</sub> O <sub>2</sub>		206.1307
Spiroketal 4 <sup>284</sup>	<i>C. cochlioides</i>		C <sub>13</sub> H <sub>20</sub> O <sub>4</sub>		240.1362
Chaetochromin A <sup>285,286</sup>	<i>C. gracile</i>	Cytotoxic, delayed liver injuries, teratogenic	C <sub>30</sub> H <sub>26</sub> O <sub>10</sub>	235(43680), 270(48230), 292(59150), 325(15470), 335(10740), 410(10470)	546.1526
Chaetochromin B <sup>287</sup>	<i>C. gracile</i>	Cytotoxic, delayed liver	C <sub>30</sub> H <sub>26</sub> O <sub>16</sub>	230(37200), 270(52100), 292(62900),	546.1526

Table 14 Secondary metabolites and mycotoxins from <i>Chaetomium</i> species					
Component	Producing species	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
		injuries, teratogenic		325(10300), 340(6500), 412(9500)	
Chaetochromin C <sup>287</sup>	<i>C. gracile</i>	Cytotoxic, delayed liver injuries, teratogenic	C <sub>29</sub> H <sub>24</sub> O <sub>10</sub>	233(33700), 270(37700), 293(45200), 325(12000), 338(8100), 414(7900)	532.1369
Chaetochromin D <sup>287</sup>	<i>C. gracile</i>	Cytotoxic, delayed liver injuries, teratogenic	C <sub>30</sub> H <sub>24</sub> O <sub>10</sub>	234(36300), 270(38800), 293(47500), 325(13000), 338(8200), 416(8700)	544.1323
Chaetocin B <sup>288</sup>	<i>C. virescens</i>	cytotoxic in Hela, IC <sub>50</sub> 30ng/ml	C <sub>30</sub> H <sub>28</sub> N <sub>6</sub> O <sub>6</sub> S <sub>5</sub> Unstable	Triacetyl-derivat: 209(50100), 237(20000), 299(6300)	760.0575
Chaetocin C <sup>288</sup>	<i>C. virescens</i>	cytotoxic in Hela, IC <sub>50</sub> 20ng/ml	C <sub>30</sub> H <sub>28</sub> N <sub>6</sub> O <sub>6</sub> S <sub>6</sub> Unstable	Triacetyl-derivat: 210(31600), 238(12600), 301(5000)	760.0575
Chaetocin <sup>59</sup>	<i>C. minutum</i>	Cytostatic, cytotoxic in Hela, IC <sub>50</sub> 40ng/ml	C <sub>30</sub> H <sub>28</sub> O <sub>6</sub> N <sub>6</sub> S <sub>4</sub>	306(6000)	696.0938
Chaetoglobosin A <sup>289</sup>	<i>C. globosum</i>	LD <sub>50</sub> 6-18 mg/kg in mice, multinucleated cells	C <sub>32</sub> H <sub>36</sub> O <sub>5</sub> N <sub>2</sub>	223(40700), 274(6600), 282(6600), 291(5300)	528.262
Chaetoglobosin B <sup>289</sup>	<i>C. globosum</i>	ED <sub>50</sub> 3-10 µg/ml in HeLa cells, multinucleated cells, multinucleated cells	C <sub>32</sub> H <sub>36</sub> O <sub>5</sub> N <sub>2</sub>	222(43600), 274(7900), 281(7900), 290(6700)	528.262
Chaetoglobosin C <sup>289</sup>	<i>C. globosum</i>	ED <sub>50</sub> 10-32 µg/ml in HeLa cells, multinucleated cells	C <sub>32</sub> H <sub>36</sub> O <sub>5</sub> N <sub>2</sub>	222(36300), 273(6700), 281(6700), 291(5700)	528.262
Chaetoglobosin D <sup>289</sup>	<i>C. globosum</i>	ED <sub>50</sub> 3-10 µg/ml in HeLa cells, multinucleated cells	C <sub>32</sub> H <sub>36</sub> O <sub>5</sub> N <sub>2</sub>	221(43600), 273(9100), 281(9100), 290(7500)	528.262
Chaetoglobosin E <sup>289</sup>	<i>C. globosum</i>	ED <sub>50</sub> 3-10 µg/ml in HeLa cells, multinucleated cells	C <sub>32</sub> H <sub>36</sub> O <sub>5</sub> N <sub>2</sub>	221(56200), 275(7100), 281(7000), 291(6300)	530.278
Chaetoglobosin F <sup>289</sup>	<i>C. globosum</i>	ED <sub>50</sub> 10 µg/ml in HeLa cells, multinucleated cells	C <sub>32</sub> H <sub>36</sub> O <sub>5</sub> N <sub>2</sub>	222(47800), 276(6900), 283(6700), 292(6000)	530.278
Chaetoglobosin G <sup>289</sup>	<i>C. globosum</i>	ED <sub>50</sub> 3 µg/ml in HeLa cells, multinucleated cells	C <sub>32</sub> H <sub>36</sub> O <sub>5</sub> N <sub>2</sub>	222(32300), 275(6000), 282(6000), 291(5300)	530.278
Chaetoglobosin J <sup>289</sup>	<i>C. globosum</i>	ED <sub>50</sub> 3 µg/ml in HeLa cells	C <sub>32</sub> H <sub>36</sub> O <sub>4</sub> N <sub>2</sub>	224(47800), 270(7000), 280(7000), 290(6000)	512.258
20-Dihydrochaetoglobosin A <sup>290</sup>	<i>C. subaffe</i>		C <sub>32</sub> H <sub>32</sub> N <sub>2</sub> O <sub>5</sub>	212(51286), 221(63100), 266(8510), 272(8320), 291(6600)	530.2728
20-Dihydroprochaetoglobosin II <sup>290</sup>	<i>C. subaffe</i>		C <sub>32</sub> H <sub>36</sub> N <sub>2</sub> O <sub>2</sub>	221(21880), 291(2400)	480.2779
20-Dihydroprochaetoglobosin III <sup>290</sup>	<i>C. subaffe</i>		C <sub>32</sub> H <sub>38</sub> N <sub>2</sub> O <sub>4</sub>	222(42660), 291(5250)	514.2833
Chaetohalasin A <sup>291</sup>	<i>C. brasiliense</i>	Cytotoxic in NCI's human cell line 8µg/ml, antibacterial	C <sub>27</sub> H <sub>39</sub> NO <sub>2</sub>	212 (6200)	409.2971
Chaetomin <sup>59,292</sup>	<i>C. globosum</i> , <i>C. cochliodes</i>	20ng/ml inhibits protein synthesis in HeLa cells	C <sub>31</sub> H <sub>30</sub> O <sub>6</sub> N <sub>6</sub> S <sub>4</sub>	295(8250), 284(9600), 275(9100)	710.1094
Chaetoviridin A <sup>293</sup>	<i>C. globosum</i>		C <sub>23</sub> H <sub>25</sub> ClO <sub>6</sub>	305(26000), 365(19000), 450(4600)	432.1341
Chaetoviridin B <sup>293</sup>	<i>C. globosum</i>		C <sub>23</sub> H <sub>29</sub> ClO <sub>7</sub>	290(14000), 385(27000), 405(24000), 430(11200)	452.1604
Chaetoviridin C <sup>293</sup>	<i>C. globosum</i>		C <sub>23</sub> H <sub>27</sub> ClO <sub>6</sub>	294(7600), 386(14000), 406(12600), 430(5500)	434.1498
Chaetoviridin D <sup>293</sup>	<i>C. globosum</i>		C <sub>23</sub> H <sub>28</sub> ClO <sub>8</sub>	290(8900), 395(16000), 410(13800), 430(6200)	468.1552
Chetracin A <sup>288</sup>	<i>C. abuense</i>	cytotoxic in Hela, IC <sub>50</sub> 70ng/ml	C <sub>30</sub> H <sub>28</sub> N <sub>6</sub> O <sub>6</sub> S <sub>8</sub>		855.9738
11 $\alpha$ ,11' $\alpha$ -dihydroxychaetocin <sup>288</sup>	<i>C. retardatum</i>	cytotoxic in Hela, IC <sub>50</sub> 40ng/ml	C <sub>30</sub> H <sub>28</sub> O <sub>8</sub> N <sub>6</sub> S <sub>4</sub>	242(17400), 302(2400)	728.0854
Cochliodinol <sup>294,295</sup>	<i>C. globosum</i> and <i>C. cochliodes</i>	Antibiotic.	C <sub>32</sub> H <sub>32</sub> N <sub>2</sub> O <sub>4</sub>	272(11500), 293(11200), 352(5400), 470(22400)	508.2362
Colletodiol <sup>296,297</sup>	<i>C. funicola</i>		C <sub>14</sub> H <sub>20</sub> O <sub>6</sub>	210(20500), 215(17500), 220(13400), 225(9700), 230(6400)	284.126
Differanisole A <sup>298</sup>		Induces cell differentiation in mouse leukemia cells	C <sub>11</sub> H <sub>12</sub> Cl <sub>2</sub> O <sub>4</sub>	318(2700), 257(4060), 220(23000)	278.0114
Chrysophanol <sup>186,229</sup>	<i>C. elatum</i>		C <sub>15</sub> H <sub>10</sub> O <sub>4</sub>	208(51%), 225(100%), 237(33%), 259(65%), 275(30%), 279(31%), 283(30), 287(31%), 308(30%), 428(30%)	254.24
Flavipin <sup>289</sup>					196.037
Heptelidic acid <sup>299,300</sup>		Antibiotic	C <sub>15</sub> H <sub>20</sub> O <sub>5</sub>	End abs.	280.1311
Isocochliodinol <sup>300,301</sup>			C <sub>32</sub> H <sub>32</sub> N <sub>2</sub> O <sub>4</sub>		508.2362
Mollicellin A <sup>302</sup>	<i>C. mollicellins</i>		C <sub>21</sub> H <sub>18</sub> O <sub>7</sub>		382.1052
Mollicellin B <sup>302</sup>	<i>C. mollicellins</i>		C <sub>21</sub> H <sub>18</sub> O <sub>7</sub>		382.1052
Mollicellin C <sup>302</sup>	<i>C. mollicellins</i>	Mutagenic, antibacterial	C <sub>22</sub> H <sub>20</sub> O <sub>8</sub>		412.1158
Mollicellin D <sup>302</sup>	<i>C. mollicellins</i>	Antibacterial	C <sub>21</sub> H <sub>21</sub> ClO <sub>6</sub>		404.1027
Mollicellin E <sup>302</sup>	<i>C. mollicellins</i>	Mutagenic, antibacterial	C <sub>22</sub> H <sub>19</sub> ClO <sub>8</sub>		446.0769
Mollicellin F <sup>302</sup>	<i>C. mollicellins</i>	Antibacterial	C <sub>21</sub> H <sub>17</sub> ClO <sub>8</sub>		432.0612

Component	Producing species	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
Mollicellin G <sup>301,302</sup>	<i>C. amygdalisporum</i> , <i>C. mollicellins</i>	Mutagenic, antibacterial	C <sub>21</sub> H <sub>20</sub> O <sub>6</sub>		368.1285
Mollicellin H <sup>302</sup>	<i>C. mollicellins</i>		C <sub>21</sub> H <sub>10</sub> O <sub>6</sub>		368.126
Neococochliodinol <sup>300,301</sup>	<i>C. amygdalisporum</i>		C <sub>32</sub> H <sub>32</sub> N <sub>2</sub> O <sub>4</sub>		506.0
O-methylsterigmatocystin <sup>301</sup>	<i>C. thielavioideum</i>	Carcinogenic	C <sub>19</sub> H <sub>14</sub> O <sub>6</sub>	236(40700), 310(16500)	338.0790
Oosporein <sup>303,304</sup> = Chaetomidin <sup>305</sup>	<i>C. aureum</i> , <i>C. trilaterale</i>	LD <sub>50</sub> 6 mg/mg in cockerels	C <sub>14</sub> H <sub>10</sub> O <sub>8</sub>	208(33500), 291(23000)	306.0375
Prenisatin <sup>295</sup>	<i>C. globosum</i>	Antifungal	C <sub>13</sub> H <sub>13</sub> O <sub>2</sub> N	247(19000), 299(3900), 422(1000)	215.0946
Spiroketal <sup>284</sup>	<i>C. cochlioides</i>		C <sub>13</sub> H <sub>20</sub> O <sub>2</sub>		208.1464
Sterigmatocystin <sup>301</sup>	<i>C. udagawae</i> , <i>C. thielavioideum</i>	Carcinogenic	C <sub>18</sub> H <sub>12</sub> O <sub>6</sub>	208(19000), 235(24500), 249(27500), 329(13100)	324.0633
Chaetoatrosin A <sup>306</sup>	<i>C. atrobrunneum</i>	Inhibitor of chitin synthase II	C <sub>14</sub> H <sub>14</sub> O <sub>5</sub>	225(2400), 272(1625), 408(250)	262.0841
Tomichaedin <sup>305</sup>			C <sub>12</sub> H <sub>8</sub> O <sub>5</sub>		276.9984

Component	Producing species	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
Cladosporol <sup>307</sup>	<i>C. cladosporioides</i>	$\beta$ -glucan inhibitor	C <sub>20</sub> H <sub>16</sub> O <sub>6</sub>	214(19500), 260(11200), 338(6000)	352.0947
Cladospolide A <sup>308</sup>	<i>C. cladosporioides</i> , <i>C. tenuissimum</i>	Plant growth regulator	C <sub>12</sub> H <sub>20</sub> O <sub>4</sub>	217(10650)	228.1362
Cladospolide B <sup>308</sup>	<i>C. cladosporioides</i> , <i>C. tenuissimum</i>	Plant growth regulator	C <sub>12</sub> H <sub>20</sub> O <sub>4</sub>	211(5730)	228.1362
Cladospolide C <sup>309</sup>	<i>C. tenuissimum</i>	Plant growth inhibitor	C <sub>12</sub> H <sub>20</sub> O	214(3.9)	228.1362
Calphostin A <sup>310,311</sup>	<i>C. cladosporioides</i>	Inhibitor of protein kinase C	C <sub>44</sub> H <sub>38</sub> O <sub>12</sub>	225(56199), 476(20400), 686(9880), 269(25300), 543(10200)	758.2363
Calphostin B <sup>310,311</sup>	<i>C. cladosporioides</i>	Inhibitor of protein kinase C	C <sub>37</sub> H <sub>34</sub> O <sub>11</sub>	225(49500), 476(21800), 585(10900), 269(26600), 543(11000)	654.2101
Calphostin C <sup>310,311</sup>	<i>C. cladosporioides</i>	Inhibitor of protein kinase C	C <sub>44</sub> H <sub>38</sub> O <sub>14</sub>	223(58200), 476(22900), 586(11200), 270(29400), 543(11600)	790.2262
Calphostin D <sup>310,311</sup>	<i>C. cladosporioides</i>	Inhibitor of protein kinase C	C <sub>30</sub> H <sub>30</sub> O <sub>10</sub>	226(44800), 474(23500), 582(12000), 269(29500), 539(11900)	550.1839
Calphostin I <sup>310,311</sup>	<i>C. cladosporioides</i>	Inhibitor of protein kinase C	C <sub>44</sub> H <sub>38</sub> O <sub>15</sub>	217, 258, 348, 475, 540, 582	806.2211
Indoleacetic acid <sup>96</sup>					
Cladosporide A <sup>312</sup>		Antifunga	C <sub>25</sub> H <sub>40</sub> O <sub>3</sub>	284(162)	388.2977
23,24,25,26,27-Pentanolanost-8ene-3 $\beta$ -22-diol <sup>312</sup>		Antifunga	C <sub>25</sub> H <sub>42</sub> O <sub>2</sub>		374.3187
Isocladosporin <sup>313</sup>	<i>C. cladosporioides</i>	Antifungal, inhibiting growth of wheat	C <sub>16</sub> H <sub>20</sub> O <sub>5</sub>	218(20900), 269(13030), 306(5984), 231(11950)	292.1312
Cladosporin <sup>313,314</sup>	<i>C. cladosporioides</i>	Antifungal, inhibiting growth of wheat	C <sub>16</sub> H <sub>20</sub> O <sub>5</sub>	217(20900), 270(13030), 303(5984), 230(11950)	292.1312

Component	Producing species	Biologically effect	Elementary composition	$\lambda(\log \epsilon)$	M (Da)
1-hydroxy-6-methyl-8-(hydroxymethyl)xanthon <sup>315,316</sup>	<i>U. botrytis</i>	Antibacterial	C <sub>15</sub> H <sub>14</sub> O <sub>4</sub>		258.0892
Ulocladol <sup>317</sup>	<i>U. botrytis</i>	Tyrosin kinase inhibitor	C <sub>16</sub> H <sub>14</sub> O <sub>7</sub>	251(12880), 299(3465)	318.074

## Reference List

1. Anonymous 1991. Atomic Weights of the elements 1989. Pure and Applied Chemistry **63**: 975-990.
2. Eppley, RM, Mazzola, EP, Hight, RJ, Bailey, WJ. 1977. Structure of Satratoxin H, a metabolite of *Stachybotrys atra*. Application of Proton and Carbon-13 Nuclear Magnetic Resonance. J.Org.Chem. **42**: 240-243.
3. Jarvis, BB, Sorenson, WG, Hintikka, E-L, Nikulin, M, Zhou, Y, Jiang, J, Wang, S, Hinkley, SF, Etzel, RA, Dearborn, DG. 1998. Study of Toxin Production by Isolates of *Stachybotrys chartarum* and *Memnoniella echinata* isolated during a study of pulmonary hemosiderosis in infants. Appl.Env.Microb. **64**: 3620-3625.
4. Eppley, RM, Mazzola, EP, Stack, ME, Dreifuss, PA. 1980. Structure of Satratoxin F and Satratoxin G, a metabolites of *Stachybotrys atra*. Application of Proton and Carbon-13 Nuclear Magnetic Resonance Spectroscopy. J.Org.Chem. **45**: 2522-2523.
5. Eppley, RM, Bailey, WJ. 1973. 12,13-Epoxy- $\Delta^9$ -Trichothecenes as the Probable Mycotoxins Responsible for Stachybotryotoxicosis. Science. **181**: 758-760.
6. Hinkley, SF, Jarvis BB. 2000. Chromatographic method for Stachybotrys toxins. In Pohland A, Trucksess MW. (eds.), Methods Molecular Biology. 157. Mycotoxin Protocols. p. 173-194. Humana Press, Totowa.
7. Croft, WA, Jarvis, BB, Yatawara, CS. 1986. Airborne outbreak of Trichothecene Mycotoxicosis. Atmos.Env. **20**: 549-552.
8. Jarvis, BB, Lee, Y-W, Comezoglu, SN, Yatawara, CS. 1986. Trichothecenes Produced by *Stachybotrys atra* from Eastern Europe. Appl.Env.Microb. **51**: 915-918.
9. Bloem, RJ, Smitka, TA, Bunge, RH, French, JC. 1983. Roridin L-2, a new trichothecene. Tetrahedron Lett. **24**: 249-252.
10. Ayer, WA, Miao, S. 1993. Secondary metabolites of the aspen fungus *Stachybotrys cylindrospora*. Can.J.Chem. **71**: 487-493.
11. Hinkley, SF, Jiang, J, Mazzola, EP, Jarvis, BB. 1999. Atranones: Novel diterpenoids from the toxigenic mold *Stachybotrys atra*. Tetrahedron Lett. **40**: 2725-2728.
12. Hinkley, SF, Mazzola, EP, Fettinger, JC, Lam, YKT, Jarvis, BB. 2000. Atranones A-G, from the toxigenic mold *Stachybotrys chartarum*. Phytochem **55**: 663-673.
13. Vesper, SJ, Dearborn, DG, Yike, I, Allen, T, Sobolewski, J, Hinkley, SF, Jarvis, BB, Haugland, RA. 2000. Evaluation of *Stachybotrys chartarum* in the House of an Infant with Pulmonary Hemorrhage: Quantitative Assessment before, during, and after Remediation. J.Urb.Health **77**: 68-85.
14. Tomishige, T, Miyazaki, K. 1992. Tumor necrosis factor-liberation inhibitors containing sesquiterpene analogs or their salts. Patent
15. Miyazaki, K, Saigo, S. 1991. Antidiabetics containing sesquiterpenes. Patent
16. Hong, K, Kinoshita, T, Miyazaki, W, Izawa, T, Inoue, K. 1979. An anticomplementary agent, K-76 monocarboxylic acid: its site and mechanism of inhibition of the complement activation cascade. J.Immunol. **122**: 2418-2423.
17. De Silva, LB, Herath, WHMW, Gunawardena, DSS, Wijesundera, RLC, Medis, SA, Choudhari, MI, Clardy, J. 1997. Bisbynin, a novel secondary metabolite from the fungus *Stachybotrys bisbyi* (srinivasan) barron. Tetrahedron Lett. **36**: 1997-2000.
18. Fujioka, T, Yao, K, Hamano, K, Hosoya, T, Kagasaki, T, Furkuva, Y, Haruyama, H, Sata, S, Koga, T, Tsuita, Y. 1996. Epi-cochliquinone A, a novel Acyl-CoA: Cholesterol Acyltransferase Inhibitor produced by *Stachybotrys bisbyi*. J.Antib. **49**: 409-413.
19. Kiyoshi, H. 1992. New compound epi-cocliquinone A. Patent JP4334383.
20. Sakai, K, Watanabe, K, Masuda, K, Tsuji, M, Hasumi, K, Endo, A. 1995. Isolation, characterization and biological activities of novel triprenyl phenols as pancreatic cholesterol esterase inhibitors produced by *Stachybotrys* sp. F-1839. J.Antib. **48**: 447-456.
21. Endo, A. 1994. Cholesterol esterase inhibitor. Patent JP6184133.
22. Sakamoto, K, Tsujii, E, Miyauchi, M. 1993. FR901459, a novel immunosuppressant isolated from *Stachybotrys chartarum* No. 19392. Taxonomy of the producing organism, fermentation, isolation, physicochemical properties and biological activities. J.Antib. **46**: 1788-1798.
23. Shizue, I. 1993. Fr901459 substance, and its production and use. Patent JP5271267.
24. Kaise, H, Shinohara, M, Miyazaki, W, Izawa, T, Nakano, Y, Sugawara, M, Sugiura, K, Sasaki, K. 1979. Structure of K-76, a complement inhibitor. J.Chem.Soc.,Chem.Com. 726-727.
25. Miyazaki, W, Tamaoka, H, Shinohara, M, Kaise, H, Izawa, T, Nakano, Y, Kinoshita, T, Inoue, K. 1980. A complement inhibitor produced by *Stachybotrys complementi*, nov. sp. K-76, a new species of fungi imperfecti. Microbiol.Immunol **24**: 1091-1108.
26. Singh, SB, Zink, DL, Williams, M, Polishook, JD, Sanchez, M, Silverman, KC, Lingham, RB. 1998. Kampansols: novel ras farnesyl-protein transferase inhibitors from *Stachybotrys kampalensis*. Bioorg.Medicin.Let. **8**: 2071-2076.
27. Lam, YKT, Wichman, CF, Huang, L, Burg, RW, Monaghan, RL, Jackson, R, Reid, G, Maguire, JJ, McKnight, AJ, Ragan, CI. 1992. A novel inositol mono-phosphatase inhibitor from *Memnoniella echinata*. J.Antib. **45**: 1397-1403.
28. Kaneto, R, Dobashi, K, Kojima, I, Sakai, K, Shibamoto, N, Yoshioka, T, Nishid, AH, Okamoto, R, Akagawa, H, Mizuno, S. 1994. Mer-nf5003b, mer-nf5003e and mer-nf5003f, novel sesquiterpenoids as avian-myeloblastosis virus protease inhibitors produced by *Stachybotrys* sp. J.Antib. **47**: 727-730.
29. Giocobbe, RA, Huang, L, Kong, YL, Lam, YT, Del, SM, Wichman, CF. 1991. Drug for treating manic depression. Patent 4981980.
30. Dobashi, K. 1995. New sesquiterpene derivative. Patent JP7145161.



31. Endo, A. 1995. New cholesterol esterase inhibitor. Patent JP7070102.
32. Orii, Y, Kawamura, Y, Mizobe, F, Sakai, N, Hanada, K. 1994. Extraction of nerve growth factor enhancer from cultured *Stachybotrys parvispora* F-4708. Patent
33. Orii, Y. 1994. NGF action enhancer. Patent JP6239869.
34. Nozawa, Y. 1995. Benzopyran-based compound. Patent JP7215958.
35. Nozawa, Y, Yamamoto, K, Ito, M, Sakai, N, Mizoue, K, Mizobe, F, Hanada, K. 1997. Stachybotrin C and parvisporin, novel neuritogenic compounds .1. Taxonomy, isolation, physico-chemical and biological properties. *J.Antib.* **50**: 635-640.
36. Kohyama, T, Hasumi, K, Hamanaka, A, Endo, A. 1997. SMTP-1 and -2, novel analogs of staplabin produced by *Stachybotrys microspora* IFO30018. *J.Antib.* **50**: 172-174.
37. Hasumi, K, Ohyama, S, Kohyama, T, Ohsaki, Y, Takayasu, R, Endo, A. 1998. Isolation of SMTP-3, 4, 5 and -6, novel analogs of staplabin, and their effects on plasminogen activation and fibrinolysis. *J.Antib.* 1059-1068.
38. Hu, W, Ohyama, S, Hasumi, K. 2000. Activation of fibrinolysis by SMTP-7 and -8, novel staplabin analogs with a pseudosymmetric structure. *J.Antib.* **53**: 241-247.
39. Roggo, BE, Hug, P, Moss, S, Stämpfli, A, Kriemler, H-P, Peter, HH. 1996. Novel spirodihydrobenzofuranlactams as antagonists of endothelin and as inhibitors of HIV-1 protease produced by *Stachybotrys* sp. II. Structure determination. *J.Antib.* **49**: 374-379.
40. Roggo, BE, Petersen, F, Sills, M, Roesel, JL, Moerker, T, Peter, HH. 1996. Novel spirodihydrobenzofuranlactams as antagonists of endothelin and as inhibitors of HIV-1 protease produced by *Stachybotrys* sp. I. Fermentation, isolation and biological activity. *J.Antib.* **49**: 13-19.
41. Ogawa, K, Nakamura, M, Hayashi, M. 1995. Stachybocin, novel endothelin receptor antagonists, produced by *Stachybotrys* sp. M6222 II. Structure determination of stachybocins A, B and C. *J.Antib.* **48**: 1396-1400.
42. Nakamaru, M, Ito, Y, Ogawa, K, Michisui, Y, Sato, S-I, Takada, M, Hayashi, M, Yaginuma, S, Yamamoto, S. 1995. Stachybocins, novel endothelin receptor antagonists, produced by *Stachybotrys* sp. M6222. *J.Antib.* **48**: 1389-1395.
43. 1994. Substance am6222, its production and use thereof. Patent JP6184181.
44. Yaginuma, S. 1995. New physiologically active substance stachybocin d and production thereof. Patent JP7330622.
45. Kamalov, LS, Aripova, SF, Isaev, MI. 1997. Low-molecular-mass metabolites of fungi. I. Stachybotrin from *Stachybotrys alternans*. *Chem.Nat.Comp.* **33**: 462-468.
46. Kamalov, LS, Aripova, SF, Isaev, MI. 1999. Low-molecular-mass metabolites of fungi IV. The structures of stachybotrin A and stachybotral. *Chem.Nat.Comp.* **35**: 82-85.
47. Tadashi, Y. 1993. ACAT inhibitor. Patent JP5310771.
48. Sato, T, Nagai, K, Fukunaga, Y, Sugita, Y. 1993. New Q-11270 compounds with anti-complement activity-used for treatment of nephritis, rheumatism & SLE, obtained by culturing *Stachybotrys chartarum* Q-11270. Patent JP5170769.
49. 1994. Physiologically active substance BR-011. Patent JP6206843.
50. Xu, X, Deguzman, FS, Gloer, JB, Shearer, CA. 1992. Stachybotrin-a and stachybotrin-b - novel bioactive metabolites from a brackish water isolate of the fungus *Stachybotrys* sp. *J.Org.Chem.* **57**: 6700-6703.
51. Taishi, T, Takechi, S, Mori, S. 1998. First total synthesis of stachyflin. *Tetrahedron Lett.* **39**: 4347-4350.
52. Kamigaito, T. 1998. New benzoxacyclotridecane compound and medicinal composition containing the same. Patent JP10101666.
53. Sakai, K. 1998. Protease-inhibiting substance and its production. Patent JP10251262.
54. Kamigaito, T. 1999. 2H-indene spiro-(3'-cyclohexene) compound. Patent JP11158109.
55. Vesper, SJ, Magnuson, ML, Dearborn, DG, Yike, I, Haugland, RA. 2001. Initial Characterization of the Hemolysin Stachylysin from *Stachybotrys chartarum*. *Infect.immun.* **69**: 912-916.
56. Shinohara, C, Hasumi, K, Hatsumi, W, Endo, A. 1996. Staplabin, a novel fungal triprenyl phenol which stimulates the binding of plasminogen to fibrin and U937 cells. *J.Antib.* **49**: 961-966.
57. Endo, A. 1997. Fibrinolytic activator. Patent JP9003070.
58. Holker, JSE, Kagal, SA. 1968. 5-Methoxysterigmatocystin, a metabolite from a mutant strain of *Aspergillus versicolor*. *Chem.Commun* 1574-1575.
59. Cole, RJ, Cox, RH. 1981. Handbook of Toxic Fungal Metabolites. Academic Press, London.
60. Grandjean, J. 1971. Structure of averufin. Metabolite of *Aspergillus versicolor*. *J.Chem.Soc.D.* 1060
61. Katsube, Y, Tsukihara, T, Tanaka, N, Ando, K, Hamaski, T, Hatsuda, Y. 1972. Crystal and molecular structure of averufin. *Bull.Chem.Soc.Jap* **45**: 2091-2096.
62. Berger, Y, Jadot, J, Ramaut, J. 1976. Isolation and structure of deoxyaverufinon and dehydroaverufin: two metabolites of *Aspergillus versicolor* (Vuillemin) Tiraboschi. *Bull.Soc.Chim.Belg.* **85**: 161-166.
63. Pohland, AE. 1977. Studies concerning the metabolites produced by *Stachybotrys atra*, *Penicillium islandicum*, *Penicillium viridicatum* and *Aspergillus versicolor*. *Ann.Nutr.Aliment* **31**: 663-684.
64. Hatsuda, Y, Hamaski, T, Ishida, M, Hara, S. 1972. Dihydrosterigmatocystin and dihydrodemethylsterigmatocystin, new metabolites from *Aspergillus versicolor*. *Agric.Biol.Chem.* **36**: 521-522.
65. Hamaski, T, Renbutsu, M, Hatsuda, Y. 1976. Red pigment from *Aspergillus versicolor* (Vuillemin) Tiraboschi. *Agric.Biol.Chem.* **31**: 1513-1514.
66. Fukuyama, K, Tsukihara, T, Katsube, Y, Hamasaki, T, Hatsuda, Y, Tanaka, N, Ahida, T, Kakudo, M. 1975. Crystal and molecular structure of sterigmatin, a metabolite of *Aspergillus versicolor*. *Bull.Chem.Soc.Jpn* **48**: 1639-1640.
67. Horak, RM, Steyn, PS, Vleggaar, R. 1982. Investigation of a toxigenic strain of *Aspergillus ustus*: the structure of 8-deoxy-6-o-methylversicolorin and of four new xanthenes. *S.Afr.J.Chem.* **35**: 60-62.
68. Steyn, PS, Vleggaar, R. 1974. Austocystins. Six novel dihydrofuro[3',s': 4,5]furo,3,2-b-xanthenones: from *Aspergillus ustus*. *J.Chem.Soc.Perkin I* **1**: 2250-2256.

69. Hamaski, T, Hatsuda, Y, Terashima, N, Renbutsu, M. 1967. Metabolic products of *Aspergillus versicolor*. V. Isolation and structures of three new metabolites, versicolorins A, B, and C. *Agric.Biol.Chem.* **31**: 11-17.
70. Fukuyama, K, Tsukihara, T, Katsube, Y, Hamaski, T, Hatsuda, Y. 1975. Crystal and molecular structure of versicolorin C, a metabolite of *Aspergillus versicolor*. *Bull.Chem.Soc.Jpn.* **48**: 2648-2652.
71. Aucamp, PJ, Holzapfel, CW. 1969. Toxic substances from *Aspergillus versicolor*. *J.S.Afr.Chem.Inst.* **22(Spec. Issue)**: 35S-40S.
72. Fukuyama, K, Ashida, T, Katsube, Y, Kakudo, M. 1979. The crystal and molecular structures of 6-deoxyversicolorin A and versicolorin A, metabolites from *Aspergillus versicolor*. *Bull.Chem.Soc.Jpn* **52**: 677-683.
73. Hamaski, T, Nakagomi, T, Hatsuda, Y, Fukuyama, K, Katsube, Y. 1980. 5,6-Dimethoxysterigmatocystin and related metabolites from *Aspergillus multicolor*. *Agric.Biol.Chem.* **44**: 1149-1155.
74. Kingston, GD, Chen, PN, Vercellotti, JR. 1976. Metabolites of *Aspergillus versicolor*: 6,8-dimethylnidurufin, griseofulvin, dechlorogriseofulvin and 33,8-dihydroxy-6-methylxanthone. *Phytochem* 1037-1039.
75. Hatsuda, Y. 1971. 6,8-O-dimethylversicolorin A, a new metabolite from *Aspergillus versicolor*. *Agric.Biol.Chem.* **35**: 444
76. Berger-Deguee, M, Berger, Y. 1982. Structure of versicolorone isolated from *Aspergillus versicolor*. *Phytochem* **21**: 1449-1451.
77. Helms, GL, Linemeyer, DL, Horn, WS, Dombrowski, AW, Jones, ETT, Koupal, L, Bartizal, KF, Rozdilsky, W. 1992. Cholesterol lowering agents and antifungal agents prepared with *Aspergillus versicolor*. Patent EP 92-302267.
78. Hu, H, Zhu, B, Gong, B. 1999. Studies on new bioactive compounds from *Aspergillus versicolor* SIPI-17-SIPI-1-2, 3 and 4. *Zhongguo Yaoxue Zazhi* **34**: 337-339.
79. Fukuyama, K, Tsukihara, T, Katsube, Y. 1976. Structure of versiol, a new metabolite from *Aspergillus versicolor*. *Tetrahedron Lett.* **3**: 189-190.
80. Barnes, CL, Eng-Wilmot, DL, Van der Helm, D. 1984. Ferricrocin (C<sub>29</sub>H<sub>44</sub>FeN<sub>9</sub>O<sub>13</sub>.7H<sub>2</sub>O), an iron(III)-binding peptide from *Aspergillus versicolor*. *Acta Crystallogr. Sec. C.* **C40**: 922-926.
81. Fidelis, K, Hossain, MB, Jalal, MAF, Van der Helm, D. 1990. Structure and molecular mechanics of ferrirhodin. *Acta Crystallogr. Sec. C.* **C46**: 1612-1617.
82. Cole, M, Rolinson, GN. 1969. New antibiotic from *Aspergillus versicolor* fermentation. Patent
83. Cole, M, Newbolt, R. 1970. Methyl  $\alpha$ -(methylsuccimido)acrylate. Patent GB1187070.
84. Cole, M, Rolinson, GN. 1972. Microbial metabolites with insecticidal properties. *Appl.Microbiol* **24**: 660-662.
85. Brown, AG. 1970. Versimide, a metabolite of *Aspergillus versicolor*. *J.Chem.Soc.(C)* 2572-2573.
86. Frisvad, JC, Thrane U. 1993. Liquid chromatography of mycotoxins. In Betina V. (ed.), *Chromatography of mycotoxins: Techniques and applications*. Journal of Chromatography Library. p. 253-372. Elsevier, Amsterdam.
87. Lafont, P, Lafont, J. 1970. Production de nidulotoxin par des aspergilli appartenant a diverse especes. *Experientia* **37**: 807-808.
88. Belofsky, GN, Jensen, PR, Renner, MK, Fenical, W. 1998. New Cytotoxic Sesquiterpenoid Nitrobenzoyl Esters from a Marine Isolate of the Fungus *Aspergillus versicolor*. *Tetrahedron* **54**: 1715-1724.
89. 1994. New Suncreen compound (*Aspergillus versicolor*). Patent JP06329576.
90. Rahbæk, L, Christophersen, C, Frisvad, JC, Bengaard, HS, Larsen, S, Rassing, BR. 1997. Insulicolide A: A new nitrobenzoyloxy-substituted sesquiterpene from the marine fungus *Aspergillus insulicola*. *J.Nat.Prod.* **60**: 811-813.
91. Carvalho, MR, Barbosa, LCA, Queiroz, JH, Howarth, OW. 2001. Novel lactones from *Aspergillus versicolor*. *Tetrahedron Lett.* **42**: 809-811.
92. Dhar, AK, Bose, SK. 1969. A new metabolite antibiotic from *Aspergillus versicolor*. *J.Antib.* **19**: 156-157.
93. Dhar, AK, Bose, SK. 1969. Studies on versicolin, a new antifungal antibiotic from *Aspergillus versicolor*. *Tetrahedron Lett.* **55**: 4871-4874.
94. Rickards, RW. 1971. Structure of the antifungal antibiotic versicolin. *J.Antib.* **24**: 715-716.
95. Dhar, AK, Bose, SK. 1968. Studies on versicolin, a new antifungal antibiotic from *Aspergillus versicolor*. II. Isolation and purification. *Appl.Microbiol* **16**: 749-752.
96. Basu, S, Das, SK, Majumdar, S, Bose, SK. 1987. Multiplicity of antibiotic production in *Aspergillus versicolor* N5 under mutagenesis: versilin a new antifungal antibiotic. *Indian J.Exp.Biol.* **25**: 207-208.
97. Samanta, AK, Bose, SK, Mahato, SB. 1984. Mycoversilin, a new antifungal antibiotic. II. Structure elucidation. *J.Antib.* **37**: 733
98. Samanta, AK, Kole, HK, Goswami, SK, Bose, SK. 1983. Mycoversilin, a new antifungal antibiotic from a mutant derivative of *Aspergillus versicolor*. *Indian J.Exp.Biol.* **21**: 577-578.
99. Samanta, AK, Bose, SK. 1984. Mycoversilin, a new antifungal antibiotic. I. Fermentation, isolation and biological properties. *J.Antib.* **37**: 728-732.
100. Steyn, PS. 1973. The structures of five diketopiperazines from *Aspergillus ustus*. *Tetrahedron* **29**: 107-120.
101. Steyn, PS, Vleggaar, R. 1976. 12,13-dihydro-12-hydroxyaustamide, a new dioxopiperazine from *Aspergillus ustus*. *Phytochem* **15**: 355-356.
102. Singh, SB, Smith, JL, Sabnis, GS, Dombrowski, AW, Schaeffer, JM, Goetz, MA, Bills, GF. 1991. Structure and conformation of ophiobolin K and 6-epiophiobolin K from *Aspergillus ustus* as a nematocidal agent. *Tetrahedron Lett.* **47**: 6931-6938.
103. Horak, RM, Steyn, PS, Rooyen, PH, Vleggaar, R. 1981. Structures of the austalides A-E, five novel toxic metabolites from *Aspergillus ustus*. *J.Chem.Soc.,Chem.Com.* 1265-1267.
104. Horak, RM, Steyn, PS, Vleggaar, R, Rabie, CJ. 1985. Metabolites of *Aspergillus ustus*. Part 3. Structure elucidation of austalides G-L. *J.Chem.Soc.Perkin I* 363-367.

105. Horak, RM, Steyn, PS, Vleggaar, R. 1985. Metabolites of *Aspergillus ustus*. Part 1. Application of the heteronuclear selective population inversion (SPI) NMR technique to the structure elucidation of the australides A-F, novel ortho esters meroterpenoids. *J.Chem.Soc.Perkin I* **1**: 345-356.
106. Steyn, PS, Vleggaar, R. 1976. The structure of dihydrodeoxy-8-epi-austdiol and the absolute configuration of the azaphilones. *J.Chem.Soc.Perkin I* 204-206.
107. Simpson, TJ, Stenzel, DJ, Bartlett, AJ, Holker, JES. 1982. Studies on fungal metabolites. Part 3. <sup>13</sup>C NMR spectral and structural studies on austin and new related meroterpenoids from *Aspergillus ustus*. *J.Chem.Soc.Perkin I* 2687-2692.
108. Chexal, KK, Spinger, JP, Clardy, J, Cole, RJ, Kirksey, JW, Dorner, JW, Cutler, HG, Strawter, BJ. 1976. Austin, a novel polyisoprenoid mycotoxin from *Aspergillus ustus* [letter]. *J Am Chem Soc.* **98**: 6748
109. Steyn, PS, Vleggaar, R. 1975. Dihydrofuro[3',s': 4,5]furo,3,2-b-xanthenones: the structures of austocystins G, H and I. *Journal of South Afric.Chem.Inst.* **XXVIII**: 375-377.
110. Cutler, HG, Crumley, FG, Springer, JP, Cox, RH. 1981. Dihydropergillin: A new fungal metabolite with moderate plant growth inhibiting properties from *Aspergillus ustus*. *J Agr.Food Chem.* **29**: 981-983.
111. Hayes, MA, Wrigley, SK, Chetland, I, Reynolds, EE, Ainsworth, AM, Renno, DV, Latif, MA, Cheng, XM, Hupe, DJ, Charlton, P, Doherty, AM. 1996. Novel drimane sesquiterpene esters from *Aspergillus ustus* var. *pseudodeflectus* with endothelin receptor binding activity. *J.Antib.* **49**: 505-512.
112. Mizuno, R, Kawahara, N, Nozawa, K, Yamazaki, M, Nakajima, S, Kawai, K. 1995. Stereochemistry of an 18,22-cyclosterol, Mer-NF8054X, from *Emericella heterothallica* and *Aspergillus ustus*. *Chem.Pharm.Bull.* **43**: 9-11.
113. Cutler, HG, Crumley, FG, Cox, RH, Springer, JP, Arrendale, RF, Cole, RJ, Cole, PD. 1984. Ophibolins G and H: New fungal metabolites from a novel source *Aspergillus ustus*. *J Agr.Food Chem.* **32**: 778-782.
114. Cutler, HG, Crumley, FG, Springer, JP, Cox, RH, Cole, RJ, Dorner, JD, Thean, JE. 1980. Pergillin: A nontoxic fungal metabolite with moderate plant growth inhibiting properties from *Aspergillus ustus*. *J Agr.Food Chem.* **28**: 989-991.
115. Kanoh, K, Kohno, S, Asai, T, Hrada, T, Katada, J, Muramatsu, M, Kawashma, H, Sekiya, H, Uno, I. 1997. (-)-phenylahistin: a new mammalian cell cycle inhibitor produced by *Aspergillus ustus*. *Bioorg.Medicin.Lett.* **7**: 2847-2852.
116. Kanoh, K, Kohno, S, Katada, J, Hayashi, Y, Muramatsu, M, Uno, I. 1994. Antitumor activity of phenylahistin in vitro and in vivo. *Biosci.Biotech.Biochem.* 1130-1133.
117. Kohno, J, Hiramatsu, H, Nishio, M. 1999. Structures of TMC-120A, B and C, Novel Isoquinoline Alkaloids from *Aspergillus ustus* TC 1118. *Tetrahedron* **55**: 11247-11252.
118. Kohno, J, Sakurai, M, Kameda, N, Shi, N, Matsubara, S. 1999. Production, isolation and biological properties of TMC-120A, B and C, novel inhibitors of eosinophil survival from *Aspergillus ustus*. *J.Antib.* **52**: 913-916.
119. Raistrick, H, Stickings, CE. 1951. Studies in the biochemistry of micro-organisms. Ustic acid, a metabolic product of *Aspergillus ustus* (bainier) Thom & Church. *Biochem.* **48**: 53-66.
120. Raistrick, H, Stickings, CE. 1952. Studies in the biochemistry of micro-organisms. *Biochem.J.* **48**: 53
121. Tepaske, MR, Gloer, JB, Wicklow, DT, Dowd, PF. 1989. Three new aflavinines from the sclerotia of *Aspergillus turbinigenis*. *Tetrahedron* **45**: 4961-4968.
122. Banks, RM, Blanchflower, SE, Everett, JR, Manger, BR, Reading, C. 1997. Novel anthelmintic metabolites from an *Aspergillus* species; the aspergillimides. *J.Antib.* **50**: 840-846.
123. Bugni, TS, Abbanat, D, Bernan, VS, Maisese, WM, Greenstein, M, Van Wagoner, RM, Ireland, CM. 2000. Yanuthones: Novel metabolites from a marine isolate of *Aspergillus niger*. *J.Org.Chem.* **65**: 7195-7200.
124. Almassi, F, Ghisalberti, EL, ROWLAND, CY. 1994. ALKYL CITRATE-DERIVED METABOLITES FROM *ASPERGILLUS-NIGER*. *J.Nat.Prod.* **57**: 833-836.
125. Isogai, A, Washizu, M, Kondo, K, Murakoshi, S, Suzuki, A. 1984. Isolation and identification of (+)-hexylitaconic acid as a plant growth regulator. *Agric.Biol.Chem.* **48**: 2607-2609.
126. Weidenmüller, H-L, Cavagna, F, Fehlhaber, HW, Präve, P. 1972. 2-Carbocymethyl-3-N-hexyl-maleic acid anhydride, a novel metabolite from an *Aspergillus*. *Tetrahedron Lett.* **33**: 3519-3522.
127. Gorst-Allman, CP, Steyn, PS, Rabie, CJ. 1980. Structure elucidation of the nigerones, four new naphthopyrones from cultures of *Aspergillus niger*. *J.Chem.Soc.Perkin I* 2474-2479.
128. Fujimoto, Y, Miyagawa, H, Tsurushima, T, Irie, H, Okamura, K, Ueno, T. 1993. Structure of antafumicins A and B, novel antifungal substances produced by the fungus *Aspergillus niger* NH-401. *Biosci.Biotech.Biochem.* **57**: 1222-1224.
129. Guang-yi, L, Lenz, J, Franck, B. 1989. Asniopyrones, A and B, two novel metabolites from *Aspergillus niger*. *Heterocycles* **28**: 899-904.
130. Varoglu, M, Crews, P. 2000. Biosynthetically diverse compounds from a saltwater culture of sponge-derived *Aspergillus niger*. *J.Nat.Prod.* **63**: 41-43.
131. Varoglu, M, Corbett, TH, Valeriote, FA, Crews, P. 1997. Asperazine, a selective cytotoxic alkaloid from sponge-derived culture of *Aspergillus niger*. *J.Org.Chem.* **62**: 7078-7079.
132. Rabache, M, Neumann, J, Lavollay, J. 1974. Phenylpolyenes D'Aspergillus niger: Structure et propriétés de'Aspergillus niger. *Phytochem* **1974**: 637-642.
133. Hayashi, H, Nishimoto, Y, Akiyama, K, Nozaki, H. 2000. New paratyic alkaloids, asperparalines A, B and C, from *Aspergillus japonicus* JV-23. *Biosci.Biotech.Biochem.* **64**: 111-115.
134. Tanimori, S, Fukubayashi, K, Kirihata, M. 2000. Synthesis of the spirosuccinimide moiety of asperparaline A. *Biosci.Biotech.Biochem.* **64**: 1758-1760.
135. Rabache, M, Laborey, F, Neumann, J, Lavollay, J. 1970. Chimie végétale - Isolement et détermination de la structure d'un pigment phenylpolyénique du mycelium s'Aspergillus niger: ester méthylique de l'acide déméthyl-2,12phenyl-13-tridécahexène-2,4,6,8,10,12 oléique. *C.R.Acad.Paris* **271**: 795-797.
136. Tanaka, H, Wang, P-L, Yamada, O, Tamura, H. 1966. Yellow pigments of *Aspergillus niger* and *A. awamori*. I. Isolation of aurasperone A and related pigments. *Agric.Biol.Chem.* **30**: 107-113.

137. Ghosal, S, Biswas, K, Chakrabarti, DK. 1979. Toxic naphtho-gamma-pyrone from *Aspergillus niger*. J Agr.Food Chem. **27**: 1347-1351.
138. Ehrlich, KC, DeLuca, AJ, Ciegler, A. 1984. Naphtho-gamma-pyrone production by *Aspergillus niger* isolated from stored cottonseed. Appl.Env.Microb. **48**: 1-4.
139. Kodukula, K, Arcuri, M, Cutrone, JQ, Huggill, RM, Lowe, SE, Pirnik, DM, Shu, Y-Z. 1995. BMS-192548, a tetracyclic binding inhibitor of neuropeptide Y receptors, from *Aspergillus niger* WB2346. Taxonomy, fermentation, isolation and biological activity. J.Antib. **48**: 1055-1059.
140. Shu, Y-Z, Cutrone, JQ, Klohr, SE, Huang, S. 1995. BMS-192548, a tetracyclic binding inhibitor of neuropeptide Y receptors from *Aspergillus niger* WB2346. II. Physico-chemical properties and structural characterization. J.Antib. **48**: 1060-1065.
141. Ikeda, S, Sugita, M, Yoshimura, A, Sumizawa, T, Douzono, H, Nagata, Y, Akiyama, S. 1990. *Aspergillus* species strain M39 produces two naphtho-gamma-pyrone that reverse drug resistance in human KB cells. Int J Cancer **45**: 508-513.
142. Galmarini, OL, Stodola, FH. 1965. Fonsecin, a pigment from an *Aspergillus fonsecaeus*. J.Org.Chem. **30**: 112-115.
143. Priestap, HA. 1984. New naphthopyrones from *Aspergillus fonsecaeus*. Tetrahedron **40**: 3617-3624.
144. Cutler, HG, Crumley, FG, Cox, RH, Hernandez, O, Cole, PJ, Dorner, JW. 1979. Orlandin: A novel nontoxic metabolite with plant growth inhibiting properties. J Agr.Food Chem. **27**: 592-595.
145. Frisvad, JC. 1989. The connection between the penicillia and aspergilli and mycotoxins with special emphasis on misidentified isolates. Arch.Env.Contam.Tox. **18**: 452-467.
146. Kim, K-W, Sugawara, F, Yoshida, S, Murofushi, N, Takahashi, N, Curtis, RW. 1993. Structure of malformin B, a phytotoxic metabolite produced by *Aspergillus niger*. Biosci.Biotech.Biochem. **57**: 787-791.
147. Kobbe, B, Cushman, M, Wogan, GN, Demain, AL. 1977. Production and antibacterial activity of malformin C, a toxic metabolite of *Aspergillus niger*. Appl.Env.Microb. **33**: 996-997.
148. Iwamoto, T, Shima, S, Hirota, A, Isogai, A, Sakai, H. 1983. Nigerazine B, a new metabolite from *Aspergillus niger* screening, isolation and chemical and biological properties. Agric.Biol.Chem. **47**: 739-743.
149. Varga, J, Kevei F, Hamari Z, Toth B, Teren J, Croft JH, Kozakiewicz Z. 2000. Genotypic and phenotypic variability among black Aspergilli. In Samson RA, Pitt JI. (eds.), Integration of modern taxonomic methods from *Penicillium* and *Aspergillus* classification. p. 397-411. Harwood academic publishers, Amsterdam.
150. Turner, WB, Aldridge, DC. 1983. Fungal metabolites II. Academic Press, London.
151. Barnes, CL, Steiner, JR, Torres, E, Pacheco, R, Marquez, H. 1990. Structure and absolute configuration of pyrophen, a novel pyrone derivative of L-phenylalanine from *Aspergillus niger*. Int.J.Peptide Protein Res. **36**: 292-296.
152. Yamazaki, M, Okuyama, E, Kobayashi, M, Inoue, H. 1981. The structure of paraherquamide, a toxic metabolite from *Penicillium paraherquie*. Tetrahedron Lett. **22**: 135-136.
153. Tepaske, MR, Gloer, JB, Wicklow, DT, Dowd, PF. 1989. The structure of turbingensin B: a cytotoxic carbazole alkaloid from the sclerotia of *Aspergillus turbingensis*. Tetrahedron Lett. **30**: 5965-5968.
154. Frisvad, JC, Filtenborg, O. 1989. Terverticillate penicillia: Chemotaxonomy and mycotoxin production. Mycologia **81**: 837-861.
155. Bergman, J, Brynolf, A. 1990. Synthesis of chrysogine, a metabolite of *Penicillium chrysogenum* and some related 2-substituted 4-(3H)-quinazolinones. Tetrahedron **46**: 1295-1310.
156. Chadwick, DJ, Easton, IW. 1983. 2-Acetyl-4(3H)-quinazolinone, C<sub>10</sub>H<sub>8</sub>N<sub>2</sub>O<sub>2</sub>. Acta Cryst. **C39**: 454-456.
157. Kimura, Y, Inoue, T, Tamura, S. 1973. Isolation of 2-pyruvylaminobenzamide as an antiauxin from *Colletotrichum lagenarium*. Agric.Biol.Chem. **37**: 2213-2214.
158. Suter, PJ, Turner, WB. 1967. 2-Pyruvylaminobenzamide, a metabolite of *Penicillium chrysogenum* and *Penicillium notatum*. J.Chem.Soc.(C) 2240-2242.
159. Dai, MC, Tabacchi, R, Saturnin, C. 1993. Nitrogen-containing aromatic compounds from the culture medium of *Penicillium chrysogenum* Thom. Chimia **47**: 226-229.
160. Ru-Dong, W, Still, PE, Smalley, HK, Schoes, FM. 1973. Isolation and partial characterization of a mycotoxin from *Penicillium roqueforti*. Appl.Microbiol **25**: 111-114.
161. Hikino, H, Nabetani, S, Takemoto, T. 1973. Structure and biosynthesis of chrysogine, a metabolite of *Penicillium chrysogenum*. Yakugaku Zasshi **93**: 619-623.
162. Schlunegger, US, Kuchen, A, Clemencon, H. 1976. Phenoxazin-derivate in *Calocybe gambosa*. Helv.Chim.Acta **59**: 1383-1388.
163. Zarnack, HBJ, Pfeifer, S. 1971. Phenoxazinones in kulturlösungen von *Penicillium notatum* Westl. Chem.Ber. 314-314.
164. Cram, DJ, Tishler, M. 1948. Mold metabolites. I. Isolation of several compounds from clinical penicilin. Biochem.J. **70**: 4238-4239.
165. Cram, DJ. 1948. Mold metabolites. II. The structure elucidation of sorbicillin, a pigment produced by the mold *Penicillium notatum*. J Am Chem Soc. **70**: 4240-4241.
166. Trifonov, LS, Bieri, JH, Prewo, R, Dreiding, AS, Hoesch, L, Rast, DM. 1983. Isolation and structure elucidation of three metabolites from *Verticillium intertextum*: sorbicillin, dihydro-sorbicillin and bisvertinoquinol. Tetrahedron **39**: 4243-4256.
167. Miller, RF, Huang, S. 1995. Isolation and structure of sorrentanone: A new tetrasubstituted quinone from *Penicillium chrysogenum*. J.Antib. **48**: 520-521.
168. Pfeifer, S, Bär, H, Zarnack, J. 1972. Über stoffwechlenprodukte der Xanthocillin (Brevicid) bildenden mutante von *Penicillium notatum* Westl. Pharmazie **27**: 536-542.
169. Hagedorn, I, Tönjes, H. 1957. Konstitutionsaufklärung von Xanthocillin - einem neuen antibioticum. Pharmazie **12**: 567-580.
170. Takatsuki, A, Suzuki, S, Ando, K, Tamura, G, Arima, K. 1968. New antiviral antibiotics: Xanthocillin X mono- and dimethylether and methoxy-xanthocillin X dimethylether. J.Antib. **XXI**: 671-675.

171. Ando, K, Tamura, G, Arima, K. 1968. A new antibiotic. 1-(p-hydroxyphenyl)-2,3-diisocyano-4-(p-meyhoxyphenyl)-buta-1,3-diene. II. Elucidation of the structure. *J.Antib.* **21**: 587-591.
172. Stodola, FH, Wachtel, JL, Moyer, AJ, Coghill, RD. 1945. Penitric acid, a new pigment from *Penicillium notatum*. *J.Biochem.* **159**: 67-70.
173. Achenback, H, Strittmatter, H, Kohl, W. 1972. Die strukturen der xanthocilline Y1 und Y2. *Chem.Ber.* **105**: 3061-3066.
174. Usher, JJ, Hughes, DW, Lewis, MA, Chiang, SJD. 1992. Determination of the rate-limiting step(s) in the biosynthetic pathways leading to penicillin and cephalosporin. *J.Ind.Microb.* **10**: 157-163.
175. Clutterbuck, PW, Lovell, R, Raistrick, H. 1932. The formation from glucose by members of the *Penicillium chrysogenum* series of a pigment, an alkali-soluble protein and penicillin - the antibacterial substance of Flemming. *Biochem.* **XXVI**: 1907-1918.
176. Steyn, PS. 1970. The isolation, structure and absolute configuration of secalonic acid D, the toxic metabolite of *Penicillium oxalicum*. *Tetrahedron* **26**: 51-57.
177. Andersen, R, Büchi, G, Kobbe, B, Demain, AL. 1977. Secalonic acids D and F are toxic metabolites of *Aspergillus aculeatus*. *J.Org.Chem.* **42**: 352-353.
178. Ueno, Y. 1985. Toxicology of Mycotoxins. *Crit.Rev.Toxicol* **14**: 99-132.
179. Kurobane, I, Vining, LC, McInnes, AG. 1979. Biosynthetic relationships among the secalonic acids. Isolation of emodin, endocrin and secalonic acids from *Pyrenochaeta terrestris* and *Aspergillus aculeatus*. *J.Antib.* **31**: 1256-1266.
180. Trifonov, LS, Hilpert, H, Floersheim, AS, Dreid, M, Rast, R. 1986. Bisvertinols: A new group of dimeric vertinoids from *Verticillium intertextum*. *Tetrahedron* **42**: 3157
181. Ayer, WA, van Altena, I, Browne, LM. 1990. Three piperazinediones and a drimane diterpenoid from *Penicillium brevicompactum*. *Phytochem* **29**: 1661-1665.
182. McCorkindale, NJ, Calzadilla, CH. 1981. The structure and chemistry of pebrolide, desacetylpebrolide, and 1-deoxypebrolide. Sesquiterpene benzoates from *Penicillium brevicompactum*. *Tetrahedron* **37**: 649-653.
183. Andersen, B. 1991. Consistent production of phenolic compounds by *Penicillium brevicompactum* from chemotaxonomic characterization. *Ant.van Leeuwenhoek* **60**: 115-123.
184. Oxford, AE, Raistrick, H. 1932. 3,5-Dihydroxyphthalic acid, a new product of the metabolism of glucose by *Penicillium brevicompactum* and relate species. *Biochem.J.* **27**: 1902-1906.
185. Godin, P. 1953. Etude du metabolisme ternaire de *Penicillium brevicompactum*. *Biochim.Biophys.Acta* **11**: 114-118.
186. Godin, P. 1953. Etude du metabolisme ternaire de *Penicillium brevicompactum*. II. Analyse chromatographique de la solution glucosee substituee au milieu culture initial. *Biochim.Biophys.Acta* **11**: 119-112.
187. Grove, JF. 1979. The synthesis and reactions of some derivatives of C-acetylorelic acid. *J.Chem.Soc.Perkin I* 337-343.
188. Godin, P. 1955. Separation, par chromatographie sur colonne de cellulose, des substances phenoliques produites par *Penicillium brevicompactum* et analyse chinique sommaire de L'une D'entre elles. *Ant.van Leeuwenhoek* **21**: 362-366.
189. Takahashi, T, Kazukiko, T, Shuji, T. 1994. Adenophosins, newly discovered metabolites of *Penicillium brevicompactum*, act as agonists of the inositol 1,4,5-triphosphate receptor. *J Biol Chem* **269**: 369-272.
190. Takahashi, S, Kinoshita, T, Takahashi, M. 1994. Adenophostins A and B: potent agonists of inositol-1,4,5-trisphosphate receptor produced by *Penicillium brevicompactum*: structure elucidation. *J.Antib.* **47**: 95-100.
191. Murphy, CT, Riley, AM, Lindley, CJ, Jenkins, DJ, Westwick, J, Potter, BVL. 1997. Structural analogs of D-myo-inositol-1,4,5-trisphosphate and adenophostin A: recognition by cerebellar and platelet inositol-1,4,5-trisphosphate receptors. *Mol.Pharmacol.* **52**: 741-748.
192. Bird, BA, Campbell, IM. 1982. Disposition of mycophenolic acid, brevianamide A, asperphenamate, and ergosterol in solid cultures of *Penicillium brevicompactum*. *Appl.Env.Microb.* **42**: 345-358.
193. Bird, BA, Campbell, IM. 1982. Occurrence and biosynthesis of asperphenamate in solid cultures of *Penicillium brevicompactum*. *Phytochem* **21**: 2405-2406.
194. Moreau, S, Lablache-Comber, A, Biguet, J, Foulon, C, Delfosse, M. 1982. Botrydiplodin, a mycotoxin synthesised by a strain of *P. roqueforti*. *J.Org.Chem.* **47**: 2358-2359.
195. Fujimoto, Y, Kamiya, M, Tsunoda, H, Ohtsubo, K, Tatsuno, T. 1980. Reserche toxicologique des substances metaboliques de *Penicillium carneo-lutescens*. *Chem.Pharm.Bull.* **248**: 1062-1067.
196. Moule, Y, Decloitre, F, Hamon, G. 1981. Mutagenicity of the mycotoxin botrydiplodin in the Salmonella typhimurium/Microsomal activation test. *Env.Mutagen.* **3**: 287-291.
197. Sanzcervera, JF, Glinka, T, Williams, RM. 1993. Biosynthesis of brevianamide-a and brevianamide-b - in search of the biosynthetic diels-alder construction. *Tetrahedron* **49**: 8471-8482.
198. Birch, AJ, Wright, JJ. 1970. Biosynthesis. XLII. Structural elucidation and some aspects of the biosynthesis of the brevianamides-A and -E. *Tetrahedron* **26**: 2329-2344.
199. Birch, AJ, Wright, JJ. 1969. The brevianamides: a new class of fungal alkaloid. *J.Chem.Soc.,Chem.Com.* 644-645.
200. Birch, AJ, Russel, RA. 1972. Studies in relation to biosynthesis- XLIV. Structural elucidation of Brevianamides-B, -C -D and -F. *Tetrahedron* **28**: 2999-3008.
201. Kusano, M, Sotoma, G, Koshino, H, Fujioka, S. 1998. Brevicompanines A and B: new plant growth regulators produced by the fungus, *Penicillium brevicompactum*. *J.Chem.Soc.Perkin I* 2823-2826.
202. McCorkindale, NJ, Baxter, RL. 1981. Brevigellin, a benzoylated cyclodepsipeptide from *Penicillium brevicompactum*. *Tetrahedron* **37**: 1795-1801.
203. Macias, FA, Varela, RM, Simonet, AM, Cutler, HG, Cutler, SJ, Ross, SA, Dunbar, DC, Dugan, FM, Hill, RA. 2000. Allelochemicals from New Zealand fungi. (+)-Brevione A. The first member of a novel family of bioactive spiroditerpenoids isolated from *Penicillium brevicompactum* Dierckx. *Tetrahedron Lett.* **41**: 2683-2686.
204. Moya, P, Primo-Yufera, E. 1997. Brevioxime: A New Juvenile Hormone Biosynthesis Inhibitor Isolated from *Penicillium brevicompactum*. *J.Org.Chem.* **62**: 8544-8545.

205. Castillo, M-A, Moya, P, Couillaud, F, Carcera, MD, Marinez-Pardo, R. 1998. A heterocyclic oxime from a fungus with anti-juvenile hormone activity. *Arch.Insect Biochem.Physiol* **37**: 287-294.
206. Hanson, JR, O'Leary, MA. 1981. New piperazinedione metabolite from *Gliocladium deliquesens*. *J.Chem.Soc.Perkin I* **218**
207. Kirby, GW, Rao, GV, Robins, DJ. 1988. New co-metabolites of *Gliocladium virens*. *J.Chem.Soc.Perkin I* **301**
208. Brown, AE, Smale, TC, King, TJ, Hasenkamp, R, Thompson, RH. 1976. Crystal and molecular structure of compactin, a new antifungal metabolite from *Penicillium brevicompactum*. *J.Chem.Soc.Perkin I* **11**: 1165-1170.
209. Campbell, IM, Hernandez Calzadilla, C, McCorkindale, NJ. 1966. Some new metabolites related to mycophenolic acid. *Tetrahedron Lett.* **42**: 5107-5111.
210. Birkinshaw, JH, Bracken, A, Morgan, EN, Raistrick, H. 1948. The molecular constitution of mycophenolic acid, a metabolic product of *Penicillium brevicompactum* Dierckx. Part 2. Possible structural formulae for mycophenolic acid. *Biochem.J.* **43**: 216-223.
211. Hayakawa, Y, Sohda, K, Seto, H. 1995. Selective cytotoxicity of mycophenolic acid against transformed cells. *J.Antib.* **48**: 1182-1184.
212. Cantin, A, Moya, P, Miranda, MA, Primo, J, Primo-Yufera, E. 1998. Isolation of N-(2-methyl-3-oxodecanoyl)pyrrole and N-(2-methyl-3-oxodec-8-enoyl)pyrrole, two new natural products from *Penicillium brevicompactum*, and synthesis of analogs with insecticidal and fungicidal activity. *J Agr.Food Chem.* **46**: 4748-4753.
213. Moya, P, Castillo, M-A, Primo, J, Miranda, MA, Primo-Yufera, E. 1998. Isolation, Structural Assignment, and Synthesis of N-(2-Methyl-3-oxodecanoyl)-2-pyrroline, a New Natural Product from *Penicillium brevicompactum* with in Vivo Anti-Juvenile Hormone Activity. *J.Org.Chem.* **63**: 8530-8535.
214. Doerfler, DL, Bird, BA, Campbell, IM. 1981. N-benzoylphenylalanine and N-benzoylphenylalaninol and their biosynthesis in *Penicillium brevicompactum*. *Phytochem* **20**: 2303-2304.
215. McCorkindale, NJ, Baxter, RL, Roy, TP, Shields, HS, Steward, RM, Hutchinson, SA. 1978. Synthesis and chemistry of N-benzoyl-o-[N'-benzoyl-l-pennylanyl]-l-pennylalaninol, the major mycelial metabolite of *Penicillium canadense*. *Tetrahedron* **34**: 2791
216. McCorkindale, NJ, Calzadilla, CH, Baxter, RL. 1981. Biosynthesis of pebrolide. *Tetrahedron* **37**: 1991-1993.
217. Frisvad, JC, Lund F. 1993. Toxic and secondary metabolite production by *Penicillium* species growing in stored cereals. In Scudamore KA. (ed.), p. 146-171. Central Science Laboratory, Berks.
218. Steyn, PS, Vlegaar, R. 1985. Tremorgenic mycotoxins. *Fortschr.Chem Org.Naturst.* **48** : 1-80.
219. Huang, Q, Tezuka, Y, Hatanka, Y, Kikuchi, T, Nishu, A. 1995. Studies on metabolites of mycoparasitic fungi III. New sesquiterpene alcohols from *Trichoderma koningii*. *Chem.Pharm.Bull.* **43**: 1035-1038.
220. Shirota, O, Pathak, V, Hossain, CF, Sekita, S, Takatori, K, Satake, M. 1997. Structural elucidation of trichotetronines: polyketides possessing a bicyclo[2,2,2]octane skeleton with a tetronic acid moiety isolated from *Trichoderma* sp. *J.Chem.Soc.Perkin I* **2961-2964**.
221. Almassi, F, Ghisalberti, EL, Narbey, MJ, Sivasithamparam, K. 1991. New antibiotics from strains of *Trichoderma harzianum*. *J.Nat.Prod.* **54**: 396-402.
222. Baldwin, JE, Bansal, HS, Chondrogianni, J, Field, LD, Taha, AA, Rhaller, V, Brewer, D, Taylor, A. 1985. Biosynthesis of 3-3'-isocyanocyclopent-2-enylidene)propionic acid by *Trichoderma hamatum* (Bon.) Bain. *Tetrahedron* **41**: 1931-1938.
223. Mukhopadhyay, T, Roy, K, Sawant, SN, Deshmukh, SK, Ganguli, BN, Fehlhaber, HW. 1996. On an unstable antifungal metabolite from *Trichoderma koningii* - Isolation and structure elucidation of a new cyclopentenone derivative (3-dimethylamino-5-hydroxy-5-vinyl-2-cyclopenten-1-one). *J.Antib.* **49**: 210-211.
224. Ghisalberti, EL, ROWLAND, CY. 1993. Antifungal metabolites from *Trichoderma harzianum*. *J.Nat.Prod.* **56**: 1799-1804.
225. Claydon, N, Allan, M, Hanson, JR, Avent, AG. 1987. Antifungal alkyl pyrones of *T. harzianum*. *Trans.Brit.Myc.Soc.* **88**: 503-513.
226. Parker, SR, Cutler, HG, Jacyno, JM, Hill, RA. 1997. Biological activity of 6-pentyl-2h-pyran-2-one and its analogs. *J Agr.Food Chem.* **45**: 2774-2776.
227. Abe, N, Murata, T, Hirota, A. 1998. Novel oxidized sorbicillin dimers with 1,1-diphenyl-2- picrylhydrazyl-radical scavenging activity from a fungus. *Biosci.Biotech.Biochem.* **62**: 2120-2126.
228. Andrade, R, Ayer, WA, Mebe, P. 1992. The metabolites of *Trichoderma longibrachiatum*. Part 1. Isolation of the metabolites and the structure of trichodimerol. *Can.J.Chem.* **70**: 2526
229. Slater, GP, Haskins, RH, Hogge, LR, Nesbitt, LR. 1967. Metabolic products from a *Trichoderma viride* Pers. ex Fries. *Can.J.Chem.* **45**: 92-96.
230. Schmidt, FJ, Vanderah, DJ, Hollenbeak, KH, Enwall, CEL, Gropichand, Y, Sengupta, PK, Hossain, MB, Helm, D. 1983. Metabolites from the marine sponge *Tedania ingis*. A new antisenediol and several known diketopiperazines. *J.Org.Chem.* **48**: 3941
231. Cutler, HG, Jacyno, JM, Phillips, RS, VonTersch, RL, Cole, PD. 1991. Cyclonerodiol from a novel source, *Trichoderma koningii*: Plant growth regulator activity. *Agric.Biol.Chem.* **55**: 243-244.
232. Abe, N, Yamamoto, K, Hirota, A. 2000. Novel fungal metabolites, demethylsorbicillin and oxosorbicillin, isolated from *Trichoderma* sp. USF-2690. *Biosci.Biotech.Biochem.* **64**: 620-622.
233. Faull, JL, Graemecook, KA, Pilkington, BL. 1994. PRODUCTION OF AN ISONITRILE ANTIBIOTIC BY AN UV-INDUCED MUTANT OF TRICHODERMA-HARZIANUM. *Phytochem* **36**: 1273-1276.
234. Hodgson, MJ. 2000. Sick building syndrome. *Occup.Med.Rev.* **15**: 571-585.
235. Augustiniak, H, Forche, E, Reichenbach, H. 1991. Isolation and Structure Elucidation of Ergokonin A and B; Two New Antifungal Sterol Antibiotics from *Trichoderma koningii*. *Liebigs Annalen Der Chemie* **1991**: 361-366.
236. Claydon, N, Hanson, JR, Truneh, A. 1991. Harzianolide, a butenolide metabolite from cultures of *Trichoderma harzianum*. *Phytochem* **30**: 3802

237. Corley, DG, Miller-Wideman, M, Durley, RC. 1994. Isolation and structure of harzianum A: A new Trichothecene from *Trichoderma harzianum*. J.Nat.Prod. **57**: 442-425.
238. Brewer, D, Gabe, EJ, Hanson, AW, Taylor, A, Keeping, JW, Thaller, V, Das, EC. 1979. Isonitrile acids from cultures of the fungus *Trichoderma hamatum* (bon) Bain. aggr., X-ray structure. J.Chem.Soc.,Chem.Com. 1061-1063.
239. Dunlop, RW, Simon, A, Sivasithamparam, K, Ghisalberti, EL. 1989. An antibiotic from *Trichoderma koningii* active against soilborne plant pathogens. J.Nat.Prod. **52** : 67-74.
240. Mannina, L, Segre, L, Ritieni, A, Fogliana, V, Vinale, FV, Randazzo, G. 1997. A new fungal growth inhibitor from *Trichoderma viride*. Tetrahedron **53**: 3135-3144.
241. Cutler, HG, Himmelsbach, DS, Arrendale, RF, Cole, PD. 1989. Konongin A: A novel plant growth regulator from *Trichoderma koningii*. Agric.Biol.Chem. **53**: 2605-2611.
242. Cutler, HG, Himmelsbach, DS, Yagen, B, Arrendale, RF, Jacyno, JM, Cole, PD, Cox, RH. 1991. Koningin B: A biological Active Congener of Koningin A from *Trichoderma harzianum*. J Agr.Food Chem. **39**: 977-980.
243. Parker, SR, Cutler, HG, Schreiner, PR. 1995. Koningin E: Isolation of a Biological active Natural Product from *Trichoderma koningii*. Biosci.Biotech.Biochem. **59**: 1747-1749.
244. Cutler, HG, Himmelsbach, DS, Yagen, B, Arrendale, RF, Jacyno, JM, Cole, PD, Cox, RH. 1991. Koningin B: Biologically active congener of Koningin A from *Trichoderma koningii*. J Agr.Food Chem. **39**: 977-980.
245. Cutler, HG, Cutler, SJ, Ross, SA, El Sayed, K, Dugan, FM, Bartlett, MG, Hill, AA, Hill, RA, Parker, SR. 1999. Koningin G, a new metabolite from *Trichoderma aureoviride*. J.Nat.Prod. **62**: 137-139.
246. Lee, CH, Koshino, H, Chung, MC, Lee, HJ, Kho, YH. 1995. MR304A, a new Melanin synthesis inhibitor produced by *Trichoderma harzianum*. J.Antib. **48**: 1168-1171.
247. Lee, C, Chung, M, Lee, H, Kho, Y. 1995. MR-93A, New oxazole from *Trichoderma harzianum*. J.Nat.Prod. **58**: 1605-1607.
248. Andrade, R, Ayer, WA, Trifonov, LS. 1996. The metabolites of *Trichoderma longibrachiatum*. Part II. The structure of trichodermolide and sorbiquinol. Can.J.Chem. **74** : 371-379.
249. Ichinoe, M, Kurata H. 1983. Trichothecene-producing Fungi. In Ueno Y. (ed.), Trichothecenes - Chemical, Biological and Toxicological Aspects. p. 73-81. Elsevier, Amsterdam.
250. Ollis, WD, Rey, M. 1980. The constitution of the antibiotic trichoviridin. Tetrahedron **36**: 515-520.
251. Meyer, CE. 1966. U-21,963 a new antibiotic. II. Isolation and characterization. Appl.Env.Microb. **14**: 511-512.
252. Sawa, Y, Mori, Y, Iinuma, H, Naganawa, H, Hamada, M, Yoshida, S, Furutani, H, Kajimura, Y, Fuwa, T, Takeucji, T. 1994. Harzianic acid, a new antimicrobial antibiotic from a fungus. J.Antib. **47**: 731
253. Oh, S, Lee, S, Kim, J, Yoo, I. 2000. Structure determination of new antibiotic peptides, atroviridins, A, B and C from *Trichoderma atroviride*. Tetrahedron Lett. **41**: 61-64.
254. Augeven-Bour, I, Rebuffat, S, Auvin, C, Goulard, C, Prigent, Y, Bodo, B. 1997. Harzianin HB I, an 11-residue peptaibol from *Trichoderma harzianum*: Isolation, sequence, solution synthesis and membrane activity. J.Chem.Soc.Perkin I **1**: 1587-1594.
255. Rebuffat, S, Goulard, C, Bodo, B. 1995. Antibiotic peptides from *Trichoderma harzianum* - harzianins hc, proline-rich 14-residue peptaibols. J.Chem.Soc.Perkin I 1849-1855.
256. Rebuffat, S, Hlimi, S, Prigent, Y, Goulard, C, Bodo, B. 1996. Isolation and structural elucidation of the 11-residue peptaibol antibiotic, harzianin HK VI. J.Chem.Soc.Perkin I 2021-2027.
257. Becker, D, Kiess, M, Bruckner, H. 1997. Structures of peptaibol antibiotics hypomurocin A and B from the ascomycetous fungus *Hypocrea muroiana* Hino et Katsumoto. Liebigs Annalen-Recueil 767-772.
258. Wada, S, Nishimura, T, Iida, A, Toyama, N, Fujita, T. 1994. Primary structures of antibiotic peptides, trichocellin-a and trichocellin-b from *Trichoderma viride*. Tetrahedron Lett. **35**: 3095-3098.
259. Iida, A, Sanekata, M, Fujita, T, Tanaka, H, Enoki, A, FUSE, G, Kanai, M, Rudewicz, PJ, Tachikawa, E. 1994. Fungal metabolites .16. Structures of new peptaibols, trichokindins i-vii, from the fungus *Trichoderma harzianum*. Chem.Pharm.Bull. **42**: 1070-1075.
260. LIN, A, Lee, TM, Rern, JC. 1994. Tricholin, a new antifungal agent from *Trichoderma viride*, and its action in biological-control of *Rhizoctonia solan*. J.Antib. **47**: 799-805.
261. LIN, A, Chen, CK, Chen, YJ. 1991. Molecular action of tricholin, a ribosome-inactivating protein isolated from *Trichoderma viride*. Mol.Micro. **5**: 3013
262. Iida, A, Sanekata, M, Wada, S, Fujita, T, Tanaka, H, Enoki, A, FUSE, G, Kanai, M, Asami, K. 1995. Fungal metabolites .18. New membrane-modifying peptides, trichorzins i-iv, from the fungus *Trichoderma harzianum*. Chem.Pharm.Bull. **43**: 392-397.
263. Lorito, M, Farkas, V, Rebuffat, S, Bodo, B, Kubicek, DP. 1996. Cell wall synthesis is a major target of mycoparasitic antagonism by *Trichoderma harzianum*. J bacteriol. **178**: 6382-6385.
264. Goulard, C, Hlimi, S, Rebuffat, S, Bodo, B. 1995. Trichorzins HA and MA, antibiotic peptides from *Trichoderma harzianum* .1. fermentation, isolation and biological properties. J.Antib. **48**: 1248-1253.
265. Hlimi, S, Rebuffat, S, Goulard, C, Duchamp, S, Bodo, B. 1995. Trichorzins HA and MA, antibiotic peptides from *Trichoderma harzianum* .2. sequence determination. J.Antib. **48**: 1254-1261.
266. Duval, D, Cosette, P, Rebuffat, S, Duclouhier, H, Bodo, B, Molle, G. 1998. Alamethicin-like behaviour of new 18-residue peptaibols, trichorzins PA. Role of the C-terminal amino-alcohol in the ion channel forming activity. Biochim.Biophys.Acta-Biomemb. **1369**: 309-319.
267. Duval, D, Riddell, FG, Rebuffat, S, Platzter, N, Bodo, B. 1998. Ionophoric activity of the antibiotic peptaibol trichorzin PA VI: a Na-23- and Cl-35-NMR study. Biochim.Biophys.Acta-Biomemb. **1372**: 370-378.
268. Hou, CT, Ciegler, A, Hesseltine, CW. 1972. New mycotoxin, trichotoxin A, from *Trichoderma viride* isolated from southern leaf blight-infected corn. App.Microb. **23**: 183-185.

269. Brückner, H, König, WA, Greiner, M, Jung, G. 1979. The sequences of the membrane-modifying peptide antibiotic trichotoxin A-40. *Angew.Chem Int Ed.Engl.* **18**: 476-477.
270. Auvinguetta, C, Rebuffat, S, Vuidepot, I, MASSIAS, M, Bodo, B. 1993. Structural elucidation of trikoningin-ka and trikoningin-kb, peptaibols from *Trichoderma-koningii*. *J.Chem.Soc.Perkin I* 249-255.
271. Huang, Q, Tezuka, Y, Kikuchi, T, Nishi, A, Tubaki, K, Tanaka, K. 1995. Studies on metabolites of mycoparasitic fungi. II. Metabolites of *Trichoderma koningii*. *Chem.Pharm.Bull.* **43**: 223-229.
272. Huang, Q, Tezuka, Y, Hatanka, Y, Kikuchi, T, Nishi, A, Tubaki, K. 1996. Studies on metabolites of mycoparasitic fungi. V. Ion-spray ionization mass spectrometric analysis of trichokonin-II, a peptaibol mixture obtained from the culture broth of *Trichoderma koningii*. *Chem.Pharm.Bull.* **44**: 590-593.
273. Hinkley, SF, Fettingner, JC, Dudley, K, Jarvis, BB. 1999. Memnobotrins and Memnoconols: Novel Metabolites from *Memnoniella echinata*. *J.Antib.* **52**: 988-997.
274. Jarvis, BB, Zhou, Y, Jiang, J, Wang, S, Sorenson, WG, Hintikka, E-L, Nikulin, M, Parikka, P, Etzel, RA, Dearborn, DG. 1996. Toxicogenic Moulds in Water-Damaged Buildings: Dechlorogriseofulvins from *Memnoniella echinata*. *J.Nat.Prod.* **59**: 553-554.
275. Sundholm, EG. 1978. <sup>13</sup>C NMR spectra of lichen xanthons. Temperature dependent collapse of long range couplings to hydrogen-bonded hydroxyl protons. *Acta Chem.Scand.* **B32**: 117-181.
276. Huneck, S, Höfle, G. 1978. Struktur und <sup>13</sup>C-NMR-spektroskopie von chlorhaltigen flechtenxanthonen. *Tetrahedron* **34**: 2491-2500.
277. Stefanelli, S, Sponga, F, Ferrari, P, Sottani, C, Corti, E, Brunati, C, Islam, K. 1996. Inhibitors of myo-inositol monophosphatase, ATCC 20928 factors A and C isolation, physicochemical characterization and biological properties. *J.Antib.* **49**: 611-616.
278. Montemurro, N, Visconti A. 1992. *Alternaria* metabolites. In Chelkowski J, Visconti A. (eds.), *Alternaria. Biology, plant disease and metabolites.* p. 449-557. Elsevier, Amsterdam.
279. Ren, P, Ahearn, DG, Crow, SA. 1998. Mycotoxins of *Alternaria alternata* produced on ceiling tiles. *J.Ind.Microb.* **20**: 53-54.
280. Panigrahi, S, Dallin, S. 1994. Toxicity of the *Alternaria* spp metabolites, tenuazonic acid, alternariol, altertoxin-i, and alternariol, monomethyl ether to brine shrimp (*Artemia salina* L) larvae. *J.Sci.Food Agric.* **66**: 493-496.
281. Stack, ME, Prival, MJ. 1986. Mutagenicity of the *Alternaria* metabolites altertoxins I, II, and III. *Appl.Env.Microb.* **52**: 718-722.
282. Kind, R, Zeeck, A, Grabley, S, Thiericke, R, Zerlin, M. 1996. Secondary metabolites by chemical screening .30. Helmidiol, a new macrodiolide from *Alternaria alternata*. *J.Nat.Prod.* **59**: 539-540.
283. Park, SH, Stierle, A, Strobel, GA. 1994. Metabolism of maculosin, a host-specific phytotoxin produced by *Alternaria alternata* on spotted knapweed (*centaurea-maculosa*). *Phytochem* **35**: 101-106.
284. Abraham, WR, Arfmann, HA. 1992. Rearranged tetrahydrofurans from *Chaetomium cochlioides*. *Phytochem* **31**: 2405-2408.
285. Koyama, K, Natori, S, Litaka, Y. 1987. Absolute configuration of chaetochromin A and related bis(naphtho- $\gamma$ -pyrone) mold metabolites. *Chem.Pharm.Bull.* **35**: 4049-4055.
286. Koyama, K, Natori, S. 1989. Biosynthesis of chaetochromin A, a bis(naphtho-gamma-pyrone), in *Chaetomium* spp. *Chem.Pharm.Bull.* **37**: 2022-2025.
287. Koyama, K, Natori, S. 1987. Chaetochromins B, C and D, bis(naphtho-gamma-pyrone) derivatives from *Chaetomium gracile*. *Chem.Pharm.Bull.* **35**: 578-584.
288. Saito, T, Suzuki, Y, Koyama, K, Natori, S, litaka, Y, Kinoshita, T. 1988. Chetracin A and Chaetocin B and C, three epipolythiodioxo-piperazines from *Chaetomium* spp. *Chem.Pharm.Bull.* **36**: 1942
289. Sekita, S, Yoshihira, K, Natori, S, Udagawa, S, Sakabe, F, Kurata, H, Umeda, M. 1982. Chaetoglobosins, cytotoxic 10-(indol-3-yl)-[13]cytochalasans from *Chaetomium* spp. I. Production, isolation and some cytological effects of chaetoglobosins A-J. *Chem.Pharm.Bull.* **30**: 1609-1617.
290. Oikawa, H, Murakami, Y, Ichihara, A. 1997. 20-Ketoreductase activity of chaetoglobosin A and prochaetoglobosin in a free-cell system of *Chaetomium subaffine* and the isolation of new chaetoglobosins. *Biosci.Biotech.Biochem.* **57**: 628-631.
291. Oh, H, Swenson, DC, Gloer, JB, Wicklow, DT, Down, PF. 1998. Chatochalsin A: a new bioactive metabolite from *Chaetomium brasiliense*. *Tetrahedron Lett.* **39**: 7633-7636.
292. Safe, S, Taylor, A. 1972. Sporidesmins. 8. Ovine ill-thrift in Nova Scotia. 3. The characterisation of chetomin a toxic metabolite of *Chaetomium cochlioides* and *Chaetomium globosum*. *J.Chem.Soc.Perkin I* **4**: 472-479.
293. Takahashi, M, Koyama, K, Natori, S. 1990. Four new azaphilones from *Chaetomium globosum* var *flavo-viridae*. *Chem.Pharm.Bull.* **38**: 625-628.
294. Brewer, D, Jerram, WA, Taylor, A. 1968. The production of cochliodinol and a related metabolite by *Chaetomium* species. *Can.J.Microbiol.* **14**: 861-866.
295. Breinholt, J, Demunt, H, Heide, M, Jensen, GW, Møller, IL, Nielsen, RI, Olsen, CE, Rosendahl, CN. 1996. Prenisatin (5-(3-Methyl-2-butenyl)-indole-2,3-dione): an Antifungal Isatin Derivative from *Chaetomium globosum*. *Acta Chem.Scand.* **50**: 443-445.
296. Grove, JF, Speake, RN, Ward, G. 1966. Metabolic products of *Colletotrichum capsici*. Isolation and characterisation of acetylcolletotrichin and colletodiol. *J.Chem.Soc.(C)* 230-234.
297. Powell, JW, Whalley, WB. 1969. The chemistry of fungi. 58. Structures of colletodiol, a metabolite of *Chaetomium funicola*. *J.Chem.Soc.Perkin I* **6**: 911-912.
298. Oka, H, Asahi, K, Morishima, H, Sanada, M, Shiratori, K, Iimura, Y, Sakurai, T, Uzawa, J, Iwadare, S, Takahashi, N. 1985. Differanisole A, a new differentiation inducing substance. *J.Antib.* **38**: 1100-1102.



299. Itoh, Y, Kodama, K, Furuya, K, Takahashi, S, Haneishi, T, Takiguchi, Y, Arai, M. 1980. A new sesquiterpene antibiotic, heptelidic acid producing organisms, fermentation, isolation and characterization. *J.Antib.* **33**: 468-473.
300. Sekita, S, Yoshihira, K, Natori, S. 1981. Isocochliodinol and neocochliodinol, indolylbenzoquinones from *Chaetomium* sp. *Chem.Pharm.Bull.* **29**:
301. Sekita, S, Yoshihira, K, Natori, S, Udagawa, S, Muroi, T, Sugiyama, Y, Kurata, H, Umeda, M. 1981. Mycotoxin production by *Chaetomium* spp. and related fungi. *Can.J.Microbiol.* **27**: 766-772.
302. Stark, AA, Kobbe, B, Matsuo, D, Büchi, G, Wogan, GN, Demain, AL. 1978. Mollicellins: mutagenic and antibacterial mycotoxins. *Appl.Env.Microb.* **36**: 412-420.
303. Kögl, F, Wessem, C. 1944. Untersuchungen über pilzfarbstoffe. XIV Über oosporein, den farbstoffe von *Oospora colorans* van Beyma. *Recl.Trav.Chim.Pays-bas Belg.* **63**: 5-12.
304. Cole, RJ, Kirksey, JW, Cutler, HG, Davis, EE. 1974. Toxic effects of oosporein from *Chaetomium trilaterale*. *J Agr.Food Chem.* **22**: 517-520.
305. Itahashi, M, Murakami, Y, Nichikawa, H. 1955. On the structure of tomichaedin (biochemistry of filamentous fungi X). *Tohoku J.Agric.Res.* **5**: 281-283.
306. Kwang, E-I, You, B-S, Kim, Y-K, Kwong, B-M, Kim, H-G, Lee, H-B, Bae, K-S, Kim, S-U. 2000. Chaetoatrosin A, a novel chitin synthase II inhibitor produced by *Chaetomium atrobrunneum* F449. *J.Antib.* **53**: 248-255.
307. Sakagami, Y, Sano, A, Hara, O, Mikawa, T, Marumo, S. 1995. Cladosporol,  $\beta$ -1,3-glucan biosynthesis inhibitor, isolated from the fungus, *Cladosporium cladosporioides*. *Tetrahedron Lett.* **36**: 1469-1472.
308. Hirota, A, Sakai, H, Isogai, A. 1985. New plant growth regulators, cladospolide A and B, macrolides produced by *Cladosporium cladosporioides*. *Agric.Biol.Chem.* **49**: 731
309. Fujii, Y, Fukuda, A, Hamasaki, T, Ichimoto, I, Nakajima, H. 1995. 12-Membered lactones produced by *Cladosporium tenuissimum* and the plant-growth retardant activity of cladospolide-b. *Phytochem* **40**: 1443-1446.
310. Kobayashi, E, Ando, K, Nakano, H, Lida, T, Ohno, H, Morimoto, M, Tamaoki, T. 1989. Calphostins (UCN-1028), novel and specific inhibitors of protein kinase C. I. Fermentation, isolation, physico-chemical properties and biological activities. *J.Antib.* **42**: 1470-1474.
311. Lida, T, Kobayashi, E, Yoshida, M, Sano, A. 1989. Calphostins (UCN-1028), novel and specific inhibitors of protein kinase C.II. Chemical structures. *J.Antib.* **42**: 1475-1481.
312. Hosoe, T, Okada, H, Itabashi, T, Nozawa, K, Okada, K, Takaki, GMD, Fukushima, K, Miyaji, M, Kawai, K. 2000. A new pentanorlanostane derivative, cladosporide A, as a characteristic antifungal agent against *Aspergillus fumigatus*, isolated from *Cladosporium* sp. *Chem.Pharm.Bull.* **48**: 1422-1426.
313. Jacyno, JM, Harwood, JS, Cutler, HG, Lee, MK. 1993. Isocladosporin, a biologically active isomer of cladosporin from *Cladosporium cladosporioides*. *J.Nat.Prod.* **56**: 1397-1401.
314. Scott, PM, Walbeek, W, MacLean, WM. 1971. Cladosporin, a new metabolite from *Cladosporium cladosporioides*. *J.Antib.* **24**: 747
315. Hein, SM, Gloer, JB, Koster, B, Malloch, D. 1998. Arugosin F: A new antifungal metabolite from the Corophiilous fungus *Ascodesmis sphaerospora*. *J.Nat.Prod.* **61**: 1566-1567.
316. Ayer, WA, Taylor, DR. 1976. Metabolites of bird's nest fungi. Part 5. the isolation of 1-hydroxy-6-methyl-8-hydroxymethylxanthone, a new xanthone, from *Cyathus intermedius*. Synthesis via photoenolisation. *Can.J.Chem.* **54**: 1703-1707.
317. Holler, U, Konig, GM, Wright, AD. 1999. A new tyrosine kinase inhibitor from a marine isolate of *Ulocladium botrytis* and new metabolites from the marine fungi *Asteromyces cruciatus* and *Varicosporina ramulosa*. *Eur.J.Org.Chem.* 2949-2955.

Mould growth in buildings is associated with adverse health effects among the occupants of the building. However actual growth only occurs in damp and water-damaged materials, and is an increasing problem in Denmark, due to less robust constructions, inadequate maintenance, and too little ventilation. This project was started to determine if mycotoxins are produced in damp and water-damaged buildings as well investigating the influence of environmental conditions (humidity and temperature) on the production of fungal growth and secondary metabolism.

1. edition, 2002  
ISBN 87-563-1130-3

